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Abstract 
Alzheimer’s disease (AD), the commonest form of dementia, is a chronic, 
progressive neurodegenerative disease which manifests clinically as a slow 
global decline in cognitive function, including deterioration of memory, 
reasoning, abstraction, language and emotional stability, culminating in a 
patient with end-stage disease, totally dependent on custodial care. With an 
ageing population, there is predicted to be a marked increase in the number of 
people diagnosed with AD in the coming decades, making this a significant 
challenge to socio-economic policy and aged care. Currently there is no cure for 
AD and while current therapies may temporarily ameliorate symptoms, death 
usually occurs approximately 8 years after diagnosis. Attention is now being 
directed to the discovery of biomarkers that may not only facilitate pre-
symptomatic diagnosis but provide an insight into aberrant biochemical 
pathways that may reveal potential therapeutic targets. AD pathogenesis 
develops over many years before clinical symptoms appear, providing the 
opportunity to develop therapy that could slow or stop disease progression well 
before any clinical manifestations develop. 
Research and understanding of AD pathology has been driven in recent years 
by advances in technologies, enabling the precise investigation of the lipidome; 
the repertoire of lipid species present in cells and tissues that reflect the net 
effect of gene and protein expression, which in turn are influenced by the 
cellular environment. Lipidomic studies have identified abnormal lipid 
metabolism as a key component of the pathological processes which lead to the 
development of AD. Therefore, lipidomic studies are crucial for advancing the 
understanding of AD pathology and for identifying potential therapeutic targets; 
these studies may also facilitate biomarker discovery. Many studies have 
reported abnormal lipid profiles in both AD plasma and brain tissue. 
This thesis investigated plasma lipid species using a “shotgun” lipidomics 
approach by electrospray ionisation tandem mass spectrometry (ESI/MS/MS). 
Additionally, Phospholipid Transfer Protein (PLTP); a protein involved in lipid 
metabolism was assayed using a commercial kit. The utility of these analytes as 
potential AD biomarkers was investigated by testing plasma samples from the 
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highly characterised Australian Imaging, Biomarkers and Lifestyle (AIBL) study. 
The study cohort comprised over 1000 participants at inception who were 
classified as either healthy control (n=733), mild cognitive impairment (MCI, 
n=125) or AD (n=204): Samples from the baseline and 18 month follow-up time 
points were utilised. Plasma PLTP activity levels were measured in a subset of 
the baseline samples (n=259). Lipid and PLTP measurements were analysed in 
conjunction with supplementary neuroimaging and blood biomarker data 
collected as part of the AIBL study. 
The thesis identified significant differences in several plasma lipids between 
clinical classification groups, including several ceramide, sphingomyelin (SM), 
phosphatidylethanolamine (PE), phosphatidylcholine (PC) and plasmalogen 
species. Additionally, a panel of lipids was identified which could distinguish AD 
participants from healthy controls with a sensitivity and specificity of 80%. 
Plasma PLTP activity was significantly lower in AD and MCI groups compared 
to healthy controls, and levels correlated with plasma Aβ in all groups and 
cerebral Aβ in the healthy controls. 
The results of this thesis validate and extend previous findings reported in the 
literature. The current findings provide evidence to indicate that several lipid 
species and PLTP show promise as potential blood biomarkers of AD. Further 
investigation using a targeted lipidomics platform and prospective longitudinal 
follow-up is warranted. 
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Chapter 1 – Review of the Literature – Lipids and AD  
1.1  Alzheimer’s Disease – Background 
Alzheimer’s disease (AD) is the commonest form of dementia, initially identified 
by Alois Alzheimer in 1906. It is a chronic, progressive neurodegenerative 
disease manifesting clinically as a disturbance in multiple higher functions of the 
brain, including memory, thinking, orientation, comprehension, calculation, 
learning capacity, language and judgement.  
It can also be accompanied by deterioration in emotional control, motivation or 
social behaviour [1, 2]. In advanced stages, care by family members and carers 
is required to assist with daily living and ultimately an inability to recognise 
family members exacerbates the huge emotional burden. On average, the 
disease progresses from initial mild symptoms to severe dementia over a period 
of about eight years, with many sufferers requiring institutional care for several 
years. 
The greatest risk factor for AD is age and so with an ageing population, there is 
predicted to be a marked increase in the number of AD cases in the coming 
decades; in both the developed and developing world [3, 4]. In Australia, 
approximately 300,000 people are suffering from dementia, with this figure 
expected to be close to 1 million by 2050 [5].  
Current estimates put a direct cost of $AUD3.2 billion to the healthcare system 
in Australia with a predicted increase to $AUD6billion within the next five years 
[6]. This represents a major economic burden to an already stretched 
healthcare budget. According to the Alzheimer’s Association in the US, unpaid 
care by family members and caregivers in 2009 represented $144 billion. These 
alarming statistics emphasise the importance of gaining a greater 
understanding of the pathophysiology of AD with the aim of developing tests 
that will identify those at risk before the clinical hallmarks of AD manifest.  
Currently, post mortem examination of the affected brain still provides the most 
affirmative diagnosis of AD, however with advances in brain imaging (amyloid 
ligand positron emission tomography (PET)), amyloid beta (Aβ) can now be 
visualised ante-mortem. This may assist in identifying pre-clinical stages of 
disease. Ultimately early diagnosis, identification of those at risk and the 
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development of intervention strategies offers the best chance of significantly 
reducing the number of AD cases.  
1.1.1  AD Pathology – hallmarks of disease 
In AD, the rate at which nerve cells deteriorate and die rapidly increases, greatly 
outstripping renewal and repair mechanisms resulting in shrinkage of several 
areas of the brain [7]. The causes and factors leading to disease progression 
are poorly understood but AD pathology is characterised by the presence of 
senile plaques, beta-amyloid (Aβ) deposits and neurofibrillary tangles in the 
cerebral cortex and sub-cortical grey matter.  
An interesting and until recently often overlooked feature of AD pathology, 
originally described by Alois Alzheimer, is an increased number of “lipoid 
granules” in the AD brain [8]. Despite this observation, understanding the 
connection between abnormal lipid metabolism and AD has progressed slowly, 
although renewed interest in this area of AD pathology is gaining momentum 
due to the technological advances in lipid analyses.  
There is much debate in the literature as to which of these hallmarks are 
causative and which result from other patho-physiological processes. Multiple 
factors have been implicated in the aetiology and pathogenesis of AD. These 
factors include genetic defects, abnormal lipid metabolism, energy metabolism 
deficits and mitochondrial defects, inflammation, abnormal amyloid precursor 
protein processing, deficiency of neurotrophic factors, glutamate excitotoxicity, 
free-radical induced neuron degeneration and trace element toxicity. It is 
unlikely that any of these factors are isolated, but when combined with 
imbalances in neurotransmitters and hormones and impaired hepatic metabolic 
and detoxification pathways, a complex web of dysfunctional biochemistry is 
established, resulting in the characteristic AD pathology [7].  
1.1.2  Amyloid Plaques 
Amyloid plaques are a characteristic feature of AD and contain aggregates of 
Aβ, a 4kDa peptide of 39-43 amino acids normally found in the brain, albeit at 
low concentrations [9]. The plaques when visualised at post-mortem are 
typically spherical and range from 10-150nm [10] (see Figure 1.1A). Aβ is a 
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protein fragment cleaved by the action of secretase enzymes from its larger 
parent protein called amyloid precursor protein (APP). APP is located in the 
plasma (outer) membrane of brain cells, including neurons, glial cells and the 
endothelial cells of the blood brain barrier. APP is an abundant protein in the 
central nervous system but is also ubiquitously expressed in the peripheral 
tissues such as epithelium, muscle and circulating cells. Platelets are a rich 
source of APP and contain concentrations similar to that of brain cells [11].  
The APP protein undergoes proteolytic cleavage by enzymes termed BACE 
(beta site APP cleaving enzyme) and the α- and γ-secretases which act via two 
competing pathways which depend on the localisation of APP to lipid rafts and 
feedback loops controlling gene transcription for the appropriate enzymes (see 
Section 1.5 and reviewed in [12].  
One product of APP cleavage is Aβ of which two main forms of Aβ are 
secreted; Aβ40 and Aβ42 consisting of 40 and 42 amino acids respectively. Aβ42 
accounts for approximately 10% of secreted Aβ, but is the main form found in 
amyloid plaques, suggesting a more pathological role for Aβ42 due to its ability 
to aggregate and polymerise into amyloid fibrils more readily than Aβ40 [9]. An 
overproduction or reduced clearance of Aβ is considered a key component of 
AD and  alterations in A kinetics may contribute to the induction of 
inflammation, oxidation and neurotoxicity, turning a physiologically relevant 
protein into a potentially toxic one [13].  
Evidence also suggests that soluble oligomers of Aβ known as amyloid beta 
derived diffusible ligands (ADDLs) accumulate and initiate a toxic cascade 
before plaque deposition and neuronal death occurs. This may explain the 
inconsistencies observed with plaque burden and cognitive deficits [14].  
There is no doubt that the evidence suggests a key role for A in the 
neuropathology of AD, but the amyloid hypothesis as the sole driver has been 
challenged by recent studies using immunisation with pre-aggregated A1-42, 
demonstrating that in spite of almost complete elimination of senile plaques 
from the AD brain, cognitive decline still progressed [15]. This evidence has 
also been corroborated by the failure in clinical trials of the gamma-secretase 
inhibitor semagacestat, which reduced A production, but failed to retard 
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disease progression [16]. However, the patients used in these trials had 
advanced disease, where any increased clearance of Aβ may have occurred 
too late to influence cognitive decline. Further trials are required that target early 
stage disease. Moreover, it has been suggested that A deposition merely 
represents a protective response to some other pathophysiological process or is 
involved with the chelation of potentially oxidative transition metals [17]. A more 
detailed section on APP processing, Aβ generation and lipids is presented later 
in the chapter (see Section 1.5.1). 
1.1.3  Neurofibrillary tangles 
Affected areas of the AD brain have significantly lower neuronal numbers and 
the remaining neurons possess reduced numbers of dendrite branches and 
synaptic densities. Neurofibrillary tangles (NFTs) arise within individual neurons 
as depositions of abnormally twisted filaments (see Figure 1B).  
The tau protein in neurons is normally organised in a linear fashion into 
microtubules, which give structural integrity and are involved in intracellular 
transport [18]. Phosphorylation of tau is part of the normal process of assembly 
of microtubules, conferring stability. However, in AD the tau proteins become 
hyper-phosphorylated or glycosylated, causing them to twist and form tangles, 
which adversely affects neuronal function and results in loss of intracellular 
communication [19-21].  
The phosphorylation and dephosphorylation of tau, as with other proteins, is 
tightly regulated by various kinases and phosphatases and dysregulation of 
these processes may contribute to the accumulation of NFTs.  
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Figure 1.1: Pathological hallmarks of Alzheimer’s disease. A) Amyloid plaques. B) 
Neurofibrillary tangles. C) Cerebral amyloid angiopathy (CAA). Amyloid plaques and NFTs 
are stained brown in 1A and 1B. Amyloid can also deposit in the cerebral and meningeal blood 
vessels as seen in 1C, where it appears to be associated with increased inflammation and risk 
of cerebral haemorrhage [22, 23]. However, both amyloid plaques and CAA can be seen in both 
cognitively normal individuals and in AD [24]. 
(Images adapted from coloradodementia.org and angiopathy.org) 
 
1.1.4  Abnormal Lipid Metabolism 
Abnormal lipid metabolism is emerging as a very important pathophysiological 
process in the development of AD. This is logical, as the adverse effects of 
abnormal lipid metabolism on neuronal biochemistry are numerous; affecting 
membrane lipid composition and a myriad of cellular signals generated by lipid 
mediators. The link between AD and lipid metabolism was firmly established 
when carriage of the apolipoprotein Eε4 allele (APOEε4) was identified as a 
major risk factor for AD [25].  
In recent years a greater understanding of the interaction between lipids, 
amyloidogenesis and tau pathology has emerged, with most classes of lipids 
being implicated. This makes sense as lipids are key components of 
membranes, providing an environment conducive for fluidity and ion 
permeability as well as regulating trafficking and proteolytic activity of key 
membrane-bound proteins (including APP, beta site APP cleaving enzyme, 
(BACE) and γ-secretase) involved in APP processing and AD [26].  
Lipids may also affect the pathogenicity of Aβ by influencing its tendency to 
aggregate [27]. Lipid mediators are generated from phospholipids, sphingolipids 
and cholesterol by activation of phospholipases, sphingomyelinases and 
cytochrome p450-dependent oxygenases respectively, which exert numerous 
effects on cellular function. These effects involve modulation of enzyme activity, 
Chapter 1: Review of the Literature – Lipids and AD 
 
6 
 
neural cell differentiation, immune responses, inflammation, oxidation, cell 
migration, mitogenesis and apoptosis and therefore imbalances in any of these 
mediators would predictably contribute to AD pathology [28].  
Later sections (Section 1.5) will outline the specifics of abnormal lipid 
metabolism and how this directly contributes to AD pathology when the 
homeostatic mechanisms become dysfunctional. This outline will be followed by 
individual discussions of the many integrated factors affecting lipid metabolism, 
bearing in mind the significant cross-talk and interaction of these regulatory 
factors. These sections have been separated in an attempt to simplify a highly 
complex and integrated system. As with other degenerative diseases, there are 
many feedback mechanisms and points of control required to maintain 
homeostasis, which when altered, synergistically combine to accelerate 
pathology.  
1.2  Current diagnostic strategies 
Current primary care approaches only detect AD once symptoms are already 
present, highlighting the need for a pre-symptomatic test. A primary care doctor 
relies upon determining a history of cognitive and behavioural change often with 
the help of an informant close to the patient.  
Other causes of cognitive decline including head trauma, stroke, cancer, 
hormone, endocrine and nutrient abnormalities must be excluded by various 
testing. If a diagnosis of AD is suspected, the patient can then be referred to a 
specialist centre where various cognitive, physical and neurological tests can be 
performed alongside brain imaging.  
Neuropsychological tests are used to assess memory, problem solving, 
communication and mood. Many population studies use a combination of these 
tests to improve sensitivity. In reality, no one test or imaging technique provides 
a definitive diagnosis and in practice combinations of assessment methods are 
used. The National Institute of Neurological and Communicative Disorders and 
Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-
ARDA) established AD diagnostic criteria 27 years ago with a reported 
sensitivity and specificity of 81% and 70% respectively. To ensure flexibility in 
the criteria so that they may be used by both general healthcare providers and 
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specialist investigators, a recent revision of these criteria by the National 
Institute on Aging and the Alzheimer’s Association (NIA/AA) now incorporates 
pre-clinical and mild cognitive impairment (MCI) stages [29].  
Imaging and other biomarkers are also integrated into research settings to 
enhance specificity of diagnosis while key clinical criteria remain the main 
diagnostic tool in clinical practice. Emerging biomarker research and validation 
is expected to enhance the specificity of these diagnostic criteria. The following 
sections outline some of the tests commonly used in current diagnostic 
strategies, including those used in the well characterised Australian Imaging, 
Biomarkers and Lifestyle (AIBL) study of ageing; the cohort utilised in this study. 
1.2.1  Neuropsychological Tests 
A battery of neuropsychological tests can be employed to assess the level of 
cognitive impairment. These tests investigate the ability to acquire and 
remember new information, ability to plan and reason, visuospatial abilities and 
language functions. Testing can also help the doctor and family understand the 
impact of the disorder on the everyday functioning of the patient. There are 
several tests widely used, each having its own strengths and weaknesses. 
Relevant tests with respect to AIBL are briefly described below. 
1.2.2  Mini Mental State Examination (MMSE) 
The MMSE assesses global cognition and represents a commonly used test to 
evaluate memory problems as well as assisting with diagnosis of dementia and 
assessing progression and severity. The test involves a brief 30 point 
questionnaire probing memory, orientation and arithmetic functions [30]. MMSE 
scores range from 0 to 30 points: Table 1.1 facilitates interpretation. 
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Table 1.1: Mini-Mental State Examination (MMSE) scores and interpretation. 
MMSE Score Interpretation 
0-9 Severe AD 
10-19 Moderate AD 
20-23 Mild cognitive impairment (MCI) 
24-30 Normal cognition 
 
Corrections to the score may have to be applied to account for age and 
education level, highlighting a limitation of this test, as a well educated person 
may score highly even when cognitive impairment is present. Equally a less 
educated, cognitively normal person may score in the lower range [31]. 
Consideration of an individual’s hearing, reading, writing and drawing ability is 
also required when interpreting the scores, however despite these limitations, 
the MMSE is a useful tool. The MMSE is also capable of differentiating other 
types of dementia as AD patients typically score lower on orientation than 
Parkinson’s, Lewy body and vascular dementia cases [32]. 
1.2.3  Clinical Dementia Rating (CDR) scale 
The CDR is a scale used to assess the severity of dementia. Developed by 
John Morris in 1997 at the Washington University School of Medicine, a 
structured interview assesses the effects of cognitive loss on everyday activities 
[33]. Memory, orientation, judgement, problem solving, community affairs, 
personal care, home and hobbies are assessed and an algorithm applied to 
obtain a combined score of 0 to 3 as follows: 
Table 1.2: Clinical Dementia Ratio (CDR) scale and interpretation. 
Total Score Dementia  
0 None 
0.5 Very mild 
1 Mild 
2 Moderate 
3 Severe 
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The CDR is capable of detecting very mild cognitive deficits but it is however 
time consuming and a subjective measure. Despite its limitations it is widely 
accepted as a valid tool for assessing cognitive function. 
1.2.4  Alzheimer’s Disease Assessment Scale – Cognitive subscale 
  (ADAS-Cog) 
This test was specifically designed to evaluate the severity of cognitive decline 
and behavioural changes in AD [34] . This test is similar to the MMSE and uses 
a structured scale to probe executive functioning (the ability to carry out daily 
tasks, planning and decision making), memory, attention, language and 
orientation [35]. Executive functioning loss is an early event in AD. 
1.2.5  Neuroimaging 
Neuroimaging is an essential component of dementia diagnosis [35, 36]. 
Structural imaging with computed tomography (CT) or magnetic resonance 
imaging (MRI) is routinely used in the clinical evaluation of patients with AD. 
These techniques are used to exclude other causes of dementia such as 
normal-pressure hydrocephalus, vascular dementia, or intracranial mass. In 
addition, the degree of atrophy can be assessed [37].  
Cortical atrophy is a consistent finding in AD, particularly within the medial 
temporal lobe structures including the hippocampus, amygdala and 
parrahippocampal gyrus [38] (see Figure 1.2). Due to its high resolution (50-
100μm), MRI can assist with diagnosis of AD by assessing specific brain region 
volumes, for example hippocampal atrophy.  
Further, a recent study has shown good correlation between MRI determined 
grey matter volumes and total tau/Aβ levels in cerebrospinal fluid (CSF; a highly 
sensitive differential diagnostic test for AD) and explored the utility of MRI as a 
predictor of CSF total tau/Aβ levels. [39]. Structural changes are likely to be a 
feature of late stage disease and are predicted by functional changes seen with 
positron emission tomography (PET). 
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1.2.6  Positron Emission Tomography (PET) 
PET is an imaging technique that enables three dimensional imaging and 
assessment of functional processes in the body by detecting gamma rays 
indirectly emitted by a positron emitting tracer such as 18F-fluorodeoxyglucose 
(FDG) or Pittsburgh compound B (PiB) [40, 41]. FDG is an analogue of glucose 
and is used to assess metabolic activity and regional glucose uptake, which is 
reduced in regions of the brain in those with AD [35].  
The use of tracers has enabled a more robust differential diagnosis of AD from 
other dementias, due to the identification of the PiB compound ([N-methyl-11C] 
2-(4’-methylaminophenyl)-6-hydroxybenzothiazole). PiB directly binds to Aβ and 
can be used to assess brain Aβ burden [42]. However, individuals can 
accumulate Aβ and remain cognitively stable, and therefore PET imaging can 
facilitate interpretation of other measures but currently cannot be used alone as 
a predictor of cognitive decline (see Figure 1.2).  
In addition, these imaging tests are currently limited to specialist or research 
centres and are expensive to perform, so the need for the development of 
other, cheaper and more accessible predictive tests is crucial.  
This study aims to identify a blood lipid biomarker panel which can facilitate 
development of a definitive diagnostic test ante-mortem. 
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Figure 1.2: Age-matched AIBL Study participants. The AD brain on the right shows cortical 
atrophy and high concentrations of bound PiB (yellow/red), indicating a high amyloid load in 
these regions. The healthy brain on the left shows minimal shrinkage and a small amount of 
bound PiB. 
Image courtesy of Professor Chris Rowe, Austin Health, Heidelberg, Victoria. 
 
1.3  AD Risk factors 
AD can be familial or sporadic. Familial Alzheimer’s disease (FAD) is rare, 
accounting for less than 5% of all cases and symptoms usually manifest before 
age 65. In FAD, the major risk factor is possession of a mutant allele in one of 
three currently identified genes, which is inherited in an autosomal dominant 
fashion. However other as yet undiscovered genes may also be involved [43]. 
The genes currently known to carry mutations in FAD are those coding for APP, 
Presenilin 1 (PS1) and Presenilin 2 (PS2). Following APP cleavage by BACE, 
the membrane-bound complex γ-secretase generates Aβ [9]. The presenilin 
genes code for the presenilin proteins that in association with nicastrin, Aph1 
(anterior pharynx defective-1) and PEN-2 (presenilin enhancer-2) form the γ-
secretase complex [44]. The many mutations identified in these three genes 
represent a fully penetrant risk factor for developing AD, and while rare 
compared to the more common sporadic form, provide a useful model for 
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studying patho-physiological processes. There are several known risk factors 
for sporadic AD; the more common form accounting for over 95% of all cases 
and typically affecting those over 65 years. These known risk factors will be 
discussed below.  
1.3.1  Age  
Advances in medical technology, control of infectious diseases and better living 
standards have resulted in an increase in the elderly population. This ensures 
an increase in age-related degenerative diseases, including age-related 
dementia; of which AD is the most common type. The following graph illustrates 
the advancing age of the Australian population since 1901. 
 
 
 
Figure 1.3: Life expectancy at birth, 1901-10 to 2008-10 in the Australian population. 
The prevalence of AD at age 65 years is estimated to be approximately 5% and 
this rises dramatically to 20% for those over 80 years [3]. The multiple factors 
that are an inevitable part of the ageing process, such as abnormal lipid 
metabolism, mitochondrial defects, inflammation, oxidation, imbalances in 
neurotransmitters and hormones, compromised immune function, reduced 
hepatic detoxification capacity, digestive disorders and nutrient deficiencies, 
likely contribute to AD pathogenesis. 
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1.3.2  Apolipoprotein E ε4 allele (APOEε4) 
The late onset form of AD accounts for the majority of AD cases (as defined 
previously); with age and possession of the APOEε4 genotype being the 
predominant risk factors [45]. In humans the APOE gene is located on 
chromosome 19q13.2 [46] and encodes for a 299 amino acid protein of which 
there are three isoforms; ε2, ε3 and ε4, resulting from the substitution of a 
cysteine with an arginine residue at codons 112 and 158 [47, 48]. Despite the 
amino acid difference at only one or two codons, the effect on risk of developing 
various diseases is quite marked due to conformational changes and the 
influence this has on binding capacity to lipids, proteins and receptors [48, 49]. 
The following table shows allele frequencies in caucasian and Australian 
populations and their influence on disease risk. 
Table 1.3: Apolipoprotein E (APOE) gene frequency and disease risk [50-53]. 
Genotype 
Allele 
Frequency 
Disease Association 
APOEε2    (Cys112 Cys158)   7% 
↑ and ↓ risk for atherosclerosis [54] 
and ↑ risk for Parkinson’s Disease 
[55] 
APOEε3    (Cys112  Arg158) 79% Considered neutral  
APOEε4    (Arg112   Arg158) 14% 
↑ risk for atherosclerosis, AD, 
cognitive impairment,  
↓ hippocampal volume, faster 
progression of multiple sclerosis, 
cerebrovascular disease and sleep 
apnoea [25, 56-61] 
 
Cys: Cysteine, Arg: Arginine. 
 
The locus within an apolipoprotein gene cluster on chromosome 19 was first 
shown to be an AD risk factor in 1993 [25]. ApoE was implicated, based on the 
facts that apoE is present in plaques and NFT, it binds to Aβ, and it is also the 
commonest brain apolipoprotein.  
Further studies then demonstrated a strong allelic association between AD and 
the APOEε4 allele [56, 62]. It is estimated that being homozygous for APOEε4 
increases the risk of developing AD by the age of 75 by ten to thirty times 
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compared to non-carriers of APOEε4 [53]. APOEε2 appears to be protective in 
terms of AD risk [53].  
Apolipoprotein E (apoE) is the protein encoded by these genes and is an 
essential lipid transporter and component of triglyceride rich particles, such as 
chylomicrons and very low density lipoproteins (VLDL). ApoE is required for 
triglyceride catabolism, is involved with cholesterol metabolism in an isoform-
dependent way and transports phospholipids and fat soluble vitamins (see 
Section 1.7 for more details). The importance of apoE was highlighted when it 
was demonstrated that familial dysbetalipoproteinaemia (type III 
hyperlipoproteinaemia) resulted from defects in the APOE gene affecting the 
function of the apoE protein. As clearance of chylomicrons and VLDL is 
impaired, elevated plasma cholesterol and triglycerides result, thereby 
increasing risk of cardiovascular and cerebrovascular disease, which are 
themselves risk factors for AD [63].  
In the central nervous system, apoE is produced by astrocytes and microglia 
and neurons express apoE receptors, which are part of the low density 
lipoprotein receptor (LDLR) family, responsible for lipid transport among brain 
cells [64]. ApoE is a ligand for cell surface lipoprotein receptors, including those 
that chaperone APP and it has been shown to be directly involved in APP 
processing.  
Studies have shown that when apoE is added to cell cultures a decrease in the 
secretion of Aβ is observed, with a rise in the APP C-terminal fragments; 
suggesting inhibition of γ-secretase and a subsequent reduction in Aβ 
generation [65]. There are several known mechanisms for clearing Aβ from the 
brain, and defects in any mechanism will contribute to an increase in brain Aβ 
load. The Aβ peptide can be cleaved directly by proteolytic enzymes, such as 
neprilysin and insulin degrading enzyme (IDE) [66]. Alternatively, Aβ can be 
internalised in apoE containing lipoprotein particles which can bind to low 
density lipoprotein receptor-related protein 1 (LRP1) receptors present on 
microglia, astrocytes and neurons – these particles are then endocytosed and 
transported to lysosomes for breakdown and recycling [67, 68].  
Aβ can also be cleared in a similar manner by receptor-mediated transport into 
the periphery, following binding to LRP1-receptors on the blood brain barrier 
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(BBB). This results in efflux from the brain into the systemic circulation for 
processing by the liver and excretion via the bile [69]. Aβ40 is transported across 
the BBB via LRP1 much faster than Aβ42 [70]. 
The interaction of apoE-associated particles with Aβ peptides may facilitate the 
conversion of soluble to fibrillar Aβ when both apoE particles and Aβ are 
increased [71]. The APOEε4 isoform has the lowest affinity for Aβ binding and 
is the least effective in promoting both Aβ clearance and cholesterol efflux [72]. 
It is also the most immuno-reactive and least antioxidant form; all factors by 
which APOEε4 increases the risk for AD [73]. Recent studies also suggest that 
APOEε4 contributes to Aβ induced apoptosis in neuronal cells by forming a 
reactive intermediate that can insert into the lysosomal membrane causing 
destabilisation and lysosomal leakage [74, 75].  
The APOEε4 allele is associated with high membrane cholesterol levels, which 
therefore promotes amyloidogenic APP processing. APOEε4 is also associated 
with a reduction in mRNA for the neuronal sortilin-related receptor 
(SorLA/LR11), a neuronal sorting protein that reduces APP trafficking to BACE 
and γ-secretase [76].  
The amount of lipid carried by apoE appears to influence Aβ metabolism. Free 
Aβ is efficiently transported across the BBB but this transport is slowed in the 
presence of apoE. In addition, the reduced efflux of Aβ is influenced both by the 
degree of lipidation of the apoE and the isoform, with APOEε4 showing the 
greatest inhibition [77]. Apolipoprotein J, (ApoJ), the other main lipoprotein 
secreted by glial cells, promotes the transport of Aβ across the BBB [70].  
Studies have shown that when Aβ binds to APOEε4 the transport of Aβ is 
redirected from LRP1 to the VLDL receptor (another member of the LDLR 
family) resulting in brain retention of Aβ as the binding affinity of the Aβ-apoE 
complexes is much lower for VLDL receptors compared to LRP1 [77]. 
Polymorphisms in the LRP1 gene itself have also been shown to increase risk 
of AD [78, 79].  
Differences in apoE levels between healthy controls and AD patients have been 
reported in plasma and cerebrospinal fluid (CSF), although the results have 
been inconsistent [80-83]. Plasma apoE levels measured in the highly 
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characterised Australian Imaging, Biomarkers and Lifestyle (AIBL) study of 
ageing cohort have recently been shown to be lower in AD, which also 
correlated to brain Aβ load determined by PiB-PET imaging [84]. 
1.3.3  Diet and Nutrition  
The type and amount of food eaten has a major influence on plasma lipid 
profiles and therefore any lipid biomarker panel. Dietary habits and nutritional 
status are also emerging as key components of chronic degenerative diseases, 
including AD. This is further compounded by the fact that AD is an age-related 
disorder with a general decline of digestive function, absorptive capacity and 
assimilation of nutrients.  
Atrophic gastritis is common in older people and can affect absorption of key 
nutrients such as vitamin B12 and folate [85, 86], which have been associated 
with hyperhomocysteinaemia and increased risk of AD [87, 88]. This can also 
affect protein absorption and therefore the supply of essential amino acids, 
such as tryptophan and tyrosine, which are required for the synthesis of 
neurotransmitters such as serotonin and catecholamines [89].  
There is an age related decline in metabolic rate [90] and coupled with a 
decrease in physical activity, elderly people tend to eat less and may consume 
inadequate micronutrients. Additionally, co-morbidities often exist, requiring 
pharmaceutical agents that may further compromise nutrient status. The well-
established risk factors for developing AD are elevated cholesterol and 
dyslipidaemia, obesity, diabetes, hypertension, depression, cardiovascular and 
cerebrovascular disease (reviewed in [91, 92]), all of which are biochemically 
connected and are influenced by diet and possible nutrient deficiencies.  
An increase in AD incidence is reported in populations who have a high intake 
of saturated fat, trans-fatty acids, refined sugar, processed foods, and total 
calories [93]. High fish consumption is inversely correlated with the 
development of dementia and moderate alcohol consumption appears to offer a 
protective effect [93-95].  
Many studies have confirmed the link between high fat/high sugar (HFS) diets 
and declining cognitive function, strongly suggesting a role for insulin resistance 
and diet-induced endocrine abnormalities [96-99]. Diets that contain high 
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saturated fat, cholesterol, added sugar, including high fructose corn syrup 
(HFCS), and high glycaemic load foods contribute to dyslipidaemia [100, 101]. 
Animal studies have shown that a diet high in fat and refined sugar influences 
brain structure and function via regulation of neurotrophins [102]. Until recently 
it was assumed that the adverse effects of such diets on AD were a direct result 
of the negative influence on insulin sensitivity, metabolism and cardiovascular 
health. While these are major contributing factors, these studies have shown a 
direct effect of such diets on the brain.  
Neuronal plasticity is the brain’s ability to compensate for challenges by 
influencing synapse formation and neurite growth. A HFS diet has been shown 
in animals to decrease brain plasticity via regulation of brain-derived 
neurotrophic factor (BDNF) [102]; a major mediator of neuronal plasticity and 
contributor to learning and memory capabilities [103, 104]. Animals that learn a 
spatial memory task faster have been shown to have more BDNF mRNA and 
protein in the hippocampus, and after feeding a HFS for two months, the 
hippocampal levels of BDNF were reduced and the animals demonstrated 
reduced spacial learning performance [102].  
In contrast to the standard western diet, comprising high fat, high refined sugar, 
low fibre and high salt, the Mediterranean diet has been shown to reduce the 
risk for AD [105, 106]. This eating style focuses on high intakes of vegetables, 
legumes, fruits, cereals and unsaturated fatty acids (mainly as oleic acid 18:1n-
9, the monounsaturated fatty acid found in olive oil). The focus is also on high 
fibre, non-refined carbohydrates, making this a low glycaemic eating plan which 
helps prevent insulin resistance.  
The intake of saturated fatty acids found in animal products is low, and fish 
intake is moderately high. Fish contains high levels of omega-3 fatty acids, 
docosahexaenoic acid (DHA 22:6n-3) and eicosapentaenoic acid (EPA 20:5n-
3). Intake of dairy products is low to moderate, with those being consumed 
mainly in the form of cheese or yoghurt. Meat and poultry intake is also low and 
there is regular consumption of wine, usually with meals [105, 107].  
The Mediterranean diet also contains numerous nutrients and plant 
phytochemicals that are anti-inflammatory, anti-oxidant and beneficial to health. 
For example low dietary intake of antioxidants may contribute to increased 
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oxidative stress, a feature of AD [93, 108]. Some of these nutrients and plant 
phytochemicals are now being shown to have a powerful influence on gene 
transcription factors that influence energy homeostasis, lipid metabolism and 
possibly longevity [109-113]. A meta-analysis involving twelve studies with a 
total of over 1.5 million people, followed for a period of 3 to 18 years showed a 
greater adherence to the Mediterranean eating style was associated with a 
reduced risk of mortality and morbidity, including AD [114]. The beneficial 
effects were seen in many markers of coagulation and inflammation, including 
homocysteine, C-reactive protein, interleukin-6, white cell count and fibrinogen. 
Blood lipids and blood pressure were also affected, all of which are risk factors 
for both cardiovascular disease and AD [115].  
1.3.4  Specific nutrients and AD risk 
The above section discussed general dietary considerations and risk for both 
metabolic disease and AD. Specific nutrient deficiencies in the elderly may 
exacerbate existing pathology in the brain, particularly in the presence of other 
risk factors [116].  
The formation and maintenance of neurons relies on an adequate supply of the 
building blocks and cofactors required for normal functioning of biochemical and 
neurotransmitter pathways, all of which must be obtained from the diet [117]. In 
addition, mitochondrial decay due to oxidation is a feature of brain ageing and 
neurodegenerative disease and an adequate supply of nutrients that protect 
mitochondrial enzymes and mitochondrial membranes is crucial to support 
cellular energy generation and prevent neurological decline [118].  
Vitamins, minerals and other metabolites act as critical cofactors for the 
synthesis of mitochondrial enzymes and other pathways and therefore diets that 
supply inadequate amounts of micronutrients can accelerate mitochondrial 
decay and neurodegeneration [119]. Nutrients supporting mitochondrial function 
include B vitamins, vitamin C, cysteine, ubiquinone (CoQ10), lipoic acid, 
sulphur, iron, copper, zinc, manganese and magnesium [119]. Deficiencies of 
several nutrients have been linked to dementia, including B vitamins, vitamin E, 
vitamin A, zinc, essential fatty acids, vitamin D and magnesium.  
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There have been several studies that have looked at various nutrient 
deficiencies in mild cognitive impairment (MCI). It is probably more ‘useful’ to 
study this group in terms of nutrient deficiencies because of the challenges 
faced in ensuring adequate dietary intakes associated with different stages of 
AD and possibly the increased nutrient requirement of a chronic disease 
process [120-123]. Table 1.4 summarises the effect of various nutrients on lipid 
metabolism and the known association with AD. 
Various nutrients influence lipid metabolism and also have specific effects on 
lipid related AD pathology. The importance of methylation pathways in 
phospholipid, sphingolipid and sterol metabolism is discussed in Section 1.3.5, 
following Table 1.4, as dietary intakes of vitamins B6, B12 and folate influence 
these pathways. Additionally epigenetic modifications controlling gene 
expression can be adversely affected. Abnormal methylation pathways can 
elevate plasma homocysteine levels; a risk factor for developing AD. The 
interaction of dietary choline with phospholipid metabolism will also be 
discussed in Section 1.3.5.. 
 
 
 
 
 
 
 
  
 
  
 
Table 1.4: Summary of specific nutrients involved in lipid metabolism that also influence AD pathology.  
Nutrient Influence on Lipid Metabolism  Influence on AD 
Vitamin B1 
(thiamine) 
Coenzyme for pentose phosphate pathway for production of pentose 
sugars and NADPH synthesis required for fatty acid synthesis [89]. 
High fat diets increase thiamine requirement  [89]. 
Thiamine a cofactor for transketolase, pyruvate dehyrodgenase, α-
ketoglutarate dehydrogenase - involved in energy generation and lipid 
/ glucose metabolism [124]. 
Thiamine dependent processes reduced in AD brain [125, 126]. 
Recent metabolomic study showed up-regulation of pentose phosphate 
pathway in those who progressed to AD [127]. 
Thiamine deficiency associated with dementia [128] and increased CSF 
phosphorylated tau  [129]. 
Nerve cell damage resulting from reduction in these enzymes [124]. 
Thiamine dependent enzymes reduced in AD brain [130-132] causing 
increased oxidative stress. Thiamine deficiency induced oxidative stress 
promotes Aβ accumulation by regulating BACE maturation [133, 134]. 
Vitamin B2 
(riboflavin) 
Precursor of FMN and FAD, redox cofactors for mitochondrial ATP 
generation and therefore lipid metabolism [118]. 
Riboflavin reduces oxidised glutathione, restoring antioxidant capacity 
and prevents lipid peroxidation [135]. FAD is cofactor for MTHFR 
which converts homocysteine to methionine in methylation pathways – 
involved with PL, SL metabolism [118, 136, 137].  
Abnormal ATP production and hypometabolism [135, 138]. 
Reduced glutathione and uric acid and increased homocysteine related to 
cognitive decline [139-141]. 
 
Vitamin B3 
(niacin) 
Required for formation of the ubiquitous redox coenzymes NAD and 
NADP, for mitochondrial ATP generation and numerous other 
biochemical processes involved with lipid metabolism [89]. 
Niacin deficiency and dementia are linked – important for DNA synthesis and 
repair, myelination, dendritic growth, cellular calcium signalling and anti-
oxidation [142-145]. Trials using niacin have shown improvement in cognitive 
scores [145, 146]. 
Vitamin B6 
(pyridoxine),  
 
Vitamin B12  
(cobalamin)  
Folate 
Coenzyme for several reactions in one carbon metabolism, including 
synthesis of PC [136]. SAH in methylation pathway is a potent inhibitor 
of PEMT, required for PC production [147]. 
Adenosylcobalamin (Vit B12 metabolite) is a mitochondrial cofactor for 
the production of succinylCoA for preventing incorporation of odd 
chain fatty acids into PLs and SLs [148]. 
Folate is associated with DHA release from the liver via PC and tissue 
concentrations of DHA are associated with folate status [149]. 
Nutrient insufficiency can increase plasma homocysteine, a risk factor for AD 
[139, 150, 151]. Abnormal methylation can increase gene expression of highly 
methylated APP, leading to increased Aβ production [152, 153]. 
Important for preventing incorporation of odd chain fatty acids into myelin 
which can affect nerve conduction [148]. 
In animals dietary folate deficiency causes depletion of DHA in neural tissue 
[154]. 
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Vitamin E 
(tocopherols) 
Prevents lipid peroxidation [155, 156]. Transported by PLTP to tissues; 
our studies show lower PLTP activity levels (unpublished data – see 
Chapter 5). Intracellular accumulation of ceramides and cholesterol 
can be blocked by vitamin E [157]. 
Gene array studies in rats have associated vitamin E deficiency with 
down-regulation of genes involved with lipid metabolism and Aβ 
clearance, including growth hormone, thyroid hormones, melatonin 
and dopaminergic neurotransmission [158]. 
Lower levels associated with AD [159]. In neuronal cultures vitamin E inhibits 
Aβ-induced lipid peroxidation and cell death [160, 161]. 
Elevated ceramides and cellular cholesterol abnormalities are a feature of AD 
[162-164]. 
Genes affecting Aβ clearance and advanced glycation end products are down-
regulated in vitamin E deficiency [165]. 
Zinc Cofactor for desaturase enzymes involved in PUFA metabolism [166-
168]. 
Insulin degrading enzyme is a zinc metallopeptidase, which breaks down Aβ 
[169]. 
Vitamin D Linked to insulin sensitivity [170]  and sex steroid  production [171, 
172]. 
Vitamin D up-regulates NPD1 production from DHA and GDNF, promoting 
neuronal survival [173]. 
Vitamin A Studies in rats have shown vit A deficiency decreases liver content of 
PLs [174], probably due to lower PC synthesis and reduced availability 
of fatty acids. This may be explained by low activation by the Retinoid 
X receptor (RXR) of peroxisome proliferator-activated receptor α 
(PPARα) which regulates lipid metabolism [175]. Affects delivery of 
PLs to other tissues. 
Essential cofactor for protein kinase C-delta (PKC-delta), a nutritional 
sensor regulating energy homeostasis [176]. 
Vitamin A involved in production of α-secretase and acetylcholine reduces 
excessive microglial activation [177, 178]. Retinoic acid is a powerful modulator 
of excessive inflammation via suppression of IL-6 and TNFα, both of which are 
induced by Aβ [178]. 
Vitamin A insufficiency may contribute to the hypometabolism seen in AD [176, 
179]. 
 
Abbreviations: ATP: Adenosine Triphosphate, APP: Amyloid Precursor Protein, BACE: Beta site APP Cleaving Enzyme, CSF: Cerebrospinal Fluid, DHA: 
Docosahexaenoic Acid, DNA: Deoxyribonucleic Acid, FAD: Flavin Adenine Dinucleotide, FMN: Flavin Mononucleotide, GDNF: Glial Derived Neurotrophic 
Factor, IL-6: Interleukin 6, MTHFR: Methylenetetrahydrofolate Reductase, NAD: Nicotinamide Adenine Dinucleotide, NADP: Nicotinamide Adenine 
Dinucleotide Phosphate, NPD1: Neuroprotectin D1, PC: Phosphatidylcholine, PEMT: Phosphatidylethanolamine Methyl Transferase, PL: Phospholipid, PLTP: 
Phospholipid Transfer Protein, PUFA: Polyunsaturated Fatty Acid, NADPH:  Reduced Nicotinamide Adenine Dinucleotide Phosphate, SAH: S-adenosyl 
Homocysteine,  SL: Sphingolipid, TNF-α: Tumour Necrosis Factor alpha. 
 
2
1
 
Chapter 1: Review of the Literature – Lipids and AD 
 
22 
 
1.3.5  Homocysteine, choline and methylation pathways 
Homocysteine is a sulphur containing amino acid that exists at a critical 
biochemical intersection in the ubiquitous methionine cycle, whose function is to 
generate one carbon methyl groups for transmethylation reactions and  
synthesise  cysteine and taurine [155] (see Figure 1.4). Methionine is converted 
to S-adenosyl-methionine (SAMe), which is the most important methyl donor in 
the body and is critical for stabilising many macromolecules such as myelin and 
DNA. Methylation of DNA is an epigenetic modification that controls gene 
expression, including the highly methylated APP gene [152]. Methylation via 
SAMe is involved with synthesis of numerous compounds including  
phosphatidylcholine, melatonin, serotonin, nor-adrenalin, Coenzyme Q10 and 
carnitine [136]. SAMe is a crucial component of both phase I and phase II 
detoxification pathways in the liver, providing the methyl group directly. In 
addition a balanced methionine cycle is required to supply taurine for bile acid 
synthesis and cysteine for both sulphur conjugation and for the formation of 
glutathione, which is both an antioxidant and a vital phase I and II component 
[136]. All these processes are crucial for both normal neurological and normal 
metabolic function.  
The link between elevated homocysteine and AD risk has been firmly 
established in several studies [139, 150, 151] and homocysteine levels are also 
correlated to vitamin B6, B12 and folate status [180-182], but the exact 
mechanisms behind the elevated homocysteine and connected metabolites 
remain to be fully elucidated. It is probable that elevated homocysteine 
promotes AD by more than one mechanism and that while homocysteine serves 
as a surrogate marker for nutrient status; which when deficient can promote 
neurological damage in its own right, evidence suggests that homocysteine has 
direct actions on the brain. Cerebral microangiopathy has been demonstrated in 
stroke associated hyperhomocysteinaemia [183] and endothelial dysfunction, 
oxidative damage and neuronal DNA damage are all reported consequences of 
elevated homocysteine [184-186]. There also appears to be an enhancement of 
Aβ mediated neurotoxicity and apoptosis where homocysteine levels are 
elevated [187, 188] and homocysteic acid, which is a metabolite of 
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homocysteine, is possibly an NMDA agonist itself, causing excitotoxicty and 
apoptosis [189, 190].  
 
Figure 1.4: Methylation pathway depicting interaction with phospholipids and 
sphingolipids. After donating the methyl group SAMe is converted into homocysteine via S-
adenosylhomocysteine (SAH). The homocysteine is then broken down by one of three 
pathways. Firstly it can be converted back to methionine by accepting a methyl group from 
methylcobalamin (vitamin B12), secondly, it can be converted to methionine by accepting a 
methyl group from trimethylglycine (betaine) or thirdly it can be converted to cysteine and 
taurine via serine and activated vitamin B6 [155].  The catabolism of homocysteine depends on 
an adequate supply of vitamin B6, folate and vitamin B12. The majority of the essential nutrient 
choline is present in phosphatidylcholine (PC) and sphingomyelin (SM), major components of all 
cell membranes. Additionally, PC and SM are precursors for the signalling molecules ceramide, 
platelet activating factor and sphingophosphorylcholine [137]. Choline is required for synthesis 
of the neurotransmitter, acetylcholine and as it is oxidised to betaine (trimethylglycine), plays a 
crucial role as a methyl donor in the methionine/homocysteine pathway. 
 
The conversion of S-adenosylhomocysteine (SAH) to homocysteine is a 
reversible reaction and so elevated homocysteine can also lead to an increase 
in SAH which is a potent inhibitor of methyltransferase enzymes (including 
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phosphatidylethanolamine methyltransferase (PEMT) required for 
phosphatidylcholine (PC) production), further reducing the capacity of SAMe to 
participate in methylation reactions: This adversely affects numerous 
biochemical processes [147]. The APP gene is highly methylated and 
decreased methylation may increase expression leading to increased Aβ 
production [152, 153]. A link between elevated SAH and polyunsaturated fatty 
acid metabolism has also been established in AD [191]. The connection 
between homocysteine and lipid metabolism has been further highlighted as 
homocysteine-induced endoplasmic reticulum stress interferes with 
phospholipid metabolism. This has the effect of activating sterol regulatory 
element binding proteins (SREBPs) associated with increased expression of 
genes involved with cholesterol and triglyceride uptake and intracellular 
accumulation of cholesterol (see Section 1.5) [192]. A regulatory feedback 
circuit has been identified where SREBP-1 controls the production of SAMe and 
therefore PC production, which is dependent on methylation reactions, and 
giving merit to the notion that nutritional or genetic factors limiting the production 
of SAMe or PC, may activate SREBP-1 and contribute to metabolic dysfunction 
[193]. The inhibition of methyltransferase enzymes by SAH is very important in 
the brain as the alternate pathway for homocysteine catabolism via 
trimethylglycine (betaine) has no activity [87] (see Figure 1.4). Central nervous 
system cells can’t export SAH and therefore conversion to homocysteine and 
extracellular transport is the only way to remove SAH, causing a subsequent 
rise in plasma homocysteine. This raises the possibility that SAH could be the 
toxic metabolite, at least in some tissues [147] and that the question of elevated 
homocysteine and increased disease risk has been difficult to answer with 
certainty.  
Dietary fat and cholesterol are transported to the liver via chylomicrons and then 
packaged into VLDL in the liver for delivery to other tissues. PC is an essential 
component of these lipoproteins and deficiency of choline and PC results in fat 
accumulation in the liver. Requirement for choline depends on the status of 
other methyl group donors such as folate and SAMe. When dietary choline is 
inadequate, the liver has a back-up pathway to provide choline from PE via a 
three step methylation pathway by SAMe; a reaction catalysed by 
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Phosphatidylethanolamine-N-methyl transferase (PEMT) [194]. Deficiencies of 
nutrients involved in this pathway, could reduce the availability of choline. 
Interestingly, oestrogen induces endogenous synthesis of choline by 
upregulating PEMT, which may put postmenopausal women at risk of choline 
deficiency, when dietary intakes are inadequate [195]. Additionally disturbed 
choline transport is suggested to play a role in various neurological disorders, 
including AD [196]. Loss of cholinergic neurons is a feature of AD and various 
choline transporters have been investigated as potential targets for increased 
choline delivery to the neurons for acetylcholine synthesis [196-198]. Studies 
have shown that one of the choline transport systems in erythrocytes is 
abnormal in patients with AD [199]. 
1.3.6  Dietary fatty acids 
Apart from dietary fatty acids being an energy generating nutrient, the amount 
and type of fat is important for determining disease risk due to the diverse 
function of lipids in general; the structure and function of which is influenced by 
the fatty acids they contain. It has already been stated that the Mediterranean 
style diet, which is low in saturated fat and cholesterol, high in monounsaturated 
and polyunsaturated fats and low glycaemic load is beneficial. High saturated 
fat intake is strongly associated with the development of dyslipidaemia, insulin 
resistance, obesity, diabetes, vascular disease and metabolic abnormalities; all 
risk factors for AD [200-202]. Saturated and trans fatty acid intakes are 
positively correlated with increased cholesterol levels and unfavourable shifts in 
low density lipoprotein: high density lipoprotein (LDL:HDL) ratios [203-205]. 
Excess palmitic acid can also upregulate ceramide production, which is 
considered a major contributor to dyslipidaemia and insulin resistance [206, 
207] (see Figure 1.15).  
The most commonly consumed fatty acids are myristic (14:0 – 14 carbon chain 
length with no unsaturated/double bonds), palmitic (16:0), stearic (18:0), oleic 
(18:1) and linoleic (18:2). Each of these fatty acids affects plasma cholesterol 
levels differently due to their impact on the LDL receptor, the activity of which is 
regulated by the sterol content of the cell via SREBP [89]. When the sterol 
content of the cell is low, a fragment of SREBP is cleaved by a protease which 
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acts as a transcription factor to activate the LDL receptor gene. Dietary fatty 
acids and cholesterol can increase the sterol regulatory pool by their effects on 
the enzyme acylCoA-cholesterol acyl transferase (ACAT) [202, 208]. The 
activity of this enzyme is determined in part by the amount and type of dietary 
fatty acid, which therefore affects plasma cholesterol levels [89]. The saturated 
fatty acid, palmitic acid partially inhibits cholesteryl ester (CE) formation by 
ACAT, therefore increasing the amount of free cholesterol. As the sterol 
regulatory pool increases, SREBP cleavage is inhibited leading to the reduced 
expression and activity of the LDL receptor. In contrast, if the liver cells are 
enriched with monounsaturated fats (MUFA) and polyunsaturated fats (PUFA), 
ACAT activity is increased as it is a preferred substrate and CE formation is 
promoted [209]. Short and medium chain saturated fatty acids (4:0, 6:0, 8:0 and 
10:0), are rapidly oxidised to acetyl CoA in the liver and do not alter the 
concentration of free cholesterol or cholesteryl esters and therefore have no 
effect on the LDL receptor. Stearic acid (18:0) has been shown to be neutral in 
respect to its effect on plasma cholesterol levels and saturated fatty acids in 
general inhibit CE formation and reduce LDL receptor number and activity, 
therefore increasing plasma cholesterol levels [202].  
Dietary trans fatty acids are known to contribute to dyslipidaemia and 
associated increased disease risk [210] and have been linked to brain ageing 
and impaired cognition [211, 212]. Most naturally occurring fatty acids have 
double bonds in a cis configuration which allows the chain to bend. The trans 
bond imparts a rigid structure which is similar to saturated fatty acids and 
increased consumption from processed and fast foods can lead to 
dyslipidaemia [210] [213]. Trans fatty acids alter membrane fluidity and 
responses of various membrane receptors through their incorporation into 
membrane phospholipids. As fatty acids are ligands for nuclear receptors, such 
as peroxisome proliferator activated receptors (PPARs), liver X receptor (LXR) 
and SREBP, regulation of gene transcription can be altered [214-216], directly 
modulating metabolic and inflammatory responses in an adverse way. The 
effects on lipid metabolism are due to several mechanisms. Firstly, trans fatty 
acids alter the secretion, composition and size of apolipoprotein B-100 
produced in the liver. This decreases the rate of LDL catabolism. The 
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catabolism of ApoAI is increased, which reduces plasma HDL cholesterol. 
Trans fatty acids increase the cellular accumulation and secretion of free 
cholesterol and cholesterol esters by the liver [217]. The effects on reducing 
HDL are thought to be due to an increase in cholesteryl ester transfer protein 
(CETP) which transfers cholesterol esters from HDL to LDL and VLDL [218]. 
Additionally the fluidity, determined by the fatty acid at the sn-2 of PC is a major 
regulator of lecithin:cholesterol acyltransferase (LCAT), which is required for the 
formation of mature HDL. Trans fatty acids reduce fluidity and can therefore 
reduce activity of LCAT [219].  
Lipids form the membrane bilayer and are important signalling molecules via the 
generation of second messengers [63, 89]. The diet provides fatty acids, or the 
precursors for their synthesis, and therefore influences structure and function of 
all lipids. Of particular importance are the long chain polyunsaturated fatty acids 
(PUFAs) and the ratio of the omega-3 and omega-6 series, which have 
opposing effects in terms of the signalling molecules generated. They are 
competitive substrates for the enzymes involved in PUFA metabolism [89], 
which makes the relative amounts important in terms of the signals generated. 
The PUFAs are converted via the action of cyclooxygenase and lipoxygenase 
enzymes to prostaglandins, leukotrienes, thromboxanes and other metabolites 
which are important mediators of cellular function and therefore the signalling 
molecules generated are partly influenced by dietary intakes [220].The omega-6 
fatty acids are more inflammatory, atherogenic and pro-thrombotic than the 
omega-3 series [89].There are two essential fatty acids that have to be obtained 
from the diet as humans lack the delta-12 and delta-15 desaturase enzymes to 
produce them from other fatty acids [221, 222]. Linoleic acid (18:2n-6) is 
abundant in plants, seeds and nuts and is the precursor for the omega-6 series 
of eicosanoids. Alpha-linolenic acid (ALA) (18:3n-3) is the precursor for the 
important eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
which is the most abundant PUFA in the central nervous system (CNS), and is 
particularly associated with phosphatidylethanolamine species [223].  
Deficiency of the essential fatty acids is rare, but conversion of ALA by the 
action of elongase and desaturase enzymes to the longer chain PUFAs is 
limited and also affected by hormone imbalances, diet and nutrient deficiencies 
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[224-226]. High intakes of omega-6 fatty acids and arachidonic acid (AA) from 
meat can elevate pro-inflammatory eicosanoids and up-regulate pro-
inflammatory cytokines. Levels of the non-enzymatically derived isoprostanes, 
which are vasoconstrictive, are also elevated in AA enriched diets [227]. 
Conversely, diets enriched in DHA from fish and fish oil are more anti-
inflammatory, anti-thrombotic and vasodilatory and have neuroprotective effects 
in terms of synaptic function and plasticity via generation of docosanoids [220, 
228]. The ratio of dietary AA to DHA would appear to influence several 
diseases, including AD, and may be important in designing nutrition-based 
strategies for disease prevention [229]. The brain relies on a supply of AA and 
DHA from the periphery, which are delivered via plasma lipoproteins and 
lysophospholipids. Unesterified AA and DHA can also enter the brain where 
they are esterified into the sn-2 position of phospholipids following activation by 
long chain fatty acyl CoA synthase (LC-FACS) [89].  
DHA and EPA are important in reducing plasma triglyceride levels as they 
regulate the activity of various nuclear receptors resulting in a repartitioning of 
fatty acids away from storage as triglycerides and towards oxidation. These 
receptors include LXR, hepatocyte nuclear factor 4α, farnesoid X-activated 
receptor (FXR), and PPARs. Each of these receptors is in turn regulated by 
SREBP-1c [230]. EPA and DHA reduce SREBP-1c which is the main genetic 
switch controlling lipogenesis. This reduces the amount of free fatty acids 
available for VLDL synthesis. EPA and DHA are highly unsaturated and are 
prone to peroxidation which stimulates the degradation of apolipoprotein B 
(ApoB), required for VLDL synthesis and their presence in lipoproteins may also 
enhance postprandial chylomicron clearance by stimulating lipoprotein lipase 
activity [230]. 
The carbohydrate responsive element binding protein (ChREBP) is a 
transcription factor that responds to glucose levels and is involved in hepatic 
lipid synthesis by the transcription of genes involved in lipogenesis, such as 
fatty acid synthase and acetylCoA carboxylase [231]. ChREBP activity can be 
inhibited or normalised by omega-3 fatty acids [230, 231]. 
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1.3.7  Dietary Carbohydrates 
The amount and type of dietary carbohydrate has a significant impact on lipid 
profiles and the risk of developing AD risk factors such as cardiovascular 
disease and type 2 diabetes. Long term consumption of high glycaemic load, 
refined carbohydrates and simple sugars can lead to insulin resistance and 
metabolic syndrome [101, 232]. Insulin resistance and metabolic syndrome are 
also known risk factors for dyslipidaemia and AD. Insulin resistance results in 
an atherogenic lipid profile which also includes a decrease in LDL particle size 
and a postprandial accumulation of triglyceride rich remnant lipoproteins. 
Adipose tissue becomes resistant to the anti-lipolytic effects of insulin which 
increases the concentration of circulating free fatty acids. The combination of 
high insulin and free fatty acids acts on the liver to increase the synthesis and 
secretion of VLDL causing hypertriglyceridaemia. Once the plasma triglyceride 
pool is increased the transfer rate of cholesterol ester by CETP from HDL to 
VLDL increases. This then reduces the HDL levels. The fractional catabolic rate 
of apolipoprotein A-1 is also increased with high triglycerides [233-235]. The 
composition of the LDL particles is also abnormal in insulin resistance as 
cholesterol ester depletion results in a small dense LDL [236]. This is due to the 
action of CETP which mediates the exchange of VLDL triglyceride for 
cholesterol ester in LDL. This triglyceride rich, cholesterol ester depleted LDL 
interacts with lipoprotein or hepatic lipase which hydrolyses the triglyceride to 
produce small, dense LDL [236]. Excess consumption of simple sugars, 
including fructose, can also have adverse effects on lipid metabolism. The liver 
rapidly absorbs and metabolises fructose and exposure to large amounts of 
fructose leads to lipogenesis and triglyceride accumulation. The accumulation of 
triglycerides contributes to reduced insulin sensitivity, hepatic insulin resistance 
and impaired glucose intolerance [237] .  
From Section 1.3.3 it is clear that diet and specific nutrients contribute to AD 
risk indirectly by increasing AD related risk factors such as cardiovascular 
disease and type 2 diabetes, but also contributing directly to many lipid-related 
processes involved in AD pathology. 
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1.3.8  Lifestyle 
Apart from dietary considerations, data from observational studies indicate that 
several lifestyle factors can reduce the risk of developing AD (reviewed in [238, 
239], including physical activity, mental stimulation, being a non-smoker, and 
social interaction. Intensity of physical activity has been investigated and 
positively associated with improved cognition [240] whilst higher levels of total 
physical activity have been shown to be linked to biological and imaging 
markers of AD [241]. Being physically active has known beneficial effects on 
body composition, insulin sensitivity and lipid profiles. Although a topic of 
intense scientific debate, the beneficial effects of physical activity on metabolic 
disease and ageing are thought to be mediated via sirtuins (SIRTs) [242]. 
SIRTs are NAD-dependent histone deacetylases which are activated by cellular 
stresses to enhance cellular defense and repair pathways and to mediate 
adaptive responses to changing energy requirements and physical activity. This 
is achieved by deacetylation and transcriptional control of numerous genes 
involved in lipid and glucose metabolism [243]. Additionally Sirt1, has been 
shown to attenuate amyloidogenic processing of APP both in cell culture 
models and in transgenic mice [244, 245], suggesting a possible mechanistic 
link between physical activity and improved markers of AD pathology. 
1.3.9  Hormones 
As balance and levels of hormones inevitably changes with ageing, many 
studies have examined the role of hormones in the pathogenesis of AD. Due to 
the highly integrated nature of the endocrine system, the metabolic, 
reproductive, adrenal, thyroid, gut-derived, adipocyte-derived and appetite 
regulating hormones all have a role to play in terms of their direct effects on AD 
pathology, but also their indirect effects due to altered metabolism. Specifically, 
all these hormones have a marked effect on lipid homeostasis. 
1.3.10  Sex Steroids and Gonadotropins  
The first clue as to hormonal involvement in AD is the reported gender 
differences in AD risk, with a higher prevalence reported in women, although in 
general women have a greater life expectancy [246, 247]. This observation also 
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appears to be study group specific with gender differences being reported in 
Swedish, Chinese, French and European populations but not within several 
large American studies, including the Framingham and Rochester studies [248]. 
This highlights the complex nature and long duration of the neurodegeneration 
seen in AD, with associated co-morbidities and hormonal influences 
complicating the picture. It has also been reported that AD pathology and 
cognitive deficits are more severe in women, which has prompted the 
investigation of sex steroids and risk of AD [249, 250]. The results of studies 
into the use of hormone replacement therapy in women to reduce the risk of AD 
have been conflicting. The Women’s Health Initiative Memory Study (WHIMS) 
showed an almost two-fold increased risk of AD and deficits in cognitive 
functioning in older women (over 65 years), but with no effect in younger 
women [251, 252]. The Women’s Health Initiative Memory Study of Younger 
Women (WHIMSY), included 1326 participants, and concluded that hormone 
therapy given to postmenopausal women at ages 50-55 years resulted in no 
differences in global cognitive function scores or individual cognitive domains 
[252]. Some studies of women who had been on hormone replacement (HRT) 
in their 50s found that the HRT did reduce the risk of dementia (whereas there 
was no effect if the women in the studies were in their 70s), suggesting that 
oestrogen needs to be taken early, perhaps to reduce early pathogenic 
mechanisms. Several reasons for these conflicting results include the type of 
hormone used, form of delivery and the combination with progesterone. Many 
past studies have used conjugated equine oestrogens and/or synthetic 
progestins. Studies are required that use bio-identical forms of these hormones. 
A recent systematic review of data recommended that hormone therapy should 
not be used for dementia prevention [253]. Animal studies into the non-
reproductive roles of oestrogen have highlighted neuroprotective and 
neurotrophic/synaptic plasticity roles and effects on attenuating Aβ 
accumulation [249]. In premenopausal women, oestrogen may protect against 
dietary choline deficiency because oestrogen induces the endogenous 
synthesis of choline from PE via the enzyme PE methyl transferase (PEMT) 
[195].  
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Testosterone has also been shown to have similar neuroprotective properties, 
which are likely mediated by the direct action of dihydrotestosterone (DHT) or 
via aromatisation to oestrogen [250]. Further, an age related decline in 
testosterone production occurs normally after about the third decade which 
correlates with cognitive decline. Sex steroid production is regulated by the 
complex feedback loops of the hypothalamic-pituitary-gonadal axis (HPG), 
involving the pituitary gonadotrophins, luteinising hormone (LH) and follicle 
stimulating hormone (FSH). Increasing gonadotrophin levels, as occurs with 
age, are now being shown to contribute to AD, with APP processing and Aβ 
production, and neuronal cell cycle abnormalities reported [254-256]. A recent 
study investigating the association between gonadotrophins, testosterone, 
plasma Aβ levels and brain amyloid burden (as determined by PiB retention) in 
the AIBL cohort, demonstrated involvement of testosterone and LH at different 
stages of disease in men and recommended consideration of their effects when 
investigating other potential biomarkers for AD [257].  
1.3.11  Metabolic Hormones 
In recent years numerous reports have highlighted the strong relationship 
between dementia and metabolic disorders that include dyslipidaemia, obesity, 
diabetes, cardiovascular disease and hypertension (reviewed in [179, 258-
262]). While the mechanisms that underpin this association are beyond the 
scope of this chapter, it is important to emphasise that the above conditions 
rarely occur in isolation, and the complex network of metabolic dysfunction 
which occurs in these conditions has been shown to influence many aspects of 
AD pathogenesis and neurodegeneration. For example, insulin is required for 
blood glucose regulation in the periphery and the brain. When peripheral insulin 
resistance (IR) develops metabolic dysfunction results and brain insulin 
signalling is altered affecting glucose utilisation, Aβ and tau pathology, 
vasculature, mitochondrial function, inflammation, oxidation, neuronal 
maintenance and plasticity [98, 179, 263, 264]. A neurodegenerative cycle 
consisting of AD pathogenesis, insulin resistance and inflammation has often 
been described. The components of this cycle have elevated ceramide levels 
as a common factor, suggesting these toxic lipids may represent the link 
between all these pieces of the AD puzzle [207, 265]. The literature is teeming 
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with reports and studies into the effects of hormones on AD, with virtually all 
known metabolic hormones being involved, including insulin, thyroid, cortisol 
(and other non-sex steroids), growth hormone, leptin, ghrelin, adiponectin and 
vitamin D to name a few. For example, thyroid hormones have a profound effect 
on lipid profiles [266] and direct effects on cognition [267] and patients with AD 
and other neurodegenerative diseases have chronically elevated cortisol levels, 
suggesting dysregulation of the hypothalamic-pituitary-adrenal axis [268]. 
Furthermore, leptin is an adipose tissue-derived hormone, involved in energy 
storage and availability, and the hormone orexin (also called hypocretin) is a 
neurotransmitter that regulates arousal, wakefulness, and appetite; and orexin 
dysregulation, insulin resistance and  leptin resistance, which can all occur with 
obesity, have all been linked to neurodegeneration [269].  
1.4  Lipids and Lipidomics 
Lipidomic approaches have greatly improved understanding of the mechanisms 
of disease and have lead to the development of biomarkers and therapeutic 
strategies for a wide range of conditions including cardiovascular disease, 
metabolic disease and cancer [270-272]. Altered lipid metabolism has clearly 
been established as a contributor to neurodegenerative disease. The nervous 
system has the second highest concentration of lipids, exceeded only by 
adipose tissue. Lipids in the nervous system also show enormous structural 
diversity and by studying lipid profiles, insight into the biochemical pathways 
that alter levels of individual species is obtained, leading to a greater 
understanding of pathology. The lipid profiling part of this project for the 
identification of a lipid blood biomarker focuses on analysing phospholipid and 
sphingolipid species.  
Cell membranes are dynamic and require continuous remodelling of 
phospholipids for function. A major factor determining the shape of 
phospholipids is the nature of the side group and the fatty acids linked to sn-1 
and sn-2 positions of the glycerol backbone (see Figures 1.5 and 1.6). The 
length of the carbon chain and number of double bonds of the fatty acid 
determines the length and shape. The molecular shape of the phospholipid in 
the membrane bilayer is also influenced by the compatibility between the size of 
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its polar head group and the hydrophobic tail [273]. A huge variety of lipid 
species arise from the various combinations of fatty acids with backbone 
structures such as glycerol and sphingoid bases [274] (see Figures 1.5 and 
1.6). The most common class of lipids consist of fatty acids linked by either an 
ester bond to glycerol (a trihydric alcohol) or other alcohols such as cholesterol 
or by amide bonds to sphingoid bases. In addition they may contain alkyl 
moieties other than fatty acids, phosphoric acid, organic bases, carbohydrates 
and various other components, which can be released by various hydrolytic 
processes [275]. 
 
PE:Phosphatidylethanolamine, PC: Phosphatidylcholine, PG: Phosphatidylglycerol, PI: 
Phosphatidylinositol, PS: Phosphatidylserine, PA: Phosphatidic Acid. 
Fig 1.5: General structure of phospholipids. The fatty acids at positions sn-1 and sn-2 can 
vary in chain length and number of double bonds. In this example, the fatty acid at the sn-1 
position contains 16 carbon atoms and has no double/unsaturated bonds (palmitic acid). The 
example at the sn-2 position contains 18 carbon atoms and has 4 unsaturated/double bonds 
(stearidonic acid). The linkage of the sn-1 acyl group determines the subclass. i.e. ester linkage 
forms phosphatidyl species, where a vinyl ether linkage forms the plasmenyl or plasmalogen 
species. The linkage of the side group to the phosphate (P) group at the sn-3 position 
determines the phospholipid species. If X=ethanolamine, phosphatidylethanolamine (PE) or 
ethanolamine plasmalogen will be formed. 
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Fig 1.6: General structure of sphingolipids. The fatty acid can vary in chain length and 
number of double bonds. In this example the fatty acid has 16 carbon atoms (C) and no 
unsaturated/double bonds (palmitic acid). The group attached at X determines the sphingolipid 
species. For example if X is hydrogen, ceramide is formed. 
 
It is evident that many neurological disorders involve complex interactions 
between proteins and lipids, and in AD, lead to the increased formation of 
protein deposits [276]. A key development in the study of lipids and 
neurodegenerative disease has been in the advancement of technologies to 
determine profiles of lipids and their interacting partners. This is of major 
importance, as it is known that cellular signalling and membrane trafficking are 
often regulated by peripheral proteins, which reversibly interact with membrane 
lipid molecules in highly regulated spatial and temporal fashions. Lipidomic 
research has particular relevance to biomarker development. In the case where 
there is great overlap with AD and other conditions involving altered lipid 
metabolism, such as cardiovascular disease and diabetes, there are new 
technologies that may help distinguish between them, including computational 
biology, cellular lipid mapping, and single molecule imaging [270, 277]. This will 
be of value as specific lipid classes and sub-classes are believed to play an 
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important role in AD, and many changes in brain lipid composition have been 
reported [273]. 
1.5  Lipidomics and AD 
The specific relevance of each lipid class and their contribution to known 
pathological processes in AD will be described in the following sections. It is 
apparent that disturbances in lipid metabolism in general have an effect on AD 
pathology and the discovery of blood lipid biomarkers may help predict some of 
these pathological changes at an early stage of disease or even pre-clinically.  
1.5.1  Lipids, APP processing and Aβ 
Amyloid precursor protein (APP) is a transmembrane protein expressed by 
many tissues and is concentrated in the synapses of neurons [278]. While its 
primary function remains to be elucidated it is thought to be involved with 
synapse formation, neural plasticity and iron export [279, 280]. APP expression 
is up-regulated during neuronal differentiation, following neural injury and this 
protein is involved in cell surface protein signalling [278]. APP has also been 
shown to have ferroxidase activity which catalyses the oxidation of iron during 
iron transport. Accumulated Aβ may trap zinc, which inhibits this enzyme and 
subsequent transport of iron. Imbalances in redox metals are a contributor to 
increased oxidative stress and AD pathology [280]. As previously mentioned in 
Section 1.1.2, APP can be processed by two different pathways, depending on 
the localisation of APP to lipid rafts and feedback loops controlling gene 
transcription for the appropriate enzymes (see Figure 1.7); processes which are 
influenced by membrane composition. 
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α: α-secretase, β: Beta site APP cleaving enzyme, γ: γ-secretase, N and C: N and C terminals 
of APP, AICD: APP intracellular domain, C99: carboxyterminal fragment (CTF) 99, C83: CTF 
83, APPsβ and APPsα: secreted APP β and α respectively, NPD1: neuroprotectin D1, LTP: 
long term potentiation, LRP1: LDL-receptor related protein 1. 
 
Figure 1.7: APP processing - The non-amyloidogenic and amyloidogenic pathways and 
relationship to cholesterol. The non-amyloidogenic processing of APP involves cleavage by α 
and γ secretases resulting in generation of a secreted form of APP (APPsα), CTF83, AICD and 
P3. APPsα has neuroprotective properties via its effect on NPD1 production, enhancing LTP 
and neurite outgrowth. The amyloidogenic processing of APP involves cleavage by β and γ 
resulting in generation of secreted APPβ (APPsβ), CTF99 and Aβ. Under certain conditions the 
Aβ42 can be overproduced or inefficiently cleared. A toxic cascade of neuro-inflammation and 
oxidation ensues resulting in neuronal death. The AICD can translocate to the nucleus to 
suppress or transcribe several genes. By suppression of LRP1 it may act as a cellular 
cholesterol sensor. The biological relevance of the CTFs and P3 remain to be determined. 
 
LRP1 
? cholesterol sensor 
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The APP protein undergoes proteolytic cleavage (see Figure 1.7) in the non-
amyloidogenic pathway by α-secretase or in the amyloidogenic pathway by beta 
site APP cleaving enzyme (BACE), formerly known as β-secretase [281]. In 
both cases, initial cleavage is followed by an additional cleavage by γ-secretase 
[282]. Several enzymes including ADAM 10, ADAM 17 (a disintegrin and 
metalloproteinase 10 or 17) and TACE (tumour necrosis factor α-converting 
enzyme) show α-secretase activity [9]. α-secretase cleaves within the Aβ 
domain of APP liberating a soluble APP fragment (APPsα), which precludes the 
formation of Aβ and has neurotrophic and neuroprotective properties [282]. The 
soluble APP fragment (APPsα) is thought to be neuro-protective by promoting 
neuronal cell survival and repair following cellular injury. An up-regulation of the 
enzymes phospholipase A2 (PLA2) and/or 15-lipoxygenase, required for the 
biosynthesis of DHA-derived neuroprotectin D1 (NPD1), may elicit this 
neurotrophic activity and represent a complimentary cell survival mechanism 
activated early in AD pathogenesis [283]. APP is processed by BACE and γ-
secretase in the amyloidogenic pathway to release the Aβ peptide. Under 
certain conditions these peptides can become potent, self aggregating 
neurotoxins when they accumulate as a result of increased production or poor 
clearance [13]. The fate of APP in terms of processing is determined by its 
location within the cell membrane and cellular compartments and the up-
regulation of enzymes in response to various signals, which in turn appear to be 
influenced by factors including genetic make-up, diet, nutritional status, lifestyle 
and hormonal status.  
APP clusters in cholesterol-rich lipid rafts in the membranes of neurons, 
astrocytes and microglia [284]. Lipid rafts are domains within the plasma 
membrane bilayer consisting of cholesterol, glycosphingolipids and protein 
receptors. These specialised regions compartmentalise cellular processes and 
act as organising centres for assembly of signalling molecules. Rafts also 
influence membrane fluidity and are involved with membrane protein and 
receptor trafficking and the regulation of neurotransmitters [285]. When the 
cholesterol content of the rafts increases, the activity of α-secretase decreases 
and the activity of BACE increases, thereby promoting amyloidogenic 
processing of APP [284]. The immediate precursor to Aβ is the C-terminal 
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domain of APP called C99 (see Figure 1.7 – APP processing), the product of 
BACE cleavage of APP and has an affinity for cholesterol. The localisation of 
APP/C99 is therefore directed to the cholesterol-rich rafts, where the BACE and 
γ-secretase are concentrated, thereby increasing amyloidogenic processing of 
APP [284]. The α-secretase and BACE are concentrated in different areas of 
the cell [286]. Optimal α-secretase activity is found in cell surface regions that 
contain few lipid rafts, in particular fluid regions with a high DHA content [286]. 
When APP accumulates at the cell surface, it is more likely to be cleaved by α-
secretase. When APP is shifted inside the cell to the Golgi apparatus, 
endosome or lysosome, BACE activity predominates and Aβ is more likely to be 
produced. Evidence is emerging which suggests cholesterol and low density 
lipoprotein receptors (LDLR) influence where APP accumulates [287]. 
Dysregulation of APP processing occurs early in the disease process, possibly 
as a result of cardiovascular risk factors such as insulin resistance, lipid 
dysregulation, inflammation, hormonal imbalances and oxidative stress, 
resulting in overproduction of Aβ42, Aβ aggregation (causing toxicity and further 
oxidative stress) and eventually fibril and plaque deposition, as well as NFT 
formation [9]. This is the basis of the “amyloid hypothesis”, which states that Aβ 
accumulation is central in the aeitology of AD [288]. Cholesterol and plasma 
membrane lipids have roles in regulating APP metabolism [45] and although Aβ 
is proposed as a main driver for AD, the BACE and γ-secretases that generate 
it are up-regulated by high membrane cholesterol levels. This suggests that a 
possible physiological role for Aβ is to recycle brain cholesterol and promote its 
efflux into the systemic circulation and thus protect against elevated brain 
cholesterol [289].  
Aβ increases cholesterol efflux from cells by assembling high-density 
lipoprotein-like particles during secretion [290]; this assembly being mediated by 
the ATP-binding cassette transporter 1 (ABCA1) [289]. Animal studies have 
reported that Aβ containing lipoproteins are excreted much more efficiently than 
those without Aβ [69, 289]. Evidence supports the notion that the products of 
the amyloidogenic processing of APP (Aβ and AICD) act to lower cellular 
cholesterol levels [284]. Aβ stimulates the release of cholesterol and other lipids 
from cells via lipoproteins [289]. Aβ may also reduce biosynthesis of cholesterol 
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and other lipids by inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase 
(HMG-CoA reductase); the rate-limiting enzyme in the cholesterol biosynthesis 
pathway [291]. Additionally, AICD can translocate to the nucleus where it 
suppresses transcription of the gene encoding LDL-receptor related protein 
(LRP1); a major apoE receptor in the brain mediating cellular cholesterol uptake 
via endocytosis [292]. In this way APP may act as a cellular cholesterol sensor 
by creating a negative-feedback loop (see Figure 1.7) as it has been shown that 
the C-terminal (mostly intracellular) domain of APP specifically binds membrane 
cholesterol, thus favouring lipid raft localisation and promoting amyloidogenic 
processing, the products of which (in particular AICD, as mentioned) reduce 
apoE-mediated cholesterol uptake and synthesis [284]. In normal neurons the 
optimal amount of cholesterol present in the membrane confers “stiffness” 
which influences raft structure and the interaction between BACE and APP and 
thus influences Aβ generation [293]. Statins, inhibitors of hydroxymethyl co-
enzyme A-reductase, are widely prescribed for their cholesterol lowering ability. 
Statins reduce the production of cholesterol and isoprenoid intermediates 
including geranylgeranyl and farnesyl pyrophosphate. In experimental models 
of AD, statins also reduce the production of Aβ by reducing membrane 
cholesterol, disrupting secretase enzyme function and by reducing 
neuroinflammation. However these results have been questioned as some of 
the studies used levels of statins that resulted in unnaturally low levels of 
membrane cholesterol, thus disrupting normal membrane function.  
In 2000, the protein Seladin 1 was found to be down-regulated in AD-affected 
brain regions, this protein was later found to be an enzyme (DHCR24) that 
converts desmosterol into cholesterol. Interestingly, 17β-oestradiol increases 
Seladin 1 levels as well as membrane cholesterol levels, and is known to 
protect cells against Aβ aggregate-induced toxicity [294]. In support of this, 
other cell culture studies have shown that a reduction in membrane cholesterol 
and associated reduction in rigidity facilitates the interaction of exogenous Aβ 
with the membrane, allowing the opening of Ca2+ pores and subsequent 
excitotoxicity [295], demonstrating a derailment of normal physiological control. 
However more recently, another study has found the levels of the cholesterol 
precursor desmosterol are lower in AD-affected brain regions compared to age-
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matched controls, suggesting Seladin 1 activity may not be the limiting step or 
factor [296]. It is likely that there is an optimum level for membrane cholesterol, 
above or below which membrane protein metabolism is disrupted, and further 
studies are needed to clarify all these aspects of brain cholesterol metabolism. 
1.5.2  Cholesterol and metabolites 
The brain contains almost 25% of total body cholesterol, the majority of which is 
unesterified and is present in myelin and the plasma membranes of neurons 
and astrocytes [297]. Unlike fatty acids which are also synthesised by the liver 
and delivered to the CNS [298], brain cholesterol is mainly synthesised de novo 
by glial cells, reflecting the importance of adequate amounts and lack of 
reliance on peripheral supply for maintenance of brain function [297]. When 
released from degenerating neurons and glial cells, cholesterol is actively 
recycled by astrocytes. Cholesterol dysregulation in the brain is suggested as 
an important factor for Aβ overload [45, 284], with both increased and reduced 
levels influencing neurodegeneration [162, 299, 300]. Cholesterol homeostasis 
is maintained by a complex interplay of synthesis, transport and metabolic 
pathways. Cholesterol and other lipids are transported in the CNS as 
lipoproteins. Lipoproteins in the CNS resemble plasma HDL in terms of size, 
density and composition; the major difference being that CNS HDL contains 
apoE as its predominant protein compared to apoAI in plasma HDL. ApoE is 
abundantly synthesised by microglia and astrocytes [301]. Normally small 
amounts of cholesterol can be delivered from the periphery through the small 
HDL, which can cross the blood brain barrier (BBB). ApoAI is not synthesised in 
the brain, but low levels are found in the CSF, supporting the fact that 
peripheral HDL, or at least apoAI can cross the BBB [302]. The larger peripheral 
LDL and VLDL are thought to be excluded by the BBB, however recent 
evidence challenges this concept as it has been shown that frequent, 
persistent, post-prandial elevated plasma cholesterol can result in significant 
amounts of cholesterol and therefore the Aβ they contain being delivered to the 
CNS. This is suggested to be a consequence of vascular injury, inflammation 
and subsequent impairment of BBB function [179, 303], thereby contributing to 
increased Aβ load. The cholesteryl esters released from degenerating nerve 
cells are hydrolysed by cholesterol esterase. The free cholesterol is cleared by 
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binding, mainly to apoE, which delivers cholesterol back to neurons [63]. 
Excess free cellular cholesterol is converted into cholesteryl esters by acyl 
CoA:cholesterol acyl transferase 1 (ACAT1) [304]. 
Cholesterol equilibrium is maintained by a negative feedback loop between free 
cholesterol, Aβ and HMG-CoA reductase. Inhibition of HMG-CoA reductase by 
statins has been shown in animal models to reduce Aβ [305] but clinical trial 
results in terms of reducing AD risk have been inconsistent [306]. ACAT 
inhibition is also a therapeutic target to reduce Aβ as increasing levels of 
cholesteryl ester enhances Aβ release in cultured cells [307].  
Cholesterol homeostasis is maintained in the brain by a balance between 
synthesis and removal. Brain cholesterol is metabolised by conversion to 24-S-
hydroxycholesterol (24SHC) by 24-cholesterol hydroxylase (CYP46A10), an 
enzyme found almost exclusively in the brain [45]. 24SHC readily crosses the 
blood brain barrier and is excreted by the liver [45]. Since most of the circulating 
24SHC originates from the brain, plasma levels may reflect cholesterol turnover 
in the CNS [303]. In a mouse model of AD, genetic ablation of ACAT1 also 
increases 24SHC, suggesting a potential role for this oxysterol in decreasing 
amyloidogenesis [308]: The increased free cholesterol being metabolised into 
24SHC, which crosses the BBB and is removed from the CNS, may explain 
this. 27-hydroxycholesterol (27HC) is a peripheral cholesterol metabolite that 
can also cross the BBB [309]. Brain levels of oxysterols are key regulators of 
brain cholesterol via their influence on gene expression, in particular sterol 
regulatory element binding protein (SREBP), LDL receptor and HMGCoA 
reductase [310]. Recent studies have also suggested that α-secretase and 
BACE activity are regulated by 24HSC and 27HC. In cultured neuroblastoma 
cell lines 24HSC was shown to decrease BACE and increase α-secretase 
activity, thereby reducing amyloidogenic APP processing [311].  This would 
suggest that the balance between free cholesterol and cholesteryl esters might 
represent a key factor in regulating amyloidogenesis [307]. Cholesterol efflux 
may also control generation of Aβ via the ATP-binding cassette transporter 
(ABCA1) [310, 312].  
The cross regulation of lipid pathways is also highlighted by studies showing 
that oxysterols activate glycerophospholipid and sphingomyelin synthesis by 
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activating CTP:phosphocholine cytidyltransferase (CCT); the rate limiting step in 
the Kennedy pathway for PC synthesis [313], possibly to protect cells from 
excess sterol accumulation (see Figure 1.9). Membrane composition is 
determined by the co-ordinated synthesis, breakdown and efflux of cholesterol, 
phospholipids and sphingolipids, ensuring membrane integrity and preventing 
the accumulation of bioactive lipids, such as ceramides and diacylglycerol 
(DAG), which can be detrimental to the cell [313]. An inability of PC synthesis to 
proceed at the same pace as cholesterol accumulation can lead to activation of 
the endoplasmic reticulum (ER) unfolded protein response and apoptosis [314].  
Cellular cholesterol homeostasis is regulated by two main nuclear ligand-
activated transcription factors; liver-X-receptors (LXR) and sterol regulatory 
element binding proteins (SREBPs), which activate over thirty genes involved in 
synthesis, uptake and processing of cholesterol, fatty acids, triglycerides and 
phospholipids [64, 315, 316]. SREBP-2 functions to increase cellular cholesterol 
whereas LXRs (LXRα/LXRβ) facilitate reverse cholesterol transport (RCT) 
leading to cholesterol removal via the liver. SREBP-2 is activated when the 
cellular sterol pool is decreased. SREBP-2 is present as an inactive precursor in 
the ER bound to SREBP cleavage-activating protein (SCAP). SCAP is retained 
in the ER when bound to Insigs (insulin induced gene) and prevents transport of 
the SCAP/SREBP complex to the Golgi apparatus. Sterols mediate feedback 
inhibition of SREBP-2 via Insigs and when cholesterol levels decrease the 
SCAP/SREBP-2 complex moves to the Golgi apparatus for proteolytic 
cleavage. An active fragment is then released which enters the nucleus and 
binds to sterol response elements on the promoter region of target genes such 
as HMGCoAR and the LDL receptor gene, leading to increased cholesterol 
synthesis and uptake [312, 317]. Insigs also inactivate HMGCoAR within the ER 
by promoting ubiquitination and degradation when sterols accumulate [317]. 
Diabetes and the associated impairment of insulin signaling have been shown 
to suppress key enzymes in the cholesterol biosynthesis pathway by inhibition 
of SREBP-2 in the brain. Reduced synaptosomal membrane cholesterol 
synthesis results, with associated defects in neuronal function [318]. LXRs form 
dimers with the retinoid-X-receptor (RXR) which result in gene transcription 
[319]. In the CNS LXRβ is more abundant [320] and acts as a cholesterol 
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sensor to prevent cellular cholesterol overload. LXRs stimulate cholesterol 
efflux by promoting gene expression to increase transporters (ABCA1 and 
ABCG) and apoE in the CNS and apoAI in the periphery for transport back to 
the liver. The main physiological LXR activators are oxysterols, which can be 
intermediates in the cholesterol synthesis pathway, intermediates of the steroid 
hormone synthesis pathway or cholesterol breakdown pathways [321]. LXRs 
also suppress several inflammatory genes coding for cytokines such as tumour 
necrosis factor (TNFα), interleukins IL-6 and IL-1β and enzymes such as 
cyclooxygenase-2 and inducible nitric oxide synthase, suggesting reciprocal 
regulation of lipid metabolism and inflammation [322]. LXR agonists could 
potentially alleviate AD pathology by simultaneously acting on brain lipid 
metabolism and therefore Aβ deposition, while reducing inflammation; both 
being pieces of the AD puzzle [323].  
ABCA1 regulates both the levels and amount of lipid associated with apoE by 
promoting the efflux of excess intracellular cholesterol and its subsequent 
binding to lipoproteins, including unlipidated apoE [324]. Studies using cultured 
cells have shown that increasing levels of ABCA1 lowers Aβ, and in a mouse 
model of AD, deletion of the ABCA1 gene leads to a substantial reduction in 
both brain and peripheral apoE, leading to increased Aβ deposits [325, 
326].This increase in Aβ deposition could be mediated by an increase in the 
degradation of poorly lipidated apoE; a process paralleled in the periphery by 
increased renal catabolism of poorly lipidated plasma apoAI [327]. The degree 
of lipidation of apoE may be more important for Aβ metabolism and 
amyloidogenesis than total brain levels of apoE. ABCA1 mediated lipidation of 
apoE is reported to assist with degradation of Aβ by both the extracellular 
insulin degrading enzyme (IDE) secreted by microglia and astrocytes, and the 
intracellular neprilysin in microglia [328]. In vitro studies have shown that 
APOEε4 is the least efficient at promoting Aβ degradation and microglial Aβ 
catabolism is impaired in the absence of both ABCA1 and apoE [328]. 
Phospholipid transfer protein (PLTP) plays a major role in lipid metabolism and 
Aβ clearance by modulating apoE secretion by astrocytes and through its 
influence on ABC transporters, reverse cholesterol transport (RCT) and 
lipoprotein modelling (see Section 1.7 and Chapter 5). 
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1.5.3  Phospholipids  
All human cells are contained by a plasma membrane which is composed of a 
lipid bilayer with embedded proteins. This lipid bilayer is fluid and selectively 
restricts the exchange of compounds between the extracellular fluid and the 
intracellular compartments. The main lipids in the bilayer are phospholipids 
(phosphatidylcholine, PC; phosphatidylethanolamine, PE; and 
phosphatidylserine, PS) with the polar head groups facing the aqueous media 
and the fatty acyl chains forming the hydrophobic core. Another major 
component is the sphingolipid, sphingomyelin (SM). PC is the most abundant in 
most cell types and the sphingolipids are generally the most variable [63, 89, 
275]. The bilayer composition is also asymmetric with PC and SM being more 
abundant in the outer leaflet and PS and PE higher in the inner leaflet. PS has a 
net negative charge which contributes to membrane potential and binds 
positively charged molecules. Phosphatidylinositol (PI) is only found in the inner 
membrane and is a signalling intermediate for hormones and neurotransmitters 
[275].  
The fluidity of the membrane is highly dependent on cholesterol, which is 
interspersed between the phospholipids. The unsaturated fatty acid chains of 
the phospholipids are in the cis conformation which forms a pocket for 
cholesterol by binding its hydrophilic OH group and therefore the hydrophobic 
steroid nucleus is anchored in the membrane core. This interaction prevents the 
hydrophobic chains from packing too closely together and allows protein and 
lipids that are not bound to structural proteins to move laterally and rotate within 
the membrane [275]. The fluidity of the membrane is partially determined by the 
fatty acid composition of the diet, particularly the unsaturated fatty acids. This 
maybe one of the reasons why high consumption of trans fatty acids is 
detrimental to one’s health as it reduces fluidity of the membranes [210, 213]. 
Membrane composition is non-uniform, and is dynamic, such that sections of 
the membrane can bud off into vesicles to remove membrane components to 
other parts of the cell. The membrane also accepts vesicles formed in the Golgi 
apparatus and other parts of the cell to enable delivery of new and recycled 
components back to the membrane. Individual fatty acids can be hydrolysed 
from the membrane lipids by various enzymes and replaced as required [329].  
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Flippase enzymes (P4 ATPases) transfer lipids between membrane leaflets and 
are required for maintenance of membrane asymmetry [330]. Loss of 
asymmetry on the extracellular surface of a cell is proposed to be an early 
marker of apoptosis, such as the appearance of PS on the outer leaflet where it 
is not normally present [331]. Aβ is capable of initiating this response in neurons 
and this mechanism has been proposed to contribute to Aβ toxicity [332]. 
Additionally, genome wide association studies in AD have identified a SNP in 
ATP8B4 (cation transport ATPase) as a potential AD risk factor, resulting in P4 
ATPase deficiency [333]. 
PLs make up more than 60% of the total brain lipids, with the majority being 
incorporated into cell membranes. The six most abundant phospholipids in the 
brain are PC, PE, PS, PI, SM and ethanolamine plasmalogen. Studies have 
shown that the phospholipid profile of the brain is consistent: it is not 
significantly altered by different metabolic conditions. Thus,  alterations in the 
profile may reflect changes in membrane biology [334]. Using 31PNMR 
spectroscopy, the following phospholipid composition was determined in various 
fractions of the healthy brain [334]. 
 
 
 
PC: phosphatidylcholine, PE: phosphatidylethanolamine, PS: phosphatidylserine, PI: 
phosphatidylinositol, SM: sphingomyelin, PlsEtn: plasmalogen ethanolamine 
 
Figure 1.8: Phospholipid distribution in healthy brain. This figure shows the predominance 
of PE and PC in all three regions, with SM also being a major component of white matter and 
myelin. Plasmalogen species are notably abundant in white matter and myelin. 
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Changes in composition and metabolism of several phospholipids have been 
described in brain tissue from AD patients when compared to age-matched 
control brains, including phosphatidylcholine (PC), phosphatidylethanolamine 
(PE), phosphatidylinositol (PI) and plasmalogens [270, 335, 336]. Various 
groups have reported differences in lipid biochemistry in both brain tissue [337-
339] and plasma [120, 127, 272]. A recent lipidomic study of the metabolic 
syndrome and obesity showed these conditions were associated with elevated 
plasma LysoPC, PC and PE species as well as reduced ether phospholipids 
(plasmalogens) [340]. In AD, lower peripheral ethanolamine plasmalogen 
(PlsEtn) has been reported, and these levels not only appear to correlate with 
disease severity, but also linear regression models suggest that serum PlsEtn 
levels decrease years before clinical symptoms appear, thus providing a 
potential early disease marker [341].  
Glycerophospholipids are a source of lipid mediators, including arachidonic acid 
(AA) and docosahexaenoic acid (DHA), which are released from membrane 
phospholipids by the action of phospholipases. Variations in phospholipid 
metabolising enzymes, such as phospholipase A2, phospholipase C, 
phospholipase D and phosphoinositidases have also been reported in AD [342, 
343]. Initially most PLs have a saturated fatty acid at the sn-1 position and an 
unsaturated fatty acid at the sn-2 position of the glycerol backbone. However 
due to cellular requirements, the fatty acid distribution is constantly in flux by 
remodelling that occurs through the action of various phospholipases. Once 
synthesised, the PLs bud off from the ER in vesicles and are then orientated in 
the various cellular membranes by the action of flippase and floppase enzymes 
[344, 345]. All nucleated cells are capable of de novo synthesis of PLs by two 
pathways. The predominant “Kennedy” pathway occurs in the endoplasmic 
reticulum (ER) membrane from cytosolic precursors in most cells or alternatively 
synthesis occurs via activated diacylglycerol (DAG) described in Figure 1.9. 
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Figure 1.9: Phospholipid synthesis and connection with sphingolipid and cholesterol 
metabolism. ACh: Acetylcholine, CDP:cytidine diphosphate, CCT:CTP-phosphocholine 
cytidyltransferase, SAH: S-adenosyl homocysteine, HCy: Homocysteine, Meth: Methionine, 
SAMe: S-adenosyl methionine, PEMT: phosphatidylethanolamine methyltransfersase,  SM: 
sphingomyelin, PAF: platelet activating factor, DAG: diacylglycerol 
All nucleated cells are capable of de novo synthesis of PLs by two pathways. The predominant 
“Kennedy” pathway occurs in the endoplasmic reticulum (ER) membrane from cytosolic 
precursors in most cells and utilises a cytidine-diphosphate (CDP)-activated polar head group 
(choline or ethanolamine) for attachment to the phosphate of phosphatidic acid. Alternatively a 
CDP-activated diacylglycerol is attached to an inactivated polar head group (glycerol, serine or 
inositol) [63, 275, 346]. The importance of the methylation pathway is highlighted to provide 
methyl groups for PC production from PE when dietary sources are inadequate to meet 
demand. The cross regulation of steroid, PL and SL pathways is shown by oxysterol activation 
of CCT, the rate limiting step in PC synthesis to maintain optimal steroid to PL ratios in the 
membrane. 
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1.5.4  Phosphatidylcholine (PC) 
Choline is phosphorylated by choline kinase to phosphocholine. Cytidine di 
phosphate (CDP) is then added to form CDP-choline. CDP-choline then reacts 
with diacylglycerol to form PC (catalysed by choline phosphotransferase- 
CPT1). This process is referred to as the Kennedy pathway for de novo 
synthesis of PC (see Figure 1.9). The liver has a back up pathway via the 
second most abundant PL, PE to provide choline when dietary sources of this 
essential compound are low. This pathway involves a three step methylation by 
SAMe, catalysed by PEMT [194, 196, 347] (see Figure 1.9). PC is required for 
the secretion of VLDL from hepatocytes and is a major source of the second 
messengers DAG, PA, LysoPA, LysoPC, platelet activating factor and AA for 
eicosanoid synthesis. PC is also a direct substrate for the formation of SM via 
sphingomyelin synthase which transfers the choline-phosphate group to 
ceramide [348]. 
1.5.5  Phosphatidylethanolamine (PE) 
Ethanolamine cannot be synthesised and therefore must be obtained from 
dietary lipids. PE is synthesised via the Kennedy pathway described above and 
by the carboxylation of PS [346] (see Figure 1.9). Additionally LysoPE can be 
acylated by a LysoPE-acyltransferase [349]. PE species make up 45% of the 
total brain PLs (see Figure 1.8), where its conical shape and ability to form 
reversed non-lamellar structures, facilitate membrane fusion and fission; 
processes that are particularly important in the brain [349, 350]. PE also confers 
curvature to the cell membrane which influences structure, folding and activity 
of membrane proteins [346]. As the nitrogen group on ethanolamine can be 
positively charged, PE is a zwitterion, enabling establishment of hydrogen 
bonds with various amino acid residues and thereby anchoring proteins. Like 
PC, PE is a precursor to many signalling molecules, such as DAG, FAs and PA. 
Ethanolamine is also a precursor for anandamide (an N-acyl ethanolamine), 
which is a ligand for cannabinoid receptors in the brain [351]. 
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1.5.6  Phosphatidylserine (PS) 
The brain is enriched with PS compared to other tissues where the brain PS 
acyl chains are highly enriched with DHA [352, 353]. As shown in Figure 1.9, 
PS is an important precursor for mitochondrial PE by conversion via PS 
carboxylase. PS is mainly located on the inner leaflet of the membrane bilayer 
and is thought to become an apoptotic signalling molecule when relocated to 
the outer leaflet. This surface exposure is a recognition signal for phagocytic 
removal [354, 355]. 
1.5.7  Plasmalogens 
Plasmalogens are a sub-class of phospholipid characterised by a vinyl-ether 
linkage at the sn-1 position and an acyl linkage at sn-2 of the glycerol 
phospholipid backbone. Plasmalogens contribute to membrane integrity and are 
involved in many cellular processes such as vesicle formation and membrane 
fusion, ion transport and the generation of secondary signal mediators such as 
platelet activating factor [63]. The presence of the vinyl ether bond imparts 
antioxidant properties which reduces free radical based cellular damage as the 
products of enol ether oxidation do not propagate the oxidation of 
polyunsaturated fatty acids (PUFA); a benefit in the CNS with PUFAs in 
abundance and a high metabolic rate. Studies have shown a significant loss of 
plasmalogen in post mortem AD brains [337, 356, 357]. Ethanolamine 
plasmalogen (PlsEtn) is a subclass of PE and plays important roles as a 
reservoir for AA release, in the facilitation of membrane fusion and as an 
antioxidant [337]. PlsEtn is a major component of neuronal membranes, 
accounting for approximately 30% of the total phospholipids and 90% of the PE 
species [339]. Plasmalogens and their precursors are synthesised in the liver 
and transported to the brain bound to transport proteins. The PlsEtn species in 
grey matter contain mainly arachidonate and docosahexaenoate, whereas 
PlsEtn in the white matter contain mainly monounsaturated acyl chains at the 
sn-2 position. Plasmalogen deficiency in the grey matter may be directly related 
to neurodegeneration as deficiency leads to membrane instability [358]. 
Plasmalogens are key regulators of cholesterol and studies have shown that 
plasmalogen deficient cells exhibit lower HDL-mediated cholesterol efflux and 
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impaired LDL-mediated transport [359-361]. This results in an increase in free 
cellular cholesterol and reduced levels of cholesteryl esters via suppression of 
sterol-O-acyltransferase gene expression and therefore reduced levels of the 
enzyme it encodes: acyl-coenzyme A:cholesterol acyl transferase (ACAT). 
ACAT is a critical membrane bound cholesterol processing enzyme which 
promotes the formation of cholesteryl esters and increases LDL receptor 
expression [356]. The synthesis of plasmalogens is dependent on peroxisomes 
to generate 1-alkyl-glyceryl ether lipid precursors and peroxisomal function 
decreases with age. A recent study showed that decreased plasmalogen 
precursor levels in the CNS correlate with functional decline in AD [357]. 
1.5.8  Phosphatidylinositol (PI) 
Phosphatidylinositol (PI) is an important membrane constituent and participates 
in essential metabolic processes via a number of phosphorylated metabolites. It 
is abundant in brain tissue, comprising 10% of phospholipid species. PI has a 
characteristic high content of stearic acid (C18:0) linked to sn-1, and 
arachidonic acid (C20:4) linked to sn-2 [274]. This makes PI a primary source of 
arachidonic acid required for eicosanoid synthesis via the action of 
phospholipase A2 [274]. Phosphoinositol phosphates (PIPs) have roles in both 
signal transduction, by generation of second messengers (diacylglycerol (DAG) 
and inositiol triphosphate) and as membrane docking sites for protein signalling, 
such as the insulin receptor [63]. PI changes have been linked to several 
diseases, including diabetes and cancer [362]. Evidence suggests that 
alterations in PI metabolism may play a role in AD too as PI kinases play a key 
role in the transport and sorting of newly synthesised proteins, thus affecting the 
intracellular trafficking of APP [363]. Phosphatidylinositol 4,5-biphosphate (PIP2) 
is important in the regulation of ion channels and membrane trafficking. In 
familial forms of AD, presenilin mutations cause an imbalance in PIP2 
metabolism, with studies suggesting that this imbalance may contribute to Aβ42 
generation by modulating the trafficking of γ-secretase [364]. It is suggested 
that PIP2 competitively interferes with γ-secretase cleavage of APP [365] and in 
fact an inverse correlation between cellular PIP2 and secreted Aβ42 has been 
demonstrated in cultured fibroblasts [364]. An increased turnover of PIP2 by 
increased phopholipase C (PLC) activity has also been shown in familial AD 
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resulting from presenilin mutations, as PLC inhibitors cause a reduction in Aβ42 
secretion [364]. On the other hand, PLC hydrolysis of PIP2 produces 
diacyglycerol (DAG) which has been shown to stimulate α-secretase and 
therefore promote the non-amyloidogenic processing of APP [366]. It would 
appear therefore that in familial AD at least, that PI metabolism is disturbed 
when presenilin mutations are present. Phosphatidylinositol 3-kinase (PI3K) is a 
key enzyme involved in PI metabolism and in vitro and in vivo studies using 
wortmannin, an inhibitor of phosphatidylinositol 3-kinase, have reported the 
inhibitor reduces levels of Aβ: This provides further evidence for a role for PI in 
AD [367, 368]. Epidemiological studies have shown an increased risk of 
dementia in patients with diabetes mellitus (DM) and the role of insulin receptor 
dysfunction in AD is an active area of AD research [369]. Hyperphosphorylation 
of the tau protein is a key step in the formation of neurofibrillary tangles. This 
phosphorylation is catalysed by various protein kinases, including glycogen 
synthase kinase 3β (GSK3β) [369]. This enzyme is negatively controlled by the 
PI-3-kinase/phospho-Akt pathway, which is stimulated by insulin. This suggests 
one possible mechanism by which impaired insulin signalling contributes to AD 
pathology. A recent study found reduced PI3K activity in peripheral blood 
mononuclear cells in AD compared to age matched controls [369], supporting a 
role for this enzyme in contributing to the pathogenesis of AD. Identification and 
quantification of phosphatidylinositol phosphate (PIP) and phosphatidylinostiol 
biphosphate (PIP2) with different fatty acid compositions may uncover 
abnormalities in PI metabolism in AD [370]. 
1.5.9  Phospholipases 
Phospholipids are constantly being remodelled in terms of their fatty acyl chains 
and polar head groups and also in the generation of second messengers. This 
occurs through the action of various phospholipase enzymes as illustrated in 
the following figure. 
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Fig 1.10: Phospholipase enzymes and site of action. 
PLA1: phospholipase A1, PLA2: phospholipase A2, PLC: phospholipase C, PLD: phospholipase 
D, R1 and R2: fatty acyl chains, R3: phospholipid head group 
 
Phospholipase D (PLD), which hydrolyses PC to produce phosphatidic acid 
(PA) and choline, has also been implicated in AD pathology [343]. With the 
creation of animal models to study PLD, this enzyme is emerging as a key 
player in regulating phospholipid metabolism and is now a therapeutic target for 
several brain disorders, including AD, due to its multiple roles in signal 
transduction pathways [343]. PLD1 has been shown to be involved with APP 
and presenilin intracellular trafficking and PLD2 involved with Aβ signalling. 
Ablation of PLD2 in a transgenic model of AD, has been shown to be 
neuroprotective [343]. In addition, elevated levels of PL degradation products 
have also been described [371] suggesting that the delicate equilibrium of PL 
metabolism is disturbed in AD. PLD is also involved in the generation of N-acyl 
ethanolamines (endocannabinoids) from their precursors, N-acyl PEs. 
Endocannabinoids are lipid signalling molecules that are implicated in a diverse 
range of processes including pain, cognition, appetite, inflammation, memory 
and hippocampal neurogenesis [372-374].  
Increased expression or activation of PLA2 in AD has recently been measured 
in CSF and was shown to correspond to an increase in PL breakdown products, 
particularly PE [375]. The resulting defects in membrane structure can expose 
membrane bound proteins, such as APP to abnormal processing, and the 
production of Aβ and is consistent with the reported co-localisation of PLA2 with 
amyloid plaques [376]. Activation of various phospholipases can lead to 
Phospholipase B (lysophospholipase) has 
both PLA1 and PLA2 activity. 
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alterations in membrane fluidity, permeability and ion balance resulting in 
oxidative stress [377]. The release of AA and DHA is highly regulated and the 
fate of both is determined by numerous signals. These polyunsaturated fatty 
acids (PUFAs) can undergo oxidation by both enzymatic and non-enzymatic 
pathways, producing an array of interconnected lipid mediators that influence 
oxidative stress and neuro-inflammation; key components of AD pathology [28]. 
Glycerophospholipid degradation products generated enzymatically include 
eicosanoids, lysophospholipids, docosanoids, platelet activating factor (PAF), 
and endocannabinoids [28]. Many of these mediators are pro-inflammatory and 
their generation activates astrocytes and microglia to release inflammatory 
cytokines such as tumour necrosis factor (TNF), interleukin 1 (IL1) and 
interleukin 6 (IL6). These cytokines in turn promote and intensify further 
oxidative stress and neuroinflammation, by up-regulating various isoforms of 
PLA2, cyclooxygenases (COX) and nitric oxide synthases (NOS) [378]. It is 
suggested that Aβ accumulation itself may increase cytosolic PLA2 (cPLA2) 
activity [379]. Ceramide and ceramide-1-phosphate, generated from 
sphingolipids, have also been shown to stimulate cPLA2 [380]. The Ca
2+-
independent PE-PLA2 isoform may contribute to neural damage by decreasing 
plasmalogen levels causing increased membrane permeability, Ca2+ flux and 
excitotoxicity [377]. The increased Ca2+ flux also promotes the relocation of 
cPLA2 from the cytosol to the plasma and nuclear membranes where it 
accelerates the breakdown of PC [28]. As Ca2+ levels increase further, the 
secretory isoform of PLA2 is activated (sPLA2), exacerbating neural cell injury 
[28]. Increased levels of lipid mediators derived from AA and DHA by the action 
of PLA2 can result in abnormal and imbalanced signalling leading to 
neurodegeneration. The proportion of AA and DHA in PLs varies in different 
regions of the brain, with AA being more evenly distributed throughout grey and 
white matter and DHA more concentrated at synaptic membranes [381]. PL 
balance is maintained through regulated hydrolysis by phospholipases and 
synthesis by reacylation and deacylation. There is also some de novo synthesis 
in the brain [28].  
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1.5.10  Phospholipid derived metabolites 
The following figure shows the different actions of the PL derived metabolites 
involving arachidonic acid and docosahexaenoic acid. 
 
 
Figure 1.11: Phospholipid derived metabolites from the action of PLA2. 
PLA2: phospholipase A2, AA: arachidonic acid (20:4), DHA: docosahexaenoic acid (22:6), 
BDNF: brain-derived neurotrophic factor, COX-1 and 2: cyclooxygenase-1 and 2, 15-LO-1: 15-
lipoxygenase-1. Bcl-2: B cell lymphoma-2 regulatory proteins. 
The free AA and DHA are released from membrane phospholipids. Cyclooxygenases or 
lipoxygenases transform these into eicosanoids from AA and docosanoids from DHA. The 
eicosanoids are potent inflammatory, vasoconstricting and platelet aggregating compounds 
important in immunity and wound healing. The docosanoids, including neuroprotectin D1 
suppress inflammation and promote neuronal cell survival via production of anti-apoptotic 
proteins and suppression of pro-apoptotic proteins, such as those of the Bcl-2 family. 
Docosanoid production is promoted by neurotrophins, such as BDNF. Non-enzymatic 
transformation of AA and DHA also occurs (depending on the redox state of the cell) to produce 
neuroprostanes and isoprostanes respectively: These can exacerbate oxidative stress and 
damage to cell membranes. 
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1.5.11  AA and metabolites 
AA is the most important omega-6 fatty acid in the brain, present as free fatty 
acid and enriched in phospholipids [382]. The brain relies on a steady supply of 
AA from the plasma via lipoproteins and LysoPLs as very little linoleic acid (LA), 
the essential fatty acid precursor of AA, is present in brain and even when 
present, it is not readily converted to AA [383]. AA has several important 
physiological effects as it can increase neuronal firing and enhance synaptic 
transmission and long term potentiation (LTP), thus influencing learning and 
memory. It is still not clear how AA does this, but one suggestion has been that 
AA rapidly increases the level of α-amino-3-hydroxy-5-methyl-4-
isoxazaolepropionic acid receptors (AMPAR) at the neuronal surface, which 
might increase neuronal activity by increasing currents through Ca2+-permeable 
AMPAR [384]. AA may also influence brain function indirectly via the generation 
of eicosanoids (such as prostaglandins), which regulate inflammation, blood 
clotting and vascular tone (see Figure 1.11) [385]. Increases in neuronal activity 
must be matched by increased delivery of oxygen and nutrients through the 
neurovascular unit of the BBB, and PLA2- and AA- derived mediators play an 
important role in this regulation [386, 387]. AA also regulates the activity of 
many enzymes, including choline transferase and protein kinases A and C, 
involved with acetylcholine production and glucose/lipid metabolism respectively 
[388]. Glutamate excitotoxicity can be enhanced by AA and its inflammatory 
mediators, as activated microglia impair the astrocytic ability to sequester 
glutamate and therefore imbalances in AA or its metabolites contribute to 
neuronal damage [389, 390]. 
1.5.12  DHA and metabolites 
DHA is a major component of neural membrane lipids where it has both a 
structural and functional role. The fluidity of the membrane is crucial for 
membrane protein interaction, speed of signal transduction, neurotransmission 
and the formation of lipid rafts. DHA has the unique ability to shift its shape 
millions of times per second, which provides membrane fluidity [286]. DHA is 
mainly obtained from the diet, although small amounts can be made by a series 
elongation and desaturation reactions of its precursor -linolenic acid (18:3n-3): 
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This process occurs in the liver and astrocytes with the final elongation and 
saturation reaction occurring in peroxisomes; function of which is known to 
decline with age. However endogenous production of DHA is not sufficient to 
meet the brain’s neuroprotective needs. Regardless of the source, DHA is 
rapidly internalised by neurons and incorporated mainly into PS and PE [391]. 
Evidence from animal studies demonstrates that DHA exerts a protective effect 
against several pathological signs of AD, including Aβ accumulation and 
hyperphosphorylation of tau. DHA has been shown to attenuate Aβ generation 
and increase synthesis of the DHA derived messenger, neuroprotectin D1 
(NPD1) [392].   
DHA is a direct signalling molecule as it binds and activates various nuclear 
receptors, including peroxisome proliferator-activated receptors (PPARs), 
retinoid X receptors (RXR) and sterol regulatory-element binding protein 
(SREBP). These nuclear receptors activate genes involved in anti-inflammatory 
processes, lipid metabolism and other brain functions. DHA can specifically bind 
RXR, regulating pathways involved in synaptic plasticity and memory [393]. 
PUFAs bind to PPARs more readily than saturated or monounsaturated fatty 
acids. The RXR receptor, normally regulated by retinoic acid, can also be 
activated by DHA. Retinoic acid signalling is involved in synaptic plasticity and 
memory, and abnormal retinoid metabolism has recently been suggested as a 
possible contributor to AD pathology [176, 394, 395].  
Total DHA levels are decreased in the AD brain [396]. This deficiency may be 
due to enhanced free radical – mediated lipid peroxidation, decreased dietary 
intakes and/or impaired liver DHA shuttling to the brain [283]. It is generally 
assumed that fatty acid transport into the brain occurs from the non-esterified 
pool (NEFA), bound to albumin. Albumin also binds lysophospholipids, mainly 
lysophosphatidylcholine (LysoPC). In addition to the LysoPC generated by the 
action of phospholipase enzymes, it is also produced when lecitihin cholesterol 
acyl transferase (LCAT) transfers the acyl chain from the sn-2 position of HDL-
phosphatidylcholine to free cholesterol to form cholesteryl ester in HDL. Studies 
have shown that DHA uptake by the brain is around 10 times more efficient 
when incorporated into LysoPC compared to the NEFA form. LysoPC-DHA may 
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therefore represent a privileged form of DHA transport into the brain and may 
have implications for abnormal lipid metabolism and reduced HDL [397]. 
Studies with primary neurons in culture, stressed by Aβ and interleukin-1β (IL-
1β) have shown up-regulation of PLA2 [286] and may explain the increase in 
unesterified DHA seen in AD. The bioavailability of unesterified DHA is a highly 
regulated event. Once DHA is freed from membrane phospholipids it can go 
down two different pathways – one protective and one damaging (see Figure 
1.11). The pathway taken appears to be influenced by the redox balance of 
cells [398]. DHA is the most unsaturated fatty acid, making it a target for primary 
lipid peroxidation. During periods of excessive oxidative stress, DHA may be 
non-enzymatically oxidised into neuroprostanes [352]. Generation of 
docosanoids from DHA is an emerging area of research. Resolvins and 
neuroprotectins are derived from DHA by the action of 15-lipoxygenase and 
maresins are formed by the action of 14-lipoxygenase and are so called 
because they “resolve” inflammation and promote “protection” of cells against 
injury [274]. It would therefore appear that the beneficial actions of DHA in the 
brain are a result of direct maintenance of neuronal plasma membrane fluidity 
and through the generation of docosanoids. The docosanoids are similar in 
structure to eicosanoids and appear to antagonise the potent inflammatory and 
immunoregulatory functions of the omega-6 generated counterpart [399]. 
Therefore deficits in DHA or its metabolites may contribute to the inflammatory 
signalling, apoptosis and neuronal dysfunction seen in AD [286]. Resolvins 
have been shown to block TNF induced cytokine release from microglial cells 
and regulate leucocyte infiltration in the brain [400].  
A major DHA derived mediator is neuroprotectin D1 (NPD1) or 10R,17S-
dihydroxy-docosa-4Z,7Z,11E,15E,19Z hexaenoic acid. NPD1 is synthesised as 
an alarm response to oxidative stress and by neurotrophic activation in an 
attempt to maintain cellular integrity and promote brain cell survival and repair, 
through anti-apoptotic and anti-inflammatory signalling [286, 401]. Recent 
evidence suggests that synthesis of NPD1 is activated by growth factors and 
neurotrophins. NPD1 is also being shown to interact with the mechanisms 
associated with APP and A peptide [286]. Both DHA and NPD1 promote non-
amyloidogenic processing of APP and decrease the rate of Aβ generation. 
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NPD1 has been shown to specifically down regulate A1-42-induced expression 
of the pro-inflammatory cyclooxygenase-2 (COX-2) and BACE1, while activating 
ADAM10 and increasing production of the neuro-protective sAPP [402]: This 
diminishes Aβ-mediated pro-inflammatory, pro-apoptotic and pathogenic 
consequences. NPD1 also reduces brain cell damage by shifting the balance 
from expression of apoptotic proteins such as caspase-3, to expression of the 
anti-apoptotic, survival promoting members of the Bcl-2 gene family during 
oxidative stress [403] (see Figure 1.11).  Animal and in vitro studies have 
helped to clarify the mechanisms of NPD1 protection and have shown that 
along with DHA it also interacts with PPARγ, a transcription factor regulating 
lipid metabolism, inflammation and insulin sensitivity [402].  Studies using the 
PPARγ agonist rosiglitazone (Avandia), the irreversible antagonist GW9662 
and overexpression of PPARγ demonstrated that NPD1- mediated down 
regulation of BACE and Aβ42 peptide release are PPARγ activation dependent  
[402]. PPARγ activation leads to anti-inflammatory, anti-amyloidogenic and anti-
apoptotic actions, as does NPD1. The molecular mechanisms of the Aβ-
lowering effects by PPARγ remain unclear, although several mechanisms have 
been proposed: Induction of Aβ ubiquitination, leading to enhanced 
degradation, is one possible mechanism. Alternatively, Aβ clearance may be 
enhanced by improved insulin sensitivity and increased insulin degrading 
enzyme activity in the brain, which plays a major role in degrading Aβ [404]. 
Additional studies have also shown that NPD1’s stimulation of non-
amyloidogenic pathways can also be PPARγ-independent.  
1.5.13  Lysophospholipids and Platelet Activating Factor (PAF) 
Lysophospholipids are transiently produced during phospholipid metabolism by 
the action of PLA2 and include LysoPC, LysoPE, LysoPS, LysoPI, LysoPA and 
Lysoplasmalogens [63]. Apart from being intermediates of PL metabolism, at 
high concentrations they influence membrane permeability and interact with 
membrane bound enzymes and other membrane lipids, affecting various 
functions and growth factors [28]. LysoPLs can be reacylated to restore PLs to 
membranes or acetylated to form platelet activating factor (PAF); a potent 
inflammatory lipid with multiple signalling roles [405]. LysoPC is involved in 
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microglial and immune activation in the brain, where activated microglia help 
clear cellular debris in areas where senile plaques and neurofibrillary tangles 
are accumulating [28]. Analysis of CSF in AD patients has shown LysoPC to be 
significantly reduced compared to controls, indicating abnormal PC metabolism 
with resulting alterations in membrane fluidity, permeability, ion homeostasis 
and promotion of oxidative stress [371]. However, a recent study contradicted 
these findings by reporting an increase in the LysoPC:PC ratio in both 
nanometer particle fractions (more representative of brain tissue) and 
supernatant fractions of CSF in AD [375], which was accompanied by increased 
PLA2 activity. LysoPA is involved in neurotransmitter action, including 
stimulation of noradrenaline and dopamine release [406].  
1.5.14  Non-enzymatic derived lipid mediators 
Non-enzymatic degradation of glycerophospholipids results in the formation of 
isoprostanes, neuroprostanes, isofurans, neurofurans, isoketals, neuroketals, 4-
hydroxynonenal (4-HNE), 4-hydroxyhexanal (4-HHE) and malondialdehyde 
[407]. These prostaglandin-like compounds trigger further reactive oxygen 
species (ROS) generation, exacerbating damage to cellular membranes. 
Neuroprostane-containing phospholipids adversely affect neuronal function by 
interfering with membrane function [408]. AA peroxidation results in the 
formation of 4-HNE, which is highly reactive and increases the expression and 
activity of BACE1 [28]. Measurement of F4-neuroprostanes (derived from DHA) 
and hydroxynonenal (HNE) reflect the general state of oxidative stress and lipid 
peroxidation in ‘stressed’ brain cells and these molecules may be useful 
biomarkers for neurodegeneration [409]. Notably F4-neuroprostanes are 
elevated in the cortex of AD brains [410] and may therefore serve as a potential 
biomarker for the specific oxidation of DHA [352]. 
1.5.15  Sphingolipids 
Sphingolipids, including sphingomyelin, ceramides, sulphatides and 
glycosphingolipids are key components of lipid rafts and therefore affect APP 
processing and Aβ binding and aggregation. Ceramides are central 
components of sphingolipid metabolism and are core constituents of most 
sphingolipids, which are either synthesised from fatty acyl CoA and serine, 
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sphingosine or produced by enzymatic hydrolysis of other sphingolipids [63]. 
The following figure depicts sphingolipid metabolism. 
 
 
 
Figure 1.12: Sphingolipid metabolism. 
Sphingolipid synthesis begins with ceramide which can be formed de novo from palmitoyl-CoA 
and serine or be produced from other sphingolipids by the action of various enzymes. Ceramide 
reacts with phosphatidylcholine (PC) to form sphingmyelin (SM) and can react with uridine 
diphosphate (UDP) sugars to form cerebrosides (usually galactose or glucose). 
Galactoceramide (cerobroside) can react with 3’-phosphoadenosine 5’-phosphosulphate 
(PAPS, an active sulphur donor) to form sulphatides. Additional sugars may be added to 
ceramide to form globosides (glycoSLs). Gangliosides are produced by the addition of N-
acetylneuraminic acid. (Figure adapted from [411]). 
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Sphingomyelin (SM) and glycosphingolipids, in particular gangliosides, are 
abundant in the brain and are major components of neuronal membranes. 
Sphingolipids are also directly involved with APP processing, which in turn 
affects cholesterol and sphingomyelin metabolism. This suggests a cross 
regulation of both processes and a link between Aβ-regulated cholesterol and 
sphingomyelin metabolism, with γ-secretase activity controlling various 
enzymes involved in lipid metabolism [291]. Inhibition of sphingomyelinase, the 
enzyme that converts sphingomyelin to ceramide, results in SM accumulation, 
which in turn reduces Aβ secretion due to inhibition of γ-secretase. Studies 
have shown that activation of neutral sphingomyelinase (SMase) by Aβ42 
reduces SM and increases ceramide. However, Aβ40 lowers cholesterol by 
inhibition of HMGCoA reductase and reducing de novo cholesterol synthesis. 
The reduced membrane cholesterol and SM produced by Aβ affects γ-
secretase activity and therefore normally provides a feedback mechanism [291] 
(see Figure 1.13): This suggests a role for sphingolipids as γ-secretase 
modulators. Additionally the presence of a sphingolipid binding sequence on Aβ 
has been identified that increases affinity of Aβ to bind lipid rafts rich in 
cholesterol and sphingolipids [412]. This binding sequence may have 
implications for aggregation and processing of Aβ, which can influence 
pathogenicity as studies have shown that Aβ aggregation requires an 
environment rich in SM [291].  
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Figure 1.13: Interactions between Cholesterol, Sphingolipids and APP processing. 
APP: Amyloid Precursor Protein, γ: Gamma secretase complex, β: Beta site APP cleaving 
enzyme (BACE), Chol: Cholesterol, SM: Sphingomyelin, MAOS: Membrane Associated 
Oxidative Stress, SMase: Sphingomyelinase, HMGCoR: 3-hydroxy-3-methyl-glutaryl-CoA 
reductase. 
APP, BACE and γ-secretase are concentrated in lipid rafts which are rich in Cholesterol and 
SM. Cholesterol increases the activities of BACE and γ-secretase, increasing production of 
Aβ42, which can directly activate SMase resulting in increased ceramide production. 
Additionally, age-related increases in oxidative stress and Aβ42 induce membrane-associated 
oxidative stress which also activates SMase. An increase in ceramides can impair synaptic 
function and damage neurons. Aβ40 inhibits HMGCoAR, the rate limiting step in the cholesterol 
biosynthesis pathway. An increase in the Aβ42/Aβ40 ratio will therefore increase levels of 
cholesterol and decrease SM in membranes. 
 
SM is a major source of ceramides and sphingomyelinases which hydrolyse 
phosphocholine from sphingomyelin to produce ceramides, are activated by 
inflammatory cytokines and oxidative stress [157]. Ceramides are potent 
second messengers that regulate diverse cellular processes. They activate 
enzymes involved in stress signalling and are linked to caspase activation and 
pro-apoptotic signalling via reactive oxygen intermediates. In early stages of 
AD, marked decreases in sulphatides have been described, apparently not due 
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to deficiencies in production, but rather due to greater conversion to ceramides, 
which are a class of potential degradation products of sulphatides [413]. 
Accumulation of ceramide, with increased brain and CSF levels has been 
reported at the earliest clinically recognisable stages of AD [273, 337]. 
Ceramide levels have been found to be more than three-fold higher in white 
matter of the AD brain compared to normal control brain. It appears that gene 
expression changes in the early stages of AD shift sphingolipid metabolism 
towards accumulation of ceramide, depletion of glycosphingolipids and a 
reduction in the anti-apoptotic signalling molecule, sphingosine-1-phosphate 
[335]. Lipid metabolism is tightly connected to APP processing, and Aβ42 may 
activate sphingomyelin catabolism causing accumulation of ceramide which 
exacerbates neurodegeneration [414]. Adverse consequences result from 
ceramide accumulation, including up-regulation of cytokines, reactive oxygen 
species generation, mitochondrial dysfunction and apoptosis [415]. Ceramides 
act directly on mitochondria to induce membrane permeability transition and the 
release of cytochrome c, thereby compromising ATP generation and promoting 
cell death [157]. Ceramides have also been shown to increase APP processing 
by BACE, by enhancing BACE stability through the formation of ceramide-
enriched platforms in the lipid rafts [416] (see Figure 1.14). The substantial 
elevation of ceramide in the AD brain might also be a consequence of 
sulphatide degradation and an increase in synthesis or catabolism of SM and/or 
cerebroside (see Figure 1.12) [337].  
Sialylation of glycoceramides produces gangliosides, which are currently 
receiving considerable attention as accelerators of AD pathology [27, 411, 417]. 
Aβ is thought to exert its toxic affects by interacting with cell membranes and 
membrane proteins, which alters the folding of the peptide. The abnormal Aβ 
then interferes with cell signalling and membrane integrity and reacts with other 
components, which promote aggregation [418]. A possible mechanism by which 
Aβ assembles into insoluble fibrils is through binding to the ganglioside GM1. 
The conformation of Aβ from random coils to structures with increased β-sheet 
content results when Aβ is bound to GM1 [27]. In this way, the membrane 
bound GM1 acts as a seed for Aβ aggregation. This process is increased with 
ageing and appears to be facilitated by cholesterol rich environments, such as 
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lipid rafts [419]. Aβ bound to gangliosides in plaques may also escape immune 
surveillance and indirectly promote further plaque formation by decreasing 
microglial clearance of Aβ [420].  
Sulphatides are a class of myelin-specialised glycosphingolipids, involved in 
various cellular processes, including cell growth, protein trafficking, signal 
transduction, cell-cell recognition, neuronal plasticity and cellular integrity [421]. 
Studies have shown that apoE is associated with sulphatide transport and 
mediates sulphatide homeostasis in the CNS through lipoprotein metabolism 
pathways. Alterations in apoE mediated sulphatide trafficking have been shown 
to deplete sulphatide in the brain, and CNS levels of sulphatide have been 
shown to be apoE isoform dependent, with the lowest levels observed with 
APOEε4 [71]. An increased rate of apoE/sulphatide containing particle uptake 
and increased expression of lipoprotein receptors can lead to increased 
breakdown of sulphatide, depleting sulphatide from the myelin sheath. 
Sulphatide containing apoE-associated particles facilitate Aβ clearance. This 
may represent a further mechanism through which APOEε4 increases the risk 
for AD [71]. Studies with APP transgenic mice have demonstrated that 
clearance of increased Aβ production requires increased apoE, which 
collectively increases sulphatide trafficking and degradation [71].  
Serum SM and ceramide levels were measured in women as part of the 
longitudinal WHASII study of cognitive impairment and the results suggest that 
these lipids may be used as biomarkers of memory impairment and disease 
progression [163, 422]. However, this study gave conflicting results between 
cross sectional and longitudinal data. Lower levels of serum ceramide and SM 
were found to be associated with memory impairment cross-sectionally, but 
higher ceramide levels were found to be associated in the longitudinal data 
[163, 423]. The potential reasons for these differences will be explored in 
Chapters 3 and 4. The potential link between ceramides and AD pathology can 
be summarised in the following figure: 
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Figure 1.14: The potential mechanisms for both direct and indirect effects of increased 
ceramides influencing AD risk.  
CSF: Cerebrospinal Fluid. 
Elevated plasma ceramides are a feature of diabetes mellitus (DM), atherosclerosis, insulin 
resistance (IR) and metabolic dysfunction; all risk factors for developing Alzheimer’s disease 
(AD). (reviewed in [207, 265]). Additionally it is hypothesised that the existence of a 
liver/peripheral-brain axis of neurodegeneration results in the increased production and delivery 
of ceramides across the blood brain barrier (BBB): This provides a possible explanation for the 
cognitive impairment seen in DM and non-alcoholic steatohepatitis (NASH) [165]. In the central 
nervous system, the elevated ceramides have direct effects on AD pathology by stabilising beta 
site APP cleaving enzyme (BACE) and increasing Aβ generation [416]. Ceramides may also 
induce brain insulin resistance, which alters brain glucose metabolism and interferes with 
numerous signalling pathways involved with synapse maintenance and brain plasticity [263, 
265]. (Figure adapted from [424]). 
 
A recent probe into the plasma lipidome of individuals with metabolic syndrome 
and obesity showed various changes including increased ceramide species 
[340].  
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1.6  Control of lipid metabolism 
Section 1.3.3 discussed diet and nutrition as risk factors for developing AD. The 
composition of the diet and nutrient status has profound effects on lipid 
metabolism through their influence on the endocrine system and energy 
homeostasis via transcription factors regulating metabolic gene expression, 
including SIRT1, adenosine monophosphate kinase (AMPK) and PPAR-gamma 
coactivator 1-α (PGC1α) (reviewed in [425-427]). A recent publication has also 
shown that metabolic stress modulates BACE gene transcription via effects on 
SIRT1, PPARγ and PGC1α in neurons [428]. Due to the integrated nature of the 
endocrine system, virtually all hormones will have some influence on lipid 
metabolism and therefore influence a myriad of cellular functions. These 
hormones therefore, may need consideration when interpreting blood lipid 
profiles. Insulin is a master hormone regulating glucose uptake and utilisation, 
but it also has many other effects on metabolism in general and acts as a 
signalling molecule for a vast array of cellular processes. As previously 
described, it has wide ranging effects on the CNS and is considered a key 
player in the AD picture [98, 179]. The effects of insulin on cholesterol 
metabolism via gene expression changes in SREBP and HMGCoAR have also 
been described in previous sections. Insulin has a major influence on peripheral 
plasma lipid profiles due to its affect on directing metabolism towards energy 
storage. When insulin resistance is present increased circulating free fatty acids 
(FFA) result from increased adipose tissue lipolysis as insulin normally inhibits 
this process. The increased FFAs eventually lead to increased VLDL secretion, 
increased cholesterol and an associated increased amyloid burden [260]. 
Insulin has also been shown to induce fatty acid desaturase expression in 
monocytes and may provide an explanation of the increased inflammation 
promoted by post-prandial hyperinsulinaemia when the dietary omega-6 to 
omega-3 ratio is high [429]. Of particular relevance to lipidomics is the emerging 
evidence to suggest an association between insulin resistance and ceramides; 
where toxic ceramides may be the intermediate that links excess dietary 
saturated fatty acids and inflammatory cytokines with insulin resistance [265]: 
This is depicted in the following diagram. 
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Fig 1.15: Ceramides – the toxic intermediate linking metabolic dysfunction, inflammatory 
cytokines and insulin resistance? TNFα: tumour necrosis factor alpha, CoA: Coenzyme A. 
NFκB: nuclear factor kappa B, iNOS: inducible nitric oxide synthase, NO: nitric oxide, Bcl2: B cell 
lymphoma 2 anti-apoptotic proteins, IRS-1: insulin receptor substrate-1, PI3-K: 
phosphatidylinositol-3 kinase, Akt/PKB: serine/threonine-specific protein kinase. 
When adipose tissue exceeds its storage capacity, adipokines increase inflammation which 
increases ceramides. This inhibits insulin signalling, further increasing lipolysis and increasing 
the release of fatty acids for ceramide synthesis. Ceramide promotes apoptosis and the 
elevated saturated fatty acids inhibit the Bcl2 family of anti-apoptotic proteins. 
 
1.7  Lipoprotein metabolism and phosholipid transfer protein 
  (PLTP) 
Lipoproteins are complexes of protein and lipids that solubilise lipids so they 
can be transported in the circulation between tissues. Lipoproteins are 
synthesised in the intestines from dietary lipids or in the liver from endogenous 
lipids and can also be remodelled from precursor lipoproteins under the 
influence of various metabolic signals. Lipoproteins are generally spherical 
structures, typically consisting of a neutral lipid core of cholesteryl esters and 
triglycerides and a surface layer of phospholipids, unesterified cholesterol and 
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various apolipoproteins. These apolipoproteins not only solubilise the lipids but 
also act as ligands for cell surface receptors and cofactors for plasma enzymes. 
High LDL, VLDL and low HDL are known risk factors for vascular disease, 
diabetes and AD [430-432] and dyslipidaemia has been shown to be more 
prevalent in AD patients with BBB impairment [433]. Lipoproteins are very 
dynamic and are constantly being modified by the action of enzymes, lipid 
transfers and apolipoprotein exchange. This ensures specific lipid delivery to 
different tissues [63, 89]. Lipoprotein metabolism and the associated lipid 
transfer proteins are shown in the following figure: 
 
 
Figure 1.16: Lipoprotein metabolism and lipid transfer proteins. 
CM: Chylomicrons, LPL: Lipoprotein lipase, CR: Chylomicron remnants, PLTP: Phospholipid 
transfer protein, Chol: Cholesterol, PL: Phospholipid, ABC-1: ATP binding Cassette Transporter 
1, HDL: High density lipoprotein, LDL: Low density lipoprotein, VLDL: Very low density 
lipoprotein, IDL: Intermediate density lipoprotein, SR-B1: Scavenger receptor B1, CETP: 
Cholesteryl ester transfer protein, LCAT: Lecithin-Cholesterol acyl transferase, VitE: Vitamin E, 
LPS: Lipopolysaccharide 
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CM are assembled from dietary fat in the intestine and enter the circulation. At 
the same time lipid poor apolipoprotein AI (apoAI) is secreted from the intestine 
and reaches the circulation. The triglycerides of CM undergo lipolysis by 
lipoprotein lipase and the surface remnants (phospholipids and apolipoproteins) 
of the CR are transferred via PLTP to apoAI. The CRs are then taken up by the 
LDL/remnant receptor in the liver. Triglyceride rich lipoproteins (VLDL) are 
secreted by the liver. VLDLs also contain a large amount of cholesteryl ester 
and are enriched with apolipoprotein B100 (apoB100) and 
phosphatidylethanolamine (PE). The CE is transferred from HDL by CETP and 
moves most of the CEs to apoB containing lipoproteins which can be cleared by 
the liver. LPL hydrolyses the TG of VLDL to form IDL, which are further modified 
by hepatic lipase to form LDL. The surface PLs and protein remnants at each 
stage are transferred to HDL via PLTP. Lipid poor apoAI acquire free 
cholesterol and phospholipids via ABCA-1 mediated efflux from the liver and 
peripheral cells (and from VLDL and CR via PLTP) to form nascent pre-β HDL, 
which progressively acquire additional PL and cholesterol via ABCA-1 efflux 
from tissues. The cholesterol acquired by these discoid nascent HDL is then 
esterified by LCAT (synthesised and secreted by the liver), which the HDL 
obtains from the circulation. If the cholesterol is not modified within the HDL 
particle it can move out again so conversion to CEs ensures that cholesterol is 
trapped within HDL as CEs move to the centre of the HDL, producing the more 
spherical -HDL. The activity of LCAT is crucial for maintaining a steady 
gradient of free cholesterol allowing the HDL to accept additional cholesterol 
from other sources. CETP also enriches HDL with TG which enhances lipolysis 
of PLs and TG by hepatic lipase leading to smaller HDL3 and preβ-HDL. Large 
mature HDL particles enriched with CE are removed from the circulation by the 
liver scavenger receptor-B1 (SR-B1). PLTP, by transferring PLs and 
apolipoproteins is constantly remodelling HDL for reverse cholesterol transport. 
It also transfers vitamin E and lipopolysaccharides from and to HDL3 
respectively. 
In plasma there are two main lipid transfer proteins; cholesterol ester transfer 
protein (CETP) and phospholipid transfer protein (PLTP). CETP is secreted 
mainly by the liver and circulates bound to HDL. It redistributes cholesteryl 
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esters from HDL to TG rich lipoproteins (CM and VLDL) and transfers TGs from 
VLDL and CM to LDL and HDL [434]. PLTP facilitates the transfer of 
phospholipids from TG rich lipoproteins to HDL and together with CETP is 
important in reverse cholesterol transport by modifying the size and function of 
HDL. The physiological relevance of PLTP is highlighted in PLTP-deficient 
mice, which demonstrate a total absence of PL transfer from VLDL to HDL and 
markedly reduced PLTP and HDL levels [435, 436]. The lack of substrate 
specificity of PLTP is also highlighted by its ability to transfer DAG, which are 
released by lipoprotein lipase in capillary endothelium and during lipolysis in 
adipose tissue [437]. DAG is also transported by HDL. PLTP also facilitates the 
transport of other lipophilic substances such as -tocopherol [438]. Dietary -
tocopherol (Vitamin E) is incorporated in CM and transported to the liver where 
it is packaged into VLDL. Vitamin E is important in preventing LDL oxidation 
and subsequent uptake of oxidised LDL by vascular endothelium [439]. PLTP 
deficiency in the brain has been shown to result in reduced -tocopherol and an 
increase in oxidative injury, leading to neurological dysfunction [440]. This 
suggests that PLTP is a local transporter of -tocopherol and may transport -
tocopherol across the BBB. A major function of PLTP is to maintain the plasma 
sub species of HDL [441, 442] and the CNS HDL like lipoproteins [443]. The 
literature regarding the role of PLTP in disease is not straightforward and 
conflicting. Most studies have been conducted in relation to atherosclerosis and 
metabolic disease and are contradictory with some finding higher PLTP activity 
levels and increased risk of disease [444, 445] and others finding lower levels 
associated with disease [446, 447]. These conflicting results may be due to 
study design as some were prospective and others cross-sectional. Assay 
methodology may also contribute to the disparate results as there are notable 
differences in the assays used. The protective or disease promoting effects of 
PLTP remain unclear as HDL cholesterol levels vary in response to PLTP gene 
overexpression or deficiency [448, 449]. It may be that the effect of PLTP on 
disease depends on the background lipid profile, metabolic landscape, co-
morbidities, medication use and dietary considerations. Research into PLTP 
and disease is gaining momentum. The emerging diverse roles and involvement 
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in both lipid metabolism and AD pathology certainly make this a protein of 
enormous interest and an intriguing addition to the lipidomic part of this study. 
1.8  Lipidomics and AD biomarkers  
The remarkable diversity of plasma lipids was recently highlighted by a study 
which measured over 500 distinct lipid species in a pooled human plasma 
sample [450]. The greatest challenge when studying the CNS is to ascertain 
direct links between blood-based analytes and neuronal biochemistry. The BBB 
separates the CNS from the periphery but in terms of lipids, some are excluded 
and others are not. In addition, ageing and inflammation can disrupt the integrity 
of the BBB and complicate the picture. Metabolic dysfunction, which is common 
in ageing and present as a risk factor for AD, can also disturb normal lipoprotein 
metabolism resulting in abnormal lipid transfer between the periphery and the 
CNS [302, 443]. CSF is thought to be the most relevant sample for studying the 
CNS but its collection, however, is an invasive procedure, requiring specialised 
clinicians and is therefore not appropriate for large population screening and 
follow-up. Conversely, blood is an easily obtainable and convenient sample to 
use for this study with the additional benefit of accessing samples from a highly 
characterised cohort of ageing where lipid profiles can be assessed in the 
context of other AD-related biomarkers such as cerebral amyloid load. 
Diagnostic strategies were discussed in detail earlier in this chapter (see 
Section 1.2). Ante-mortem diagnosis of AD is currently made using 
neuropsychological assessments and neuroimaging in some cases. Imaging of 
the brain for amyloid burden enables AD to be identified pre-clinically, but is not 
feasible for large population screening and some individuals can accumulate Aβ 
but remain cognitively stable. [36, 41, 42]. Definitive diagnosis can only be 
made by examination of the brain post-mortem and therefore the need for the 
development of biomarkers to enable early diagnosis and monitoring of disease 
progression ante-mortem is a priority. Such biomarkers will enable therapeutic 
and intervention strategies to be implemented prior to manifestation of 
irreversible neurodegeneration.   
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A biomarker can be defined as: 
“A characteristic that is objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention (an indicator of disease status, both clinical and 
sub-clinical)”. [451].  
In addition an appropriate AD biomarker should be able to detect 
neuropathology, should be accurate, non-invasive, reliable, reproducible and 
inexpensive. It should also be validated in confirmed AD and non-AD cases 
[452]. The development of a blood-based biomarker would represent a huge 
leap forward in terms of meeting the non-invasive, simple to perform and 
inexpensive criteria. However, due to the complex nature of AD and presence of 
co-morbidities, it is unlikely that a single biomarker will be identified offering 
sensitivity and specificity of greater than 80%. It is more likely that a panel of 
biomarkers will be identified comprising lipids, proteins and gene variants. This 
study aims to contribute towards the identification of such a panel. 
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1.9  Hypotheses 
1. AD patients have abnormal plasma lipid profiles. 
2. Altered plasma lipid profiles will reflect altered cerebral Aβ deposits. 
3. Lipid profiling of plasma will yield sensitive and specific markers of AD. 
4. Plasma PLTP activity levels are different between AD patients and 
healthy controls. 
1.10  Aims of the study 
These hypotheses will be addressed by the following specific aims: 
1. To determine plasma lipid profiles of baseline and 18 month follow up 
AIBL samples using electrospray ionisation mass spectrometry (ESI-
MS/MS). 
2. To determine differences in plasma lipid profiles between healthy 
controls and AD, by using a shotgun lipidomics approach. In particular 
plasma levels of phosphatidylcholine (PC), phosphatidylethanolamine 
(PE), phosphatidylserine (PS), phosphatidylinositol (PI), 
phosphatidylglycerol (PG), sphingomyelin (SM), lysophospholipids, 
ceramides and plasmalogens will be measured. 
3. In addition, lipoprotein metabolism will be investigated using the 
measurement of phospholipid transfer protein (PLTP) activity.  
4. To correlate candidate lipid biomarkers to disease progression, using 
standard uptake value ratios (SUVR). 
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Chapter 2 - Materials and Methods 
This chapter describes the ethics, research design, the study cohort, 
biomarkers (blood and imaging) and genotypes that have been used for the 
work described in this thesis. The overall aim of the methods used was to 
evaluate associations between blood lipid biomarkers and other Alzheimer 
disease (AD)-related variables of interest and to investigate the potential of a 
biomarker panel as an early predictive test for AD. 
2.1  Ethics 
The Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) is 
approved by research ethics committees from the major participating 
institutions: St Vincent’s Health, Austin Health, Hollywood Private Hospital and 
Edith Cowan University. All participants were provided with information and 
consent documentation outlining all procedures which included information on 
potential risks and benefits associated with participation in the study. After 
being provided with this documentation, a signed consent form was obtained 
from each participant before commencement of data collection. This project 
involved utilisation of previously collected blood samples and analysis of 
supplementary AIBL data (neuroimaging, genotypes, clinical classifications and 
blood analyte measurements) and therefore no participant interaction was 
involved. 
2.2   Study Population 
The AIBL volunteer database was created as a joint venture between leading 
Australian researchers in Alzheimer’s disease and the Australian 
Commonwealth Scientific Industrial and Research Organisation (CSIRO) in 
2005 [453]. The aims of this collaboration were to recruit a cohort of Australian 
subjects aged 60 years and over (n = 1112) and to collect comprehensive 
information including cognitive function status, amyloid brain load, blood 
biomarkers and lifestyle habits. This information has been collected every 18 
months since study inception. Only baseline and 18 month time point data and 
blood samples were used for this study. The cohort consisted of three main 
groups: 
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 Cognitively healthy controls (HC) which can further be divided into non-
memory complainers (NMC) and subjective memory complainers (SMC) 
 Individuals with mild cognitive impairment (MCI) 
 Individuals with early-stage AD 
 
Figure 2.1 illustrates the cohort breakdown by clinical classification at baseline 
and 18 month follow-up. 
 
Figure 2.1: AIBL cohort at baseline and 18 months. There were 1,112 baseline samples. 
These were classified as 211 AD, 133 MCI and 768 healthy controls (372 non-memory 
complainers (NMC) + 396 subjective memory complainers (SMC)). 115 of the baseline 
participants did not return for 18 month follow-up and of these 28 were deceased. There were 
968 18 month follow-up samples which were classified as 196 AD, 81 MCI and 691 healthy 
controls (317 NMC + 374 SMC). One participant in the MCI group was reclassified as non-AD 
dementia due to Parkinson’s Disease (PDD). The arrows and associated numbers reflect the 
individuals moving between groups. 
Schematic adapted from an image provided by the AIBL Study Scientific Management 
Committee. 
Several high impact studies investigating cognitive function in the aged, 
lifestyle, neuroimaging and blood biomarkers of AD have been published 
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utilising data from the AIBL study: A list of these publications can be found at 
www.aibl.csiro.au. 
2.2.1  Recruitment, eligibility screening and exclusion criteria 
Volunteers for this study were recruited in Melbourne and Perth, Australia, via 
media advertisements (television, radio and newspapers). Over 4000 
individuals responded who then underwent eligibility screening by telephone to 
obtain basic demographics (contact details, sex and age). In addition, 
information regarding medical history, with specific information related to 
eligibility was obtained. Information on alcohol intake was also collected. All 
AIBL volunteers were aged 60 years and above at baseline, and excluded if 
they had a history of non-AD dementia, schizophrenia, bipolar disorder, 
significant current depression (geriatric depression scale score or “GDS” > 5), 
Parkinson’s disease, cancer within the last two years (except basal cell skin 
carcinoma), symptomatic stroke, insulin-dependent diabetes, uncontrolled 
diabetes mellitus or current regular alcohol consumption exceeding four 
standard drinks per day for men or two per day for women. There was no 
maximum age for inclusion. 
2.2.2  Classification of Study Population 
Classification of individuals into AD, MCI or cognitively healthy groups was 
made by utilising all available information, including medical history, memory 
complaints, information from family and neuropsychological test data. A 
consensus diagnosis was assigned for each participant by a clinical review 
panel, which included consideration of diagnostic criteria, DSM-IV diagnosis 
(Diagnostic and Statistical Manual of Mental Disorders, version IV) and ICD-10 
diagnosis (International Statistical Classification of Disease) [454]. Where 
appropriate, ICD-10 dementia severity rating, NINCDS-ADRDA (National 
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s 
Disease and Related Disorders Association) AD diagnosis (probable or 
possible) and MCI classifications were applied. Diagnosis of individuals with 
MCI was made according to the internationally agreed criteria [455, 456] and 
these participants had also reported memory difficulties either personally or 
through an informant. The clinical review panel comprised a neurologist, a 
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geriatrician, neuropsychologists and geriatric psychiatrists to ensure 
consistency of diagnoses.  
2.2.3  Study visit 
All participants who met the inclusion criteria were scheduled for a study visit at 
one of three locations in Melbourne and one location in Perth. On the morning 
of the appointment, measurements of pulse, blood pressure, height, weight and 
abdominal circumference were obtained. Following these measurements, an 
80mL blood sample (following an overnight fast) was collected from the 
antecubital vein using standard venipuncture technique. Following blood 
collection, participants were given a light breakfast and then required to 
complete a medical history questionnaire. A series of cognitive and mood 
assessments were then performed. Separate appointments were made for the 
purpose of undertaking brain scans. All procedures were repeated at the 18 
month follow up assessment. 
2.2.4  Demographics, medical history and medication use 
A detailed questionnaire regarding demographic information, medical history, 
medication use and lifestyle (alcohol consumption and smoking) was completed 
by each participant. Demographic information included marital status, country of 
birth, primary language spoken, living arrangements, handedness, occupation 
(past/present), primary source of income, years of education, pet ownership and 
participation in community activities. Medical questions included current or past 
history of cardiovascular disease, hypertension, stroke, diabetes, visual defects 
(including colour deficiency), cancer, history of falls, thyroid/parathyroid disease, 
gastrointestinal complaints, arthritis, kidney disease, liver disease, joint 
replacement, epilepsy, serious head injury, neurological disorders, depression, 
anxiety and psychiatric disorders. Current medication use including name, dose 
and frequency was also recorded. 
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2.3  Blood Biomarkers 
2.3.1  Sample collection [453] 
At baseline and 18 month follow-up, 80mL of fasted blood was collected. From 
each participant, three different blood collection tubes were used: 
 Lithium heparin 
 EDTA with added prostaglandin E1 (Sapphire Biosciences, 33.3ng/mL) 
 Serum tubes 
 
27mL of the 80mL collected was sent to either PathWest Laboratory Medicine, 
Nedlands, Western Australia or Melbourne Health, Victoria for analysis of full 
blood count, erythrocyte sedimentation rate, urea and electrolytes, creatinine, 
androgen levels, globulin levels, sex hormone binding globulin (SHBG), 
glomerular filtration rate, calcium, liver function tests, serum lipids, 
homocysteine, serum and red cell folate, B12, glucose, insulin, caeruloplasmin, 
ferritin/transferrin/iron, oestradiol, luteinising hormone, thyroid function tests 
(thyroid stimulating hormone, free thyroxine, free triiodothyronine) and prostate 
specific antigen (males only). 0.5mL of whole blood was sent for apolipoprotein 
E (APOE) genotyping (see Section 2.3.2). The remaining blood was 
fractionated into the following components: 
 Serum 
 Plasma 
 Platelets 
 Red blood cells 
 White blood cells (in distilled water) 
 White blood cells in RNA later, (Ambion, Thermo Fisher Scientific, 
Waltham, MA, USA). 
 
These blood fractions were stored in NUNC cryovials (Nalge Nunc International, 
Rochester, NY, USA) in liquid nitrogen in aliquots which ranged in size from 
0.25mL to 1.0mL.  
The EDTA plasma samples were used for lipid extraction and profiling. 
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2.3.2  DNA extraction and APOE genotyping 
DNA was extracted from 200μL of whole blood using a Qiagen Blood Mini-Kit 
(Qiagen, Hilden, Germany). 200μL of whole blood was added to 200μL of buffer 
containing proteinase K, pulse vortexed for 15 seconds and then incubated for 
10 minutes at 56°C. After centrifugation, 200μL of absolute ethanol was added 
to the tube. The mixture was then applied to the QIAamp Mini Spin Column and 
centrifuged for 1 minute at 6,000g. The filtrate was discarded and the QIAamp 
Mini Spin Column placed into a clean tube, followed by the addition of 500μL of 
buffer and centrifugation for 1 minute at 6,000g. Again the filtrate was discarded 
and the QIAamp Mini Spin Column placed into a clean tube with the addition of 
500μL of buffer and centrifugation for 3 minutes at 20,000g. The column was 
placed into a clean tube with the addition of 200μL distilled water and incubated 
at room temperature for 1 minute before centrifugation at 6,000g for 1 minute. 
The extracted DNA was genotyped by the following published method [457]: 
PCR reaction: 
200nM primer Forward: 5’ GCCTACAAATCGGAACTGGA 3’ 
   Reverse: 5’ ACCTGCTCCTTCACCTCGT 3’ 
1 unit Platinum Taq Polymerase (Invitrogen, Carlsbad, CA, USA) 
1.5mM Magnesium chloride 
200μM deoxyribonucleotide triphosphate  
94°C 7 secs denaturation 
(94°C for 30 secs, 55°C for 30 secs, 72°C for 30 secs) x 30 cycles 
Sequencing with the forward primer was carried out with BDV3.1 on a 3130-xl 
genetic analyser (Applied Biosystems, Foster City, CA, USA). 
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The APOE genotype was then determined using the following fragments: 
Table 2.1: APOE genotype and fragment size as determined by DNA sequencing.  
Genotype Fragment Size (bp) 
ε2/ε2 91 + 83 
ε2/ε3 91 + 83 + 48 + 35 
ε2/ε4 91 + 83 + 72 + 48 + 35 
ε3/ε3 91 + 48 + 35 
ε3/ε4 91 + 72 + 48 + 35 
ε4/ε4 72 + 48 + 35 
 
bp: base pairs. 
APOE genotyping was undertaken and the protocol provided by Dr Simon 
Laws. 
2.3.3  Sample extraction for lipid profiling 
A modified Bligh and Dyer method was used [458]. 
900µL of ice-cold organic solvent mixture (chloroform/methanol 1:2 v/v) was 
added to 150µL of plasma (in duplicate) and vortexed for 15 seconds. The 
samples were then incubated in a vacuum (Desi-Vac Container) on ice inside a 
4°C dark room with agitation at 180rpm for one hour. After incubation, 250µL of 
ice-cold water and 300µL of ice-cold chloroform were added to the sample to 
break the phase. The samples were then vortexed for 15 seconds and 
incubated on ice for one minute and then vortexed again for 15 seconds. The 
samples were subsequently centrifuged at 9,000rpm for 2 minutes at 4°C. The 
lower organic phase was transferred into a clean eppendorf tube and 500µL of 
ice cold chloroform added to the original tube for a second extraction. After 
vortexing for 15 seconds this sample was placed in a vacuum on ice inside a 
4°C dark room with agitation at 180rpm for 30-60 minutes. Following 
centrifugation the lower organic phase was removed and added to the original 
extracted lower phase. The pooled organic phases from both extractions were 
dried in a Savant SpeedVac® (Thermo Fisher Scientific, Scoresby, Victoria, 
Australia). The dried, extracted lipids were stored at -80°C until required for 
analysis.  
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2.3.4  Sample preparation for shotgun lipidomics (direct-flow  
  injection)  
For analysis the dried samples were reconstituted in 100L of 
chloroform/methanol (1:1 v/v). The sample was vortexed and centrifuged at 
12,000 rpm for 2 minutes. Following centrifugation 80L was added to 120L of 
chloroform/methanol (1:1 v/v). The sample was again centrifuged at 12,000 for 
2 minutes. 80L was then transferred into a sample vial with 80L of the 
working internal standard mix (shown in Table 2.2) and loaded on to the 
analyser. For the positive mode samples a further dilution was required. 10μl of 
the prepared sample (already spiked with internal standard) was removed from 
the vial and mixed in a separate vial with 80μl of chloroform/methanol (1:1 v/v). 
The internal standard mix was prepared as outlined in Table 2.2. 
Table 2.2: Internal Standards used to prepare mix for lipid profiling. 
Standard [Stock mg/mL] [Working μg/mL] 
DMPE 0.2 5 
DMPG 0.2 2 
DMPS 0.5 2 
DMPA 0.1 1 
diC8PI 0.25 2 
DMPC 0.2 10 
GluCer 0.1 2 
SM 0.5 6 
C17Cer 0.1 2 
LysoPE 0.1 0.5 
LysoPG 0.1 0.5 
LysoPI 0.1 0.5 
 
DMPE: 1,2-dimyristoyl-glycero-3-phosphoethanolamine, DMPG: dimyristoyl-
phosphatidylglycerol, DMPS: dimyristoyl-phosphatidylserine, DMPA: dimyristoyl-phosphatidic 
acid, diC8PI: dioctanoyl-phosphatidylinositol, DMPC: dimyristoyl-phosphatidylcholine, GluCer: 
C8-Glucosylceramide, SM: C-12 sphingomyelin, C17Cer: C17-ceramide, LysoPE: 
Lysophosphatidylethanolamine, LysoPG: Lysophosphatidylglycerol, LysoPI: 
Lysophosphatidylinositol. 
The diC8-PI was supplied by Echelon Bioscience Inc, USA. All other lipids were 
supplied by Avanti Polar Lipids, Alabaster, Alabama, USA. 
The working mix was stored wrapped in foil at -80°C 
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2.3.5  Shotgun lipid profiling by mass spectrometry 
Electrospray ionisation mass spectrometry (ESI-MS) was performed on an 
Applied Biosystems (Foster City, CA, USA) high performance FlashQuant™ 
workstation that incorporates a 4000Q Trap Instrument (a triple 
quadrupole/linear ion trap liquid chromatography-tandem mass spectrometer 
(MS/MS) and a Shimadzu High Performance Liquid Chromatography (HPLC) 
(Shimadzu, Kyoto, KYT, Japan) autosampler to quantify individual polar lipids 
[370]. This method combines triple quadrupole scan modes with linear ion trap 
scans, therefore allowing multiple analyses. The sample was mixed with 
chloroform/methanol (1:1 v/v) in the autosampler and then injected into the 
mass spectrometer via loop injections with the mobile phase which was 
chloroform/methanol (1:1 v/v), at a flow rate of 0.25mL/min. In the ESI chamber, 
the analyte is volatilised by the tiny charged capillary and the sample propelled 
out of the capillary in the form of an aerosol. Nitrogen gas was used as the 
carrier gas. The sample then passes through to the second chamber (MSI) and 
then through the collision induced dissociation (CID) chamber where further 
fragmentation of the analyte occurs (see Figure 2.2). The MS2 chamber is a 
quadrupole ion trap, which acts as a mass-selective filter, trapping and 
sequentially ejecting the ions.  
 
Figure 2.2: Schematic of method used for lipid profiling.  
ESI: Electrospray ionisation, MS1: mass spectrometer chamber 1, CID: Collison induced 
dissociation chamber, MS2: Quadrupole ion trap. 
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In the example used in the figure, the parent lipid is detected at 885.8 m/z 
(mass to charge) and after passing through the CID a unique fragment at 241.1 
m/z is detected. The resultant mass to charge ratio of 885.8/241.1 identifies this 
as phosphatidylinositol (PI 38:4), where the sn-1 and sn-2 side chains contain 
fatty acids with a sum of 38 carbons and 4 double bonds.  
Each individual sample is spiked with a known quantity of commercially 
available internal standard as described in Table 2.2. Multiple reaction 
monitoring (MRM) transitions were used for quantitative analyses and were set 
up based on product and precursor ion analysis of various lipid head groups. 
The signal intensity of each MRM value was normalised to the signal intensity of 
the spiked internal standards and the sum of the individual lipid species before 
being corrected for molecular weight. 
2.3.6  Phospholipid Transfer Protein (PLTP) Activity Assay 
A commercially available PLTP activity assay kit was purchased from Roar 
Biomedical, Inc. Audubon Biomedical Centre, 3960 Broadway, New York, USA 
and was utilised according to the manufacturer’s protocol. PLTP mediates the 
transfer of an exogenous fluorescent substrate in this assay. Briefly, frozen 
plasma samples were thawed on ice and then centrifuged at 12,000rpm for 10 
minutes at 4°C. A 96 well black microtitre plate (Nalge Nunc International, 
Rochester, NY, USA) was placed on wet ice to cool. A grand mix was prepared 
containing 4200μL of 1 x assay buffer and 300μL of donor particle. 45μL of this 
grand mix was added to each well of the microtitre plate. 5μL of sample or an 
assay blank (5μL of 1 x assay buffer) was added to the wells. All plasma 
samples, control samples and blanks were run in duplicate. 50μL of the 
acceptor particle was then added using an 8 tip multichannel pipette. The plate 
was covered and incubated in a 37°C water bath for 20 minutes. Following 
incubation, the plate cover was removed and the fluorescence read at 37°C 
using an Enspire Multimode Plate Reader (Perkin Elmer, Waltham, MA, USA) 
with the excitation and emission wavelengths set at 465nm and 535nm 
respectively. 
While the plate containing the samples, controls and blanks was incubating a 
standard curve was prepared for a concentration range of 0-80 picomoles. Six 
Chapter 2 – Materials and Methods 
 
85 
 
tubes were labelled S0 to S5, each containing 1mL of isopropanol, with tube S5 
containing an additional 1mL. 5μL of PLTP donor particle was added to tube S5 
which was vortexed to adequately disperse the donor particle in the 
isopropanol. 1mL of S5 was transferred to S4, 1mL of S4 transferred to S3, 1mL 
of S3 transferred to S2, 1mL of S2 transferred to S1, with vortex mixing after 
each addition. S0 is the isopropanol blank. 100μL of each standard was 
pipetted, in duplicate, into two rows of a black microtitre plate (separate to the 
sample plate) and fluorescence read (Ex:465 nm; Em:535 nm) at 37°C. A 
standard curve was created by plotting the fluorescence intensity versus the 
picomole concentrations of the standards read. The fluorescence intensity units 
transferred during the incubation time were determined by subtracting the assay 
blank (assays performed without plasma, but using 5μL 1x assay buffer) from 
the fluorescence values of the samples and then applied to the standard curve 
to obtain a PLTP activity level. 
2.3.7   Plasma beta amyloid  
Plasma Aβ1-40 and Aβ1-42 were measured according to the manufacturer’s 
protocol by a commercial kit (INNO_BIA plasma Aβ assay, Innogenetics, Inc., 
Gent, Belgium). Briefly, the thawed plasma samples were diluted 1:3 using the 
supplied buffer. Coated beads were vortexed and sonicated for 3 minutes, 
diluted 100 times in diluent and protected from light. The pre-made standards 
and controls were thawed at room temperature and loaded onto the plate after 
vortexing. All standards, controls and plasma samples were run in duplicate. 
For the measurement of Aβ1-40 and A1-42, Conjugate 1A was diluted 100 times 
with Conjugate Diluent. A 96-well polyvinylidene fluoride microfilter plate was 
washed once with Wash Solution, followed by addition of 100μL of the diluted 
bead mix to each well. The contents of the plate were aspirated by vacuum and 
25μL of diluted Conjugate 1A was then added to each well. 75μL of standards, 
controls and diluted plasma was then added to the appropriate well. Assay 
blanks used Diluent only in place of sample. The plate was covered with foil and 
incubated at 4°C overnight on an orbital plate shaker. Following overnight 
incubation, the Detection Conjugate was diluted 100x in Diluent and protected 
from light. The plate was aspirated by vacuum and washed three times with 
wash solution. 100μL of diluted Detection Conjugate was then added to each 
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well. The plate was covered with foil and incubated at room temperature for 1 
hour on an orbital plate shaker. Following incubation, the wells were aspirated 
and washed 3 times with Wash Solution. 100μL of Reading Solution was added 
to each well and the plate covered with foil and placed on an orbital plate 
shaker for at least 2 minutes to a maximum of 5 minutes. The plates were read 
using a Luminex xMAP reader system (Bio-Plex 200 System, Bio-Rad). A 
minimum of 100 beads per region were read for each sample. Data analysis 
was performed using a 5-PL logarithmic equation built into the instrument 
software, which automatically calculated for dilution factors. The plasma Aβ1-
42:Aβ1-40 ratio was calculated. The ratio is preferred to measurement of Aβ1-42 
alone as Aβ1-40 is taken into account as an internal reference. Dr Alan Rembach 
provided the protocol and performed the plasma Aβ assay. 
2.3.8  Plasma apolipoprotein E (apoE) 
Plasma apoE was measured according to the manufacturer’s protocol by a 
commercial kit (ApoE4/Pan ApoE ELISA, MBL co., Ltd., Woburn, USA). This 
sandwich enzyme-linked immunosorbent assay (ELISA) kit measures the 
amount of total ApoE using purified polyclonal antibodies against ApoE. Briefly, 
thawed plasma samples were diluted 1:500 using the Assay Diluent. Working 
concentrations of the standards were prepared from solutions of the provided 
calibrator, which was reconstituted 1:10 with the assay diluent. All standards, 
controls and plasma samples were run in duplicate. Standards or thawed, 
diluted plasma samples were loaded into microwell strips that were coated with 
anti-Human Pan-ApoE antibody. The plates were covered and incubated at 
37°C for 1 hour. Following incubation the plate was washed four times with 
wash solution. 100μL of a peroxidase conjugated anti-ApoE polyclonal antibody 
was then added and incubated at 37°C for 1 hour. The plates were again 
washed before the addition of 100μL of the peroxide substrate, followed by 
further incubation at 37°C for 30 minutes. To terminate the enzyme reaction and 
stabilise the developed colour, 100μL of an acid solution was added to each 
well. The optical density of each well was measured at 450nm using a BMG 
microplate reader. Concentrations of Pan-ApoE were determined from a 
standard curve based on reference standards. The sensitivity of the assay is 
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8ng/mL. The ApoE assay was performed and the protocol provided by Dr Veer 
Gupta. 
2.3.9   High Density Lipoprotein (HDL) cholesterol - subfractions 
Plasma HDL cholesterol sub-fractions were analysed using the Lipoprint system 
(Quantimetrix, Redondo Beach, CA, USA), according to the manufacturer’s 
protocol. Briefly, 25μL of plasma was added to loading buffer in glass gel tubes 
and left for 30 minutes to polymerise. Samples were then separated in the 
electrophoretic chamber at 3mA per tube for 1-1.5 hours. Following separation 
the gels were scanned and the sub-fraction band intensities were obtained 
using the supplied software. Ten subclasses of HDL were measured, which 
were divided into three groups; HDL large (subclasses 1-3), HDL intermediate 
(subclasses 4-6) and HDL small (subclasses 7-10). Dr Steve Pedrini and Dr 
Eugene Hone provided the protocol and performed the HDL subfraction 
analyses. 
2.3.10  Plasma clusterin  
Plasma clusterin was measured according to the manufacturer’s protocol using 
a commercial kit (Quantikine® ELISA, Human Clusterin Immunoassay, R&D 
Systems, Inc., Minneapolis, USA). This sandwich immunoassay kit measures 
the amount of clusterin using a specific monoclonal antibody. Briefly, thawed 
plasma samples were diluted 1:2000 using Calibrator Diluent RD5T. Working 
concentrations of the clusterin standard were prepared from a series of dilutions 
with calibrator diluents to a range of 0-200ng/mL. All standards, controls and 
plasma samples were run in duplicate. 100μL of RD1-19 assay diluent was 
added to the wells of the microplate that were coated with anti-human clusterin 
antibody. 50μL of standard, control or sample were loaded into the appropriate 
wells. The plates were covered and incubated for two hours at room 
temperature on a horizontal orbital microplate shaker. Following incubation 
each well was aspirated and washed with wash buffer four times. 200μL of 
Clusterin Conjugate was then added and the covered plate incubated at room 
temperature for two hours on the shaker. The plates were again aspirated / 
washed four times before the addition of 200μL of substrate solution, followed 
by further incubation at room temperature for 30 minutes. To terminate the 
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enzyme reaction, 50μL of stop solution was added to each well. The optical 
density of each well was measured at 450nm using a BMG microplate reader. 
Concentrations of Clusterin were determined from a standard curve based on 
the supplied reference standards. The sensitivity of the assay is 0.189nM/mL. 
The Clusterin assay was performed by Dr Veer Gupta. 
2.3.11  Apolipoprotein AI (ApoAI) 
Plasma ApoAI was measured as part of the Rules Based Medicine (RBM, 
Austin, TX, USA) analysis and biomarker panel used as part of the AIBL study. 
Plasma samples were analysed with a 151-analyte multiplex Human Discovery 
Map® v1.0 panel. Only ApoAI was selected for use in investigating PLTP 
activity levels (see Chapter 5). 
2.4  Neuroimaging Biomarkers 
2.4.1  Image acquisition 
2.4.1.1 Magnetic resonance imaging  
Protocol provided by Dr Pierrick Bourgeat of CSIRO, Brisbane for the AIBL study: 
“Participants underwent T1 weighted magnetic resonance imaging (MRI) using 
the ADNI 3-dimensional (3D) Magnetization Prepared Rapid Gradient Echo 
(MPRAGE) sequence, with a 1 x 1 mm in-plane resolution and 1.2 mm slice 
thickness, repetition time/echo time/inversion time = 2300 ms/2.98 ms/900 ms, 
flip angle 9°, and field of view 240 x 256 and 160 slices.” 
2.4.1.2 [11C] Pittsburgh compound-B positron emission tomography 
Protocol provided by Dr Victor Villemagne of Austin Health, Heidelberg, Victoria 
for the AIBL study: “Participants underwent a [11C] Pittsburgh compound-B 
positron emission tomography (PiB PET) scan at Austin Health Centre for PET, 
Melbourne or Western Australia PET and cyclotron service, Sir Charles Gairdner 
Hospital and Oceanic Medical Imaging, Perth. [11C] PiB production was 
performed using a one-step [11C] methyl triflate approach. The average 
radiochemical yield was 30% after a synthesis time of 45 minutes with a purity of 
> 98% and a specific activity of 30 ± 7.5 GBq/μmol. Each subject received an 
intravenous injection of ~370 MBq [11C] PiB over one minute. PET images were 
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acquired on a Phillips AllegroTM (Phillips Medical Systems, Eindhoven, The 
Netherlands) PET camera, 40-70 minutes post-PiB injection. A transmission scan 
was performed for attenuation correction. PET images were reconstructed using 
a 3D RAMLA algorithm using a voxel size of 2.0 x 2.0 x 2.0 mm3 (x y z). Summed 
images for the 40-70 minute time frame were used.” 
2.4.2   Image processing 
2.4.2.1  Magnetic resonance imaging tissue segmentation 
Protocol provided by Dr Pierrick Bourgeat of CSIRO, Brisbane for the AIBL study: 
“For each subject, the T1 weighted images were classified into grey matter, white 
matter and cerebrospinal fluid using an implementation of the expectation 
maximization segmentation algorithm [459]. Briefly, using a mix of Gaussian 
distributions, this algorithm models image intensity histograms. The parameters 
of the Gaussian mixture are iteratively updated using an expectation 
maximisation approach. In order to provide initialization and spatial consistency 
to the expectation maximisation algorithm, an atlas and associated probability 
maps of grey matter, white matter and cerebrospinal fluid were spatially 
normalized to each individual scan, first through an affine registration, and then 
using a diffeomorphic non-rigid registration [460]. The regions of interest (ROI; 
hippocampus, anterior cingulate gyrus, posterior cingulate gyrus, temporal lobes 
and others) were propagated from the atlas to the T1W to extract the various 
regional volumes. To improve the robustness of the approach, it was repeated 
nine times, with different elderly atlases, resulting in nine segmentations and nine 
ROIs. The segmentations and the ROIs were voted to generate a consensus 
grey matter, white matter and cerebrospinal fluid segmentation as well as a 
consensus ROI for the investigated brain regions. The grey matter segmentation 
was then used to mask out non grey matter voxels from the ROI. Region of 
interest volumes were averaged over both hemispheres. The processing of MRIs 
was performed by Dr Pierrick Bourgeat of CSIRO, Brisbane. All volumetric 
measures of brain regions were corrected for intracranial volume (ICV) using the 
following equation: 
Adjusted volume = raw volume – b x (ICV – mean ICV); where b is the slope of 
the regression of an ROI on ICV.” 
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2.4.2.2  Pittsburgh compound-B positron emission tomography  
   image analysis 
Protocol provided by Dr Victor Villemagne of Austin Health, Heidelberg, Victoria 
for the AIBL study: “Acquired [11C] PiB PET images were processed using a 
semi-automatic ROI method. The semiautomatic method used a preset template 
of narrow cortical ROIs that were applied to the PiB scan via placement on the 
subject’s co-registered MRI by an operator who was blind to the subject’s clinical 
status. Co-registration of each individual’s MRI with the PET images was 
performed with SPM5 [Statistical Parametric Mapping 5, University College 
London, UK; 461]. The region of interest template was placed on the co-
registered MRI and then transferred to the co-registered PET images. Follow-up 
PiB images were co-registered with the baseline PiB images and the same ROI 
templates were applied to baseline and follow-up scans. Standardised uptake 
values (SUV) for PiB were calculated for all brain regions examined and standard 
uptake value ratios (SUVR) were generated by dividing all regional SUV by the 
cerebellar cortex SUV. The cerebrellar cortex was used as a reference region as 
it is relatively devoid of senile plaques and shows no PiB binding in controls or 
AD [462, 463]. Region of interest measurements were averaged across both 
hemispheres. Neocortical Aβ burden was expressed as the average SUVR of the 
area-weighted mean for the following ROIs: frontal (consisting of dorsolateral 
prefrontal, ventrolateral prefrontal and orbitofrontal regions), superior parietal, 
lateral temporal, lateral occipital and anterior and posterior cingulate. The image 
analysis of PiB PET scans was performed by Dr Victor Villemagne and 
colleagues of Austin Health, Heidelberg, Victoria.” 
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2.5  Statistical Analysis 
Statistical analysis of the data will be described in detail in the methods section 
of each chapter. All assumptions for statistical tests were considered and met 
before detailed analysis was undertaken. All analyses were performed using R 
version 3.0.2 (R Development Core team, 2009, Vienna, Austria). Statistical 
analyses were performed by Biostatisticians Dr James Doecke and Dr 
Samantha Burnham using statistical models previously used for the AIBL study. 
Statistical methods utilised for this thesis are summarised in Table 2.3. 
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Table 2.3: Summary of statistical methods. 
Data to be analysed Statistical Method Used 
Descriptive statistics: 
Categorical variables 
Continuous variables 
MMSE 
 
χ2 
ANOVA 
Kruskal-Wallace 
Mean lipid levels differences ANOVA 
Significant differences in lipid levels 
between clinical classifications pre 
adjustment for co-variates 
LIMMA 
Significant differences in lipid levels 
between clinical classifications 
including adjustment for co-variates 
GLM 
Those lipids which are able to 
predict clinical classification with the 
greatest certainty. 
Variable selection 
Relationship between lipids selected 
by variable selection 
Partitioning Around Medoid 
Clustering (Kaufman and 
Rousseeuw, 1990)   and 
Pearson’s correlations 
Sensitivity/Specificity of predictive 
lipid panel 
ROC curve 
Longitudinal lipid data comparing 
baseline to 18 month data 
LIMMA, GLM, Multiple regression 
analysis 
Correlations between PLTP and 
other blood and neuroimaging 
biomarkers 
Pearson’s correlations 
 
Χ
2
: Chi squared, ANOVA: Analysis of variance, MMSE: Mini-mental state examination, LIMMA: 
Linear Models for Microarray Data, GLM: Generalised Linear Model, ROC: Receiver Operating 
Characteristics.
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Chapter 3 – Plasma Lipid Profiles In AIBL Baseline Samples 
3.1  Introduction 
A huge research effort in the past few decades has lead to a greater 
understanding of the patho-physiology of Alzheimer’s disease. However, 
despite these great advances many of the fundamental questions regarding AD 
remain unanswered. These questions include: what risk factors contribute to 
disease and can or how may these risk factors be modified to reduce disease 
susceptibility? Can we identify those at risk by investigating biomarkers that 
reveal increased susceptibility to disease or indicate accelerated disease 
progression? With the identification of lipid biomarkers, can we explain the 
aberrant biochemical pathways underlying these findings and use this 
information to design prevention strategies or implement therapeutic 
interventions? This study aims to contribute to the existing body of literature to 
help address these questions.  
The nervous system has the second highest concentration of lipids, exceeded 
only by adipose tissue. Lipids in the nervous system also show enormous 
structural diversity and lipidomic studies will assist in understanding the 
mechanistic significance of lipid diversity and the biology and disease of 
neurons. Neurological disorders involve a complex interaction of proteins and 
lipids, which lead to the increased formation of protein deposits such as Aβ; a 
major component of AD pathology [276].  
A key development in the study of lipids and neurodegenerative disease has 
been in the advancement of technologies to determine profiles of lipids and their 
interacting partners. The improved technology in the field of mass spectrometry 
has enabled more specific characterisation of lipid species in larger cohorts. 
Three approaches are generally used: “Shotgun lipidomics” uses direct infusion 
of the sample with multiple scan modes to provide broad coverage of lipid 
species, which are quantitated with the use of internal standards and allows 
high sample throughput [381]. A more targeted approach combines liquid 
chromatography with multiple reaction monitoring, also allowing precise 
quantitation with the use of internal standards [450, 464]. Finally a non-targeted 
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approach combines liquid chromatography with high mass accuracy analysis to 
profile as many groups of lipids as possible, some sub-species of which may be 
unidentified [465]. The method is usually selected after consideration of factors 
such as type of sample, sample number to be analysed and scope of the 
project. The direct infusion method was chosen for this project due to the high 
sample number (>1000) and requirement for broad coverage of lipid species. 
Lipidomic research has particular relevance to biomarker development and 
therefore this study, especially when there is great overlap with AD and other 
conditions involving altered lipid metabolism, such as cardiovascular disease 
and diabetes, which are themselves risk factors for AD [270]. Specific lipid 
classes and sub-classes are thought to play an important role in AD, where 
changes in brain lipid composition have been reported [273]. Lipids are now 
considered to play other important roles besides merely serving as stored 
energy or the matrix of membranes in which proteins are embedded. The 
majority of cellular lipids form the membrane bilayer, whose integrity and 
physical characteristics are vital for cellular processes. Membrane lipids are 
involved in vesicle fusion, regulation of ion fluxes and create specialised regions 
within cells that are involved with cellular communication. They are also very 
important signalling molecules via generation of second messengers created by 
the actions of a variety of intracellular enzymes. The diversity of lipids that 
participate in signalling is highlighted by the multiple integrated roles of 
eicosanoids, docosanoids, lysolipids, diacylglycerols, ceramides, phosphatidic 
acids and other cell signalling lipids. Neural lipids alter the geometric properties 
of membranes and act as ligands for proteins.  
As mentioned above, specific lipid classes and sub-classes play an important 
role in AD, where changes in brain lipid composition have been reported 
involving all classes (cholesterol, sphingolipids, phospholipids and their 
metabolites) [273]. Changes in composition and metabolism of several 
phospholipids have been described in brain tissue from AD patients, including 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphoinositol (PI) 
and plasmalogens [270, 335, 336] and loss of neuronal membrane 
phospholipids and associated fatty acids is suggested to be an early event in 
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the development of AD [466-468].  Glycerophospholipids are a source of lipid 
mediators, including arachidonic acid (AA) and docosahexaenoic acid (DHA), 
which are released from membrane phospholipids by the action of 
phospholipases. Variations in phospholipid metabolizing enzymes, such as 
phospholipase A2 (PLA2), phospholipase C, phospholipase D and 
phosphoinositidases have also been reported in AD [342, 343]. Phospholipase 
D, which hydrolyses phosphatidylcholine to produce phosphatidic acid (PA) and 
choline has been implicated in AD pathology [343]. Post mortem studies of AD 
brains compared to control brains have shown elevated levels of phospholipid 
degradation products such as LysoPC, glycerophosphocholine, and 
glycerophosphoethanolamine [371, 469, 470]. Brain sphingolipid metabolism 
has also been shown to be altered in AD [291, 335, 471]. 
Despite many reports in the literature of animal and tissue studies linking lipids 
to AD, few studies have examined cerebrospinal fluid (CSF) or blood for 
changes in lipid species. Higher CSF glycerophosphocholine levels were 
reported in AD patients compared to age-matched controls [472]. Some studies 
have reported a lower LysoPC to PC ratio in the CSF of AD patients compared 
to normal controls [371], while a more recent study reported a higher ratio of 
LysoPC to PC in AD [375]. These studies were cross-sectional and had low 
participant numbers (n=19/19 healthy controls/AD and n=70/40/29 healthy 
controls/MCI/AD respectively). Several reports have examined the association 
of levels of plasma plasmalogens. A pilot study involving 40 participants 
evaluated the relationship between serum total ethanolamine plasmalogen 
levels and Alzheimer Disease Assessment Scale–Cognitive (ADAS-Cog) 
scores. This study found that ADAS-Cog scores increased significantly in AD 
patients with circulating plasmalogen levels that were less than 75% of that of 
the age-matched controls at baseline [357]. Further, serum plasmalogen 
ethanolamine levels were measured in five independent populations comprising 
clinically demented and non-demented subjects. This study showed reduced 
serum plasmalogen levels at all stages of dementia [341]. 
Serum sphingomyelin (SM) and ceramides have been measured in several 
studies as part of the longitudinal Women’s Health and Aging study II of 
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cognitive impairment (WHASII) [163, 422, 423, 473, 474]. These studies 
showed that high ceramides were associated with memory impairment and 
hippocampal volume loss and associated with incident dementia when 
measured as an outcome. The studies found lower levels of serum ceramides 
and SM associated with memory impairment in the cross-sectional data but 
higher levels in the longitudinal data, suggesting that serum ceramides and SM 
vary according to time of onset of memory impairment. However, the number of 
AD cases in this study was low, limited to women and the samples were 
collected from individuals in a non-fasted state; a factor that can significantly 
influence plasma lipid profiles.  
A recent probe into the plasma lipidome of individuals with metabolic syndrome 
and obesity; risk factors for AD, showed various changes including increased 
LysoPC, decreased ether PLs and significant increases in some PC and PE 
species. Additionally several ceramide species were increased [340]. Therefore 
the importance of having the neuroimaging data collected as part of the study 
utilised in this thesis cannot be overstated as the SUVR shows that abnormal 
lipid profiles are likely to be AD related and facilitates delineation of abnormal 
lipid profiles associated other age-related co-morbidities that often exist with 
AD. 
Several reasons can be suggested for the discrepancies reported between 
various studies. These include study design, disease classification, analytical 
factors, sample type and sample number. However the weight of evidence is 
compelling enough to suggest that the delicate equilibrium of phospholipid and 
sphingolipid metabolism is disturbed in AD.  
The separation of the brain from the periphery presents a particular challenge 
when studying the relevance of plasma lipids to neurological disease as some 
lipids are transported across the blood brain barrier, while others appear to be 
excluded. This separation can be compromised by age-related changes in the 
integrity of the blood brain barrier, thereby altering lipid and Aβ kinetics. Chapter 
1 described in detail how changes in membrane composition in the brain can 
affect Aβ production and promote aggregation and toxicity. Chapter 1 also 
described how peripheral lipids and lipoproteins can influence pathological 
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processes in the AD brain. High plasma cholesterol has been associated with 
increased delivery of peripheral lipoprotein associated Aβ [475]. Additionally, 
peripheral lipids, influenced by diet and metabolic hormones will have an effect 
on brain biochemistry and vasculature and on increased risk of developing 
cardiovascular and metabolic disease with associated abnormal plasma lipid 
profiles; all risk factors for AD.  
The results from previous studies provide enough optimism to warrant further 
investigation of lipid profiles in the highly characterised AIBL cohort. Many 
previous studies have targeted specific lipid groups, have not had the benefit of 
neuroimaging biomarkers such as MRI and PiB-PET as indicators of AD 
pathology, and have been cross sectional in design. The AIBL cohort has 
neuroimaging and blood biomarker data and is a longitudinal prospective study. 
In addition, the cohort is made up of a large number (n=1112) of well 
characterised participants, the blood has been collected in a fasted state and is 
enriched with those carrying the APOEε4 allele; a genetic risk factor for AD. In 
contrast to other studies, a broad range of lipid species will be measured in 
plasma to facilitate identification of a sensitive and specific biomarker panel for 
AD. To my knowledge, a study of a large, highly characterised cohort with 
biomarker and lifestyle data has not been pursued with respect to biomarker 
discovery using such a broad range of lipids. 
 
3.2  Aims 
This chapter aims to investigate plasma lipid profiles via a direct infusion with a 
multiple scans technique in the highly characterised Australian Imaging, 
Biomarkers and Lifestyle study of ageing (AIBL). Differences in lipid profiles 
between clinical classifications will be compared to supplementary data 
collected as part of this study, including brain amyloid burden and APOEε4 
allele carriage. The results will also be assessed for their ability to distinguish 
AD patients from cognitively normal individuals and those with mild cognitive 
impairment (MCI). 
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3.3  Methods 
Details of the study population and the methods for sample collection, lipid 
extraction, and analysis by electrospray ionisation tandem mass spectrometry 
(ESI-MS/MS) have been described in detail in Chapter 2, Sections 2.2 and 2.3. 
A total of 189 lipids were measured including sub-species of PE, LysoPE, PC, 
Lyso PC, PI, LysoPI, PA, PG, PS, ether PLs, SM and ceramides. This chapter 
describes cross sectional results where baseline samples only were used. 
The following figure provides a detailed breakdown of the clinical classifications 
of participants in the AIBL cohort at baseline.  
 
 
Figure 3.1: The AIBL cohort at baseline. There were 1,112 baseline samples. These were 
classified as 211 AD, 133 MCI and 768 healthy controls. Healthy controls can be further divided 
into 372 non-memory complainers (NMC) + 396 subjective memory complainers (SMC). 
Psychometric testing, neuroimaging, lifestyle data collection and APOEε4 genotyping were 
carried out on the participants and the blood collected was used for lipid profiling. 
Schematic adapted from an image provided by the AIBL Study Scientific Management 
Committee. 
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3.3.1  Statistical analysis 
To assess the study population demographics between the healthy controls, 
MCI and AD groups, χ2 analyses was used to test the effect of age, gender and 
APOEε4 allele status. A Kruskal-Wallis formula was applied to MMSE scores. 
Marginalised means and p-values were obtained for the lipid levels using a t-
test for two classifications (i.e. HC and AD or HC and MCI) or ANOVA for three 
classifications (HC, MCI and AD). Additionally ANOVA was used to test inter 
group differences in SUVR and hippocampal volume. 
The heatmaps were generated using Matlab version R2006a (Massachusetts, 
USA) and R version 3.0.2 was used to calculate the p-values. LIMMA (Linear 
Models for Microarray Data) analysis was used to obtain a Q value (false 
discovery adjusted value). The fold lipid change was calculated using 
unadjusted raw expression values to provide a relative lipid difference between 
clinical classifications. A generalised linear model (GLM) was used for those 
lipids selected by LIMMA which adjusted for age, gender, APOEε4 allele carrier 
status and site of collection (Melbourne or Perth). This GLM determines the 
pairwise differences in lipid species between the healthy control, MCI and AD 
groups. Using the Bonferroni multiple adjustment approach, the α value for p-
value comparison was 2.65E-4 (0.05/189), where 189 is the number of lipid 
species.  
Variable selection and prediction of classification analyses were conducted to 
choose a short list of lipid biomarkers capable of predicting a diagnosis of AD. 
These analyses utilised all 189 lipid species and not those identified by LIMMA 
and GLM. The variable selection pipeline utilised creates an importance ranking 
for each lipid species by applying four different statistical methods; random 
forest, boosted trees, regression trees and LIMMA, while using clinical 
classification as a binary outcome factor. The statistical pipeline was run 1000 
times and each time a lipid was selected, a frequency score was assigned if it 
was chosen from all four or three out of four statistical methods. Those lipids 
with the highest frequencies of selection were clustered using Partitioning 
Around Medoids (Kaufman and Rousseeuw, 1990) to find a central lipid and 
cluster other correlated lipids (from the variable selection) around it: This 
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correlates lipids that are related to each other without consideration of clinical 
classification. A CLARA (Clustering for Large Applications) algorithm was 
applied to create a clusplot of correlated lipids. Standard Pearson’s correlations 
were applied to the lipids chosen in the variable selection pathway and these 
lipids and R-values were subjected to further statistical assessment using a 
stepwise generalised linear model (GLM) to reduce the number of lipids in the 
final predictive model. This stepwise GLM algorithm removes lipids from the 
predictive model until the lipids left are those giving the best Akaike Information 
Criterion (AIC) report, which is a measure of the relative quality of a statistical 
model for a given set of data and therefore provides a means for selecting the 
best model. Once lipids were selected using the stepwise GLM, a reduced set 
of lipids were run using the class prediction statistical pathway. This pathway 
includes taking a random sample of the data (comprising 70%) as the training 
set, performing the GLM model, and obtaining predicted probabilities for each 
participant for the model fit. These predicted probabilities are then used to 
predict the remaining 30% of the data as a test set. This class prediction 
pathway was iterated through 100 times and then repeated after each individual 
lipid removal following assessment of model prediction accuracy. A final panel 
is selected that contains the least number of lipids with maximal sensitivity and 
specificity for predicting disease classification. Figure 3.2 summarises the 
statistical analyses described and used for the study of baseline lipid profiles in 
this chapter. 
Chapter 3: Plasma Lipid Profiles in AIBL Baseline Samples 
 
101 
 
 
 
Figure 3.2: Summary of statistical methods used for analysis of AIBL baseline samples. 
ANOVA: Analysis Of Variance, LIMMA: Linear Models for Microarray Data, GLM: Generalised 
Linear Model, CLARA: Clustering for Large Applications, sens/spec: Sensitivity and Specificity, 
SUVR: Standardised uptake value ratio. 
The R statistical software environment, version 3.0.2, was used for all statistical analysis (R 
Development Core Team, 2009). 
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3.4  Results 
The following table describes the demographics of the baseline cohort divided 
according to clinical classification.  
Table 3.1: AIBL baseline demographics. 
Characteristic HC MCI AD p-value 
Number (n) 733 125 204 
 Age, years (Mean ±SD) 70.59 (±7.02) 76.09 (±7.58) 78.83 (±8.52) <0.0001 
Gender (F/M) 425/308 71/54 127/77 0.495 
ApoE4 (-ve/+ve) 531/202 62/63 76/128 <0.0001 
MMSE, score (Mean ±SD) 29 (±1.2) 26 (±2.65) 20 (±5.25) <0.0001 
SUVR (n) 163 52 49 
 SUVR (Mean ±SD) 1.42 (±0.4) 1.88 (±0.58) 2.33 (±0.37) <0.0001 
Hippocampal Volume (n) 152 43 36 
 
Hippocampal Volume (Mean ±SD) 3.15 (±0.33) 2.93 (±0.38) 2.80 (±0.49) <0.0001 
HC: Healthy Controls, MCI: Mild Cognitive Impairment, AD: Alzheimer’s Disease, F: Female, M: 
Male, APOEε4: negative or positive for the APOEε4 allele, MMSE: Mini Mental State 
Examination, SUVR: Standard Uptake Value Ratio. Hippocampal volume is measured mL. The 
characteristics were composed using analysis of variance (ANOVA) to calculate differences for 
the continuous variables and X
2 
for categorical variables. A Kruskal-Wallis formula was applied 
to the MMSE scores. 
The cohort consisted of 733 healthy controls (HC), 125 MCI and 204 AD 
participants. Whilst the number of men and women in each classification did not 
significantly differ (p-value = 0.495), significant differences in mean age were 
seen in the AD group (p=<0.0001). The AD group are older, which is expected 
as AD is an age related disease. It is worthy of note that there are more 
APOEε4 +ve individuals in the AIBL cohort compared to epidemiological allele 
frequencies reported in other studies (see Table 1.3, Chapter 1). This is 
because the AIBL cohort was enriched with APOEε4 allele carriers. As 
expected, the mean MMSE score is lower in the MCI and AD groups compared 
to healthy controls and cerebral amyloid burden as depicted by mean SUVR is 
significantly higher in the MCI and AD groups compared to healthy controls and 
significantly higher in the AD group compared to MCI. Predictably, hippocampal 
volume is reduced in MCI and AD compared to the HC group. 
Of the original 1112 baseline samples a total of 1062 plasma samples were 
analysed to profile the lipids by direct flow injection mass spectrometry (ESI 
MS/MS), using the ABSciex QTrap 4000 instrument and multi reaction 
monitoring (MRM) which fragments the headgroups from their precursor lipids. 
Chapter 3: Plasma Lipid Profiles in AIBL Baseline Samples 
 
103 
 
Method details are described in Chapter 2, Sections 2.3.3-2.3.5. The missing 
samples are accounted for by failure to extract lipids at the extraction stage or 
failure of analysis at the mass spectrometry stage due to poor sample quality. 
Table 3.2 lists the 189 lipid species that were measured.
  
 
Lipid 
PE LysoPE PC PCp or ether LysoPC PI LysoPI PG LysoPG PS PA SM Cer 
PE34.2 LysoPE16.1 PC28.1 PCp32.0 LysoPC14.1 PI32.2 LysoPI16.1 PG34.2 LysoPG16.1 PS36.2 PA32.2 SM18.16.1 Cer.d18.1.16.0 
PE34.1 LysoPE16.0 PC32.3 PCp34.2..34.3e LysoPC14.0 PI32.1 LysoPI16.0 PG34.1 LysoPG16.0 PS36.1 PA32.1 SM18.16.0 Cer.d18.1.18.0 
PE36.5 LysoPE18.2 PC32.2 PCp34.1..34.2e LysoPC16.1 PI34.3 LysoPI18.2 PG34.0 LysoPG18.2 PS38.6 PA32.0 SM18.18.1 Cer.d18.1.20.0 
PE36.4 LysoPE18.1 PC32.1 PCp34.0..34.1e LysoPC16.0 PI34.2 LysoPI18.1 PG36.4 LysoPG18.1 PS38.5 PA34.2 SM18.18.0 Cer.d18.1.22.0 
PE36.3 LysoPE18.0 PC32.0 PCp36.4/etherPC LysoPC18.3 PI34.1 LysoPI18.0 PG36.3 LysoPG18.0 PS38.4 PA34.1 SM18.20.1 Cer.d18.1.24.1 
PE36.2 LysoPE20.1 PC34.6 PCp36.3/etherPC LysoPC18.2 PI34.0 LysoPI20.4  LysoPG16.1f PS40.6 PA34.0 SM18.20.0 Cer.d18.1.24.0 
PE36.1 LysoPE20.0 PC34.5 PCp36.2/etherPC LysoPC18.1 PI36.4 LysoPI20.3  LysoPG16.0f PS40.5 PA36.1 SM18.22.1 Cer.d18.0.16.0 
PE36.0 LysoPEp16.0 PC34.3 PCp36.1/etherPC LysoPC18.0 PI36.3 LysoPI20.2  LysoPG18.2f   SM18.22.0 Cer.d18.0.18.0 
PE38.7 LysoPEp18.1 PC34.2 PCp36.0/etherPC LysoPC20.4 PI36.2 LysoPI20.1  LysoPG18.1f   SM18.24.1 Cer.d18.0.20.0 
PE38.6 LysoPEp20.0 PC34.1 PCp38.5..38.6e LysoPC20.3 PI36.1 LysoPI20.0  LysoPG18.0f   SM18.24.0 Cer.d18.0.22.0 
PE38.5  PC36.5 PCp38.4..38.5e LysoPC16e.1 PI38.6   LysoPG20.4    Cer.d18.0.24.1 
PE38.4  PC36.4 PCp38.3..38.4e LysoPC18e.1 PI38.5   LysoPG22.6    Cer.d18.0.24.0 
PE40.6  PC36.3 PCp38.2..38.3e LysoPC18e.0 PI38.4   LysoPG22.5     
PE40.5  PC36.2 PCp38.1..38.2e LysoPC22.6 PI38.3        
PE40.4  PC36.1 PCp40.6..40.7e LysoPC22.5 PI38.2        
PE34p.3  PC36.0 PCp40.5..40.6e LysoPCp16.2 PI40.6  
 
PE34p.2  PC38.6 PCp40.4..40.5e LysoPCp16.1 PI40.5  
PE36p.4  PC38.5 PCp40.3..40.4e  PI40.4  
PE36p.3  PC38.4 PCp40.2..40.3e  PI40.3  
PE36p.2  PC38.3 PCp40.1..40.2e  PI40.2  
PE36p.1  PC38.1 PC30.0e    
PE38p.6  PC40.6 PC32.0e    
PE38p.5  PC40.5 PC34.0e    
PE38p.1  PC40.4     
PE40p.7       
PE40p.6       
PE40p.5       
PE40p.4       
PE42p.6       
PE42p.5       
PE42p.4       
Table 3.2: List of plasma lipid species measured in the AIBL baseline samples. 
 PE: Phosphatidylethanolamine, PC: Phosphatidylcholine, PI: Phosphatidylinositol, PG: 
Phosphatidylglycerol, PS:Phosphatidylserine, PA: Phosphatidic acid, SM: Sphingomyelin, 
Cer: Ceramide.  
p: vinyl ether bond or plasmalogen, e: ether linkage – can be plasmanyl (vinyl ether) or 
plasmenyl (alkyl ether)- (see Figure 1.5), etherPC: where fatty acyl groups cannot be 
determined, f: An alternate mass is also detected in Q3 of the mass spectrometer 
Numbers represent carbon atoms in acyl chain and number of unsaturated/double 
bonds. For example PE38.5 is phosphatidylethanolamine with two acyl chains totalling 
38 carbons and 5 unsaturated bonds. 
1
0
4
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The mass spectrometer generates electrical signals of each of the lipid species 
detected. The signal intensities of the individual lipids are normalised against 
the signal intensities of the lipid internal standards for each respective lipid 
group, corrected for their respective molecular weights before normalisation to 
the sum of all lipid species measured. The lipid levels are expressed as molar 
fractions. A heatmap of the baseline results was plotted in Figure 3.3 to enable 
visualisation of differences in lipid species between the clinical classification 
groups. 
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Figure 3.3: Heatmaps of lipid profiles of 1062 samples between clinical 
classification groups.  
The scale on right side of the charts displays the mean lipid levels expressed as molar 
fractions. HC: Healthy Control, MCI: Mild Cognitive Impairment, AD: Alzheimer’s 
Disease, PA: phosphatidic acid, PE: phosphatidylethanolamine, PC: 
phosphatidylcholine, PS: phosphatidylserine, PI: phosphatidylinositol, SM: 
sphingomyelin, Cer: ceramide. White colour reflects low levels, while black colour 
reflects higher levels. 
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The heatmaps depicted in Figure 3.3 showed all the individual lipid species 
measured in the HC, MCI and AD groups. The heatmaps show that many of the 
PE and PEp species were higher in AD compared to the healthy control group. 
Ceramides appear to be higher and SMs lower in the AD group compared to 
healthy controls. The abundance of the various lipid species in plasma is quite 
different with PC and SM being present in the greatest amounts. To allow this 
data to be displayed graphically three separate bar charts, to account for 
abundance differences, are depicted in Figure 3.4, showing the non-adjusted 
marginalised means of the summed lipid species groups and their significance, 
as represented by ANOVA generated p-values, with respect to clinical 
classification.  
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Figure 3.4: Grouped mean lipid levels differences between clinical classifications. A: PC: 
Phosphatidylcholine, SM: Sphingomyelin, PCp: Choline plasmalogen, LysoPC, PI: 
Phosphatidylinositol. B: PEp: Ethanolamine plasmalogen, PE: Phosphatidylethanolamine, Cer: 
Ceramide, LysoPCp, LysoPE. C: LPI: LysoPI, LysoPEp, LysoPG, PA: Phosphatidic acid, PG: 
Phosphatidylglycerol, PS: Phosphatidylserine. 
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
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When lipids are grouped into their respective classes, significant changes were 
observed for total PI, total PE, total PC and total SM. Whilst Figure 3.4 shows 
the mean total levels for each lipid group, it does not provide information in 
relation to sub-species and any significant differences in these lipid sub-species 
between clinical classifications. ANOVA analysis of the individual lipid groups 
are represented in the following graphs showing how these species levels differ 
between clinical classifications. A summary of these results is presented in 
Table 3.3 immediately following the graphs in Figures 3.5 to 3.16. 
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Figure 3.5A and B: Mean PE levels between clinical classifications. 
PE: Phosphatidylethanolamine, HC: Healthy control, MCI: Mild cognitive impairment, AD: 
Alzheimer’s disease. Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
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Figure 3.6A and B: Mean Ethanolamine plasmalogen levels between clinical 
classifications.  
PE: Phosphatidylethanolamine, HC: Healthy control, MCI: Mild cognitive impairment, AD: 
Alzheimer’s disease. Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
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Figure 3.7: A: Mean Lyso-Phosphatidylethanolamine (LysoPE) and B: Mean Lyso-
ethanolamine plasmalogen levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
 
 
Figure 3.8: Mean Lyso- Phosphatidylinositol (LPI) levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05   
 HC 
MCI 
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Figure 3.9: A: Mean Phosphatidic acid and B: Mean Phosphatidylserine (PS) levels 
between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
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Figure 3.10: Mean Phosphatidylglycerol (PG) levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001 
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Figure 3.11 A and B: Mean Lysophosphatidylglycerol (LPG) levels between clinical 
classifications.  
LPG16.0, LPG18.2, LPG1.8.1 and LPG18.0 are the “f” species in Figure 3.11B (see Table 3.2). 
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
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Figure 3.12 A, B and C: Mean Phosphatidylcholine (PC) levels between clinical 
classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
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Figure 3.13 A, B and C: Mean choline plasmalogen (PCp) levels between clinical 
classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
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Figure 3.14 A and B: Mean Lysophosphatidylcholine (LPC) levels and C: Mean Lyso-
choline plasmalogen levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
 
 
 
 
 
 
Chapter 3: Plasma Lipid Profiles in AIBL baseline samples 
 
121 
 
 
 
Figure 3.15: Mean Sphingomyelin (SM) levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001  
 
Figure 3.16: Mean Ceramide levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001 
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The bar charts in Figures 3.5 to 3.16 show how the non-adjusted marginalised 
means of each individual lipid sub-species vary between the healthy controls, 
MCI and AD groups. Significant differences, as represented by the p-values 
between the lipids sub-species and the clinical classifications, were seen for 
many of the lipids, including PE, PC, PI, SM and Ceramide species. A total of 
86 out of 189 lipid species measured showed a significant difference with a p-
value of < 0.05 or < 0.001 between HC and AD, HC and MCI or MCI and AD 
groups. Table 3.3 lists those lipids that were significantly different between 
clinical classifications. 
 
  
 
 
Table 3.3: List of lipids that were significantly different between clinical classifications. 
 
The red text indicates lower mean levels in AD compared to HC, MCI compared to HC and AD compared to MCI. The black text indicates higher mean levels 
AD compared to HC, MCI compared to HC and AD compared to MCI.  
PI: Phosphatidylinositol, PE: Phosphatidylethanolamine, PC: Phosphatidylcholine, SM: Sphingomyelin, PA: Phosphatidic acid, PG: Phosphatidylglycerol, Cer: 
Ceramide.
Lipid – HC vs. AD Lipid – HC vs. MCI Lipid – MCI vs. AD 
p < 0.05 p < 0.001 p < 0.05 p < 0.001 p < 0.05 p < 0.001 
Total PI Total PE Total PC, Total SM    
PE36.1, PE40.6, PE40.5, 
PE34p.3, PE34p.2, PE36p.1, 
PE38p.5, PE40p.5, LysoPE16.0, 
LysoPE18.1p 
PE34.2, PE34.1, PE36.4, PE36.3, 
PE36.2, PE38.6, PE38.5, PE38.4, 
PE36p.2, PE40p.4 
 
PE36.4, PE36.3, PE36.2, 
PE38.5, PE38.4, 
LysoPE18.1 
PE34.2 PE34.1, PE36p.2, LysoPE18.1  
PC32.1, PC34.2, PC34.3, 
PC36.5, PC36.0, PC38.6, 
PC38.5, PC40.4, PC 40.6, 
PC32.0p, PC34.1p..34.2e, 
PC38.2p..38.3e, PCLyso14.1, 
PCLyso16.1, PCLyso16.0, 
PCLyso18.1, PCLyso22.6,  
PC32.0, PC34.1, PC34.5, 
PC34.0p..34.1e, PC34.0e 
PC36.4p/etherPC, PC38.1, 
PC36.1p/etherPC, 
PC36.0p/etherPC, 
PC38.5p..38.6e, PC32.0e 
PCLyso18e.0 
PC32.0, PC34.6, PC34.2, 
PC34.5, PC36.0, PC38.1, 
PC34.0p..34.1e, 
PC38.5p..38.6e, 
PC40.1p..40.2e, 
PC40.3p..40.4e, 
PC40.2p..40.3e 
PC34.1, PC38.1p..38.2e PC34.0e, PC36.0p/etherPC, 
PC36.1p/etherPC, 
PC34.0p..34.1e, PC38.3p..38.4e, 
PC38.1p..38.2e 
 
PI32.1, PI34.1, PI34.2, PI 36.1, 
PI36.3, PI36.4, PI38.4, PI40.3,  
PI34.0 PI32.2, PI34.0  LysoPI18.0  
 LysoPG18.0, LysoPG22.5 PG34.2 PG34.0, LysoPG22.5, 
LysoPG16.1, LysoPG18.0 
PG34.2 LysoPG16.1  
PA36.1      
SM18.16.0, SM18.18.0, 
SM18.18.1, SM18.20.0, 
SM18.24.1 
SM18.16.1, SM18.20.1, 
SM18.22.1, SM18.22.0, 
SM18.24.0 
SM18.16.0, SM18.18.0, 
SM18.20.0, SM18.22.0, 
SM18.22.1 
SM18.16.1, SM18.18.1, 
SM18.20.1, SM18.24.0 
  
Cer.d18.0.16.0, Cer.d18.0.24.1, 
Cer.d18.0.24.0 
Cer.d18.1.24.1, Cer.d18.0.22.0, 
Cer.d18.0.20.0 
  Cer.d18.0.22.0  
1
2
3
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To further examine the significance of differences in levels observed between 
lipid species and clinical classification, a LIMMA model (see Section 3.4.1) was 
applied to obtain a false discovery adjusted value for each lipid to exclude any 
false associations that may have been included following simple ANOVA. 
 
3.4.1  Linear Models for Microarray Data (LIMMA)  
LIMMA (Linear Models for Microarray Data) analysis was used to obtain Q 
values (false discovery adjusted values) and Bonferroni correction were used to 
generate stricter p-values to exclude some of the 86 lipids species level 
differences selected and displayed graphically in Figures 3.5 - 3.16 and in Table 
3.3. Using the LIMMA model, 27 out of 86 lipid species levels were significantly 
different between healthy controls and AD participants and these lipids are 
listed in Table 3.4. 
Table 3.4: Linear Models for Microarray Data (LIMMA), listed in order of most to least 
significant for Healthy Controls compared to AD.  
Lipid p.value Lipid p.value 
PC.34.0p..34.1e 4.68E-11 PE36.4 2.30E-06 
SM18.20.1 3.62E-10 PE34.1 2.31E-06 
PE34.2 4.23E-10 PE36.3 3.16E-06 
Cer.d18.0.22.0 7.92E-10 PC32.0 4.73E-06 
SM18.24.0 1.34E-09 PC34.5 1.09E-05 
PE38.5 3.59E-09 PG34.2 2.20E-05 
PE38.4 5.70E-09 SM18.16.1 3.64E-05 
PC34.1 9.44E-09 PE38.6 4.12E-05 
PC34.0e 3.07E-08 SM18.22.1 5.95E-05 
SM18.22.0 4.92E-07 PC.Lyso.18e.0 9.64E-05 
PC38.1 6.92E-07 PC36.4p or etherPC 1.34E-04 
PC.38.5p..38.6e 9.58E-07 PC32.0e 1.36E-04 
PE36.2 1.35E-06 PI34.0 1.98E-04 
PC36.0por etherPC 1.39E-06   
 
p-values less than the Bonferroni cut off (0.05/189). 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. 
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A fold lipid change was subsequently calculated using unadjusted raw 
expression values to provide a relative lipid difference between clinical 
classifications. The mean levels, difference in levels between groups, the 
directional change i.e. increased or decreased in AD compared to healthy 
controls and fold change is shown in Table 3.5. 
Table 3.5: Mean value difference in lipid species levels between groups, direction of 
change in lipid levels between HC and AD participants and fold change. 
Lipid Mean HC Mean AD Difference Direction 
of change 
Fold 
Δ 
PE34.2 0.00036 0.00046 0.00010 ↑ in AD 1.288 
PE34.1 0.00025 0.00031 0.00006 ↑ in AD 1.228 
PE36.4 0.00065 0.00076 0.00012 ↑ in AD 1.180 
PE36.3 0.00030 0.00036 0.00006 ↑ in AD 1.200 
PE36.2 0.00084 0.00100 0.00016 ↑ in AD 1.193 
PE38.6 0.00120 0.00140 0.00019 ↑ in AD 1.161 
PE38.5 0.00070 0.00084 0.00014 ↑ in AD 1.207 
PE38.4 0.00150 0.00182 0.00032 ↑ in AD 1.211 
PC.Lyso.18e.0 0.00032 0.00035 0.00003 ↑ in AD 1.091 
PC.34.0p..34.1e 0.00515 0.00564 0.00050 ↑ in AD 1.096 
PC36.0p or etherPC 0.00443 0.00473 0.00030 ↑ in AD 1.068 
PC32.0e 0.00160 0.00170 0.00010 ↑ in AD 1.066 
PC32.0 0.00629 0.00666 0.00038 ↑ in AD 1.060 
PC34.0e 0.00126 0.00137 0.00011 ↑ in AD 1.091 
PC34.1 0.10666 0.11382 0.00715 ↑ in AD 1.067 
Cer.d18.0.22.0 0.00010 0.00015 0.00005 ↑ in AD 1.435 
PI34.0 0.00012 0.00010 -0.00002 ↓ in AD 0.858 
PG34.2 9.02E-6 7.21E-6 -1.81E-6 ↓ in AD 0.799 
PC36.4p or etherPC 0.00506 0.00470 -0.00037 ↓ in AD 0.927 
PC38.5p..38.6e 0.00329 0.00296 -0.00033 ↓ in AD 0.900 
PC34.5 0.00026 0.00023 -0.00003 ↓ in AD 0.878 
PC38.1 0.00352 0.00329 -0.00024 ↓ in AD 0.933 
SM18.16.1 0.00217 0.00196 -0.00021 ↓ in AD 0.904 
SM18.20.1 0.00355 0.00302 -0.00053 ↓ in AD 0.852 
SM18.22.1 0.02032 0.01922 -0.00110 ↓ in AD 0.946 
SM18.22.0 0.03332 0.03102 -0.00229 ↓ in AD 0.931 
SM18.24.0 0.00515 0.00462 -0.00053 ↓ in AD 0.897 
 
Those lipids in the blue section indicate an increase in the mean lipid levels and those in the 
grey section indicate a decrease in mean lipid levels in AD compared to healthy controls. 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. 
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Table 3.5 shows the mean value, the difference between the mean lipid profile 
and the fold change for each of the 27 lipids identified as being significantly 
different between HC and AD by LIMMA. 16 lipid species had mean levels 
higher and 11 had mean levels lower in AD compared to healthy controls. 
Whilst Tables 3.4 and 3.5 compared healthy controls to AD, the following two 
tables show the repeat LIMMA analysis for the healthy controls compared to 
MCI groups. 
Table 3.6: Linear Models for Microarray Data (LIMMA), listed in order of most to least 
significant for Healthy Controls compared to MCI. 
Lipid p.value 
PC34.1 3.48E-05 
SM18.20.1 9.25E-05 
SM18.16.1 1.55E-04 
SM18.24.0 2.20E-04 
PE34.2 2.56E-04 
 
p-values less than the Bonferroni cut off (0.05/189).  
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine. 
Table 3.6 lists the five lipid species levels that were significantly different 
between healthy controls and MCI participants. The mean level, difference in 
level between groups, the directional change i.e. increased or decreased in MCI 
compared to healthy controls and fold change of these five lipid species is 
shown in Table 3.7. 
Table 3.7: Mean value difference in lipid species levels between groups, direction of 
change in lipid levels between HC and MCI participants and fold change. 
Lipid Mean HC Mean MCI Difference Direction 
of change 
Fold 
Δ 
PE34.2 0.00036 0.00043 0.00007 ↑ in MCI 1.198 
PC34.1 0.10666 0.11295 0.00628 ↑ in MCI 1.059 
SM18.16.1 0.00217 0.00193 -0.00024 ↓ in MCI 0.892 
SM18.20.1 0.00355 0.00313 -0.00042 ↓ in MCI 0.882 
SM18.24.0 0.00515 0.00475 -0.00040 ↓ in MCI 0.923 
 
Those lipids in the blue section indicate an increase in the mean lipid levels and those in the 
grey section indicate a decrease in mean lipid levels in MCI compared to healthy controls. 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine. 
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The above table shows the mean value, the difference between the mean lipid 
levels and the fold change for each of the five lipids identified as being 
significantly different between HC and MCI by LIMMA. Two lipid species had 
mean levels higher and three had mean levels lower in MCI compared to 
healthy controls. 
The LIMMA analysis was repeated comparing lipid species levels between MCI 
and AD classifications. Interestingly no significant difference was observed in 
the mean levels of lipid species. 
3.4.2  Generalised Linear Model (GLM) 
The LIMMA analyses, while identifying those lipids species levels that are 
significantly different between clinical classifications, do not take into 
consideration factors which may influence the significance of the observed 
differences. Consequently a generalised linear model (GLM) was created to 
control for age, APOEε4 allele carriage status, gender and collection site. The 
results from the GLM comparing HC to AD are displayed in Table 3.8. 
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Table 3.8: Generalised Linear Modelling (GLM) adjusted for age, sex, APOEε4 allele 
status (i.e. carriage or non-carriage of an APOEε4 allele) and sample collection site 
(Perth or Melbourne) in the healthy control compared to the AD group. 
Lipid  p-value Age APOEε4 Sex Site 
SM18.20.1 2.65E-06 1.52E-42 1.04E-21 0.061 0.406 
Cer.d18.0.22.0 2.69E-06 1.37E-40 3.81E-22 0.221 0.010 
PE38.4 3.33E-06 8.60E-41 1.97E-22 0.457 0.011 
PE34.2 8.98E-06 6.42E-40 8.18E-23 0.345 0.047 
PC.34.0p..34.1e 2.23E-05 3.61E-36 7.04E-24 0.311 0.041 
PE38.5 3.56E-05 5.22E-40 3.67E-22 0.533 0.015 
PC34.1 5.84E05 9.46E-40 2.49E-22 0.123 0.015 
PE36.2 0.00014 7.38E-42 9.27E-23 0.342 0.025 
PC34.0e 0.00016 1.61E-37 7.96E-24 0.229 0.026 
SM18.16.1 0.00022 1.88E-42 1.07E-22 0.146 0.007 
PE34.1 0.00025 3.86E-41 5.74E-23 0.231 0.028 
PI34.0 0.00032 1.44E-43 4.77E-23 0.158 0.090 
PC32.0 0.00038 9.00E-40 9.13E-24 0.143 0.027 
PG34.2 0.00080 4.96E-43 5.62E-23 0.344 0.188 
PE36.4 0.00092 2.55E-41 9.50E-23 0.421 0.020 
PC38.5p..38.6e 0.00105 8.52E-41 4.55E-22 0.177 0.007 
PC32.0e 0.00107 1.26E-40 1.11E-23 0.120 0.022 
SM18.24.0 0.00134 5.16E-39 3.18E-22 0.387 0.014 
PC36.0p or ether PC 0.00240 2.21E-39 3.96E-23 0.295 0.018 
PE36.3 0.00364 2.11E-41 1.73E-22 0.328 0.019 
SM18.22.1 0.00394 1.50E-41 8.31E-23 0.212 0.020 
SM18.22.0 0.00411 2.51E-40 2.26E-22 0.239 0.022 
PC34.5 0.00523 2.34E-41 2.37E-22 0.151 0.014 
PC.Lyso.18e.0 0.00661 2.25E-41 1.17E-22 0.104 0.027 
PC38.1 0.02124 1.02E-39 3.47E-22 0.317 0.007 
PE38.6 0.02217 1.44E-41 2.42E-22 0.467 0.022 
PC36.4p or ether PC 0.08371 3.55E-41 2.38E-22 0.298 0.012 
 
Those lipids above the solid line remain significant (p<0.000265) after adjustment. 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. 
 
Table 3.8 shows the p-values for each of the 27 lipids identified by LIMMA as 
being significantly different between HC and AD, adjusted through GLM for the 
following covariates; age, sex, APOEε4 allele status and collection site. The p-
values for each of the covariates are also shown in the table. The data are 
sorted by the strongest p-value for the lipid level post adjustment i.e. where the 
levels are most different between the clinical classification groups. The top 11 
lipids (above the solid line) in the table remain statistically significant (less than 
the Bonferroni cut off value of p<0.000265 (0.05/189)) after adjustment for age, 
sex, APOEε4 allele status and collection site. The p-values indicate that neither 
site of collection or gender significantly influence the results, but as expected 
age and APOEε4 allele carriage do significantly influence the results.  
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The GLM was repeated to compare the healthy control and MCI groups 
following adjustment of the LIMMA results to control for age, gender, APOEε4 
allele status and collection site. 
Table 3.9: Generalised Linear Modelling (GLM) adjusted for age, sex, APOEε4 allele 
status (i.e. carriage or non-carriage of an APOEε4 allele) and collection site (Perth or 
Melbourne) in the healthy control compared to the MCI group. 
Lipid  p-value Age APOEε4 Sex Site 
SM18.16.1 0.0001 4.20E-15 2.10E-08 0.875 0.216 
SM18.20.1 0.0007 6.82E-15 3.98E-08 0.682 0.803 
PC34.1 0.0009 3.01E-14 8.72E-08 0.790 0.286 
PE34.2 0.0045 1.48E-14 3.13E-08 0.809 0.472 
SM18.24.0 0.0269 1.86E-13 2.54E-08 0.761 0.305 
 
Those lipids above the solid line remain significant (p<0.000265) after adjustment. 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine. 
 
Table 3.9 shows the p-values for each of the five lipids identified by LIMMA as 
being significantly different between HC and MCI, adjusted through GLM for the 
same covariates (age, gender, APOEε4 allele status and collection site). The p-
values for each of the covariates are also shown in the table. The data are 
again sorted by the strongest p-value for the lipid level post adjustment. Only 
one lipid in the table (above the solid line) remained statistically significant (less 
than the Bonferroni cut off value of p<0.000265 (0.05/189)) after adjustment for 
age, sex, APOEε4 allele status and collection site. The p-values again indicate 
that neither site of collection or gender significantly influence the results, but as 
expected age and APOEε4 allele carriage do significantly influence the results.  
No GLM was created for the MCI compared to AD groups as no lipid species 
were found to be significantly different between groups after LIMMA analysis. 
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3.4.3.1 Variable selection for HC vs. AD groups 
The LIMMA and GLM models assess associations between lipids and clinical 
classification, i.e. levels of lipid species that are significantly different between 
clinical classifications. Variable selection analysis attempts to identify lipid 
species which when considered collectively are able to predict clinical 
classification with greatest certainty, i.e. if you measure levels of lipid species x, 
y, z you can determine whether an individual would be classified as healthy 
control, MCI or AD. As such the level at which clinical classification can be 
predicted, is determined by modelling the selected lipids and covariates using 
GLM and Receiver Operating Characteristics (ROC) models. 
Previous analysis of biomarkers in the AIBL cohort utilised a variable selection 
pathway to create lists of biomarkers that were chosen from four separate 
selection methods; random forest, boosted trees, regression trees and LIMMA 
and used clinical classification as a binary outcome, i.e. HC or AD [476] . In this 
study, a variable selection pathway was applied to the 189 lipid species to 
create an importance ranking (in addition to generation of p-values), where 
1000 iterations were performed to define a list of those lipid species that are 
selected most often as differing in levels when comparing clinical classifications. 
Each time a lipid was selected a frequency score was assigned if it was chosen 
from all four statistical methods or from three out of the four statistical methods. 
Table 3.10 lists the lipid species selected most often when comparing the HC 
and AD groups. The lipid species that are selected in at least 10% of the 1000 
iterations from all four statistical methods are listed in column A and the lipid 
species that were selected in at least 10% of the 1000 iterations from three of 
the four statistical methods are shown in column B. 
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Table 3.10: Lipid Markers selected by the Variable Selection Pathway for HC vs. AD. 
List A (4/4) List B (3/4) 
Lipid Frequency (/1000) Lipid Frequency (/1000) 
SM18.20.1 610 PC34.1 583 
Cer.d18.0.22.0 419 Cer.d18.0.22.0 541 
PC34.0e 173 PC34.0e 539 
PC32.0 108 PC32.0 485 
  PC38.5p...38.6e 446 
  PC34.0p...34.1e 432 
  PE34.2 421 
  SM18.20.1 385 
  PE38.4 375 
  PG34.2 331 
  SM18.24.0 291 
  PE34.1 285 
  PC32.0e 273 
  PE38.5 233 
  PC36.0p.or.etherPC 231 
  SM18.16.1 205 
  PI34.0 181 
  PE36.4 173 
  PE36.3 157 
  Cer.d18.0.20.0 156 
  PE36.2 144 
  Cer.d18.0.24.1 120 
 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. The lipids highlighted in grey appeared in 
both list A and list B. 
 
 
Those lipids with the highest frequencies of selection from both lists A and B of 
Table 3.10 were clustered using Partitioning Around Medoids (PAM) to find a 
central lipid and cluster other correlated lipids around it. This statistical method 
correlates lipids that are related to each other without consideration of clinical 
classification and is performed to see if lipids can be eliminated from a final 
model if they behave in the same way as other lipids in their respective clusters 
in terms of predicting clinical classification. A CLARA (Clustering for Large 
Applications) algorithm was applied to create a clusplot of correlated lipids 
which resulted in the formation of four lipid clusters, listed in Table 3.11 and 
represented graphically in Figure 3.17. 
 
 
 
 
 
Chapter 3: Plasma Lipid Profiles in AIBL baseline samples 
 
132 
 
Table 3.11: Four groups of clustered lipids were determined using medoid clustering in 
HC vs. AD.  
Cluster 1 Cluster 2 Cluster 3 Cluster 4 
PE34.2 PI34.0 PC34.0p..34.1e Cer.d18.0.20.0 
PE34.1 PG34.2 PC36.0p/etherPC Cer.d18.0.22.0 
PE36.4 PC38.5p..38.6e PC32.0e Cer.d18.0.24.1 
PE36.3 SM18.16.1 PC32.0  
PE36.2 SM18.20.1 PC34.0e  
PE38.5 SM18.24.0   
PE38.4    
PE34.1    
 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. 
 
 
Of the 22 lipids selected by Variable Selection Pathways for HC vs. AD, cluster 
1 has eight lipids, cluster 2 has six lipids, cluster 3 has five lipids and cluster 4 
has three lipids.  
 
 
 
Figure 3.17: Clusplot of correlated lipids showing the 8, 6, 5 and 3 lipids from clusters 1 
to 4 respectively.  
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The clusplot shows a stronger relationship for the lipids within each of clusters 
1, 3 and 4. The lipids in cluster 2 are by contrast more diffuse, suggesting a 
weaker intracluster relationship of those lipids. This may be explained by the 
fact that clusters 1, 3 and 4 all contain lipids of the same class (PE, PC and 
ceramides respectively), whilst cluster 2 is heterogeneous containing one PI 
species, one PG species, one ether PC species and three SM species.  
Standard Pearson’s correlations were applied to the lipids in each cluster to 
explore the directional grouping of the relationship between correlated lipids and 
clinical classification. These relationships between the scaled mean expression 
for HC and AD groups are shown in Figure 3.18 with the R-values for the lipid 
correlations shown in Table 3.12.  
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Figure 3.18: Correlated lipids between clinical classifications. 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. Scaled mean expression is used to enable 
graphical representation of lipids that differ in abundance. 
PE 34.2, PE 34.1, PE 36.4,       
PE 36.3, PE 36.2, PE 38.5,       
PE 38.4 
PI 34.0,   PG 34.2 
PC38.5p..38.6e, SM18.16.1 
SM18.20.1, SM18.24.0 
 
PC34.0p..34.1e, 
PC36.0p/etherPC, PC32.0e, 
PC32.0, PC34.0e 
Cer.d18.0.20.0, 
Cer.d18.0.22.0, 
Cer.d18.0.24.1   
  
 
PE34.2 PE34.1 PE36.4 PE36.3 PE36.2 PE38.5 PE38.4 Pl.34.0 PG34.2 PC.34.0p..3 PC36.0p.or PC.38.5p..3 PC32.0 PC32.0 PC34.0e PC34.1 SM18.16.1 SM18.20.1 SM18.24.0 Cer.d18.0. Cer.d18.0.2Cer.d18.0.24.1
1.000 0.625 0.640 0.643 0.707 0.483 0.538 0.131 0.178 0.162 0.067 -0.397 0.062 0.122 0.109 0.264 -0.040 -0.050 -0.069 0.070 0.048 -0.020 PE34.2
1.000 0.672 0.589 0.621 0.535 0.607 0.151 0.198 0.153 0.086 -0.331 0.044 0.171 0.124 0.336 -0.025 -0.087 -0.068 0.068 0.046 0.009 PE34.1
1.000 0.645 0.626 0.646 0.763 0.189 0.194 0.123 0.085 -0.329 0.017 0.153 0.127 0.318 -0.012 -0.011 -0.082 0.065 0.035 0.001 PE36.4
1.000 0.692 0.554 0.583 0.069 0.206 0.118 0.086 -0.368 0.006 0.041 0.072 0.202 -0.043 -0.020 -0.078 0.098 0.056 0.016 PE36.3
1.000 0.516 0.597 0.168 0.198 0.070 0.017 -0.428 -0.010 0.040 0.026 0.221 -0.048 -0.008 -0.047 0.088 0.051 0.002 PE36.2
1.000 0.718 0.049 0.087 0.113 0.120 -0.105 0.019 0.133 0.122 0.226 -0.081 -0.110 -0.135 0.098 0.075 0.006 PE38.5
1.000 0.050 0.166 0.058 0.071 -0.330 -0.026 0.070 0.079 0.226 -0.042 -0.081 -0.093 0.084 0.084 0.031 PE38.4
1.000 0.258 0.088 -0.013 -0.137 0.096 0.174 0.098 0.215 -0.017 0.290 0.056 0.082 0.008 0.008 Pl.34.0
1.000 -0.040 0.028 -0.150 -0.008 -0.052 0.008 -0.057 0.219 0.380 0.301 0.111 0.047 0.028 PG34.2
.1e 1.000 0.696 0.017 0.750 0.558 0.862 0.351 0.073 0.026 -0.026 0.077 0.037 0.004 PC.34.0p..34.1e
therPC 1.000 0.033 0.488 0.172 0.744 0.204 0.147 0.052 -0.033 -0.025 -0.025 -0.015 PC36.0p.or.etherPC
.6e 1.000 0.171 0.115 0.107 -0.327 0.100 -0.083 0.105 -0.076 -0.045 0.037 PC.38.5p..38.6e
1.000 0.619 0.773 0.150 0.123 -0.012 0.104 0.022 -0.004 0.014 PC32.0e
1.000 0.574 0.423 0.073 -0.129 0.029 -0.030 -0.076 -0.110 PC32.0
1.000 0.272 0.125 0.050 0.016 0.066 0.006 -0.008 PC34.0e
1.000 -0.300 -0.174 -0.303 0.140 0.119 0.056 PC34.1
1.000 0.305 0.525 -0.436 -0.419 -0.352 SM18.16.1
1.000 0.348 0.164 0.104 0.108 SM18.20.1
1.000 -0.111 -0.141 -0.093 SM18.24.0
.0 1.000 0.804 0.694 Cer.d18.0.20.0
.0 1.000 0.786 Cer.d18.0.22.0
.1 1.000 Cer.d18.0.24.1
 
Table 3.12: Standard Pearson’s Correlations between 22 lipid species chosen from the variable selection pathway for the HC vs. AD groups. 
Correlation coefficients (R) for each pairwise correlation are shown. Correlations of greater than 0.5 or less than -0.5 are highlighted in red. 
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The strongest correlations, as highlighted in red in Table 3.12, are seen 
between lipids of the same group. i.e. PEs, PCs or ceramides. 
Looking at the directional grouping of the relationship between correlated lipids 
and clinical classification as depicted in Figure 3.18, it can be seen that each of 
the lipids in each cluster have very similar relationships with each other. 
Taking the 22 lipids chosen from the variable selection pathway and factoring in 
their correlations as determined by the Pearson’s correlations R-values (see 
Table 3.12), the lipids were subjected to further statistical assessment using a 
stepwise generalised linear model (GLM) to reduce the number of lipids in the 
final predictive model. This GLM algorithm was run repeatedly to remove lipids 
from the predictive model until the lipids left were those giving the best Akaike 
Information Criterion (AIC) report, which is a measure of the relative quality of a 
statistical model for a given set of data and therefore provides a means for 
selecting the best model. This stepwise model also factors in covariates of age, 
gender, APOEε4 allele status and collection site, as described in the previous 
GLM (Table 3.8). This prediction model split the analysis of the 1060 study 
participant plasma lipid profiles into a run comprising 70% training (that includes 
clinical classification) and 30% test data (blind to clinical classification) and was 
repeated over 100 times until the greatest sensitivity and specificity was 
achieved. A final panel was selected that contained the least number of lipids 
with maximal sensitivity and specificity for predicting clinical classification. 
Sensitivity is the ability of a biomarker to correctly identify AD and specificity is 
the ability of a biomarker to correctly identify a healthy control. Maximal 
sensitivity and specificity (80%) for predicting participants with AD as compared 
to healthy controls was attained by variable selection and stepwise GLM with 
the following six lipids. 
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Table 3.13: List of six lipids yielding maximal sensitivity and specificity between HC and 
AD groups. 
Lipid 
PI.34.0 
PC36.0p.or.etherPC 
PC38.5p..38.6e 
PC32.0 
SM18.20.1 
Cer.d18.0.22.0 
 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PI: Phosphatidylinositol. 
All of these lipid species were also identified as being significantly different 
when assessed by the standard LIMMA analyses. 
Figure 3.19 shows a Receiver Operating Characteristic (ROC) curve from the 
GLM of the top six lipids including age, gender, APOEε4 allele status and 
collection site as covariates.  
 
Figure 3.19: ROC curve of the top six lipids from stepwise GLM showing sensitivity and 
specificity of 80% for the HC vs. AD group. 
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The ROC curve is a plot of the true positive rate (sensitivity) against the false 
positive rate (specificity) of a diagnostic test. The closer the curve follows the 
left hand border and then the top border, the more accurate the test. The 
accuracy depends on how well the panel of six lipids separates those 
participants with AD from healthy controls and is measured by the area under 
the ROC curve, which in this case indicates 80%. 
3.4.3.2 Variable selection for HC vs. MCI groups  
As for the healthy controls vs. AD groups, the variable selection pathway was 
repeated for the healthy control vs. MCI groups. This generated a list of lipids 
that were chosen from four separate selection methods as previously described 
for the HC vs. AD groups. The variable selection pathway was again applied to 
the 189 lipid species to create an importance ranking (in addition to generation 
of p-values), where 1000 iterations were performed to define a list of those lipid 
species that are selected most often as differing in levels when comparing HC 
vs. MCI. Each time a lipid was selected a frequency score was assigned if it 
was chosen from all four statistical methods or from three out of the four 
statistical methods. Table 3.14 lists the lipid species selected most often when 
comparing the HC and MCI groups. As before, the lipid species that were 
selected in at least 10% of the 1000 iterations from all four statistical methods 
are listed in column A and the lipid species that were selected in at least 10% of 
the 1000 iterations from three of the four statistical methods are shown in 
column B. 
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Table 3.14: Lipid Markers selected by the Variable Selection Pathway for HC vs. MCI 
List A (4/4) List B (3/4) 
Lipid Freq 
(/1000) 
Lipid Freq 
(/1000) 
Lipid Freq 
(/1000) 
SM18.20.1 609 PC34.1 998 SM18.18.1 274 
Cer.d18.0.22.0 418 PC.38.5p..38.6e 944 SM18.22.0 271 
PC34.0e 173 SM18.24.0 863 PC38.1 249 
PC32.0 108 SM18.20.1 841 LysoPE18.1 235 
  PE34.2 739 PC36.0p.or.etherPC 231 
  Cer.d18.0.22.0 708 PI34.0 224 
  PC32.0 641 PE36.2 201 
  PE38.4 628 PC38.1p..38.2e 190 
  SM18.16.1 612 PE40.4p 177 
  PC34.0e 539 SM18.18.0 174 
  PG34.2 476 Cer.d18.0.20.0 157 
  PE36.4 467 SM18.24.1 149 
  PC34.0p..34.1e 452 Cer.d18.0.24.1 120 
  PE36.3 316 LysoPE18.2 114 
  PE34.1 291 LysoPC18.0e 108 
  PC32.0e 277 PC34.2 101 
  PE38.5 277   
 
SM: Sphingomyelin, Cer: Ceramide, PC: Phosphatidylcholine, PE: Phosphatidylethanolamine, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. The lipids highlighted in grey appeared in 
both list A and list B. 
Those lipids with the highest frequencies of selection from both lists A and B of 
Table 3.14 were clustered as done previously for the HC vs. AD groups. 
Clustering of the lipids for the HC vs. MCI groups resulted in the formation of 
four lipid clusters listed in Table 3.15. 
Table 3.15: Four groups of clustered lipids were determined using medoid clustering in 
HC vs. MCI.  
Cluster 1 Cluster 2 Cluster 3 Cluster 4 
LysoPE18.2 PG34.2 LysoPC18.0e PC34.2 
LysoPE18.1 PC38.5p..38.6e PC34.0p..34.1e Cer.d18.0.20.0 
PE40p.4 PC38.1 PC36.0p/etherPC Cer.d18.0.22.0 
PE34.2 SM18.16.1 PC38.1p..38.2e Cer.d18.0.24.1 
PE34.1 SM18.18.1 PC32.0e  
PE36.4 SM18.18.0 PC32.0  
PE36.3 SM18.20.1 PC34.0e  
PE36.2 SM18.22.0   
PE38.5 SM18.24.1   
PE38.4 SM18.24.0   
PI34.0    
PC34.1    
 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. 
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Of the 33 lipids selected by Variable selection Pathways for HC vs. MCI, cluster 
1 has twelve lipids, cluster 2 has ten lipids, cluster 3 has seven lipids and 
cluster 4 has three lipids. A clusplot was generated (Figure 3.20) by plotting the 
lipids as clusters of correlations, which revealed that certain lipids fall into 
groups. 
 
 
 
 
Figure 3.20: Clusplot of correlated lipids showing the 12, 10, 7 and 4 lipids from clusters 
1 to 4 respectively.  
 
The clusplot shows a stronger relationship for the lipids within each of clusters 3 
and 4. The lipids in clusters 1 and 2 are by contrast more diffuse, suggesting a 
weaker intracluster relationship of those lipids. This may be explained by the 
fact that cluster 3 contains all PC species and cluster 4 contains mainly 
ceramides. Clusters 1 and 2 are more heterogeneous in terms of the lipid 
species they contain. 
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Standard Pearson’s correlations were applied to the lipids in each cluster to 
explore the directional grouping of the relationship between correlated lipids and 
clinical classification. These relationships between the scaled mean expression 
for HC and MCI groups are shown in Figure 3.21 with the R-values for the lipid 
correlations shown in Table 3.16.  
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Figure 3.21: Correlated lipids between clinical classifications. 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. Scaled mean expression is used to enable 
graphical representation of lipids that differ in abundance. The lipids species highlighted in grey 
show a different directional change than the other lipids in the cluster.                 
LysoPE18.2, LysoPE18.1, PE40p.4, 
PE34.2, PE34.1, PE36.4, PE36.3, 
PE36.2, PE38.5, PE38.4, PI34.0, 
PC34.1 
PG34.2, PC38.5p..38.6e, PC38.1, 
SM18.16.1, SM18.18.1, SM18.18.0, 
SM18.20.1, SM18.22.0, SM18.24.1, 
SM18.24.0 
LysoPC18.0e, PC34.0p..34.1e, 
PC36.0p/etherPC, PC38.1p..38.2e, 
PC32.0e, PC34.0e 
PC34.2, Cer.d18.0.20.0, 
Cer.d18.0.22.0, Cer.d18.0.24.1 
  
 
Lyso.PE18.2 Lyso.PE18.1.1 PE40p.4 PE34.2 PE34.1 PE36.4 PE36.3 PE36.2 PE38.5 PE38.4 PI.34.0 PG34.2 PC.Lyso.18e.0 PC.34.0p..34.1e PC36.0p.or.etherPC PC.38.5p..38.6e PC.38.1p..38.2e PC32.0e PC32.0 PC34.0e PC34.2 PC34.1 PC38.1 SM18.16.1 SM18.18.1 SM18.18.0 SM18.20.1 SM18.22.0 SM18.24.1 SM18.24.0 Cer.d18.0.20.0 Cer.d18.0.22.0 Cer.d18.0.24.1
1.000 0.222 0.035 0.383 0.253 0.188 0.362 0.364 0.040 0.112 0.172 0.364 0.169 0.141 0.070 -0.406 0.053 0.114 0.012 0.078 0.192 0.043 -0.024 0.166 0.080 0.068 0.212 0.363 0.140 0.176 0.020 -0.007 -0.019 Lyso.PE18.2
1.000 0.141 0.160 0.164 0.118 0.114 0.117 0.109 0.135 -0.050 0.118 0.148 0.032 0.023 -0.069 -0.064 0.025 0.034 0.026 -0.016 0.048 -0.041 0.002 0.034 0.034 -0.089 0.011 0.064 0.031 -0.006 0.016 0.012 Lyso.PE18.1.1
1.000 0.153 0.193 0.257 0.166 0.140 0.289 0.388 -0.073 0.032 0.177 0.134 0.109 -0.027 0.078 0.083 0.058 0.156 -0.149 0.007 0.089 -0.016 0.009 0.025 -0.061 -0.055 0.054 0.042 0.062 0.051 0.077 PE40p.4
1.000 0.613 0.638 0.630 0.693 0.489 0.552 0.153 0.184 -0.018 0.119 0.033 -0.413 -0.073 0.058 0.105 0.058 0.118 0.248 -0.130 0.001 0.016 0.010 -0.034 0.048 0.040 -0.020 0.013 -0.011 -0.051 PE34.2
1.000 0.664 0.568 0.604 0.531 0.588 0.176 0.176 -0.017 0.107 0.049 -0.358 -0.126 0.018 0.157 0.079 -0.046 0.341 -0.144 -0.008 -0.008 -0.028 -0.076 -0.073 0.009 -0.030 0.035 0.014 -0.008 PE34.1
1.000 0.612 0.618 0.653 0.759 0.210 0.173 -0.033 0.095 0.052 -0.352 -0.108 -0.003 0.145 0.087 -0.148 0.322 -0.163 -0.006 0.020 0.015 -0.005 -0.146 0.033 -0.075 0.031 -0.005 -0.028 PE36.4
1.000 0.680 0.552 0.566 0.098 0.189 0.041 0.103 0.070 -0.376 -0.033 0.018 0.032 0.056 0.097 0.194 -0.137 -0.054 -0.063 -0.089 -0.031 -0.016 -0.030 -0.077 0.077 0.038 -0.003 PE36.3
1.000 0.530 0.609 0.154 0.187 -0.025 0.038 0.001 -0.448 -0.102 -0.026 0.027 -0.001 0.141 0.203 -0.124 -0.033 -0.048 -0.049 -0.027 0.055 -0.019 -0.047 0.047 0.020 -0.015 PE36.2
1.000 0.715 0.053 0.078 0.086 0.067 0.084 -0.113 -0.040 -0.016 0.088 0.079 -0.191 0.191 -0.089 -0.094 -0.054 -0.045 -0.122 -0.227 -0.036 -0.119 0.080 0.053 0.004 PE38.5
1.000 0.050 0.144 0.062 0.016 0.024 -0.341 -0.103 -0.059 0.040 0.043 -0.188 0.180 -0.110 -0.038 0.025 0.030 -0.081 -0.126 0.072 -0.057 0.057 0.040 0.012 PE38.4
1.000 0.248 -0.192 0.106 0.002 -0.145 -0.004 0.113 0.221 0.119 -0.049 0.259 -0.065 -0.020 -0.050 -0.007 0.289 0.006 0.048 0.053 0.073 0.026 0.012 PI.34.0
1.000 0.049 -0.011 0.078 -0.176 0.085 0.015 -0.060 0.035 -0.172 -0.037 0.026 0.209 0.204 0.160 0.386 0.266 0.290 0.322 0.104 0.052 0.048 PG34.2
1.000 0.293 0.530 0.147 0.339 0.289 -0.064 0.393 -0.101 -0.178 0.058 0.051 0.044 0.036 -0.169 -0.003 -0.023 -0.040 0.089 0.132 0.172 PC.Lyso.18e.0
1.000 0.675 0.023 0.447 0.758 0.505 0.848 -0.009 0.302 0.002 0.074 0.081 0.137 0.037 -0.019 0.033 -0.028 0.052 -0.011 -0.046 PC.34.0p..34.1e
1.000 0.026 0.558 0.445 0.080 0.733 -0.162 0.137 0.009 0.153 0.209 0.201 0.063 0.008 -0.001 -0.048 -0.022 -0.044 -0.039 PC36.0p.or.etherPC
1.000 0.193 0.153 0.099 0.094 -0.266 -0.338 0.290 0.073 0.026 0.044 -0.106 -0.104 0.012 0.061 -0.084 -0.020 0.052 PC.38.5p..38.6e
1.000 0.312 0.021 0.456 -0.141 -0.329 0.355 0.332 0.321 0.276 0.235 0.162 0.269 0.247 0.072 0.032 0.003 PC.38.1p..38.2e
1.000 0.592 0.767 0.070 0.116 0.110 0.111 0.087 0.192 -0.016 0.036 0.092 0.107 0.017 -0.021 -0.005 PC32.0e
1.000 0.510 -0.105 0.417 0.050 0.052 -0.001 0.124 -0.145 -0.231 0.010 0.033 -0.065 -0.130 -0.153 PC32.0
1.000 -0.146 0.227 0.031 0.133 0.163 0.232 0.072 -0.031 0.046 0.026 0.047 -0.032 -0.044 PC34.0e
1.000 0.060 -0.149 -0.319 -0.329 -0.287 -0.009 0.155 -0.336 -0.179 0.200 0.199 0.147 PC34.2
1.000 -0.306 -0.308 -0.243 -0.186 -0.175 -0.416 -0.252 -0.298 0.126 0.077 0.012 PC34.1
1.000 0.299 0.101 0.224 -0.013 0.163 0.412 0.635 -0.104 -0.096 -0.051 PC38.1
1.000 0.739 0.631 0.293 0.486 0.509 0.534 -0.448 -0.429 -0.350 SM18.16.1
1.000 0.813 0.379 0.400 0.553 0.414 -0.241 -0.246 -0.208 SM18.18.1
1.000 0.306 0.358 0.548 0.488 -0.262 -0.292 -0.256 SM18.18.0
1.000 0.468 0.342 0.333 0.184 0.134 0.113 SM18.20.1
1.000 0.469 0.563 -0.120 -0.118 -0.126 SM18.22.0
1.000 0.723 -0.059 -0.064 -0.042 SM18.24.1
1.000 -0.104 -0.127 -0.094 SM18.24.0
1.000 0.814 0.712 Cer.d18.0.20.0
1.000 0.802 Cer.d18.0.22.0
1.000 Cer.d18.0.24.1
 
 
Table 3.16: Standard Pearson’s Correlations between 33 lipid species chosen from the variable selection pathway for the HC vs. MCI groups. 
Correlation coefficients (R) for each pairwise correlation are shown. Correlations of greater than 0.5 or less than -0.5 are highlighted in red. 
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The strongest correlations, as highlighted in red in Table 3.16, are seen 
between lipids of the same group. i.e. PEs, PCs or ceramides. A statistical 
correlation between the biologically related SM18.24.0 and PC38.1 is also 
shown. SM can be formed by the transfer of phosphocholine to ceramide. 
Looking at the directional grouping of the relationship between correlated lipids 
and clinical classification as depicted in Figure 3.21, it can be seen that each of 
the lipids in clusters 2 and 4 have very similar relationships with each other. 
Clusters 1 and 3 have one lipid in each cluster that behaves differently to the 
other lipids (highlighted in grey in Figure 3.21). PI34.0 and PC38.1..38.2e levels 
are decreased in MCI compared to healthy controls in clusters 1 and 3 
respectively. 
As per the statistical methodology employed for the HC vs. AD groups, taking 
the 33 lipids chosen from the variable selection pathway for HC vs. MCI and 
factoring in their correlations as determined by the Pearson’s correlations R-
values (see Table 3.16), the lipids were subjected to further statistical 
assessment using a stepwise generalised linear model (GLM) to reduce the 
number of lipids in the final predictive model. The GLM algorithm was run 
repeatedly to remove lipids from the predictive model until the lipids left were 
those giving the best AIC report, as previously described for the healthy controls 
and AD groups. This stepwise model again factors in covariates of age, gender, 
APOEε4 allele status and collection site, as described in the previous GLM 
(Table 3.9). The prediction model once again split the analysis of the 1060 
study participant plasma lipid profiles into a run comprising 70% training and 
30% test data and was repeated over 100 times until the greatest sensitivity 
and specificity was achieved.  
A final panel was selected that contained the least number of lipids with 
maximal sensitivity and specificity for predicting clinical classification. In this 
case sensitivity represents the ability of a biomarker to correctly identify MCI 
and specificity is the ability of a biomarker to correctly identify a healthy control. 
Maximal sensitivity and specificity (71%) for predicting participants with MCI as 
compared to healthy controls was attained by variable selection and stepwise 
GLM with the following four lipids listed in Table 3.17.  
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Table 3.17: List of four lipids giving maximal sensitivity and specificity between the HC 
and MCI groups. 
Lipid 
PE34.1 
PE34.2 
LysoPE18.1 
PG34.2 
 
The bolded lipid, PE34.1, was also identified in the standard LIMMA analyses.  
Lower sensitivity and specificity is observed for the 4 lipids predicting MCI as 
compared to the 6 lipids capable of predicting AD (Table 3.13). This may be due 
to the fact that the HC vs. MCI group is less discrete than the HC vs. AD group 
with more overlap between profiles. The MCI group is clinically more 
heterogeneous and often but not always represents a prodromal stage of AD. 
This may explain the sensitivity and specificity of 71% for the HC vs. MCI group 
as compared to 80% for the HC vs. AD group. 
3.4.4  Correlation with Standardised Uptake Value Ratio (SUVR) 
The previous section assessed the ability of a panel of lipids to predict clinical 
classification with the aim of identifying a sensitive and specific diagnostic blood 
lipid biomarker panel. Cerebral amyloid burden as determined by PiB-PET 
neuroimaging, whilst representing a useful AD biomarker is expensive to 
perform, requires access to specialist facilities, and is associated with radiation 
exposure. Therefore development of a blood based biomarker test to replace 
neuroimaging is highly desirable. Consequently, the relationship of the panel of 
lipids determined in section 3.4.3 by variable selection analysis was assessed 
against neocortical amyloid burden represented as SUVR; an established 
neuroimaging biomarker of AD.  Each of the 22 lipids (as they sit in the four 
clusters) identified in the variable selection pathway (Section 3.4.3) for healthy 
controls compared to AD were plotted against categories of baseline SUVR. 
Figure 3.22 shows the clusters of correlated lipids compared to baseline SUVR 
categories for the healthy controls and AD groups. 
 
 
Chapter 3: Plasma Lipid Profiles in AIBL baseline samples 
 
146 
 
 
 
 
 
 
SUVR category Interpretation 
< 1.3 Individuals with minimal accumulation of Aβ 
> 1.3 to < 1.7 
Includes individuals with borderline transitions 
from amyloid -ve to amyloid +ve 
1.7 to < 2.0 
Individuals who are definite accumulators, with 
increased rate of Aβ accumulation 
> 2.0 
Individuals with the highest Aβ accumulation 
but rate plateaus with saturation between 2-3 
 
Figure 3.22: Clustered and correlated lipids compared with baseline SUVR categories. 
The SUVR categories used in this table are those described by Villemagne et al [477]. 
It is interesting to see that many of the lipids in cluster 1 have a similar profile, 
with increased means for those participants with an SUVR of greater than 2. A 
standard Pearson’s Correlation test was performed with each of the 22 lipids 
that were selected from the variable selection pathway. This analysis shows 
PE 34.2, PE 34.1, PE 36.4,       
PE 36.3, PE 36.2, PE 38.5,       
PE 38.4 
PI 34.0,   PG 34.2 
PC38.5p..38.6e, SM18.16.1 
SM18.20.1, SM18.24.0 
 
PC 34.0p..34.1e, PC32.0e                 
PC 36.0p/etherPC, PC 32.0, 
PC 34.0e 
Cer.d18.0.20.0, 
Cer.d18.0.22.0       
Cer.d18.0.24.1 
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that the strongest correlation with SUVR was with PE34.2 (R=0.22), which 
belongs to cluster 1. However, when the panel of six lipids was assessed for its 
relationship with SUVR in the healthy control vs. AD groups no significant 
correlation was observed (data not presented). Additionally no figure is 
presented for the comparison of the HC vs. MCI groups with SUVR as this also 
did not show any significant correlation. 
3.5  Discussion 
Alterations in lipid metabolism have been demonstrated in a wide variety of 
neurological disorders, including Alzheimer’s disease and Parkinson’s disease 
[270, 478]. The amyloid precursor protein (APP) and the secretase enzymes 
associated with its processing are integral membrane proteins. Therefore the 
lipid environment in which these proteins are placed predictably regulate the 
processing of APP and formation of Aβ; ultimately influencing AD pathogenesis. 
Numerous studies have established and verified this lipid-AD connection, with 
cholesterol, phospholipids and sphingolipids all playing a role (described in 
detail in Chapter 1). These studies have also given insight into the possible 
mechanisms by which lipids influence AD pathology [291, 414, 479, 480]. 
Changes in lipid species profiles have been reported with significant decreases 
in sulphatides in the brain and CSF of those individuals in the early stages of 
AD [413, 481]. Significantly increased CSF ceramides were also reported in AD 
[413]. Various groups have investigated specific classes of plasma or serum 
lipids. Studies demonstrated lower serum total ethanolamine plasmalogen 
levels as a predictor of cognitive decline [357] and another study showed 
reduced serum plasmalogen levels at all stages of dementia [341]. There have 
been inconsistencies in results from studies investigating LysoPC and PC ratios 
with some showing elevated ratios [375] and others showing decreased ratios 
[371]. Clear outcomes have also not resulted from various sphingolipidomic 
studies when serum ceramides and sphingomyelin have been measured for 
use as potential biomarkers [163, 422].  
The advancement in technologies for lipidomic research has undoubtedly 
gained momentum in the past decade and made many of these studies 
possible. The current challenge, highlighted by a lack of consistency in previous 
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studies, is in the confident characterisation of the various lipid species to help 
establish a robust panel of lipid biomarkers that is specific and sensitive enough 
to predict clinical classification and possesses sufficient accuracy and precision 
in a laboratory setting to be feasible for routine use. The complexity of method 
choice used in lipidomic studies and the challenges associated with establishing 
large scale highly characterised cohorts can account for many of these 
inconsistencies in previous studies. A panel consisting of the least number of 
lipid species that achieves maximal sensitivity and specificity is sought as 
routine assay feasibility is a consideration, particularly as the increasing 
incidence of AD will predictably increase sample numbers requiring analysis. 
Therefore the purpose of the study presented in this chapter was to add to the 
existing literature by investigating plasma lipid profiles in a highly characterised 
cohort, where changes in lipid profiles were compared to supplementary data 
collected as part of this study, including brain amyloid burden. The highly 
characterised AIBL cohort provides a statistically relevant sample number of 
individuals whose clinical classification can be as accurate as possible with the 
aid of neuroimaging; helping to address some of the limitations of sample 
number with previous studies. The results were assessed for their ability to 
distinguish AD from cognitively normal individuals and those with mild cognitive 
impairment. The major findings from the study presented in this chapter were: 
 86 out of 189 plasma lipid species were significantly different when 
comparing the unadjusted mean values of the lipid species between 
clinical classifications. 
 Twenty seven lipids were shown to be significantly different between the 
healthy control and AD groups by LIMMA analysis when applying a 
Bonferroni correction. 
 11 of these lipids remained significant after adjustment for age, gender, 
APOEε4 allele status and collection site when comparing the HC and AD 
groups. 
 Using a variable selection pathway, a panel of six lipids was able to 
distinguish healthy controls from AD patients with a sensitivity and 
specificity of 80%. 
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 Five lipid species were shown to be significantly different between the 
healthy control and MCI groups by LIMMA analysis when applying a 
Bonferroni correction. 
 One lipid remained significant after adjustment for age, gender, APOEε4 
allele status and collection site. 
 Using a variable selection pathway, a panel of four lipids was able to 
distinguish healthy controls from those with MCI with a sensitivity and 
specificity of 71%. 
 The LIMMA and GLM models did not identify any lipids that were 
significantly different between the MCI and AD groups. 
 No significant correlation could be found when comparing SUVR 
categories and the results from the panel of six lipids identified by 
variable selection for the healthy vs. AD groups.  
 
The heatmaps shown in Figure 3.3, the barcharts in Figures 3.4 - 3.16 and 
Table 3.3 showed significant differences between the unadjusted mean lipid 
species levels and clinical classification for 86 out of the 189 lipids measured. 
This significance was strongest for the greatest number of lipids when 
comparing the healthy control and AD groups. When comparing mean levels of 
summed lipid groups, statistical significance was only shown for total 
Phosphatidylethanolamine (PE) and Phosphatidylinositol (PI) species (p<0.001 
and p<0.05 respectively) between the healthy control and AD groups. Between 
the healthy control and MCI classifications, statistical significance was only 
shown for total Sphingomyelin (SM) and Phosphatidylcholine (PC) species 
(p<0.05). Interestingly, no significant summed lipids groups were identified 
when comparing the MCI and AD groups. When investigating changes in 
summed lipid groups, changes in individual species within a group may be 
masked due to the directional change being opposite in effect i.e. some 
increased and some decreased, which would neutralise any significance when 
looking at the sum of the lipid species within a group. Therefore considering the 
individual lipid species within a group will likely provide more meaningful results 
in terms of significant different in lipid species levels between clinical 
classification. 
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When considering the individual lipid species the most significant differences in 
levels between clinical classifications were seen with Phosphatidylethanolamine 
(PE), Phosphatidylinositol (PI), Phosphatidylcholine (PC), Sphingomyelin (SM) 
and ceramide species. Many of the PE species were elevated in AD compared 
to healthy controls. Similarly, increases in LysoPC’s and ceramides were seen 
in the AD groups compared to healthy controls. The significant PI and SM 
species were lower in the AD compared to healthy controls. When comparing 
the healthy control and MCI groups, the predominant species that were 
significantly different were in the PE and SM groups, with higher and lower 
levels respectively in the MCI group. PC species were higher or lower in the 
MCI compared to the healthy control groups with the plasmalogen PC species 
being lower.  
Changes in brain and plasma lipid composition and metabolism have been 
previously reported [127, 270, 335, 336, 371, 472] and while direct comparisons of 
the results presented here with other studies cannot be made due to study 
populations, analytical methodology and sample differences, the changes 
described in other studies show some similarity with respect to specific lipid 
groups. In agreement with other plasma studies we report reduced 
sphingomyelins, increased ceramides and increased LysoPCs in AD. A recent 
plasma lipidome study in metabolic syndrome identified increases in PC, PE, 
LysoPC and ceramides, with reduced plasmalogen species, suggesting a link 
between these lipids in both metabolic syndrome and AD [340]. Cardiovascular 
disease, diabetes and metabolic syndrome have all been linked to an increased 
risk of AD, and these changes in lipid metabolism which are common to AD and 
metabolic syndrome may represent causality or a similarity in metabolic 
changes that occur in the different conditions, or a combination of these 
possibilities. Longitudinal studies will help characterise more clearly the 
relationship between these conditions. 
Our study has measured 189 lipids in plasma and has revealed changes in 
individual plasma lipid species that have not been simultaneously measured in 
previous studies. For example most studies investigating plasmalogen species 
have used a more targeted analytical approach which have focused on 
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ethanolamine plasmalogens only and have described reduced levels in AD 
[341, 357]. In contrast our study has measured PC and PE plasmalogen and 
shows that some are elevated (PE36p.2, PE40p.4, PE34p.3, PE34p.2, 
PE36p.1, PE38p.5, PE40p.5, PC34.0p..34.1e, PC36.1p/etherPC, 
PC36.0p/etherPC, PC32.0p, PC34.1p..34.2e) while others are reduced 
(LysoPE18.1p, PC36.4p/etherPC, PC38.5p..38.6e, PC32.0e). Interestingly, 
none of the species that are increased between the healthy control and AD 
groups contain DHA (22.6n-3), while one species that is reduced possibly does 
as indicated by an un-saturated bond count of at least 6 (PC38.5p..38.6e). This 
may reflect inadequate dietary intakes of polyunsaturated fatty acids or 
represent defects in the desaturase or elongase enzymes that produce the long 
chain polyunsaturated fatty acids from the essential fatty acids in AD patients. A 
more targeted analysis using liquid chromatography coupled with mass 
spectrometry would further separate the lipid subspecies and specifically 
identify the acyl chains of each species, including those with DHA.  
Plasmalogens are abundant in the CNS and ethanolamine plasmalogens make 
up 30% of the total brain phospholipids and 90% of the ethanolamine 
glycerophospholipid species [339]. Plasmalogens and their precursors are 
supplied to the CNS by the liver. Decreased plasmalogen species in neuronal 
cell membranes can lead to increased membrane cholesterol as plasmalogen 
deficient cells exhibit lower HDL-mediated cholesterol efflux [356, 359]. This 
may therefore promote amyloidogenic processing of APP and increase Aβ 
generation (described in detail in Chapter 1, Section 1.5.1 and 1.5.2). An 
increase in Aβ42 can directly activate sphingomyelinases thereby reducing SM 
and elevating ceramide levels (see Chapter 1, Figure 1.13), consistent with the 
plasma levels reported in this chapter. The synthesis of plasmalogens is 
dependent on peroxisomes to generate the 1-alkyl-glyceryl ether lipid 
precursors. The final elongation and desaturation step in the synthesis of DHA 
also occurs in peroxisomes and therefore reduced peroxisomal function can be 
suggested as a potential reason for reductions in both amongst the AD group. 
The significant differences in individual lipid species between clinical 
classifications just described were identified from non-adjusted marginalised 
Chapter 3: Plasma Lipid Profiles in AIBL baseline samples 
 
152 
 
means with an alpha level set at p < 0.05. Stricter criteria for determining any 
significant differences were applied using LIMMA analysis to identify those lipid 
species with p-values less than the Bonferroni cut off between clinical 
classifications. For the healthy control compared to AD group, 27 lipids were 
identified and for the healthy control compared to MCI group five lipids were 
identified. No lipids were significantly different between the MCI and AD groups. 
The lipids identified by LIMMA as being significant between clinical 
classifications were subjected to a Generalised Linear Model to control for age, 
APOEε4 genotype, gender and collection site. This model selected 11 of the 27 
lipids for the healthy control vs. AD groups and one lipid for the healthy control 
vs. MCI group, following adjustment. The 11 lipids consisted of five PE species 
(PE38.4, PE34.2, PE38.5, PE36.2 and PE34.1), three PC species 
(PC34.0p..34.1e, PC34.1, PC34.0e), two SM species (SM18.20.1 and 
SM18.16.1) and one ceramide species (Cer.d18.0.22.0). SM18.16.1, the lipid 
identified in the HC vs. MCI groups was also selected in the HC vs. AD analysis 
post adjustment for age, gender, APOEε4 allele status and collection site. All 
eleven lipids, except the SM species were elevated in the AD group compared 
to healthy controls. The SM species were lower in the AD and MCI groups 
compared to healthy controls. 
The four lipid groups (PE, PC, SM and Ceramide) that showed differences 
between HC and AD and the one species that was different between the HC 
and MCI groups have a strong biological relationship with each other and the 
directional change of these lipids with respect to clinical classification may be 
predicted. The interconnection of PE, PC, SM, Ceramide and sterol metabolism 
has been depicted in Chapter 1, Figure 1.9. The relative level of the lipid groups 
represents a balance between de novo synthesis, remodelling from other lipids, 
production of metabolites and breakdown. Production may be increased or 
breakdown enhanced by the action of various enzymes upregulated in 
response to a range of signals such as inflammatory cytokines, which have 
been shown to be upregulated in AD [482, 483]. We have shown that many PE 
and a few PC species are increased in AD, which could be an adaptive 
response in an attempt to increase precursors for neuronal repair. The elevated 
PE species may also be a result of reduced activity of PE methyltransferase 
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which converts PE to PC, especially when dietary choline intake is inadequate. 
The activity of this enzyme can be affected by nutrient status of the B group 
vitamins (see Chapter 1, Section 1.3.5), which may alter PC production and 
may reduce the delivery of polyunsaturated fatty acids from the liver to the 
peripheral tissues, including the CNS [149, 191]. The phosphocholine group of 
PC is transferred to ceramide for SM synthesis [348]. The increased PC, 
increased ceramide and reduced sphingomyelin may represent alterations in 
this pathway with reduced sphingomyelin synthase activity. Additionally, 
sphingomyelinase activity is increased in AD [157] and activated by 
inflammatory cytokines and oxidative stress, another likely contributor to AD 
pathogenesis [484], which can increase SM breakdown and further increase the 
ceramide pool.  
From Table 3.8 it can be seen that only one lipid species (PC38.5p..38.6e) 
identified as being significantly different by LIMMA and GLM may contain 
docosahexaenoic acid (DHA) where levels are reduced in AD compared to 
healthy controls. However, PE38.4 and PE38.5 may contain arachidonic acid 
(AA, 20.4n-6) and these are increased in the AD group compared to healthy 
controls. The balance of omega-3 to omega-6 fatty acid containing 
phospholipids may be influenced by factors such as dietary intakes of fatty 
acids and other nutrients but also metabolic factors affecting the elongation and 
desaturation steps in polyunsaturated fatty acid pathways (see Chapter 1, 
Section 1.3.6). Increases in AA containing phospholipids may have implications 
in AD pathology (see Chapter 1, Section 1.5.10). Studies investigating lipid 
metabolism in the AD brain have confirmed increased membrane turnover and 
remodelling with increased expression of enzymes such as cPLA2 (cytosolic 
phospholipase A2) and sPLA2 (secretory phospholipase A2) involved with lipid 
remodelling [485, 486] and cycloxygenase-2 (COX-2) associated with 
neuroinflammation [487]. Ante-mortem PET imaging in AD patients has also 
demonstrated increased brain AA metabolism which may increase production of 
prostaglandin E2 [488]; a potent inflammatory eicosanoid which also stimulates 
Aβ formation through internalisation of the prostaglandin E receptor 4 (EP4) 
[489]. 
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The associations between clinical classification and individual lipid species 
explored using LIMMA and GLM models in this chapter are useful in terms of 
speculating aberrant pathways that may be present in disease, but in terms of 
biomarker discovery, a different statistical approach was required to identify a 
panel of lipids that can predict clinical classification with the greatest certainty. 
The variable selection pathways, stepwise GLM model and ROC curves 
identified a panel of six lipids that gave a sensitivity and specificity of 80% when 
comparing healthy controls and AD. These lipids (also identified by the LIMMA 
analyses) were PI34.0, PC36.0p/etherPC, PC38.5p..38.6e, PC32.0, SM18.20.1 
and Cer.d18.0.22.0. The levels of PC36.0p/etherPC, PC32.0 and 
Cer.d18.0.22.0 were increased and PI34.0, PC38.5p..38.6e and SM18.20.1 
were decreased in the AD group compared to healthy controls. These six lipids 
were selected by statistical models for their ability to predict clinical 
classification rather than their ability to explain aberrant pathways which may 
explain why none of the PE species were selected when this statistical 
modelling was used. 
Lower sensitivity and specificity is observed for the 4 lipids predicting MCI as 
compared to the 6 lipids capable of predicting AD (Table 3.13).  As previously 
mentioned, this may be due to the fact that the HC vs. MCI group is less 
discrete than the HC vs. AD group with more overlap between profiles. The MCI 
group is clinically more heterogeneous and often but not always represents a 
prodromal stage of AD. This may explain the sensitivity and specificity of 71% 
for the HC vs. MCI group as compared to 80% for the HC vs. AD group. 
The correlation between SUVR, a measure of brain amyloid burden and the 
lipid panel failed to show any significance in either the HC vs. AD or the HC vs. 
MCI groups. This may reflect a limitation of SUVR to distinguish between 
clinical classifications when used in isolation i.e. it is more helpful when SUVR 
is combined with other measures such as neuropsychological test data. In fact 
published data from the AIBL study has shown that approximately 30% of 
healthy controls and approximately 60% of MCI participants have a significant 
cerebral amyloid burden with a SUVR value of >1.5. This may account for a 
lack of correlation. Amyloid deposition is known to start occurring many years 
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before symptoms appear, and it has been known for many years that amyloid 
burden is a poor indicator of disease severity, even though amyloid deposits do 
indicate the presence of AD (symptomatic or pre-clinical stages). The inclusion 
of neuropsychological data in future analyses may also have limitations 
however. For example, factors known as brain reserve and cognitive reserve 
have been shown to influence the appearance or severity of symptoms [490]. In 
simple terms, brain reserve can be related to a number of functioning neurons 
and healthy brain tissue, whereas cognitive reserve is related to a person’s 
resilience and adaptability to change, and may be associated with the number 
of synaptic or inter-neuronal connections. These two factors are influenced by 
education level and mental activity, and determine the amount of AD-related 
neuropathology that can be tolerated before symptoms of AD appear. 
Neuropsychological test data were used to categorise the cohort subjects for 
this study, and as mentioned above, the SUVR values for many of the subjects, 
even in the healthy group, indicate AD pathology is already present. Cognitive 
reserve is likely to have influenced the neuropsychological testing. In fact 
cognitive reserve is thought to play such an important role in determining 
disease severity that it has been suggested that some sort of quantitative 
measure of cognitive reserve will help dementia research considerably [491]. 
Therefore, in future studies, the best approach might be to include all three 
factors: SUVR, neuropsychological test results, as well as some measure of 
cognitive reserve. 
The next step is to analyse the 18 month time point to determine whether the 
same lipid species or lipid groups are identified. As the AIBL study is a 
prospective longitudinal study, analysis of the 18 month follow up samples will 
also enable analysis from a longitudinal perspective to facilitate identification of 
plasma lipid species that differ in those participants whose clinical classification 
changes during the study and facilitate identification of those lipids that may 
contribute to a biomarker panel capable of predicting both clinical classification 
and disease progression. This data is presented in Chapter 4.
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Chapter 4 – Plasma Lipid Profiles In AIBL 18 month samples 
4.1 Introduction 
The previous chapter investigated plasma lipid profiles in baseline samples from 
the AIBL cohort. This chapter investigates plasma lipid profiles in samples 
collected from AIBL participants at the 18 month follow up time point. The aim of 
this chapter is to determine whether lipid species identified as being significantly 
different in levels between clinical classifications at baseline are also different at 
the 18 month time point, thus corroborating the results reported in Chapter 3.  
This chapter will also provide a longitudinal perspective to the data through 
examination of which lipid species differ in levels between the transition and 
non-transition groups i.e. comparing those participants whose clinical 
classification changes versus those who remain stable over the 18 month time 
frame. Many studies investigating plasma lipid profiles in AD have been cross 
sectional in nature. A notable exception is the longitudinal Women’s Health and 
Aging study II of cognitive impairment (WHASII), where elevated ceramides 
were associated with memory impairment, hippocampal volume loss and 
incident dementia [163, 422, 474]. There is a critical need for additional 
longitudinal data collected from well-characterised ageing cohorts; the results 
reported in this chapter will help address this deficit. 
Longitudinal MRI and PiB-PET neuroimaging data is collected as part of the 
AIBL study. Whilst this data provides pathological insight, routine use as a 
biomarker of AD is unlikely due to the associated costs, radiation exposure and 
low accessibility.  Furthermore, PiB-PET determined SUVR as an indicator of 
brain amyloid burden is limited in its ability to distinguish between clinical 
classifications when used in isolation. For example, approximately 30% of 
healthy controls and approximately 60% of MCI participants in the AIBL study 
have a significant cerebral amyloid burden with a SUVR value of greater than 
1.5; therefore combining neuroimaging results with neuropsychological test data 
is required to determine clinical status [477]. This highlights the importance of 
identifying blood based biomarkers of AD which may supplement or potentially 
replace neuroimaging. 
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The lipidomic study of the baseline AIBL samples presented in Chapter 3 
showed that the mean lipid species levels differed when comparing clinical 
classifications for 86 of the 189 lipid species measured. Following adjustment 
for age, gender, APOEε4 allele status and collection site, 11 of these lipid 
species remained significant when comparing the healthy control and AD 
groups, yet only 1 lipid species remained significant when comparing the 
healthy control and MCI groups. A variable selection pathway was applied to 
choose the least number of lipids which predict clinical classification with the 
greatest sensitivity and specificity. A panel of six lipids was selected for the HC 
vs. AD groups and a panel of four lipids were selected for the HC vs. MCI 
groups, with a sensitivity and specificity of 80% and 71% respectively. When the 
panel of six lipids was compared to SUVR, no significant correlation was 
identified.  
4.2 Aims 
The aim of the work in this chapter is to investigate plasma lipid profiles via a 
direct infusion with multiple scans technique, using plasma samples obtained as 
part of the highly characterised Australian Imaging, Biomarkers and Lifestyle 
Study of Ageing (AIBL). This study will analyse samples collected at the 18 
month follow up time point. Changes in lipid profiles will be compared to 
supplementary data collected as part of the AIBL study: including brain amyloid 
burden as measured by PiB-PET determined SUVR. The results will be 
assessed for their ability to distinguish AD patients from cognitively normal 
individuals and those with mild cognitive impairment (MCI), and will be 
compared to the results obtained from the baseline samples (described in 
Chapter 3). Additionally, the data will be examined longitudinally to determine if 
changes in lipid profiles were reflected by transition to a different clinical 
classification within the 18 month follow up period. 
 
4.3 Methods 
Details of the study population and the methods for sample collection, lipid 
extraction, and analysis by electrospray ionisation tandem mass spectrometry 
(ESI-MS/MS) have been described in detail in Chapter 2, Sections 2.2 and 2.3.  
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A total of 189 lipids were measured including sub-species of PE, LysoPE, PC, 
Lyso PC, PI, LysoPI, PA, PG, PS, ether PLs, SM and ceramides. This chapter 
describes results generated following analysis of 18 month follow up AIBL study 
samples. 
Figure 4.1 provides a detailed breakdown of the clinical classifications of 
participants in the AIBL cohort at 18 months.  
 
Figure 4.1:  The AIBL cohort at 18 months. There were 968 participants at 18 month follow 
up. These participants were classified as 196 AD, 81 MCI and 691 healthy controls (317 non-
memory complainers (NMC) + 374 subjective memory complainers (SMC)). From baseline 115 
participants did not return for follow-up: Of these, 28 were deceased and one participant in the 
MCI group developed dementia associated with Parkinson’s disease and was therefore 
reclassified as non-AD dementia (PDD). Psychometric testing and neuroimaging was performed 
on participants, and blood samples collected at 18 months were used for lipid profiling. The 
numbers of non-transition and transition participants are indicated on the arrows.  
Schematic adapted from an image provided by the AIBL Study Scientific Management 
Committee. 
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At baseline and the 18 month time points the participants were classed as 
healthy control, MCI or AD. Clinical classification of participants at each time 
point was determined by a panel of clinicians with experience in diagnosing MCI 
and AD. MCI was assigned using the Petersen criteria [456] and AD was 
defined using the NINCDS-ARDA criteria [454] as outlined in Chapter 2. 
 
4.3.1 Statistical analysis 
As previously described in Chapter 3, the study population demographics were 
assessed to compare the healthy controls, MCI and AD groups. χ2 analyses 
were used to test the effect of age, gender and APOEε4 allele status. A 
Kruskal-Wallis formula was applied to MMSE scores. ANOVA was used to test 
inter-group differences in SUVR and hippocampal volume. 
Marginalised means and p-values were obtained for the lipid levels using a t-
test for two classifications (i.e. HC and AD, HC and MCI or MCI and AD) or 
ANOVA for three classifications (HC, MCI and AD).  
The heatmaps were generated and LIMMA and GLM analyses performed as 
outlined in Chapter 3. Variable selection with clustering and prediction of 
classification analyses were also conducted as described in Chapter 3. 
Additionally, LIMMA and GLM analysis were performed to assess differences in 
plasma lipid species between the transition groups. Figure 4.2 summarises the 
statistical analyses used for the study of the 18 month lipid profiles in this 
chapter. 
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Figure 4.2: Summary of the statistical methods used for analysis of AIBL 18 month 
plasma samples. 
ANOVA: Analysis Of Variance, LIMMA: Linear Models for Microarray Data, GLM: Generalised 
Linear Model, CLARA: Clustering for Large Applications, Sens: Sensitivity, Spec: Specificity. 
The R statistical software environment, version 3.0.2, was used for all statistical 
analysis (R Development Core Team, 2009). 
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4.4 Results 
The following table describes the demographics of the 18 month cohort divided 
according to clinical classification. 
Table 4.1: AIBL 18 month time point demographics. 
  HC MCI AD p-value 
Number (n) 686 74 188 
 
Age, years (Mean + SD) 71.78 (+ 6.74) 76.72 (+ 7.55) 79.22 (+ 7.93) <0.0001 
Gender (F/M) 403/283 35/39 111/77 0.156 
ApoEε4 (-ve/+ve) 502/184 44/30 57/131 <0.0001 
MMSE score (Mean + SD) 29 (+ 1.33) 27 (+ 2.29) 18 (+ 7.1) <0.0001 
SUVR (n) 152 26 32 
 
SUVR (Mean + SD) 1.38 (+ 0.39) 1.82 (+ 0.64) 2.37 (+ 0.44) <0.0001 
Hip Vol (n) 143 21 29 
 
Hip Vol (Mean + SD) 3.15 (+ 0.33) 2.93 (+ 0.38) 2.80 (+ 0.49) <0.0001 
 
HC: Healthy Controls, MCI: Mild Cognitive Impairment, AD: Alzheimer’s disease, F: Female, M: 
Male, APOEε4 (-ve/+ve): negative or positive for the APOEε4 allele, MMSE: Mini Mental State 
Examination, SUVR: Standard Uptake Value Ratio, Hip Vol: Hippocampal volume, measured in 
mL. SD: Standard deviation. The characteristics were composed using analysis of variance 
(ANOVA) to calculate differences for the continuous variables and X
2 
for categorical variables. A 
Kruskal-Wallis formula was applied to the MMSE scores. 
The cohort at 18 month follow up consisted of 686 healthy controls (HC), 74 
MCI and 188 AD participants. As was reported for the baseline demographics in 
Chapter 3, the number of men and women in each classification did not differ 
significantly (p=0.156), but significant differences in mean age were seen 
(p<0.001); the AD group is older, which is expected as AD is an age-related 
disease. The AIBL cohort was enriched with APOEε4 allele carriers, 
consequently there are more APOEε4 allele carriers compared to 
epidemiological allele frequencies previously reported (see Table 1.3, Chapter 
1). As expected, and consistent with the baseline cohort demographics 
described in Chapter 3, the mean MMSE score is lower in the MCI and AD 
groups compared to healthy controls, and cerebral amyloid burden as depicted 
by mean SUVR is significantly higher in the AD group compared to the MCI and 
healthy control groups. Further, hippocampal volume is reduced in MCI and AD 
compared to the healthy control group. 
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Of the original 968 follow-up samples, a total of 948 plasma samples were 
analysed to profile the lipids by direct flow injection mass spectrometry (ESI-
MS/MS), using the ABSciex QTrap 4000 instrument and multi reaction 
monitoring (MRM) which fragments the headgroups from their precursor lipids. 
(Details of methods are outlined in Chapter 2, Sections 2.3.3-2.3.5). The 20 
samples that were not successfully analysed failed at either the extraction or the 
MS analysis stage. The 189 lipid species measured are outlined in Table 3.2, 
Chapter 3. 
As with analysis of the baseline samples, the signal intensities of the individual 
lipids were normalised against the signal intensities of the lipid internal 
standards for each respective lipid group, corrected for their respective 
molecular weights before normalisation to the sum of all lipid species measured. 
The lipid levels were expressed as molar fractions. A heatmap of the 18 month 
lipid profiles was plotted (Figure 4.3) to enable visualisation of differences in 
lipid species levels between the healthy control, MCI and AD groups.  
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Figure 4.3: Heatmaps of lipid profiles of 948 AIBL study plasma samples collected at the 
18 month time point, illustrating differences in lipid species levels between clinical 
classification groups. The scale on the right side of the charts displays the mean lipid levels 
expressed as molar fractions. 
HC: Healthy Control, MCI: Mild Cognitive Impairment, AD: Alzheimer’s Disease, PA: 
Phosphatidic acid, PE: Phosphatidylethanolamine, PC: Phosphatidylcholine, PS: 
Phosphatidylserine, PI: Phosphatidylinositol, SM: Sphingomyelin, Cer: Ceramide. White colour 
reflects low levels, while black colour reflects higher levels. 
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The heatmaps depicted in Figure 4.3 allow comparison of each lipid species 
between the healthy control, MCI and AD groups. However, as previously 
mentioned in Chapter 3, they do not allow comparison across lipid species, as 
the relative abundance of lipids is only shown within each lipid group. The 
heatmaps show differences in many of the PE, PC, SM and ceramide species 
between clinical classifications. The abundance of the various lipid species in 
plasma is quite different with PC and SM being the most abundant. To allow this 
data to be displayed graphically three separate bar charts to account for 
abundance differences were created (Figure 4.4), showing the non-adjusted 
marginalised means of the summed lipid species groups and their inter-clinical 
classification differences, as determined by ANOVA. 
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Figure 4.4: Grouped mean lipid levels between clinical classifications. A: PC: 
Phosphatidylcholine, SM: Sphingomyelin, PCp: Choline plasmalogen, LysoPC, PI: 
Phosphatidylinositol. B: PEp: Ethanolamine plasmalogen, PE: Phosphatidylethanolamine, Cer: 
Ceramide, LysoPCp, LysoPE. C: LPI: LysoPI, LysoPEp, LysoPG, PA: Phosphatidic acid, PG: 
Phosphatidylglycerol, PS: Phosphatidylserine. 
 Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001  
 
Chapter 4: Plasma Lipid Profiles in AIBL 18 Month Samples 
 
168 
 
When lipids are grouped into their respective classes, significant differences in 
levels were observed for SM, PEp, PE, Ceramide, LysoPCp, LysoPE, LysoPG 
and PG between the healthy control and AD groups. Ceramide, LysoPCp, 
LysoPE and PG were also significantly different between the healthy and MCI 
groups. Whilst Figure 4.4 shows the mean total levels for each lipid group, it 
does not provide information in relation to sub-species or any significant 
differences between these sub-species and clinical classification. ANOVA 
analysis of the individual lipid groups are represented in the following graphs 
(Figures 4.5 to 4.17), and these show how sub-species levels differ between 
clinical classifications. A summary of these results is presented in Table 4.2 
immediately following Figure 4.17. 
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Figure 4.5A and B: Mean PE levels between clinical classifications. 
PE: Phosphatidylethanolamine, HC: Healthy control, MCI: Mild cognitive impairment, AD: 
Alzheimer’s disease. Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001 
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Figure 4.6A and B: Mean Ethanolamine plasmalogen levels between clinical 
classifications.  
PE: Phosphatidylethanolamine, HC: Healthy control, MCI: Mild cognitive impairment, AD: 
Alzheimer’s disease. Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001 
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Figure 4.7: A: Mean Lyso-Phosphatidylethanolamine (LPE) and B: Mean Lyso-
ethanolamine plasmalogen (LysoPEp) levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001        
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Figure 4.8 A and B: Mean Phosphatidylinositol (PI) levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001  
 
Figure 4.9: Mean Lyso- Phosphatidylinositol (LPI) levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001 
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Figure 4.10: A: Mean Phosphatidic acid (PA) and B: Mean Phosphatidylserine (PS) levels 
between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001 
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Figure 4.11: Mean Phosphatidylglycerol (PG) levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001 
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Figure 4.12 A and B: Mean Lysophosphatidylglycerol (LPG) levels between clinical 
classifications.  
The second LPG 16.1 from Figure 4.12A and LPG16.0, LPG18.2, LPG1.8.1 and LPG18.0 in 
Figure 4.12B (see Table 3.2). are the “f” species. HC: Healthy control, MCI: Mild cognitive 
impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p=<0.05 **p=<0.001 
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Figure 4.13 A, B and C: Mean Phosphatidylcholine (PC) levels between clinical 
classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001 
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Figure 4.14 A, B and C: Mean choline plasmalogen (PCp) levels between clinical 
classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001 
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Figure 4.15 A and B: Mean Lysophosphatidylcholine (LPC) levels and C: Mean Lyso-
choline plasmalogen levels between clinical classifications.  
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001 
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Figure 4.16: Mean Sphingomyelin (SM) levels between clinical classifications. 
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease. 
Mean + SEM. Analysis of Variance (ANOVA): * p < 0.05 ** p < 0.001 
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Figure 4.17A and B: Mean Ceramide (Cer) levels between clinical classifications. HC: 
Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.  
Mean + SEM. Analysis of Variance (ANOVA): * p < 0.05 ** p < 0.001 
 
The bar charts in Figures 4.5 to 4.17 show how the non-adjusted marginalised 
means of each individual lipid species vary between the healthy control, MCI 
and AD groups. Significant differences between the lipid species and clinical 
classifications were seen for many of the lipids including PE, PC, SM and 
ceramide species. A total of 110 out of 189 lipid species measured showed a 
significant difference (as indicated by a p-value of <0.05 or <0.001) between the 
HC and AD, HC and MCI or MCI and AD groups: These results are summarised 
in Table 4.2. 
  
  
 
Table 4.2: List of lipids that were significantly different between clinical classifications. (Table legend on following page)
Lipid – HC vs. AD Lipid – HC vs. MCI Lipid – MCI vs. AD 
p < 0.05 p < 0.001 p < 0.05 p < 0.001 p < 0.05 p < 0.001 
Total SM, Total PE, Total 
LysoPG 
Total PEp, Total Cer, Total 
LysoPCp, Total LysoPE, Total PG 
Total Cer, Total LysoPCp, 
Total LysoPE, Total PG 
   
PE36.2, PE38.7, PE38.6, 
PE40.5, PE40.4, PE34p.3, 
PE36p.3, PE36p.2, PE40p.5, 
PE42p.5,  LysoPE16.1, 
LysoPE18.2, LysoPE18.1f 
PE34.2, PE34.1, PE36.4, PE36.3, 
PE36.0, PE38.5, PE38.4, PE36p.4, 
PE38p.6, PE38p.5, PE40p.7, 
PE40p.6, LysoPE16.0, LysoPE18.1, 
LysoPE18.0 
 
PE34.1, PE36.0, 
LysoPE16.0, LysoPE18.2, 
LysoPE18.1, LysoPE18.0 
 PE36.4, PE36.0, PE38p.6, 
PE40p.7, PE40p.6 
 
PC30.0e, PC34.3, PC36.5, 
PC36.2, PC38.6, PC40.6, 
PC36.3p/etherPC, 
PC36.1p/etherPC, 
PC38.3p..38.4e, 
PC40.3p..40.4e, PCLyso16.0, 
PCLyso18.2 
PC28.1, PC32.0e, PC32.1, PC32.0, 
PC34.0e, PC34.5, PC34.1, PC36.3, 
PC38.1, PC32.0p, PC34.2p..34.3e, 
PC34.0p..34.1e, PC36.4p/etherPC, 
PC36.0p/etherPC, PC38.5p..38.6e, 
PC38.2p..38.3e, PC40.6p..40.7e, 
PC40.2p..40.3e, PC40.1p..40.2e, 
PCLyso16.1, PCLyso18.1, 
PCLyso18e.1, PCLyso18e.0 
PC34.0p..34.1e, 
PCLyso16.1, PCLyso18.1, 
PCLyso18e.0 
 PC32.1, PC32.0, PC34.0e, 
PC36.4, PC36.2, PC34.0p..34.1e, 
PCLyso18.2 
 
PI32.2, PI34.3, PI36.2, PI38.3, 
PI38.2, PI40.3, LysoPI16.1, 
LysoPI16.0, LysoPI18.1 
 PI38.2, PI40.4, PI40.3    
PS36.2, PS36.1, PS38.6, 
PS38.5, PS38.4, PS40.5 
 PS38.5, PS38.4, PS40.5    
LysoPG16.1, LysoPG18.1, 
LysoPG18.0, LysoPG16.1f, 
LysoPG18.1f 
PG34.2, PG34.1, PG36.4, PG36.3, 
LysoPG18.2, LysoPG16.0f 
PG34.2, PG36.4    
PA34.2, PA36.1 PA34.1 PA36.1    
SM18.18.0, SM18.24.1 SM18.16.0, SM18.20.0, 
SM18.22.0, SM18.24.0 
  SM18.20.0 SM18.22.0 
Cer.d18.1.22.0, 
Cer.d18.0.16.0 
Cer.d18.1.16.0, Cer.d18.1.18.0, 
Cer.d18.1.20.0, Cer.d18.1.24.1, 
Cer.d18.0.18.0, Cer.d18.0.22.0,  
Cer.d18.0.24.1 
Cer.d18.0.24.0  Cer.d18.1.16.0, Cer.d18.1.18.0, 
Cer.d18.1.22.0, Cer.d18.0.16.0, 
Cer.d18.0.18.0, Cer.d18.0.24.1 
Cer.d18.1.24.1 
1
8
2
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Table 4.2 legend: The red text indicates lower mean levels in AD compared to HC, MCI 
compared to HC and AD compared to MCI. The black text indicates higher mean levels in AD 
compared to HC, MCI compared to HC and AD compared to MCI.  
PI: Phosphatidylinositol, PE: Phosphatidylethanolamine, PC: Phosphatidylcholine, SM: 
Sphingomyelin, PA: Phosphatidic acid, PG: Phosphatidylglycerol, Cer: Ceramide. 
 
 
To test further for significant differences in lipid species levels between clinical 
classifications using stricter criteria, a linear Models for Microarray Data 
(LIMMA) model was applied to obtain a false discovery adjusted p-value for 
each lipid to exclude any false associations identified by simple ANOVA. 
4.4.1  Linear Models for Microarray Data (LIMMA) comparing clinical
 classifications 
LIMMA analysis was used to obtain Q values (false discovery adjusted values), 
and Bonferroni comparisons were used to generate p-values to reduce the 
number of lipids identified by ANOVA. This model selected 46 out of 189 lipid 
species levels that were significantly different between healthy controls and AD 
participants and these lipids are listed in Table 4.3. 
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Table 4.3: Linear Models for Microarray Data (LIMMA) for 18 month samples for HC vs. 
AD. 
Lipid p-value Lipid p-value 
Cer.d18.1.24.1 2.22E-21 PC36.4p/etherPC 2.46E-06 
Cer.d18.1.20.0 4.86E-17 PE38.5 2.98E-06 
PC34.0p..34.1e 1.19E-15 PC32.0p 8.48E-06 
PC32.0 2.85E-13 PG36.4 1.03E-05 
PC34.0e 6.16E-13 PE34.1 1.12E-05 
PG34.2 1.28E-11 PE36.3 1.62E-05 
PE36.0 1.66E-11 Cer.d18.0.18.0 2.00E-05 
Cer.d18.1.16.0 1.20E-10 PC34.5 2.42E-05 
PG34.1 1.18E-09 PC40.2p..40.3e 2.53E-05 
Cer.d18.1.18.0 1.54E-09 PCLyso18e.1 2.74E-05 
PC32.0e 8.60E-09 SM18.16.0 3.66E-05 
PC34.1 1.11E-08 PCLyso18e.0 4.13E-05 
PE38p.6 1.37E-08 PC40.6p..40.7e 4.94E-05 
SM18.22.0 3.21E-08 SM18.20.0 7.04E-05 
PE40p.6 4.63E-08 PC38.1 8.26E-05 
LysoPE16.0 7.89E-08 SM18.24.0 9.81E-05 
PE36.4 2.47E-07 PC40.1p..40.2e 9.94E-05 
PC36.0p/etherPC 2.63E-07 LysoPE18.1 1.00E-04 
PE40p.7 3.15E-07 PG36.3 1.50E-04 
LysoPE18.0 4.25E-07 PA34.1 1.72E-04 
PCLyso16.1 5.15E-07 PE38.4 2.08E-04 
PC38.5p..38.6e 5.47E-07 PC38.2p..38.3e 2.40E-04 
PC32.1 1.84E-06 PC34.2p..34.3e 2.58E-04 
 
Listed in order of most to least significant for p-values less than the Bonferroni cut off 
(0.05/189). 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol, PA: Phosphatidic acid. 
 
A fold lipid change was subsequently calculated using unadjusted raw 
expression values to provide a relative lipid difference between clinical 
classifications. The mean levels, difference in levels between groups, the 
directional change i.e. increased or decreased in AD compared to healthy 
controls and fold change is shown in Table 4.4. 
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Table 4.4: Mean value difference in lipid species levels between groups, direction of 
change in lipid levels between HC and AD participants and fold change. 
Lipid Mean HC Mean AD Difference Direction of 
change 
Fold Δ 
LysoPE16.0 4.093E-04 4.685E-04 5.923E-05 ↑ in AD 1.145 
LysoPE18.1 2.047E-04 2.325E-04 2.781E-05 ↑ in AD 1.136 
LysoPE18.0 2.304E-04 2.593E-04 2.893E-05 ↑ in AD 1.126 
PE34.1 3.056E-04 3.680E-04 6.247E-05 ↑ in AD 1.204 
PE36.4 8.717E-04 1.038E-03 1.666E-04 ↑ in AD 1.191 
PE36.3 4.615E-04 5.443E-04 8.284E-05 ↑ in AD 1.180 
PE38.5 1.105E-03 1.295E-03 1.906E-04 ↑ in AD 1.173 
PE38.4 2.305E-03 2.617E-03 3.117E-04 ↑ in AD 1.135 
PA34.1 1.44eE-05 1.607E-05 1.603E-06 ↑ in AD 1.111 
PG34.2 1.913E-05 2.393E-05 4.792E-06 ↑ in AD 1.250 
PG34.1 2.639E-05 3.104E-05 4.645E-06 ↑ in AD 1.176 
PG36.4 1.219E-05 1.393E-05 1.737E-06 ↑ in AD 1.142 
PG36.3 1.264E-05 1.146E-05 1.515E-06 ↑ in AD 1.120 
PCLyso16.1 4.122E-04 4.564E-04 4.427E-05 ↑ in AD 1.107 
PCLyso18e.1 7.051E-05 7.656E-05 6.057E-06 ↑ in AD 1.086 
PCLyso18e.0 2.568E-04 2.821E-04 2.526E-05 ↑ in AD 1.098 
PC32.0p 1.240E-03 1.313E-03 7.320E-05 ↑ in AD 1.059 
PC34.0p..34.1e 4.479E-03 4.953E-03 4.739E-04 ↑ in AD 1.106 
PC36.0p/etherPC 4.169E-03 4.463E-03 2.938E-04 ↑ in AD 1.070 
PC38.2p..38.3e 2.509E-03 2.652E-03 1.429E-04 ↑ in AD 1.057 
PC40.2p..40.3e 7.853E-04 8.387E-04 5.343E-05 ↑ in AD 1.068 
PC40.1p..40.2e 9.318E-04 9.924E-04 6.061E-05 ↑ in AD 1.065 
PC32.0e 1.302E-03 1.421E-03 1.189E-04 ↑ in AD 1.091 
PC32.1 9.965E-03 1.108E-02 1.113E-03 ↑ in AD 1.112 
PC32.0 5.407E-03 5.910E-03 5.029E-04 ↑ in AD 1.093 
PC34.0e 1.142E-03 1.272E-03 1.305E-04 ↑ in AD 1.114 
PC34.1 8.348E-02 8.897E-02 5.494E-03 ↑ in AD 1.066 
SM18.16.0 3.361E-02 3.512E-02 1.509E-03 ↑ in AD 1.045 
Cer.d18.1.16.0 1.076E-04 1.202E-04 1.263E-05 ↑ in AD 1.117 
Cer.d18.1.18.0 4.676E-05 5.421E-05 7.450E-06 ↑ in AD 1.159 
Cer.d18.1.20.0 5.192E-05 6.258E-05 1.066E-05 ↑ in AD 1.205 
Cer.d18.1.24.1 6.915E-04 8.276E-04 1.362E-04 ↑ in AD 1.197 
Cer.d18.0.18.0 9.786E-06 1.139E-05 1.605E-06 ↑ in AD 1.164 
PE38p.6 2.498E-03 2.080E-03 -4.188E-04 ↓ in AD 0.832 
PE40p.7 6.750E-04 5.631E-04 -1.118E-04 ↓ in AD 0.834 
PE40p.6 1.211E-03 1.008E-03 -2.032E-04 ↓ in AD 0.832 
PE36.0 1.514E-03 1.193E-03 -3.215E-04 ↓ in AD 0.788 
PC34.2p..34.3e 2.040E-03 1.873E-03 -1.673E-04 ↓ in AD 0.918 
PC36.4p/etherPC 3.046E-03 2.745E-03 -3.017E-04 ↓ in AD 0.901 
PC38.5p..38.6e 2.551E-03 2.274E-03 -2.771E-04 ↓ in AD 0.891 
PC40.6p..40.7e 1.344E-03 1.237E-03 -1.077E-04 ↓ in AD 0.920 
PC34.5 1.828E-04 1.591E-04 -2.376E-05 ↓ in AD 0.870 
PC38.1 3.476E-03 3.300E-03 -1.760E-04 ↓ in AD 0.949 
SM18.20.0 8.164E-02 7.831E-02 -3.330E-03 ↓ in AD 0.959 
SM18.22.0 6.482E-02 6.134E-02 -3.482E-03 ↓ in AD 0.946 
SM18.24.0 1.164E-02 1.105E-02 -5.871E-04 ↓ in AD 0.950 
 
Those lipids in the blue section indicate an increase in the mean lipid levels and those in the 
grey section indicate a decrease in mean lipid levels in AD compared to healthy controls. 
HC: Healthy Control, AD: Alzheimer’s disease, Δ: Change, PC: Phosphatidylcholine, SM: 
Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, PG: Phosphatidylglycerol, PI: 
Phosphatidylinositol. PA: Phosphatidic acid. 
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Table 4.4 shows the mean value, the difference between the mean lipid species 
between clinical classifications and the fold change for each of the 46 lipids 
identified as being significantly different between HC and AD by LIMMA. 33 lipid 
species had mean levels higher and 13 had mean levels lower in AD compared 
to healthy controls. Whilst Tables 4.3 and 4.4 compare healthy controls to AD, 
LIMMA analysis was also repeated for the healthy controls compared to MCI 
and the MCI compared to AD groups. No lipids were identified as being 
significantly different following Bonferroni correction between the HC and MCI 
groups and only one lipid (Cer.d18.1.24.1) was different (p=6.473E-6) between 
the MCI and AD groups: levels of this lipid were higher in AD compared with 
MCI. 
4.4.2 Generalised Linear Model (GLM) comparing clinical classification 
The LIMMA analyses, while identifying those lipid species levels that are 
significantly different between clinical classifications, do not take into 
consideration factors which may influence the significance of the observed 
differences between mean lipid levels. Consequently a generalised linear model 
(GLM) was created to control for age, APOEε4 allele carriage status, gender 
and sample collection site (which was either Melbourne or Perth). The results 
from the GLM comparing the HC and AD groups are displayed in Table 4.5.  
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Table 4.5: Generalised Linear Modelling (GLM) for the 18 month samples for HC vs. AD 
Lipid  p-value Age APOEε4 Sex Site 
Cer.d18.1.24.1 9.47E-14 2.63E-23 1.03E-26 0.180 0.013 
Cer.d18.1.20.0 1.72E-12 7.77E-28 2.24E-25 0.304 0.018 
PC34.0p..34.1e 1.28E-07 1.20E-23 8.18E-28 0.505 0.200 
PC32.0 1.34E-07 1.57E-25 1.40E-27 0.303 0.148 
Cer.d18.1.18.0 4.40E-07 7.56E-30 4.39E-26 0.617 0.067 
Cer.d18.1.16.0 1.01E-06 1.32E-26 9.33E-27 0.267 0.027 
PG34.2 2.55E-06 7.73E-29 2.21E-26 0.513 0.906 
PC34.0e 4.43E-06 3.99E-24 4.96E-28 0.498 0.194 
PC32.0e 2.31E-05 1.06E-26 5.05E-28 0.175 0.172 
PE36.0 4.57E-05 3.07E-29 2.14E-25 0.501 0.611 
PG34.1 8.19E-05 1.72E-28 3.26E-26 0.593 0.244 
PE38p.6 1.12E-04 5.60E-31 1.51E-25 0.466 0.714 
PCLyso16.1 2.08E-04 4.70E-31 5.57E-26 0.518 0.277 
SM18.16.0 2.09E-04 4.34E-30 5.58E-27 0.412 0.062 
PA34.1 2.18E-04 5.77E-32 2.51E-26 0.237 0.103 
PC32.0p 2.40E-04 1.15E-29 3.20E-27 0.383 0.113 
Cer.d18.0.18.0 2.44E-04 2.44E-31 3.47E-26 0.419 0.137 
PE40p.6 2.49E-04 5.75E-31 1.63E-25 0.377 0.486 
PG36.4 0.0003 1.84E-31 3.80E-26 0.353 0.241 
LysoPE18.0 0.0004 7.81E-31 2.80E-25 0.472 0.145 
LysoPE16.0 0.0005 2.09E-29 1.65E-25 0.397 0.079 
PC40.2p..40.3e 0.0007 6.55E-31 4.36E-27 0.484 0.334 
PE40p.7 0.0008 8.10E-31 1.17E-25 0.343 0.366 
PC40.1p..40.2e 0.0011 1.89E-30 1.99E-27 0.457 0.215 
PC36.4p/etherPC 0.0012 1.12E-30 2.92E-26 0.865 0.273 
PC32.1 0.0013 7.65E-30 7.88E-27 0.999 0.301 
PG36.3 0.0031 2.23E-31 2.32E-26 0.317 0.218 
PE36.4 0.0037 7.20E-29 4.86E-26 0.833 0.100 
SM18.22.0 0.0046 1.17E-28 8.37E-27 0.578 0.616 
PC34.1 0.0049 2.92E-28 1.06E-26 0.488 0.498 
PCLyso18.1e 0.0056 4.26E-30 5.34E-27 0.231 0.308 
SM18.20.0 0.0060 5.61E-31 1.97E-26 0.831 0.209 
PC40.6p..40.7e 0.0085 1.28E-31 1.06E-25 0.560 0.248 
PC36.0p/etherPC 0.0092 7.60E-29 4.30E-27 0.634 0.594 
PE36.3 0.0095 8.68E-29 7.21E-27 0.787 0.106 
PC34.2p..34.3e 0.0098 7.69E-31 3.71E-27 0.710 0.387 
PC38.5p..38.6e 0.0106 9.41E-31 1.32E-25 0.629 0.447 
PCLyso18e.0 0.0109 1.28E-30 1.47E-26 0.307 0.272 
PE34.1 0.0118 1.49E-29 3.25E-26 0.570 0.106 
PE38.5 0.0183 2.89E-29 5.31E-26 0.934 0.114 
PC34.5 0.0242 1.48E-30 1.94E-26 0.441 0.323 
LysoPE18.1 0.0351 9.05E-31 1.12E-25 0.271 0.149 
PC38.2p..38.3e 0.0653 7.40E-31 6.96E-27 0.519 0.448 
PE38.4 0.0796 4.15E-30 2.94E-26 0.767 0.123 
PC38.1 0.3542 1.55E-29 1.00E-26 0.670 0.214 
SM18.24.0 0.5028 1.35E-29 7.46E-27 0.633 0.241 
 
Adjusted for age, sex, APOEε4 allele status (i.e. carriage or non-carriage of an APOEε4 allele) 
and sample collection site (Perth or Melbourne). Lipids with a statistically significant p-value less 
than the Bonferroni cut off (0.05/189) are above the solid black line. 
 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol, PA: Phosphatidic acid, APOEε4: 
Apolipoprotein E ε4 allele. 
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Table 4.5 shows the p-values for each of the 46 lipids identified by LIMMA as 
being significantly different between HC and AD, adjusted through GLM for the 
following covariates; age, sex, APOEε4 allele status and sample collection site. 
The p-values for each of the covariates are also shown in the table. The data 
are sorted by the strongest p-value for the lipid level post adjustment i.e. where 
the levels are most different between the clinical classification groups. The top 
18 lipids (above the solid line) in the table remain statistically significant (less 
than the Bonferroni cut off value of p<0.0003 (α of 0.05 / n of 189)) after 
adjustment for age, gender, APOEε4 allele status and collection site. The p-
values indicate that neither site of collection or gender significantly influence the 
results, but as expected, age and APOEε4 allele carriage do significantly 
influence the results.  
No GLM was performed to compare the healthy control and MCI groups as no 
lipids were identified as being significantly different between these clinical 
classifications by LIMMA. 
The GLM of the MCI compared to AD groups showed that the Cer.d18.1.24.1 
species identified as being significantly different by LIMMA between these 
groups, also remained significant (p<0.0003) following adjustment for age, 
gender, APOEε4 allele status and sample collection site. 
4.4.3. Variable selection for predictive lipid panel 
As previously described for the baseline data in Chapter 3, the LIMMA and GLM 
models assess associations between lipids and clinical classification, i.e. levels 
of lipid species that are significantly different between clinical classifications. 
Variable selection analysis attempts to identify lipid species which when 
considered collectively are able to predict clinical classification with greatest 
certainty. As such, the level at which clinical classification can be predicted, is 
determined by modelling the selected lipids and covariates using GLM and 
Receiver Operating Characteristics (ROC) models. 
As described in Chapter 3, previous analysis of biomarkers in the AIBL cohort 
utilised a variable selection pathway to create lists of biomarkers that were 
chosen from four separate selection methods; random forest, boosted trees, 
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regression trees and LIMMA and used clinical classification as a binary 
outcome, i.e. HC or AD [476]. In this study, a variable selection pathway was 
applied to the 189 lipid species to create an importance ranking (in addition to 
generation of p-values), where 1000 iterations were performed to define a list of 
those lipid species that are selected most often as differing in levels when 
comparing clinical classifications. Each time a lipid was selected, a frequency 
score was assigned if it was chosen from all four statistical methods, or from 
three out of the four statistical methods. 
4.4.3.1 Variable selection for HC vs. AD groups 
Table 4.6 lists the lipid species selected most often when comparing the HC 
and AD groups. The lipid species that are selected in at least 10% of the 1000 
iterations from all four statistical methods are listed in column A and the lipid 
species that were selected in at least 10% of the 1000 iterations from three of 
the four statistical methods are shown in column B. 
Table 4.6: Lipid Markers selected by the Variable Selection Pathway for HC vs. AD in the 
18 month samples. 
List A (4/4) List B (3/4) 
Lipid Frequency (/1000) Lipid Frequency (/1000) 
Cer.d18.1.24.1 766 Cer.d18.1.20.0 626 
Cer.d18.1.20.0 362 PG34.1 466 
PC34.0p..34.1e 163 PE36.0 451 
PG34.2 127 PC34.0p..34.1e 444 
  PC32.0 444 
  PC34.0e 345 
  PG34.2 343 
  Cer.d18.1.18.0 334 
  SM18.22.0 283 
  Cer.d18.1.16.0 237 
  Cer.d18.1.24.1 230 
  PC32.0e 164 
  PC38.5p..38.6e 155 
  PC36.4p/etherPC 140 
  PE38p.6 138 
  PC34.1 133 
  LysoPE16.0 125 
 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. The lipids highlighted in grey appeared in 
both list A and list B. 
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Those lipids with the highest frequencies of selection from both lists A and B of 
Table 4.6 were clustered using Partitioning Around Medoids (PAM) to find a 
central lipid, and then cluster other correlated lipids around it. As described in 
Chapter 3, this statistical method correlates lipids that are related to each other 
without consideration of clinical classification, and is performed to see if lipids 
can be eliminated from a final model if they behave in the same way as other 
lipids in their respective clusters in terms of predicting clinical classification. A 
CLARA (Clustering for Large Applications) algorithm was applied to create a 
clusplot of correlated lipids, which resulted in the formation of four lipid clusters, 
listed in Table 4.7 and represented graphically in Figure 4.18. 
Table 4.7: Four groups of clustered lipids were determined using medoid clustering when 
comparing the HC and AD groups. 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 
LysoPE16.0 PE38p.6 PC34.0p..34.1e Cer.d18.1.16.0 
PG34.2 PE36.0 PC32.0e Cer.d18.1.18.0 
PG34.1 PC36.4p/etherPC PC32.0 Cer.d18.1.20.0 
PC34.1 PC38.5p..38.6e PC34.0e Cer.d18.1.24.1 
 SM18.22.0   
    
    
    
 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. 
 
Of the 17 lipids selected by Variable Selection Pathways for HC vs. AD, cluster 
1 has 4 lipids, cluster 2 has 5 lipids, cluster 3 has 4 lipids and cluster 4 has 4 
lipids.  
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Figure 4.18: Clusplot of correlated lipids showing the 4, 5, 4 and 4 lipids from clusters 1 
to 4 respectively.  
The clusplot shows a stronger relationship for the lipids within clusters 3 and 4. 
The lipids in clusters 1 and 2 are by contrast more diffuse, suggesting a weaker 
intracluster relationship between those lipids. The strength of these 
relationships may be explained by the fact that clusters 3 and 4 both contain 
lipids of the same class (PC and ceramides respectively), whilst clusters 1 and 
2 are more heterogeneous containing a mixture of PG, PE, PC and SM species. 
Standard Pearson’s correlations were applied to the lipids in each cluster to 
explore the directional relationship between correlated lipids and clinical 
classification. These relationships between the scaled mean expression for HC 
and AD groups are shown in Figure 4.19 with the r-values for the lipid 
correlations shown in Table 4.8. 
CLARA Cluster Plot 
St
at
is
ti
ca
l C
o
m
p
o
n
en
t 
2
 
Statistical Component 1 
Chapter 4: Plasma Lipid Profiles in AIBL 18 month samples 
 
192 
 
 
 
  
 
 
Figure 4.19: Correlated lipids between clinical classifications. 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol. Scaled mean expression is used to enable graphical representation 
of lipids that differ in abundance. 
LysoPE16.0, PG34.2, PG34.1, 
PC34.1 
PE38p.6, PE36.0, 
PC36.4p/etherPC, 
PC38.5p..38.6e, SM18.22.0 
PC34.0p..34.1e, PC32.0e, 
PC32.0, PC34.0e 
Cer.d18.1.16.0, Cer.d18.1.18.0, 
Cer.d18.1.20.0, Cer.d18.1.24.1 
  
 
Table 4.8: Standard Pearson’s Correlations between 17 lipid species chosen from the variable selection pathway for the HC vs. AD groups. 
 
Correlation coefficients (R) for each pairwise correlation are shown. Correlations of greater than 0.5 or less than -0.5 are highlighted in red.
  
A B C D E F G H I J K L M N O P Q  
 1 -0.113130 -0.092540 0.024544 0.291661 0.217801 -0.171040 0.009912 0.182172 0.179702 0.204909 0.043866 -0.005970 0.238777 0.205044 0.293567 0.303768 A Lyso.PE16.0 
 
1 0.769412 -0.298200 -0.125650 -0.155970 0.534321 0.530812 -0.144360 -0.145240 -0.066340 -0.232740 -0.030280 -0.127930 -0.070670 -0.106140 -0.150560 B PE38p.6 
  
1 -0.286610 -0.105350 -0.246010 0.415336 0.646169 -0.168570 -0.102940 -0.155530 -0.275870 0.038010 -0.128800 -0.094130 -0.140680 -0.159100 C PE36.0 
   
1 0.362691 0.061308 -0.152030 -0.194020 0.003428 0.059416 0.031222 0.225135 -0.112510 0.090714 0.108925 0.123625 0.193643 D PG34.2 
    
1 0.047099 -0.192260 -0.144210 -0.025630 0.145080 0.084246 0.267404 -0.243100 0.128726 0.227648 0.227120 0.303871 E PG34.1 
     
1 -0.042850 -0.014050 0.788231 0.475870 0.855177 0.302029 -0.079970 0.313523 0.170491 0.204510 0.318756 F PC.34.0p..34.1e 
      
1 0.693248 0.013221 0.011570 -0.006280 -0.177810 -0.234220 -0.167150 -0.104370 -0.188880 -0.169820 G PC36.4p.or.ethPC 
       
1 0.067121 0.040785 0.031442 -0.375050 0.032488 -0.015490 -0.046800 -0.079600 -0.052150 H PC.38.5p..38.6e 
        
1 0.614448 0.783217 0.131912 -0.049800 0.338028 0.128871 0.108996 0.266251 I PC32.0e 
         
1 0.547570 0.457070 -0.347740 0.190831 0.128015 0.056191 0.204358 J PC32.0 
          
1 0.275150 -0.166950 0.263676 0.203571 0.195802 0.274928 K PC34.0e 
           
1 -0.528100 -0.066970 0.057543 0.003977 0.058526 L PC34.1 
            
1 0.175049 -0.063300 0.046131 -0.053410 M SM18.22.0 
             
1 0.528673 0.545311 0.626519 N Cer.d18.1.16.0 
              
1 0.666193 0.595002 O Cer.d18.1.18.0 
               
1 0.667528 P Cer.d18.1.20.0 
                
1 Q Cer.d18.1.24.1 
1
9
3
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The strongest correlations, as highlighted in red in Table 4.8 were seen 
between lipids of the same class. i.e. PCs, PEs and ceramides. A correlation 
was also shown between PC34.1 and SM18.22.0. It is important to note that 
sphingomyelin can be formed by the transfer of phosphocholine to ceramide. 
Looking at the directional grouping (increased or decreased in AD compared to 
HC) of the relationship between correlated lipids and clinical classification as 
depicted in Figure 4.19, it can be seen that the lipids in each cluster have a very 
similar relationship.  
Taking the 17 lipids chosen from the variable selection pathway, and factoring 
in their correlations as determined by the Pearson’s correlation R-values (see 
Table 4.8), the lipids were subjected to further statistical assessment using a 
stepwise generalised linear model (GLM) to reduce the number of lipids in the 
predictive model. This methodology was also utilised for the baseline data in 
Chapter 3. The GLM algorithm was run repeatedly to remove lipids from the 
predictive model until the lipids left were those giving the best Akaike 
Information Criterion (AIC) report, which is a measure of the relative quality of a 
statistical model for a given set of data, and therefore provides a means for 
selecting the best model, as previously described in Chapter 3. This stepwise 
model also factors in covariates of age, gender, APOEε4 allele status and 
collection site, as described for the previous GLM. This prediction model split 
the analysis of the 948 study participant plasma lipid profiles into a run 
comprising 70% training (that includes clinical classification) and 30% test data 
(blind to clinical classification), and was repeated over 100 times until the 
greatest sensitivity and specificity was achieved. A final panel of 9 lipids was 
selected that contained the least number of lipids with maximal sensitivity and 
specificity for predicting disease classification: these 9 lipids are listed in Table 
4.9. 
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Table 4.9: List of the nine lipids that yielded maximal sensitivity and specificity between 
HC and AD groups at the 18-month follow-up time point. 
Lipid 
LysoPE16.0 
PG34.2 
PC34.0p..34.1e 
PC38.5p..38.6e 
PC32.0e 
PC32.0 
SM18.22.0 
Cer.d18.1.20.0 
Cer.d18.1.24.1 
 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol. Those lipids highlighted in grey were also selected from the baseline 
data. 
All 9 lipid species were also identified as being significantly different when 
assessed by the standard LIMMA analyses (Tables 4.3 and 4.4). 
PC38.5p..38.6e and PC32.0 were also selected in the variable selection 
pipeline for the baseline data in Chapter 3. 
Maximal sensitivity and specificity (80%) for predicting participants with AD as 
compared to healthy controls is shown in the Receiver Operating Characteristic 
(ROC) curve in Figure 4.20, with respect to the GLM of the top nine lipids 
adjusted for age, gender, APOEε4 allele status and collection site. 
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Figure 4.20: Receiver Operating Characteristics (ROC) curve of the top nine lipids from 
stepwise Generalised Linear Modelling (GLM) showing sensitivity and specificity of 80% 
for the HC vs. AD group. 
 
As previously described in Chapter 3, the ROC curve is a plot of the true 
positive rate (sensitivity) against the true negative rate (specificity) and is 
therefore a measure of the accuracy of a diagnostic test, which in this case is 
the ability of the panel of nine lipids to distinguish those participants with AD 
from healthy controls. A sensitivity and specificity of 80% for the panel of nine 
lipids is indicated by the area under the ROC curve. Although there were only 
two lipids (PC38.5p..38.6e and PC32.0) in the predictive panel for the 18 month 
data that were also selected in the baseline predictive panel, the remainder 
were common to the same classes yet were different sub-species at both time 
points. Despite slight differences in the lipids selected at 18 months compared 
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to baseline, the sensitivity and specificity of the predictive panel remained 
unchanged at 80%. 
4.4.3.2 Variable Selection for HC vs. MCI groups 
As carried out for the healthy controls vs. AD groups, the variable selection 
pathway was repeated for the healthy control vs. MCI groups. This generated a 
list of lipids that were chosen from four separate selection methods as 
previously described for the HC vs. AD groups. Table 4.10 lists the lipid species 
selected most often when comparing the HC and MCI groups. As before, the 
lipid species that were selected in at least 10% of the 1000 iterations from all 
four statistical methods are listed in column A and the lipid species that were 
selected in at least 10% of the 1000 iterations from three of the four statistical 
methods are shown in column B. 
Table 4.10: Lipid Markers selected by the Variable Selection Pathway for HC vs. MCI in 
the 18 month samples. 
List A (4/4) List B (3/4) 
Lipid Frequency (/1000) Lipid Frequency (/1000) 
  LysoPG16.1 376 
  PI38.2 205 
  PS38.5 173 
  PCLyso16.1 167 
  PS36.2 125 
    
    
 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol.  
The variable selection pipeline for the HC vs. MCI groups selected seven lipids 
(PI38.2, PS38.5, PA36.1, LysoPE18.1, LysoPE18.0, LysoPE18.2, PG36.4) from 
all four statistical methods: the maximum frequency however was 1.5%, thus 
too low to be on the list above. The five lipids with the highest frequencies of 
selection from list B of Table 4.10 were clustered as previously described: As 
too few lipids were selected however, a CLARA (Clustering for Large 
Applications) was not generated. Adding the five lipids listed in Table 4.10B to 
the predictive GLM/ROC models gave a sensitivity and specificity of just 69% 
for distinguishing those participants with MCI from healthy controls following 
adjustment for age, gender, APOEε4 allele status and collection site. 
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4.4.3.3 Variable selection MCI vs. AD groups 
As described previously, the variable selection pathway was repeated for the 
MCI vs. AD groups. Table 4.11 lists the lipid species selected most often when 
comparing the MCI and AD groups. As before, the lipid species that were 
selected in at least 10% of the 1000 iterations from all four statistical methods 
are listed in column A and the lipid species that were selected in at least 10% of 
the 1000 iterations from three of the four statistical methods are shown in 
column B. 
Table 4.11: Lipid Markers selected by the Variable Selection Pathway for MCI vs. AD in 
the 18 month samples. 
List A (4/4) List B (3/4) 
Lipid Frequency (/1000) Lipid Frequency (/1000) 
Cer.d18.1.24.1 377 Cer.d18.1.20.0 325 
    Cer.d18.1.24.1 299 
  SM18.22.0 203 
      Lyso.PG16.1f   112 
  PE40p.4 107 
 
Cer: Ceramide, SM: Sphingomyelin, PE: Phosphatidylethanolamine, LysoPG: 
Lysophosphatidylglycerol. The lipid highlighted in grey appeared in both list A and list B. 
The variable selection pipeline for the MCI vs. AD groups selected only one lipid 
(Cer.d18.1.24.1) from all four statistical methods in at least 10% of the 1000 
iterations. Those lipids with the highest frequencies of selection from both lists A 
and B of Table 4.11 were clustered as previously described. However, as too 
few lipids were once again selected, a CLARA (Clustering for Large 
Applications) was not generated. Adding the five lipids listed in Table 4.11 to the 
predictive GLM/ROC models also gave a sensitivity and specificity of just 69% 
for distinguishing those participants with AD from MCI following adjustment for 
age, gender, APOEε4 allele status and collection site. 
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4.4.4  Correlation with Standardised Uptake Value Ratio  (SUVR) 
The previous sections assessed the ability of a panel of lipids to predict clinical 
classification as the aim of the study was to develop a sensitive and specific 
diagnostic blood biomarker lipid panel. In this section, as with the baseline data, 
the relationship of the lipids determined (Section 4.4.4) by variable selection 
analysis was assessed against neocortical amyloid burden represented by 
SUVR; an established neuroimaging biomarker of AD. Each of the 17 lipids 
identified by the variable selection pathway for the healthy control vs. AD 
groups (Table 4.6) was plotted by cluster (Table 4.7) against categories of 
SUVR measured at the 18 month time point; see Figure 4.21 below. 
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SUVR category Interpretation 
< 1.3 Individuals with minimal accumulation of Aβ 
> 1.3 to < 1.7 
Includes individuals with borderline transitions 
from amyloid -ve to amyloid +ve 
1.7 to < 2.0 
Individuals who are definite accumulators, with 
increased rate of Aβ accumulation 
> 2.0 
Individuals who have the highest accumulation 
but rate plateaus with saturation between 2-3 
 
Figure 4.21: Clustered and correlated lipids identified by the variable selection pathway 
for the healthy control vs. AD groups compared with 18 month SUVR categories.  
AD: Alzheimer’s disease, SUVR: Standard uptake value ratio. Aβ: Amyloid Beta. The SUVR 
categories used in this table are those described by Villemagne et al. [477]. 
LysoPE16.0, PG34.2, PG34.1, 
PC34.1 
PE38p.6, PE36.0, 
PC36.4p/etherPC, 
PC38.5p..38.6e, SM18.22.0 
PC34.0p..34.1e, PC32.0e, 
PC32.0, PC34.0e 
Cer.d18.1.16.0, Cer.d18.1.18.0, 
Cer.d18.1.20.0, Cer.d18.1.24.1 
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Figure 4.21 shows that some of the lipids in each cluster behave in a similar 
way when compared to SUVR categories. The lipids levels in clusters 2 and 3 
are approximately the same at SUVR of <1.3 and >2. Cluster 4 contains four 
ceramide species which show very similar relationships with SUVR, rising 
between a SUVR of (> 1.3 to < 1.7) and (1.7 < 2.0), then a sudden decline 
between a SUVR of (1.7 < 2.0) and (> 2), the point at which Aβ accumulation 
plateaus. 
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4.4.5 LIMMA and GLM comparing the transition groups 
To assess the lipid profile data longitudinally rather than cross-sectionally, a 
LIMMA with Bonferroni comparisons was applied to participants following 
classification as either non-transition (classification remained the same: 
excepting stable AD), transition (classification changed to a different group) or 
stable AD (remained in the AD group) over the 18 month follow up period. The 
transition group also included those participants with MCI: “transition” in the 
AIBL cohort is defined as transition towards AD or declining mental health as 
determined by neuropsychological testing [492]. Table 4.12 shows the 
demographics of each classification group for the 948 individuals assessed 
longitudinally, i.e. for whom lipid profiles were measured at both baseline and 
18 month follow up. 
Table 4.12: Demographics of AIBL participants classified as either non-transition, 
transition or stable AD over the 18 month follow up period. 
  Non-transition Stable AD Transition p-value 
Count (n) 679 155 114 
 Age, years (Mean +SD) 71.76 (+ 6.75) 79.25 (+ 7.96) 77.22 (+ 7.63) <0.0001 
Gender (F/M) 400/279 94/61 55/59 0.077 
APOEε4 (-ve/+ve) 498/181 50/105 55/59 <0.0001 
MMSE (Mean + SD) 29 (+ 1.33) 18 (+ 7.05) 26 (+ 3.06) <0.0001 
SUVR (n) 149 23 38 
 SUVR (Mean + SD) 1.38 (+ 0.39) 2.37 (+ 0.48) 1.93 (+ 0.63) <0.0001 
Hip Vol (n) 140 22 31 
 Hip Vol (Mean + SD) 3.15 (+ 0.33) 2.80 (+ 0.49) 2.85 (+0.42) <0.0001 
 
Non-transition: Classification remained the same (excepting stable AD), Stable AD: Remained 
in the AD group, Transition: Classification changed to a different group over the 18 month follow 
up period, AD: Alzheimer’s Disease, F: Female, M: Male, APOEε4 (-ve/+ve): Negative or 
positive for the Apolipoprotein (APOE) ε4 allele, MMSE: Mini Mental State Examination, SUVR: 
Standard Uptake Value Ratio, Hip Vol: Hippocampal volume (measured in mL), SD: Standard 
deviation. The characteristics were composed using analysis of variance (ANOVA) to calculate 
differences for the continuous variables and X
2 
for categorical variables. A Kruskal-Wallis 
formula was applied to the MMSE scores. 
The 948 individuals in whom lipid profiles were measured at both baseline and 
18 month follow up consisted of: 679 non-transition, 114 transition and 155 
stable AD participants. The number of men and women in each classification 
did not significantly differ, but significant differences in mean age, APOEε4 
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allele status, MMSE, SUVR and hippocampal volume were observed between 
groups. 
LIMMA analysis of the non-transition vs. stable AD groups identified 44 out of 
the 189 lipid species measured that were significantly different in levels 
between groups.  Table 4.13 lists these lipids. 
Table 4.13: Linear Models for Microarray Data (LIMMA) for 18 month samples comparing 
the non-transition vs. stable AD groups. 
Lipid p-value Lipid p-value 
Cer.d18.1.20.0 3.71E-18 PC32.1 2.40E-06 
Cer.d18.1.24.1 4.43E-18 PC36.4p/etherPC 5.03E-06 
PC34.0p..34.1e 1.16E-15 PE40p.7 5.11E-06 
PC34.0e 5.11E-13 PE38.5 5.46E-06 
PC32.0 7.53E-12 PC40.2p..40.3e 6.30E-06 
PE36.0 1.35E-10 SM18.20.0 8.65E-06 
Cer.d18.1.16.0 2.88E-10 PCLyso18.1 1.41E-05 
PG34.2 4.02E-10 SM18.24.0 1.56E-05 
PC34.1 9.12E-09 PCLyso18e.0 1.93E-05 
Cer.d18.1.18.0 9.35E-09 PC38.1 2.12E-05 
PG34.1 1.43E-08 PG36.4 2.96E-05 
PC32.0e 6.33E-08 PC34.5 3.86E-05 
LysoPE16.0 6.38e-08 LysoPE18.1 4.78E-05 
PE38p.6 6.53E-08 PE34.1 5.30E-05 
SM18.22.0 7.52E-08 PC34.2p..34.3e 6.14E-05 
PC36.0p/etherPC 7.68E-08 PC38.2p..38.3e 6.53E-05 
PE36.4 1.61E-07 PC32.0p 6.68E-05 
PCLyso16.1 3.10E-07 SM18.16.0 1.21E-04 
LysoPE18.0 4.19E-07 PA34.1 1.85E-04 
PE40p.6 5.37E-07 Cer.d18.0.22.0 1.86E-04 
PCLyso18e.1 1.61E-06 Cer.d18.0.18.0 2.20E-04 
PC38.5p..38.6e 1.96E-06 PE36.3 2.47E-04 
 
p-values less than the Bonferroni cut off (0.05/189). 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol, PA: Phosphatidic acid. 
A fold lipid change was subsequently calculated using unadjusted raw 
expression values to provide a relative lipid difference between transition 
classifications. The mean levels, difference in levels between groups, the 
directional change i.e. increased or decreased in stable AD compared to the 
non-transition group and fold change is shown in Table 4.14. 
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Table 4.14: Mean value difference in lipid species levels between groups, direction of 
change in lipid levels between the non-transition and stable AD and groups and fold 
change. 
Lipid Mean Non-
trans 
Mean 
Stable AD 
Difference Direction of 
change 
Fold Δ 
LysoPE16.0 4.086E-04 4.734E-04 -6.480E-05 ↑ in stable AD 1.159 
LysoPE18.1 2.041E-04 2.355e-04 -3.148E-05 ↑ in stable AD 1.154 
LysoPE18.0 2.298E-04 2.610E-04 -3.123E-05 ↑ in stable AD 1.136 
PE34.1 3.025E-04 3.672E-04 -6.193E-05 ↑ in stable AD 1.203 
PE36.4 8.704E-04 1.053E-03 -1.822E-04 ↑ in stable AD 1.209 
PE36.3 4.614E-04 5.374E-04 -7.599E-05 ↑ in stable AD 1.165 
PE38.5 1.101E-03 1.300E-03 -1.992E-04 ↑ in stable AD 1.181 
PA34.1 1.444E-05 1.616E-05 -1.720E-06 ↑ in stable AD 1.119 
PG34.2 1.908E-05 2.376E-05 -4.685E-06 ↑ in stable AD 1.246 
PG34.1 2.639E-05 3.106E-05 -4.673E-06 ↑ in stable AD 1.177 
PG36.4 1.219E-05 1.395E-05 -1.769E-06 ↑ in stable AD 1.145 
PCLyso16.1 4.119E-04 4.610E-04 -4.907E-05 ↑ in stable AD 1.119 
PCLyso18.1 3.508E-03 3.824E-03 -3.157E-04 ↑ in stable AD 1.090 
PCLyso18e.1 7.030E-05 7.777E-05 -7.467E-06 ↑ in stable AD 1.106 
PCLyso18e.0 2.562E-04 2.845E-04 -2.835E-05 ↑ in stable AD 1.111 
PC32.0p 1.239E-03 1.310E-03 -7.121E-05 ↑ in stable AD 1.057 
PC34.0p..34.1e 4.473E-03 4.988E-03 -5.147E-04 ↑ in stable AD 1.115 
PC36.0p/etherPC 4.163E-03 4.496E-03 -3.335E-04 ↑ in stable AD 1.080 
PC38.2p..38.3e 2.507E-03 2.676E-03 -1.689E-04 ↑ in stable AD 1.067 
PC40.2p..40.3e 7.842E-04 8.462E-04 -6.197E-05 ↑ in stable AD 1.079 
PC32.0e 1.301E-03 1.422E-03 -1.211E-04 ↑ in stable AD 1.093 
PC32.1 9.970E-03 1.116E-02 -1.190E-03 ↑ in stable AD 1.119 
PC32.0 5.406E-03 5.914E-03 -5.080E-04 ↑ in stable AD 1.094 
PC34.0e 1.140E-03 1.282E-03 -1.423E-04 ↑ in stable AD 1.125 
PC34.1 8.346E-02 8.943E-02 -5.967E-03 ↑ in stable AD 1.071 
SM18.16.0 3.359E-02 3.510E-02 -1.512E-03 ↑ in stable AD 1.045 
Cer.d18.1.16.0 1.075E-04 1.208E-04 -1.325E-05 ↑ in stable AD 1.123 
Cer.d18.1.18.0 4.674E-05 5.437E-05 -7.639E-06 ↑ in stable AD 1.163 
Cer.d18.1.20.0 5.182E-05 6.367E-05 -1.185E-05 ↑ in stable AD 1.229 
Cer.d18.1.24.1 6.909E-04 8.250E-04 -1.342E-04 ↑ in stable AD 1.194 
Cer.d18.0.18.0 9.779E-06 1.128E-05 -1.505E-06 ↑ in stable AD 1.154 
Cer.d18.0.22.0 1.732E-05 2.074E-05 -3.417E-06 ↑ in stable AD 1.197 
PE38p.6 2.499E-03 2.065E-03 4.341E-04 ↓ in stable AD 0.826 
PE40p.7 6.751E-04 5.663E-04 1.088E-04 ↓ in stable AD 0.839 
PE40p.6 1.212E-03 1.010E-03 2.028E-04 ↓ in stable AD 0.833 
PE36.0 1.514E-03 1.179E-03 3.347E-04 ↓ in stable AD 0.779 
PC34.2p..34.3e 2.040E-03 1.842E-03 1.976E-04 ↓ in stable AD 0.903 
PC36.4p/etherPC 3.047E-03 2.729E-03 3.187E-04 ↓ in stable AD 0.895 
PC38.5p..38.6e 2.549E-03 2.263E-03 2.863E-04 ↓ in stable AD 0.888 
PC34.5 1.828E-04 1.577E-04 2.508E-05 ↓ in stable AD 0.863 
PC38.1 3.472E-03 3.267E-03 2.055E-04 ↓ in stable AD 0.941 
SM18.20.0 8.169E-02 7.767E-02 4.015E-03 ↓ in stable AD 0.951 
SM18.22.0 6.479E-02 6.111E-02 3.676E-03 ↓ in stable AD 0.943 
SM18.24.0 1.163E-02 1.092E-02 7.038E-04 ↓ in stable AD 0.939 
 
Those lipids in the blue section indicate an increase in the mean lipid levels and those in the 
grey section indicate a decrease in mean lipid levels in stable AD compared to the non-
transition groups. 
Non-trans: Non-transition (classification stayed the same (excepting stable AD) from baseline to 
18 month follow up), AD: Alzheimer’s disease, Δ: Change, PC: Phosphatidylcholine, SM: 
Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, PG: Phosphatidylglycerol, PI: 
Phosphatidylinositol. PA: Phosphatidic acid. 
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The above table shows the mean levels for the groups, the difference between 
the group mean lipid species levels, and the fold change for each of the 44 
lipids identified as being significantly different between the non-transition and 
stable AD groups by LIMMA. For 32 of the lipid species, mean levels were 
higher and for 12 of the lipid species, mean levels lower, when comparing the 
stable AD group with the non-transition group. The LIMMA analysis, while 
identifying 44 lipid species levels that are significantly different between the 
non-transition and stable AD groups, does not take into consideration factors 
which may influence the significance of the observed differences in mean lipid 
levels. Consequently a generalised linear model (GLM) was created to control 
for age, APOEε4 allele carriage status, gender and collection site. The results of 
the GLM are displayed in Table 4.15. 
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Table 4.15: Generalised Linear Modelling (GLM) for the 18 month samples in the non-
transition compared to the stable AD group.  
Lipid  p-value Age APOEε4 Sex Site 
Cer.d18.1.20.0 5.29E-14 4.20E-25 6.31E-21 0.246 0.003 
Cer.d18.1.24.1 7.08E-12 1.08E-21 1.69E-22 0.187 0.005 
PC34.0p..34.1e 8.18E-08 3.45E-21 2.17E-23 0.465 0.084 
PC32.0 2.07E-07 1.98E-23 1.98E-23 0.269 0.052 
Cer.d18.1.16.0 3.80E-07 2.44E-24 2.33E-22 0.239 0.006 
Cer.d18.1.18.0 4.57E-07 1.26E-27 6.54E-22 0.581 0.023 
PC34.0e 1.93E-06 1.14E-21 1.13E-23 0.456 0.077 
PG34.2 1.48E-05 9.94E-27 2.43E-22 0.473 0.633 
PC32.0e 3.10E-05 1.35E-24 1.16E-23 0.161 0.065 
PE36.0 8.48E-05 7.21E-27 3.02E-21 0.446 0.319 
LysoPE18.0 8.83E-05 2.31E-28 5.45E-21 0.411 0.046 
LysoPE16.0 9.86E-05 8.56E-27 3.30E-21 0.331 0.021 
PCLyso16.1 1.31E-04 2.52E-28 1.36E-21 0.463 0.113 
PG34.1 1.91E-04 4.18E-26 4.83E-22 0.533 0.095 
PE38p.6 2.08E-04 2.00E-28 2.10E-21 0.422 0.381 
PA34.1 2.26E-04 3.44E-29 6.13E-22 0.213 0.036 
PG36.4 2.29E-04 5.54E-29 5.10E-22 0.319 0.098 
SM18.16.0 2.40E-04 1.46E-27 8.28E-23 0.401 0.021 
PC40.2p..40.3e 0.0003 2.89E-28 1.33E-22 0.429 0.170 
PE40p.6 0.0005 1.49E-28 1.76E-21 0.337 0.236 
PCLyso18e.1 0.0007 5.07E-27 1.39E-22 0.157 0.137 
Cer.d18.0.22.0 0.0008 5.69E-29 1.68E-22 0.355 0.133 
PC32.0p 0.0008 3.76E-27 5.74E-23 0.382 0.044 
PE36.4 0.0012 4.06E-26 8.71E-22 0.780 0.029 
PCLyso18.1 0.0014 2.22E-28 7.42E-22 0.128 0.162 
PC32.1 0.0017 3.63E-27 1.59E-22 0.911 0.123 
Cer.d18.0.18.0 0.0024 1.46E-28 5.49E-22 0.391 0.058 
SM18.20.0 0.0026 5.73E-28 5.77E-22 0.800 0.080 
PC36.4p/etherPC 0.0026 4.87E-28 6.04E-22 0.768 0.119 
PE40p.7 0.0027 2.16E-28 1.54E-21 0.320 0.157 
PC34.1 0.0040 2.16E-25 1.95E-22 0.423 0.242 
PCLyso18e.0 0.0043 7.17E-28 3.32E-22 0.255 0.115 
PC34.2p..34.3e 0.0053 4.90E-28 9.64E-23 0.662 0.181 
SM18.22.0 0.0055 3.23E-26 1.72E-22 0.504 0.312 
PC36.0p/etherPC 0.0068 5.98E-26 9.37E-23 0.592 0.332 
LysoPE18.1 0.0082 7.06E-28 2.71E-21 0.195 0.044 
PE34.1 0.0133 4.50E-27 4.88E-22 0.512 0.037 
PC38.5p..38.6e 0.0134 3.17E-28 1.91E-21 0.552 0.209 
PE38.5 0.0159 1.14E-26 9.53E-22 0.872 0.038 
PE36.5 0.0230 9.95E-27 1.18E-22 0.692 0.042 
PC34.5 0.0238 5.23E-28 4.15E-22 0.405 0.147 
PC38.2p..38.3e 0.0301 3.59E-28 1.81E-22 0.461 0.249 
PC38.1 0.1620 1.75E-26 2.67E-22 0.670 0.074 
SM18.24.0 0.2443 1.80E-26 1.95E-22 0.634 0.094 
 
Adjusted for age, sex, APOEε4 allele status (i.e. carriage or non-carriage of an APOEε4 
allele) and sample collection site (Perth or Melbourne). Lipids with a statistically significant p-
value less than the Bonferroni cut off (0.05/189) are above the solid black line. 
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, 
PG: Phosphatidylglycerol, PI: Phosphatidylinositol, PA: Phosphatidic acid. APOEε4: 
Apolipoprotein E ε4 allele. 
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Table 4.15 shows the p-values for each of the 44 lipids identified by LIMMA as 
being significantly different between the non-transition and stable AD groups, 
adjusted through GLM for the following covariates; age, sex, APOEε4 allele 
status and collection site. The p-values for each of the covariates are also 
shown in the table. The data are sorted by the strongest p-value for the lipid 
level post adjustment, i.e. where the levels are most different between the 
classification groups. The top 18 lipids (above the solid line) in the table remain 
statistically significant (less than the Bonferroni cut off value of p<0.0003 
(0.05/189)) after adjustment for age, gender, APOEε4 allele status and 
collection site. The p-values indicate that neither site of collection or gender 
significantly influence the results, but as expected age and APOEε4 allele 
carriage do significantly influence the results.  
Whilst Tables 4.13 and 4.14 compare the non-transition to stable AD groups, 
LIMMA analysis was also repeated for the non-transition compared to transition 
groups and the transition compared to the stable AD groups. Three lipids were 
identified as being significantly different following Bonferroni correction between 
the non-transition and transition groups (PG34.2, PC34.0p..34.1e and PA36.1) 
but these did not remain significant following adjustment for age, gender, 
APOEε4 allele status and collection site. One lipid (Cer.d18.1.20.0) was 
identified by LIMMA as being significantly different between the transition and 
stable AD groups, where levels of this lipid were higher in stable AD compared 
to the transition group. This difference remained significant after adjusting for 
age, gender, APOEε4 allele status and collection site following assessment by 
GLM. 
The results reported in Tables 4.13, 4.14 and 4.15 and in the above text 
examined the relationship between the non-transition, transition and stable AD 
groups. These classification groups were defined as described for previous 
analysis of data from the AIBL cohort  [492]. Using this definition, the transition 
group also included those participants with MCI, where “transition” in the AIBL 
cohort represents transition towards AD, or declining mental health as 
determined by neuropsychological testing. A different analysis was then 
undertaken to explore the relationship between lipid profiles and ‘clinical 
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classification transition’, i.e. analysis included those individuals classified at 
baseline as HC or MCI who had transitioned to MCI classification or AD 
diagnosis by the time of the 18 month follow up, yet excluded those participants 
who were classified as MCI at both baseline and the 18 month follow up. This 
reduced the sample number to n=40. LIMMA analysis identified Cer.d.18.1.24.1 
and PG34.2 as being significantly different in those participants who 
transitioned by the 18 month follow up. These two lipids remained significant 
following adjustment for age, gender, APOEε4 allele status and collection site. 
Taking the top markers from the non-transition vs. the transition groups, and 
after removing those that were highly correlated the best sensitivity and 
specificity (78%) was achieved using Cer.d18.1.24.1, PG34.2, PC32.0, 
Cer.d18.0.18.0. 
A recent report by Mapstone et al published in Nature Medicine [493] identified 
a panel of 10 lipid biomarkers that were able to predict phenoconversion to 
either amnestic MCI or AD within 2-3 years with over 90% accuracy. This lipid 
panel comprised of 8 PC species (LysoPC18.2, PC36.6, PC38.0, PC38.6, 
PC40.1, PC40.2, PC40.6, PCp40.6) and 2 acyl carnitine species (Propionyl AC 
and C16.1-OH). Out of the ten lipid species identified in this lipid panel, only 
four were measured in our study (PC 38.6, PC40.6, PC40.6p and LysoPC18.2). 
Using these four lipids in a model to predict those participants whose clinical 
classification transitioned within the 18 month follow up period gave an average 
sensitivity of 73.5%. 
4.4.6  Comparison of baseline and 18 month data 
To enable comparisons between the results obtained in Chapters 3 and 4, 
Table 4.16 displays significant differences in lipid species levels and the 
predictive lipid panels between clinical classifications for both the baseline and 
18 month data. The lipid species which showed different levels when comparing 
the original classification groups, as well as transition groups at baseline and at 
the 18-month follow-up are also displayed. 
  
 
Table 4.16: Summary of the significant differences in lipid species levels following adjustment for age, gender, APOEε4 allele status and collection 
site assessed by GLM, and for the predictive lipid panel generated by the variable selection pathways at both baseline and 18 month follow up. 
Significant Lipids identified by GLM 
Baseline 18 month Transition groups 
HC vs. AD HC vs. MCI MCI vs. AD HC vs. AD HC vs. MCI MCI vs. AD NonT vs. St AD NonT vs.Tran Tran vs. St AD 
SM18.20.1, 
Cer.d18.0.22.0, 
PE38.4,  
PE34.2, 
PC34.0p..34.1e, 
PE38.5,  
PC34.1,  
PE36.2,  
PC34.0e, 
SM18.16.1, 
PE34.1 
SM18.16.1  Cer.d18.1.24.1, 
Cer.d18.1.20.0, 
PC34.0p..34.1e, 
PC32.0,  
Cer.d18.1.18.0 
Cer.d18.1.16.0, 
PG34.2, 
PC34.0e, 
PC32.0e. 
PE36.0, PG34.1, 
PE38p.6, 
PCLyso16.1, 
SM18.16.0, 
PA34.1, 
PC32.0p, 
Cer.d18.0.18.0, 
PE40p.6 
 Cer.d18.1.24.1 Cer.d18.1.20.0, 
Cer.d18.1.24.1, 
PC34.0p..34.1e, 
PC32.0, 
Cer.d18.1.16.0, 
Cer.d18.1.18.0, 
PC34.0e, 
PG34.2, 
PC32.0e, PE36.0, 
LysoPE18.0, 
LysoPE16.1, 
PCLyso16.1, 
PG34.1, 
PE38p.6, PA34.1, 
PG36.4, 
SM18.16.0 
 Cer.d18.1.20.0 
Variable Selection Pathways For Predictive Model 
Baseline 18 month Sensitivity and Specificity 
HC vs. AD  HC vs. MCI MCI vs. AD HC vs. AD  HC vs. MCI  MCI vs. AD  HC vs. AD HC vs. MCI MCI vs. AD 
PI34.0, 
PC36.0p/etherPC, 
PC38.5p..38.6e, 
PC32.0, 
SM18.20.1, 
Cer.d18.0.22.0 
 
PE34.1, PE34.2, 
LysoPE18.1, 
PG34.2 
Not done LysoPE16.0, 
PG34.2, 
PC34.0p..34.1e, 
PC38.5p..38.6e, 
PC32.0e, 
PC32.0, 
SM18.22.0, 
Cer.d18.1.20.0, 
Cer.d18.1.24.1 
Lyso.PG16.1f, 
PI.38.2, 
PS.38.5, 
PC.Lyso.16.1, 
PS.36.2  
Cer.d18.1.20.0, 
Cer.d18.1.24.1, 
SM18.22.0, 
Lyso.PG16.1f, 
PE40p.4               
B/L 18 B/L 18 B/L 18 
80% 80% 71% 69% n/d 69% 
HC: Healthy control, AD: Alzheimer’s disease, MCI: Mild cognitive impairment, NonT: Non-transition, Tran: Transition, St AD: Stable AD, PC: 
Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, PG: Phosphatidylglycerol, PI: Phosphatidylinositol, B/L: Baseline, 
18: 18 months, GLM: Generalised Linear model, APOEε4: Apolipoprotein E ε4 allele, n/d: Not done. 
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Table 4.16 summarises the results from analysis of the baseline and 18 month 
samples. Lipid sub-species of the same lipid groups were consistently identified 
in all comparisons and in the predictive modelling. Of particular note are the 
ceramides, sphingomyelins and several ether PC species. There were no 
consistent differences in PI, PA, PG or PS species. The only lipids that were 
different when considering the HC vs. MCI and MCI vs. AD groups were one 
SM species and one ceramide species respectively, probably due to the fact 
that there is considerable overlap between these classification groups in terms 
of stages of AD pathology. The ability of the predictive model to predict clinical 
classifications reliably gave the highest sensitivity and specificity (80%) for the 
HC vs. AD groups in both the baseline and 18 month samples, which might be 
expected as these groups are much more clinically and pathologically discrete. 
However, the lipids that were chosen for the baseline and 18 month panels 
differed, with the exception of PC38.5p..38.6e and PC 32.0.  
Many lipids identified as being different when considering any change of clinical 
classification (transition groups) over the 18 month follow up period were also 
identified in the 18 month samples when comparing clinical classifications (see 
Table 4.16). There were a few notable differences; e.g. two extra LysoPE 
species were identified as differing between the non-transition and stable AD 
groups. The greatest differences were observed between the non-transition and 
stable AD groups, which again reflects the greater clinical and pathological 
separation between these two groups. The only lipid that was different between 
the transition and stable AD groups was Cer.d18.1.20.0. 
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4.5  Discussion 
The aim of the work in this chapter was to investigate plasma lipid profiles in the 
18 month time point samples from the AIBL cohort, and to compare the results 
with those obtained from analysis of the baseline samples presented in Chapter 
3. In addition, plasma lipid profiles were investigated after the cohort was 
classified differently, into non-transition, transition and stable AD groups. The 
major findings reported in this chapter are as follows: 
 110 out of 189 plasma lipid species were significantly different when 
comparing the unadjusted mean values of the lipid species between 
clinical classifications. 
 46 lipids were significantly different between the healthy control and AD 
groups by LIMMA analysis when applying a Bonferroni correction. 
 18 of these lipids remained significant after adjustment for age, gender, 
APOEε4 allele status and collection site when comparing the HC and AD 
groups using a GLM. 
 Using a variable selection pathway, a panel of nine lipids was able to 
distinguish healthy controls from AD patients with a sensitivity and 
specificity of 80%. 
 No lipids were identified by LIMMA as being significantly different 
between the HC and MCI groups. 
 Cer.d18.1.24.1 plasma levels were identified by LIMMA as being 
significantly different between the MCI and AD groups, and remained 
significant following adjustment for age, gender, APOEε4 allele status 
and collection site using a GLM. 
 The variable selection pathways identified a panel of five lipids with a 
sensitivity and specificity of 69% for predicting clinical classification when 
comparing the HC and MCI groups. 
 The variable selection pathways identified a panel of five lipids with a 
sensitivity and specificity of 69% for predicting clinical classification when 
comparing the MCI and AD groups. 
 No significant correlation could be found when comparing SUVR 
categories and the results from the predictive panel identified by variable 
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selection for the HC vs. AD groups, although the levels of four ceramide 
species showed a distinct relationship with SUVR categories. 
 After re-classifying at 18 months into non-transition, transition and stable 
AD, 44 lipids were significantly different between the non-transition and 
stable AD groups by LIMMA analysis, when applying a Bonferroni 
correction. 
 18 of the 44 lipids remained significant after adjustment for age, gender, 
APOEε4 allele status and collection site when comparing the non-
transition and stable AD groups using a GLM. 
 No lipids were significantly different between the non-transition and 
transition groups following adjustment for age, gender, APOEε4 allele 
status and collection site using a GLM. 
 The plasma levels of Cer.d18.1.20.0 was identified by LIMMA as being 
significantly different between the transition and stable AD groups, and 
remained significant following adjustment for age, gender, APOEε4 allele 
status and collection site using a GLM. 
 
The heatmaps shown in Figure 4.3, the bar charts in Figures 4.4 – 4.17 and 
Table 4.2 showed significant differences between the unadjusted mean lipid 
species levels and clinical classification for 110 out of the 189 lipids measured 
in the 18 month follow up samples. This was more than the 86 species identified 
in the baseline samples, although there was considerable overlap between the 
species identified at both time points. The differences in levels were greatest 
when comparing the healthy control and AD groups. When comparing mean 
levels of summed lipids groups, statistical significance was shown for total SM, 
PE, LysoPG, PEp, Ceramides, LysoPCp, LysoPE and PG at the 18 month time 
point (see Figure 4.4). While differences in total SM and PE were also observed 
in the baseline data, the other summed groups identified in the 18 month 
samples were not identified as being significantly different between clinical 
classifications at baseline. This variation between the baseline and 18 month 
results highlights the fact that measuring summed lipid groups has limited ability 
to show differences between clinical classifications and its use may be 
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restricted to identifying lipid groups that warrant further investigation through 
measurement of the individual sub-species within the lipid group.  
There were noticeable similarities to the baseline results when considering the 
individual lipid species measured at the 18 month time point: the most 
significant differences in levels between clinical classifications were seen with 
PE, PC, SM, PI and Ceramides. Despite the similarities, a few notable 
directional differences between the baseline and 18 month results were 
observed in those lipids identified as differing significantly between clinical 
classifications. The mean plasma level of PE36.2p was shown to be higher in 
AD when compared to HC at the baseline time point, yet at 18 months, PE36.2p 
levels were lower in AD when compared to HC. Further, mean plasma levels of 
PG34.2, SM18.16.0, SM18.18.0 and SM18.24.1 were lower in AD compared to 
HC at baseline, yet were found to be higher in AD compared to HC at 18 
months. 
In agreement with other studies, some of the similarities observed between the 
baseline and 18 month samples involved sub-species of ceramides, choline and 
ethanolamine plasmalogens [163, 341, 357, 422]. Despite the similarities there 
were differences in some ethanolamine species levels in the 18 month samples 
that were not found in the baseline samples; at 18 months, plasma mean levels 
of PE38.7, PE36p.4, PE38p.6, PE40p.6 and PE40.7p were shown to be 
significantly lower in AD compared to healthy controls. With respect to the 
choline plasmalogen species, the baseline and 18 month data showed general 
agreement in terms of species that were identified as being significantly 
different between clinical classifications. Of note however, in the 18 month 
samples, the mean plasma level of PC40.6p..40.7e was identified as being 
significantly lower in AD compared to the HC group. Therefore, all of these PE 
and PC species which showed reduced mean plasma levels in AD (PE38.7, 
PE38p.6, PE40p.6, PE40p.7 and PC40.6p..40.7e) could contain DHA (22:6n-3) 
as one of the acyl chains (represented by an unsaturated bond count of 6 or 
greater). As previously described for the baseline data, this could reflect 
inadequate dietary intakes of omega-3 polyunsaturated fatty acids, or defects in 
the desaturase or elongase enzymes required to produce long chain fatty acids 
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from their precursor essential fatty acids. Additionally, lower levels of the 
ethanolamine plasmalogen species may be a result of elevated ceramides, as it 
is also suggested that ceramides can induce a plasmalogen-selective 
phospholipase A2 [494], although no significant change in LysoPEp species (a 
product of the action of plasmalogen-selective phospholipase A2 on PEp) were 
observed. 
Furthermore, several of the LysoPE and LysoPC species were elevated in the 
AD compared to the healthy control group, which may suggest increased PLA2 
activity associated with inflammatory processes [28, 405]. 
Overall when comparing the baseline and 18 month samples there are many 
similarities. Any differences may potentially be explained by analytical factors 
and by the fact that the characteristics of the cohort at each time point will differ 
slightly: for example, each participant is 18 months older and for those in the 
MCI or AD groups, pathological processes have advanced. Cross sectional 
analysis of plasma lipid profiles at the 36 month time point may assist in 
determining whether these differences are due to changes in lipid profiles within 
an individual or due to analytical and sample handling factors.  
The significant differences in individual lipid species between clinical 
classifications just described were identified from non-adjusted marginalised 
means with an alpha level set at 0.05. Stricter criteria for determining any 
significant differences were applied using LIMMA analysis to identify those lipids 
species with p-values less than the Bonferroni cut off of 0.05/189 (α/n) between 
clinical classifications. LIMMA analysis identified 46 differences in the lipids 
when comparing HC vs. AD, yet only one significant lipid difference when 
comparing MCI vs. AD. No lipids were identified for the HC vs. MCI group. 
These lipids identified by LIMMA were then controlled in a GLM for age, gender, 
APOEε4 allele status and collection site. A comparison of the adjusted 
significant lipids identified in the baseline and 18 month samples is presented in 
Table 4.16. 
The GLM identified 18 lipid species that remained significant following 
adjustment when comparing the HC and AD groups. These 18 lipids consisted 
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of five ceramide species (Cer.d18.1.24.1, Cer.d18.1.20, Cer.d18.1.18.0, 
Cer.d18.1.16.0 and Cer.d18.0.18.0), six PC species (PC34.0p..34.1e, PC32.0, 
PC34.0e, PC32.0e, PCLyso16.1 and PC32.0p), two PG species (PG34.2 and 
PG34.1), three PE species (PE36.0, PE38p.6 and PE40p.6) one PA and one 
SM species (PA34.1 and SM18.16.0). All mean plasma levels were higher in 
AD compared to healthy controls except for PE36.0, PE38p.6 and PE40p.6, 
which were lower in AD compared to healthy controls. Two of these species 
(PE38p.6 and PE40p.6) may contain DHA as indicated by an unsaturated bond 
count of 6. PE38p.6 and PE40p.6 were not significantly different between the 
HC and AD groups at baseline. However, the significantly lower plasma levels 
of PE38p.6 and PE40p.6 shown in the AD compared to healthy control group 
observed at 18 months is in agreement with previous studies showing disease 
severity is associated with decreased levels of circulating ethanolamine 
plasmalogens [341, 357]. This association with disease severity could also 
provide an explanation as to why these lipids were not identified at baseline: 
pathology may have progressed sufficiently at the 18 month time point to 
enable differences between the AD and HC groups to be determined. 
As previously mentioned, several species that were lower in AD compared to 
healthy controls possibly contain DHA. This may be explained by inadequate 
intakes and/or the presence of abnormal biochemical pathways involving DHA.  
While DHA can be obtained from dietary sources, an adequate supply to the 
brain also relies on peroxisomal production. The elongation and desaturation of 
fatty acids occurs in the endoplasmic reticulum (ER) or microsomes, but the 
conversion of eicosapentaenoic acid (EPA, 20:5n-3) to DHA requires a final 
additional step that only occurs in peroxisomes [495]. EPA undergoes two 
further elongation steps and a final delta-6 desaturation occurs in the ER to 
yield tetracosahexaenoic acid (24:6n-3). This very long chain fatty acid is 
transported to the peroxisome for a final β-oxidation step to remove 2 carbons 
to yield DHA (22:6n-3)[496]. This additional step is suggested as a reason for 
inefficient conversion of the essential fatty acid, α-linolenic acid (18:3n-3) to 
DHA and why additional dietary intakes of DHA may be required to meet the 
needs of the brain. A recent study has shown deficient liver biosynthesis of DHA 
in AD patients, as higher levels of the DHA precursor tetracosahexaenoic acid 
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(24:6n-3), and lower expression of peroxisomal D-bifunctional protein (required 
for the conversion of 24:6n-3 to 22:6n-3) were detected in AD patients [497]. 
Any accumulation of very long chain fatty acids can adversely affect 
mitochondrial function [498], and it is important to remember that mitochondrial 
dysfunction and oxidative stress are thought to be central to AD pathogenesis. 
Additionally, as previously mentioned in Chapter 3, the plasmalogen precursors 
(1-alkyl-glyceryl ether lipids) are also synthesised in peroxisomes and 
peroxisomal dysfunction in the liver and brain has been reported as a feature of 
AD [498, 499].  
It is also worthy of note that all of the elevated PC and PE species seen in the 
AD group compared to the HC group at both time points contain few 
unsaturated bonds and have smaller acyl chain lengths: inferring the intriguing 
possibility that abnormal elongase and desaturase enzyme activity could be 
present in AD, resulting in a lower than normal production of longer chain 
polyunsaturated fatty acids (PUFAs). This may then have multiple 
consequences including reduced membrane fluidity and an imbalance in PUFA-
derived signalling molecules such as eicosanoids and docosanoids. Delta 6-
desaturase acts as a gateway for the flow of fatty acids into the elongation and 
desaturation pathways; and the activity of this enzyme may be influenced by 
dietary intakes of fatty acids, various nutrients such as zinc, magnesium and 
vitamin B6 [224] and metabolic hormones [500, 501]. Insulin is known to affect 
activity of both delta 5 and delta 6 desaturases [225] and by reducing the supply 
of long chain PUFA to the brain, may represent an additional mechanism by 
which metabolic dysfunction and associated insulin resistance could contribute 
to AD. 
Significant elevations were seen in five species of ceramide in AD compared to 
healthy controls and additionally Cer.d18.1.24.1 was also significantly elevated 
in AD compared to MCI. The results presented in this chapter are in general 
agreement with other reports showing elevated ceramides and reduced SM in 
AD compared to HC and MCI [163, 422, 502], although some variation in the 
individual sub-species is noted, which may reflect the different methodologies 
used in these studies. Sulphatide depletion in the AD cortex has been reported 
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[338, 413], and studies have shown that when individual sulphatide species are 
measured, the major depleted species contain d18.1.24.1 (nervonic acid), 
d18.1.24.1h (α-hydroxynervonic acid) and d18.1.26.1 (hexacosaenoic acid) 
[503]. Sulphatides are synthesised from cerebroside (galactosylceramide), with 
the reaction being catalysed by galactocerebroside sulphotransferase. 
Importantly, activities of this enzyme or the levels of precursor cerebrosides do 
not appear to be altered in the AD cortex [335], strongly suggesting that 
sulphatide breakdown is the major reason for the observed sulphatide 
depletion. As ceramides are a product of sulphatide catabolism, this could 
explain the increase in nervonic acid containing Cer.d18.1.24.1. Decreases in 
sulphatides in the AD cortex are reflected by large increases in ceramides in 
both the cortex and CSF [413, 471, 504]. If increased plasma ceramide levels 
parallel those changes observed in the brain and CSF, plasma levels of 
Cer.d18.1.24.1 could possibly represent a surrogate measure of sulphatide 
status; plasma levels of which are very low and therefore difficult to measure. It 
also appears that brain sphingolipid levels vary depending on extent of 
neurodegeneration, with the greatest changes occurring in early disease [413]. 
Figure 4.21 shows the scaled mean expression levels of four ceramides 
(Cer.d18.1.16.0, Cer.d18.1.18.0, Cer.d18.1.20.0 and Cer.d18.1.24.1) in the 18 
month plasma samples and how the levels relate to SUVR categories, which 
are representative of cerebral amyloid burden. There is a clear increase in 
levels of all these ceramides between the SUVR categories of (> 1.3 to < 1.7) 
and (1.7 to < 2) with 1.5 being considered the cut off between PiB-PET negative 
and positive. Interestingly, a dramatic drop in the plasma levels of these 
ceramides follows as SUVR reaches a value of > 2. At this more advanced 
stage, cerebral amyloid burden is severe and the rate at which further amyloid 
accumulation occurs plateaus. The results provide compelling evidence of 
abnormal sphingolipid metabolism which warrants further investigation, and the 
inclusion of ceramides and sphingomyelins in a potential diagnostic blood 
biomarker panel seems justified. 
The endogenous ceramide pool consists of production from three main 
pathways. The de novo pathway, the sphingomyelinase pathway which 
catabolises SM and the salvage pathway which breaks down complex 
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sphingolipids such as sulphatides, gangliosides and cerebrosides [505]. In the 
de novo pathway ceramides are produced from palmitoyl CoA and serine by the 
coordinated action of four enzyme groups; Serine palmitoyltransferase (SPT), 3-
ketodihydrosphingosine reductase, dihydroceramide synthases (CerS1-6) and 
finally dihydroceramide desaturase (DES). The dihydroceramide synthases 
(CerS1-6) are specific for fatty acyl chain lengths (CerS1: C18, CerS2: C20-26, 
CerS3: C18 and 24, CerS4: C18 and C20, CerS5: C16, and CerS6: C14 and 
C16) [506]. The various fatty acyl chains introduced by these specific CerS are 
thought to alter membrane dynamics but the exact biological function of the 
different species remains to be elucidated. However, the existence of 6 specific 
individual CerS enzymes implies the different species are likely to have different 
roles [507]. The final step in the synthesis of ceramide is the desaturation of 
dihydroceramide by DES. The formation of SM via incorporation of 
phosphocholine and complex sphingolipids is then facilitated by the action of 
SM synthase and glucosyl or galactosyl ceramide synthases respectively [505]. 
Ceramides can also be produced from the catabolism of SM via 
sphingomyelinase enzymes (SMases). It would appear that sphingolipid 
metabolism is regulated by a complex interplay of synthesis from basic 
precursors and catabolism of both SM and more complex sphingolipids. Altered 
activities of the many enzymes involved in these pathways are emerging as not 
only contributors to AD pathology but also potential targets for therapeutic 
intervention.  
Studies have shown elevated acid SMase activity is associated with an increase 
in ceramides, Aβ and phosphorylated tau, as well as an associated reduction in 
SM in the AD brain [471]. Serine palmitoyltransferase (SPT), which is the first 
enzyme and likely the rate limiting step in the de novo ceramide synthesis 
pathway [508] has also recently been shown to be regulated by the APP 
intracellular domain (AICD). Increased SPT activity has been demonstrated in 
APP knock-in mice missing a functional AICD domain, and increased SPT 
activity has also been reported in both familial and sporadic post mortem AD 
brains [509]. Inhibition of SPT with L-cycloserine was recently shown to down 
regulate production of cortical Aβ42 and hyperphosphorylated tau in a mouse 
AD model [510]. Dihydroceramide desaturase (DES), the final enzyme in the de 
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novo ceramide synthesis pathway that converts dihydroceramide to ceramide is 
receiving attention for its role in sphingolipid metabolism [511]. Dihydroceramide 
and dihydrosphingomyelin may interfere with lipid raft processes by increasing 
rigidity within these microdomains [512]. APP processing by secretases is 
fundamental to AD pathology and inhibition of DES1 has been proposed as a 
potential target to reduce secretase activity and therefore Aβ production. 
Interestingly, DES regulation has been shown to be influenced by fatty acids in 
a cell culture model, with palmitate increasing levels of DES1 mRNA and 
therefore increasing ceramide levels, whereas oleate did not induce this 
increase [513]: This could represent another link between the protective effects 
of the Mediterranean diet, rich in olive oil, on AD and metabolic disease. The 
plasma levels of the dihydroceramide species in our study (Cer.d18.0.18.0) 
were significantly different between healthy controls and the AD group. The 
plasma levels of dihydroceramides or ratio of dihydroceramides to ceramides 
may become an important tool for monitoring response to therapy should DES 
inhibitors be introduced into any clinical trials. 
Another recent study compared the brain levels of six ceramide subspecies, 
differing in the length of their acyl moieties, and found elevations in Cer16, 
Cer18, Cer20 and Cer24 in AD [514], consistent with our plasma findings. 
These authors then investigated the possible mechanisms underlying the 
increase in levels of these ceramides by evaluating the expression of acid 
SMase, neutral SMase2 (which breaks down SM), UDP-glucose ceramide 
glucosyltransferase (UGCG, which catalyses the conversion of ceramides into 
glycosphingolipids) and galactosylceramidase (GALC, which produces 
ceramide from galactosylceramide, a major SL of myelin and precursor for 
sulphatides). The results suggested abnormal expression patterns in AD, with 
increased expression of GALC, acid SMase and neutral SMase and reduced 
expression of UGCG; all of which may  increase ceramides [514].  
As ceramides can easily cross the blood brain barrier [515], it is possible that 
plasma ceramides can influence gene expression changes in the brain, and 
elevated ceramides in the brain can influence plasma levels. All these studies 
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present intriguing avenues for future research, and the measurement of plasma 
ceramide levels will be an important inclusion. 
As described in Chapter 3 for the baseline data, a variable selection pathway 
was also used in the analysis of the 18 month data, to identify a panel of lipid 
biomarkers capable of predicting clinical classification with the greatest 
certainty. The variable selection pathways, stepwise GLM and ROC curves 
identified a panel of nine lipids that gave a sensitivity and specificity of 80% 
when analysing the healthy control and AD groups. These lipids (also identified 
by LIMMA analyses) were LysoPE16.0, PG34.2, PC34.0p..34.1e, 
PC38.5p..38.6ePC32.0e, PC32.0, SM18.22.0, Cer.d18.1.20.0 and 
Cer.d18.1.24.1. All of these lipids, except for PC38.5p..38.6e and SM18.22.0 
were elevated in AD compared to healthy controls. The sensitivity and 
specificity of the separate lipid panels chosen by variable selection for the HC 
and MCI and MCI and AD groups was only 69% however; this may reflect the 
fact that MCI is a more clinically heterogeneous group which can often overlap 
both the HC and AD groups and often, but not always represents a prodromal 
stage of AD.  
Whilst the lipids chosen by the statistical pipeline were able to differentiate 
between the healthy control and AD groups with a sensitivity and specificity of 
80% at both baseline and 18 months, the lipid panels selected at the two time 
points were different. Table 4.16 lists the predictive lipid panels for both 
baseline and the 18 month time points. Only two of the predictive lipids 
(PC38.5p..38.6e and PC32.0) were common to both the baseline and 18 month 
time points, however the subclasses identified were very similar, excepting 
PI34.0 at baseline and LysoPE at 18 months. The observed differences 
between time points may once again be due to analytical and sample handling 
factors, or may reflect a difference in the characteristics of the cohort over time, 
as previously described. Analysis of samples collected at the 36 month time 
point may help to obtain a clearer picture of lipids that are able to predict clinical 
classification with the greatest certainty. 
The analytical methods chosen for this study were based on the need for 
simultaneous quantification of a broad range of lipids in a large number of 
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samples. The analytical techniques that were employed have been useful in 
identifying which lipids are significantly different between clinical classifications 
and to speculate on aberrant pathways that may be present in AD. Further 
studies using a more targeted approach with LC separation is warranted, 
particularly with the PC, PE, sphingolipids and plasmalogen species, which 
appear to offer the best prospect of forming a lipid biomarker panel.  
As in the previous chapter, the possibility of correlations between SUVR, a 
measure of brain amyloid burden, and lipid species was investigated. When 
comparing the predictive lipid panels identified by variable selection, no 
significant correlations were identified. However as described earlier, an 
intriguing pattern emerged when assessing the relationship of mean ceramide 
levels with SUVR (see Figure 4.21). This analysis showed the levels of four 
ceramide species (Cer.d18.1.16.0, Cer.d18.1.18.0, Cer.d18.1.20.0 and 
Cer.d18.1.24.1) were relatively low if the SUVR was below 1.7, high at a SUVR 
between 1.7 and 2 and yet markedly lower again at a SUVR above 2, at which 
stage amyloid accumulation plateaus according to PiB-PET, with saturation 
occurring between 2-3 [477]. Statistical significance may not be revealed when 
looking at the means of the lipid levels for each SUVR category; however, it 
may be useful to investigate how an individual’s lipid levels vary with SUVR, as 
this may reveal a significant correlation between these ceramide species and 
SUVR. 
For the longitudinal study, the diagnostic classifications were revised at the 18 
month time point and participants were classified into three groups: non-
transition, transition or stable AD (remained in the AD group). The non-transition 
group included those participants whose clinical classification was the same at 
inception and 18 months (excepting stable AD). The transition group included 
those participants whose clinical classification was different at inception and 18 
months as well as including the MCI group, who are considered to be in 
transition towards AD or declining mental health [492]. The stable AD group 
included individuals who were classified as AD at both baseline and 18 month 
follow up. The greatest difference in mean lipid species levels was observed 
between the non-transition and stable AD groups; these groups are the most 
clinically and pathologically discrete. Between the non-transition and stable AD 
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groups, 44 lipid species were identified as being significantly different. Following 
adjustment for age, gender, APOEε4 allele status and collection site, 18 of 
these 44 lipid species remained significant. Most of these lipids were the same 
as those identified as being significantly different between the healthy control 
and AD group, except PG36.4, LysoPE16.0 and LysoPE18.0, which were 
identified as being significantly different between the non-transition and stable 
AD groups only.  
The ceramide species Cer.d18.1.20.0 was the only lipid to have significantly 
different mean plasma levels between the transition and stable AD groups. 
Interestingly, a previous study identified elevated plasma levels of very long 
chain ceramides as being predictive of memory loss and right hippocampal 
volume loss amongst people with MCI [423]. While any association of the very 
long chain ceramides with hippocampal volume and cognitive scores was not 
assessed in this study, it clearly warrants further investigation. Correlations 
between the transition groups and SUVR were not assessed here, as intra-
individual levels of cerebral Aβ do not differ significantly between baseline and 
18 month time points: This requires evaluation at subsequent time points, which 
is beyond the scope of this thesis. As described earlier, however, an intriguing 
pattern was uncovered when assessing the relationship between mean 
ceramide levels and SUVR cross-sectionally at the18 month follow up (see 
Figure 4.21). 
When the MCI group was excluded from the analysis and only those 
participants whose clinical classification ‘transitioned’ from HC to MCI, HC to AD 
or MCI to AD were included, only Cer.d18.1.24.1 and PG34.2 were identified as 
being significantly different. Taking the top markers from the non-transition vs. 
the transition groups, and after removing those that were highly correlated the 
best sensitivity and specificity (78%) was achieved using Cer.d18.1.24.1, 
PG34.2, PC32.0, Cer.d18.0.18.0. However the number of participants that were 
re-classified at the 18 month follow up (after removing the MCI group) was only 
40 and therefore analysis of the samples collected at the 36 month time point 
may improve the statistical power of the longitudinal analysis. 
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As previously described, a recent report by Mapstone et al published in Nature 
Medicine [493] identified a panel of 10 lipid biomarkers that were able to predict 
phenoconversion to either amnestic MCI or AD within 2-3 years with over 90% 
accuracy. This lipid panel comprised of 8 PC species and 2 acyl carnitine 
species; the levels of which were reduced in the plasma of those study 
participants who phenoconverted compared to the control group. The levels of 
these lipids also remained lower in the converters and in MCI and AD groups 
compared to controls. The analytical approach used in this reported study 
combined untargeted and targeted analyses facilitating the measurement of a 
large number of lipid species. Out of the ten lipid species identified in the lipid 
panel, only four were measured in our study (PC 38.6, PC40.6, PC40.6p and 
LysoPC18.2); all levels of which were lower in the MCI and AD groups 
compared to healthy controls. When these four lipids were used in a prediction 
model, a sensitivity and specificity of only 73.5% was achieved. The predictive 
ten lipid panel identified in the study by Mapstone et al, predicted conversion 
between 2-3 years and therefore analysis of the transition group samples with 
the inclusion of the other six lipids measured in their study may become more 
relevant in the AIBL 36 month follow up time point. 
Plasma lipid profiles are influenced by many factors such as diet, nutrient 
status, hormone balance, medication use and the existence of co-morbidities 
such as diabetes and cardiovascular disease. The plasma levels of individual 
lipid species are also the net result of a complex set of synthesis, metabolic and 
catabolic pathways influenced by a myriad of signals and catalytic enzymes. In 
addition, lipoprotein metabolism and lipid species are regulated by a number of 
proteins including phospholipid transfer protein (PLTP), cholesterylester transfer 
protein (CEPT) and lecithin-cholesterol acyl transferase (LCAT). One of these 
proteins, PLTP, will be investigated in Chapter 5 for both its relationship to 
plasma lipid species levels and its association with clinical classification. PLTP 
has been shown to be associated with some features of AD pathology and has 
been studied for its role in metabolic and cardiovascular disease: consequently, 
correlations between plasma PLTP activity and other AD biomarkers will also be 
investigated.
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Chapter 5 - Plasma PLTP Activity 
5.1  Introduction 
The previous two chapters investigated plasma lipid profiles, their association 
with clinical classification and the ability of a panel of lipid species to predict 
clinical classification. Plasma lipids are influenced by many factors such as diet, 
nutrient status, hormone balance, medication use and the existence of co-
morbidities such as diabetes and cardiovascular disease; which also happen to 
be risk factors for AD.  
Phospholipid transfer protein (PLTP) is one of two or more lipid transfer proteins 
that are found in plasma, and one of its major roles involves the transfer of 
phospholipids from triglyceride-rich lipoproteins to high density lipoprotein 
(HDL), thus regulating the size and composition of HDL. Due to its role in 
peripheral lipid and lipoprotein metabolism, and its role in other processes that 
may influence AD pathology, PLTP may represent a mechanistic link between 
abnormal lipid metabolism in the periphery and that of the brain. This chapter 
will investigate whether there is any association between plasma PLTP activity 
levels and the lipid profiles measured in the previous chapters, whether PLTP 
activity levels differ with clinical classification, and whether levels correlate with 
those of other biomarkers measured in the AIBL cohort. 
PLTP is a ubiquitously expressed protein belonging to the family of 
lipopolysaccharide (LPS) binding and lipid transfer genes that includes LPS 
binding protein (LBP), neutrophil bactericidal permeability increasing protein 
(BPI) and cholesteryl ester transfer protein (CETP) [516-518]. Despite its name, 
PLTP is emerging as a multifaceted protein involved in lipoprotein remodelling, 
reverse cholesterol transport, phospholipid transfer and immunity. In plasma, 
PLTP is mainly associated with high-density lipoproteins (HDL) as mentioned 
above, yet in addition to phospholipids, it also efficiently transfers α-tocopherol 
(a form of vitamin E), diacylglycerol, lipopolysaccharides, cerebrosides 
(monoglycosylceramides; important components of nerve cell membranes) and 
other amphiphilic molecules such as Aβ [519, 520]. This multi-functionality 
suggests important roles not only in lipoprotein metabolism but also 
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inflammation and oxidative stress, which are thought to be involved in AD 
pathogenesis [482, 484].  
Dietary -tocopherol is incorporated in chylomicrons and transported to the liver 
where it is packaged into very low density lipoproteins (VLDL) for release into 
the circulation [521]. The tocopherols are important in preventing low density 
lipoprotein (LDL) oxidation and subsequent uptake of oxidised LDL by vascular 
endothelium [439]. A deficiency of PLTP in PLTP (-/-) transgenic mice has been 
shown to result in a reduced delivery of -tocopherol to the brain and an 
associated increase in oxidative injury, which may contribute to neurological 
dysfunction. This suggests that PLTP is a local transporter of -tocopherol and 
that it may transport this antioxidant vitamin across the blood brain barrier 
(BBB) [440]. More recent studies of PLTP knockout mice demonstrated that 
intracerebral injection of Aβ25-35 oligomers caused memory deficits and 
oxidative stress (effects not seen in wild-type mice), and that chronic dietary 
supplementation with vitamin E could reduce these symptoms. These studies 
demonstrate the importance of PLTP in vitamin E transport and/or delivery to 
the brain, and how a PLTP deficiency can lead to an inability to prevent 
oxidative damage [522].  
PLTP transfers phospholipids from triglyceride-rich and apoB-containing 
lipoproteins (chylomicrons and VLDL) to HDL during lipolysis by lipoprotein 
lipase. It also facilitates the formation of LDL and maturation of HDL by the 
transfer of surface lipids between lipoproteins [523, 524]. Studies have shown 
that PLTP transfers all major phospholipid classes although 
phosphatidylethanolamine (PE) is transferred more slowly. Transfer is not 
influenced by chain length of the acyl groups or their sn-1 or sn-2 positions on 
the phospholipid molecule [437, 525]. Studies into cellular ceramide 
homeostasis, have shown that PLTP can also transfer sphingomyelin (SM) from 
vesicles to HDL [164]. Evidence suggests that newly synthesised hepatic 
ceramides are secreted via VLDL, and PLTP may be one of the proteins that 
facilitates the transfer of sphingolipids onto nascent lipoproteins [164, 526, 527]. 
The physiological relevance of PLTP is highlighted in PLTP-deficient mice, 
which demonstrate a total absence of phospholipid transfer from VLDL to HDL 
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and subsequently markedly reduced HDL levels [436]. The PLTP gene 
promoter region contains response elements for farnesoid X-activated receptor 
(FXR), peroxisome proliferator-activated receptor α (PPARα) and the liver X-
activated receptor (LXR); involved in bile acid, fatty acid, glucose and 
cholesterol metabolism respectively [528, 529]. A major function of PLTP is in 
maintaining the heterogeneity of plasma HDL which therefore facilitates reverse 
cholesterol transport due to its ability to generate nascent preβ-HDL. Preβ-HDL 
particles are primary acceptors of cell derived cholesterol, and facilitate 
cholesterol and phospholipid efflux from peripheral cells via the ATP-binding 
cassette transporters ABCA1 and ABCG [442, 530, 531].  
Two different forms of PLTP exist in plasma: An active form, measured by its 
ability to transfer phosphatidylcholine (PC) to HDL and an inactive form that 
lacks this capability [532, 533]. Plasma contains varying amounts of the active 
and inactive PLTP forms [518, 534]. Active and inactive PLTP levels also 
appear to be tissue-dependent, with no inactive form being detected in CSF or 
tear fluid and the majority of the inactive form being present in the vascular 
compartment [535-537]. Additionally, plasma levels of the inactive form have 
been shown to decrease, and the active form increase in correlation with acute 
phase response inflammatory markers, such as C-reactive protein [538, 539]; 
suggesting that one function of the inactive form is to act as a reserve that may 
be converted to the active form in response to changes in the physiological or 
pathological landscape. The active form may then transfer more phospholipids 
to cells for membrane repair and maintenance of integrity during inflammatory 
stress [540, 541]. The complete repertoire of inactive PLTP function is currently 
unknown but while it is unable to transfer lipids from PC-containing vesicles to 
HDL in vitro or mediate other activities involved with lipoprotein metabolism of 
its active counterpart, it can bind lipids with equal capacity and has been shown 
to attach strongly to surface phospholipids [542]. It would therefore appear 
prudent to suggest that inactive PLTP may activate signal transduction 
pathways. In plasma, both forms of PLTP are present in complexes, some of 
which are lipid-protein complexes whilst others contain protein only. Studies 
using anti-PLTP antibodies and proteomics have identified several proteins in 
these complexes, including clusterin (apoJ), fibrinogen, transthyretin, 
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plasminogen and apoAI [518, 538]. Some of these proteins are thought to 
stabilise or determine lipid transfer activity of PLTP within these complexes and 
a large number of these proteins are actually acute phase proteins involved in 
inflammatory pathways and compliment activation; suggesting a major role for 
PLTP in immunity and inflammation, in addition to its role in lipid transfer [541, 
543].  
As PLTP is now being shown to play a role in processes other than lipid 
transfer, research efforts are changing direction, and the idea that PLTP acts as 
a regulator of signal transduction is being actively explored [544, 545]. Initial 
studies have shown that both apoAI and PLTP participate in lipid efflux via 
ABCA1, but in slightly different ways. The ApoAI pathway utilises lipid-poor HDL 
particles whereas PLTP requires the presence of mature, lipidated HDL [544, 
546]. PLTP has been shown to bind to and stabilise ABCA1 and at the same 
time competitively inhibit apoAI binding to ABCA1, suggesting PLTP mimics 
apolipoproteins with respect to the transfer of cellular lipids, particularly 
cholesterol. More recent studies have expanded this work and have shown that 
like apoAI, PLTP is involved in signal transduction pathways - binding of PLTP 
to ABCA1 activates the Janus kinase 2 / Signal Transducer and Activator of 
Transcription (JAK2/STAT3) pathway in macrophages, which significantly 
reduces secretion of pro-inflammatory markers [518, 547]. Recent evidence has 
also demonstrated that in macrophages, PLTP inhibits nuclear factor kappa B 
(NFκB); a transcription factor involved in cellular responses to stimuli such as 
stress, cytokines, oxidative stress, oxidised-LDL and antigens [548, 549]. These 
authors have also shown that PLTP modulates two other ABCA1–independent, 
signal transduction pathways in human neuronal cells; the PI3K/Akt/GSK3β 
pathway via the insulin receptor and the Dab1-dependent (reelin) pathway 
[550]. Collectively, these findings suggest PLTP has the ability to modulate  a 
selection of cell signalling pathways (irrespective of its lipid transfer properties) 
that are linked to many functions in the brain that are adversely affected in AD, 
such as plasticity, insulin signalling, tau phosphorylation and neurogenesis. 
Neuronal cells require a constant supply of cholesterol and other lipids for 
membrane and acetylcholine synthesis and while de novo synthesis of a wide 
Chapter 5 – Plasma PLTP Activity Levels 
229 
 
range of lipids occurs in neurons there is still a reliance on exogenous sources 
contained in lipoproteins, which are bound and internalised from the 
extracellular fluid [302, 551]. Excess lipids also need to be eliminated, which 
occurs via a bidirectional lipoprotein mediated transport involving apoE [443]. 
ApoE, the major apolipoprotein synthesised by astrocytes, is usually present in 
the CSF in a lipidated state [552], where it exists as cholesterol rich, discoidal 
complexes, resembling plasma HDL. These complexes readily target LDL–
receptor related protein (LRP), which is abundantly expressed on the surface of 
neurons [302]. As in plasma, CSF lipoproteins can also be remodelled by 
lecithin-cholesterol acyltransferase (LCAT) and PLTP; reflecting the key role of 
HDL like particles in cholesterol homeostasis within the central nervous system 
(CNS) [443]. ApoE secretion by astrocytes is modulated by PLTP and a 
correlation between CSF levels of apoE and PLTP has been shown [553]. HDL 
and the metabolism of Aβ, the accumulation of which is a key feature of AD 
pathology, are also intimately connected [554].  
An increase in the production of Aβ occurs in response to higher cellular 
cholesterol levels, most likely due to the influence of membrane cholesterol on 
lipid rafts and on the activity of APP cleavage enzymes [26] (see Chapter 1, 
Section 1.5.1). It has also been suggested that PLTP and apoE-containing HDL 
in the brain may exert several neuroprotective effects via suppression of Aβ 
production, by activation of reverse cholesterol transport, mediated by ATP-
binding cassette (ABC) transporters [555]. Studies have shown that the apoE in 
HDL can bind to Aβ and prevent its oligomerisation [554], and that HDL 
transports Aβ in both the CSF and plasma and represents a method of 
elimination from the brain. PLTP may have a crucial role in this process as it 
also transports amphiphillic molecules, such as Aβ.  
ApoAI has been shown to be present in the CNS and as this molecule is not 
thought to be locally synthesised, it is probably of plasma origin [302]. In 
addition to mediating cholesterol removal, ApoAI is considered to be anti-
inflammatory [556], and may represent the mechanistic link between low 
plasma HDL and memory deficits [557].  
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Cells of the BBB express several ABC transporters, of which ABCA1 and 
ABCB1 play an important role in Aβ removal from the CNS. ABCB1 (also known 
as P-glycoprotein 1 and multidrug resistant protein 1) is highly expressed on the 
luminal side of endothelial cells within the BBB. Aβ can be transported into the 
periphery via Aβ binding to ABCB1 or via LRP-1 (which can bind Aβ directly or 
via Aβ ligands, such as apoE) [558, 559]. ABCA1 is expressed in astrocytes 
and microglia and at the abluminal side of the endothelium where PLTP-
mediated lipidation of apoE is enhanced; facilitating Aβ trafficking to the BBB for 
elimination via ABCB1 [555].  
The widespread distribution of PLTP in the human CNS has been 
demonstrated, with synthesis by glia and neurons having been confirmed; 
furthermore, a study has reported a significant increase in PLTP in the AD brain 
compared to control brain [535]. The authors of this study suggest that an 
increase in PLTP levels in brain tissue may represent a compensatory response 
to an underlying aberrant metabolic process present in AD [535], and the 
accumulation of PLTP in myelin fibres, as shown by immunohistochemistry, 
suggest a role for PLTP in preserving the functional and structural integrity of 
myelin [535].  
Sulphatides are a class of myelin-specialised glycosphingolipids involved in 
various cellular processes, including cell growth, protein trafficking, signal 
transduction, cell-cell recognition, neuronal plasticity and cellular integrity [270, 
421]. Sulphatide levels in the AD brain are markedly reduced [413]. Studies 
have shown that apoE is associated with sulphatide transport and mediates 
sulphatide homeostasis in the central nervous system through lipoprotein 
metabolism pathways. Alterations in apoE mediated sulphatide trafficking have 
been shown to deplete sulphatide in the brain [337]. An increased rate of 
apoE/sulphatide particle uptake and an increased expression of lipoprotein 
receptors can lead to increased degradation of sulphatide-containing apoE 
particles, resulting in accelerated sulphatide depletion from the myelin sheath. 
[71]. CNS levels of sulphatide have been shown to be apoE isoform-dependent, 
the lowest levels being seen with the APOEε4 genotype [71]. Sulphatide 
containing apoE-associated particles facilitate Aβ clearance, thus APOEε4 
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carriers having the lowest sulphatide levels represent a further mechanism for 
APOEε4 increasing the risk for AD [71]. A role for PLTP in Aβ clearance could 
be strongly suggested due to its importance in lipid transfer, lipoprotein 
metabolism, transport of amphiphilic molecules, and its association with apoE, 
in addition to its widespread CNS distribution.  
A study of PLTP activity, serum apoE concentration and APOE genotype in a 
Finnish population, showed apoE levels to be highest in APOEε2 carriers and 
lowest in APOEε4 carriers, yet with no difference observed between the groups 
in terms of PLTP activity [534]. However, this study utilised a cognitively normal 
population. In another study, CSF PLTP activity levels were shown to be 
significantly lower in AD compared to healthy controls, suggesting sequestration 
of PLTP in brain tissue [536]. In cognitively normal individuals, a significant 
physiological link between CSF levels of PLTP, apoE, APP and tau has also 
been demonstrated [553]. 
The importance of PLTP in lipoprotein metabolism and the discovery of new 
roles for this protein have understandably driven research into its association 
with cardiovascular, metabolic, inflammatory and neoplastic diseases. However, 
due to the complexity of function, tissue specific distribution, genetic 
polymorphisms, the regulatory proteins and lipids, and different isoforms, it is 
not surprising that determining possible associations with disease has not been 
straightforward. A recent comparison of relationships between cardiovascular 
disease and plasma PLTP has highlighted inconsistencies, due to conflicting 
results [449]. PLTP and cholesteryl ester transfer protein (CETP) are proteins 
involved in the exchange of phospholipids and cholesteryl esters (respectively) 
between HDL and other lipoproteins, and low CETP and high PLTP activity both 
result in higher plasma HDL-cholesterol levels. Activities of both these enzymes 
were recently measured in the Framingham Heart Study cohort, which showed 
a lower plasma CETP and higher PLTP activity was associated with an 
increased risk of cardiovascular disease, but in men only [444]: A gender 
difference has not previously been reported in other studies. The relevance of 
plasma PLTP activity levels in AD is currently unknown but despite the obvious 
caveats, and due to its wide ranging functions involving lipid metabolism, 
Chapter 5 – Plasma PLTP Activity Levels 
232 
 
inflammation, oxidation and possible removal of Aβ, it is highly likely to play a 
significant role and therefore warrants further investigation.  
It is known from the literature that PLTP activity levels both influence and are 
associated with plasma lipoprotein levels. What is less clear is any association 
between plasma lipid species levels (e.g. such as those measured in Chapters 
3 and 4) and plasma PLTP activity levels. To our knowledge this is the first 
study to investigate any association between plasma lipidomics and PLTP 
activity in a highly characterised ageing cohort.  
5.2  Aims 
This chapter aims to investigate any association of the lipid species levels 
measured in Chapter 3 with plasma PLTP activity levels determined using a 
commercial assay kit. Differences in PLTP activity levels between clinical 
classifications will be compared to supplementary data collected as part of the 
AIBL study, including brain amyloid burden as measured by PiB-PET 
determined SUVR, and APOEε4 allele status. The results will also be assessed 
for correlation with other AD-related blood biomarkers measured in the cohort 
including plasma Aβ, ApoE and clusterin levels.  
5.3 Methods 
Details of the study population and the methods for sample collection, 
neuroimaging, lipid extraction, analysis by electrospray ionisation tandem mass 
spectrometry (ESI/MS/MS), and determination of plasma PLTP activity levels, 
plasma Aβ levels, plasma ApoE levels, clusterin levels and HDL-cholesterol 
subfraction levels have been described in detail in Chapter 2, Sections 2.2, 2.3 
and 2.4. Plasma PLTP activity levels were measured in a subset of the AIBL 
study baseline samples (n=259). 
 
 
 
 
Chapter 5 – Plasma PLTP Activity Levels 
233 
 
5.4 Statistical analysis 
Pearson’s correlations and logistic regression were used to assess possible 
linear relationships between plasma PLTP activity levels and plasma levels of 
each of the 189 lipids species measured in Chapter 3. To assess the study 
population demographics between the healthy controls, MCI and AD groups, χ2 
analyses were used to test the effect of age, gender and APOEε4 allele status. 
A Kruskal-Wallis formula was applied to MMSE scores. Marginalised means 
and p-values were obtained for the lipid levels using a student’s unpaired t-test 
for two classifications (i.e. HC and AD, or HC and MCI) or ANOVA for three 
classifications (HC, MCI and AD). Additionally ANOVA was used to test inter 
group differences in SUVR and hippocampal volume.  
The statistical analysis was performed using R version 3.0.2 (R Development 
Core team, 2009, Vienna, Austria) and IBM SPSS Statistics version 22 (SPSS 
Inc., Chicago, IL, USA). 
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5.5 Results 
5.5.1 Correlation of plasma PLTP activity levels with lipid species 
Plasma PLTP activity levels were measured in a subset of AIBL study baseline 
samples and the activity levels were correlated (independent of clinical 
classification) with the mean plasma lipid species levels of 189 lipid species 
measured in Chapter 3 (see Table 3.2). Figure 5.1 shows the correlation of the 
summed lipid groups with plasma PLTP activity levels; the strongest association 
is indicated by a higher adjusted R squared value. 
 
 
 
Figure 5.1: Correlation between plasma PLTP activity levels and summed lipid groups. 
Pearson’s correlations adjusted for age, gender and APOEε4 allele status. 
PLTP: Phospholipid transfer protein, LysoPE: Lysophosphatidylethanolamine, SM: 
Sphingomyelin, PG: Phosphatidylglycerol, PE: Phosphatidylethanolamine, PC: 
Phosphatidylcholine, PEp: Ethanolamine plasmalogen, PS: Phosphatidylserine, LysoPEp: Lyso-
ethanolamine plasmalogen, PI: Phosphatidylinositol, Cer: Ceramide, LPI: 
Lysophosphatidylinositol, PA: Phosphatidic acid, PCp: Choline plasmalogen, LysoPG: 
Lysophosphatidylglycerol, LysoPC+P: Lysophosphatidylcholine plus Lyso-choline plasmalogen. 
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Plasma PLTP activity levels showed the strongest correlation with the levels of 
LysoPE, SM and PG groups; these relationships are statistically significant 
(Figure 5.1) (p < 0.05; Pearson’s correlations adjusted for age, gender and 
APOE ε4 allele carriage). None of the other lipid groups significantly correlated 
with plasma PLTP activity levels. The correlation between plasma PLTP activity 
levels and plasma total LysoPE, total SM and total PG levels are shown in 
Figure 5.2. 
A 
 .  
B 
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Figure 5.2: Correlation between plasma PLTP activity and plasma lipid levels of (A) Total 
LysoPE, (B) Total SM, (C) Total PG. Lipid levels expressed as molar fractions. Pearson’s 
correlations, adjusted for age, gender and APOEε4 allele status. p value < 0.05. 
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, LysoPE: 
Lyso-phosphatidylethanolamine, SM: Sphingomyelin. PG: Phosphatidylglycerol.  
Figure 5.2A shows a positive correlation between the mean plasma total 
LysoPE levels and plasma PLTP activity levels. When mean plasma total 
LysoPE levels were measured in the baseline cohort, no significant difference 
was observed between clinical classifications (see Figure 3.4B). 
Figure 5.2B shows a positive correlation between the mean plasma total SM 
levels and plasma PLTP activity levels. When mean plasma total SM levels 
were measured in the baseline cohort, a significant difference was observed 
between the HC and MCI groups (see Figure 3.4A), where levels were lower in 
the MCI group compared to the HC group. Significant differences in the mean 
plasma levels of many sub-species of SM were also observed between clinical 
classifications with SM species levels lower in the MCI and AD groups 
compared to healthy controls (see Figure 3.15). 
Figure 5.2C shows a positive correlation between the mean plasma total PG 
levels and plasma PLTP activity levels. When mean plasma total PG levels 
were measured in the baseline cohort, no significant differences were observed 
between clinical classifications (see Figure 3.4C). However, a significant 
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difference in the mean plasma level of the PG sub-species PG34.2 was shown 
between clinical classifications with PG34.2 lower in the MCI and AD groups 
compared to healthy controls (see Figure 3.10). 
The association between plasma PLTP activity levels and mean plasma levels 
of the individual lipid species was then assessed. Figures 5.3 and 5.4 show the 
correlation of the individual 189 lipid species with plasma PLTP activity levels; 
the strongest association is indicated by a higher adjusted R squared value. 
Chapter 5 – Plasma PLTP Activity Levels 
238 
 
 
Figure 5.3: Correlation between plasma PLTP activity levels and individual lipid species. 
Pearson’s correlations adjusted for age, gender, APOE ε4 allele status. 
PLTP: Phospholipid transfer protein, LysoPE: Lysophosphatidylethanolamine, SM: 
Sphingomyelin, PG: Phosphatidylglycerol, PE: Phosphatidylethanolamine, PC: 
Phosphatidylcholine, PEp: ethanolamine plasmalogen, PS: Phosphatidylserine, LysoPEp: Lyso-
ethanolamine plasmalogen, PI: Phosphatidylinositol, Cer: Ceramide, LPI: 
Lysophosphatidylinositol, PA: Phosphatidic acid, PCp: Choline plasmalogen, LysoPG: 
Lysophosphatidylglycerol. 
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Figure 5.4: Correlation between plasma PLTP activity levels and individual lipid species. 
Pearson’s correlations adjusted for age, gender, APOE ε4 allele status. 
PLTP: Phospholipid transfer protein, LysoPE: Lysophosphatidylethanolamine, SM: 
Sphingomyelin, PG: Phosphatidylglycerol, PE: Phosphatidylethanolamine, PC: 
Phosphatidylcholine, PEp: ethanolamine plasmalogen, PS: Phosphatidylserine, LysoPEp: Lyso-
ethanolamine plasmalogen, PI: Phosphatidylinositol, Cer: Ceramide, LPI: 
Lysophosphatidylinositol, PA: Phosphatidic acid, PCp: Choline plasmalogen, LysoPG: 
Lysophosphatidylglycerol. 
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From the overall model assessing association of the levels of the 189 lipids 
against plasma PLTP activity levels (shown in Figures 5.3 and 5.4), the top 5 
lipids (SM18.20.1, PCLyso18.2, PC32.2, PCLyso16.0 and PC34.0p..34.1e) 
were individually assessed for significant relationships with plasma PLTP 
activity using partial Pearson’s correlations.  
 
 
Figure 5.5: Correlation of SM18.20.1 with plasma PLTP activity levels.  
Levels of SM18.20.1 expressed as molar fraction. SM: Sphingomyelin, PLTP: Phospholipid 
transfer protein, ρmol/μL/h: Picomole per microlitre per hour.  
Pearson’s correlation: *** p < 0.001, adjusted for age, gender, APOE ε4 allele status. 
 
Figure 5.5 shows a significant positive correlation between plasma mean levels 
of SM18.20.1 and plasma PLTP activity levels. Interestingly, the mean level of 
this sphingomyelin species was also the most significantly different between the 
healthy control and AD groups after adjustment for age, gender, APOEε4 allele 
status and collection site when assessed by general linear model (GLM) in 
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Chapter 3 (see Table 3.8). Additionally, it was one of the lipid species chosen 
by the variable selection pipeline for inclusion in the panel for predicting clinical 
classification (see Chapter 3, Section 3.4.3.1). 
Whilst a positive association between SM18.20.1 and plasma PLTP activity 
levels was seen, the other 4 of the top 5 lipids from Figure 5.3 (PCLyso18.2, 
PC32.2, PCLyso16.0 and PC34.0p..34.1e) failed to show any statistical 
significance (data not presented). 
The data presented thus far in this chapter show that plasma PLTP activity 
levels are significantly associated with the levels of several lipid groups (total 
LysoPE, total SM and total PG) and the levels of a sphingomyelin sub-species 
(SM18.20.1), which has also been shown in Chapter 3 to differ in mean plasma 
levels between clinical classifications. In the next section, the association 
between plasma PLTP activity and clinical classification will be investigated.  
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5.5.2 Plasma PLTP activity levels and clinical classification 
The PLTP activity data was analysed to determine whether there was any 
relationship between activity levels and clinical classification. Table 5.1 
describes the demographics of the study population stratified by clinical 
classification. 
Table 5.1: Demographics of the AIBL baseline sub cohort in which PLTP activity levels 
were determined. 
Characteristic HC MCI AD p-value 
Number (n) 158 38 63 
 Age, years (Mean ± SD) 71.58 (± 7.39) 74.71 (± 7.16) 77.03 (± 9.70) < 0.0001 
Gender (F/M) 80/78 16/22 41/22 0.0536 
APOEε4 (-ve/+ve) 91/67 18/20 23/40 < 0.05 
MMSE, score (Mean ± SD) 29 (± 1.27) 26 (± 3.04) 20 (± 4.84) < 0.0001 
SUVR (n) 158 38 26 
 SUVR (Mean ± SD) 1.42 (± 0.41) 1.97 (± 0.59) 2.28 (± 0.52) < 0.0001 
PiB status (-ve/+ve) 108/50 10/28 2/24 < 0.0001 
Hippocampal Volume (n) 145 32 17 
 Hippocampal Volume,  (Mean ± SD) 3.15 (± 0.33) 2.93 (± 0.38) 2.80 (± 0.49) < 0.0001 
 
HC: Healthy Controls, MCI: Mild Cognitive Impairment, AD: Alzheimer’s disease, F: Female, M: 
Male, APOEε4 (-ve/+ve): Negative or positive for the Apolipoprotein E ε4 allele, MMSE: Mini 
Mental State Examination, SUVR: Standard Uptake Value Ratio, PiB status (-ve/+ve): 
Pittsburgh Compound B negative (SUVR < 1.5), or positive (SUVR ≥ 1.5), SD: Standard 
deviation. Analysis of variance (ANOVA) was used to calculate differences for the continuous 
variables and X
2 
for categorical variables. A Kruskal-Wallis formula was applied to the MMSE 
scores. Hippocampal volume measured in mL. 
The AIBL study baseline sub cohort (n=259) in which plasma PLTP activity 
levels were determined comprised of 158 healthy controls (HC), 38 MCI and 63 
AD participants. Whilst the number of men and women in each classification 
group did not significantly differ (p=0.0536), the AD group are significantly older 
(p < 0.0001), which is expected as AD is an age related disease. The 
percentage of APOEε4 allele carriers was significantly different between clinical 
classifications (42%, 53% and 63% for the HC, MCI and AD groups 
respectively) and is higher than reported epidemiological allele frequencies (see 
Table 1.3, Chapter 1) due to deliberate enrichment of the AIBL cohort with 
APOEε4 allele carriers. As expected (and partly by definition), the mean MMSE 
score is lower in the MCI and AD groups compared to healthy controls and the 
cerebral amyloid burden as measured by mean SUVR is significantly higher in 
the MCI and AD groups compared to healthy controls and significantly higher in 
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the AD group compared to MCI. Predictably, hippocampal volume is reduced in 
MCI and AD compared to the HC group. 
Plasma PLTP activity levels were measured in the samples obtained from 259 
AIBL subjects described above, and the activity means for each of the clinical 
classifications are displayed graphically in Figure 5.6.  
 
 
Figure 5.6: Mean differences in plasma PLTP activity levels between clinical 
classifications. 
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, HC: Healthy 
control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease. One way ANOVA: * p < 0.05, 
** p < 0.01 with Bonferroni post hoc test. 
 
Figure 5.6 shows that mean plasma PLTP activity levels are lower in MCI and 
AD groups compared to HC (p < 0.01, p < 0.05 respectively, using one way 
ANOVA with Bonferroni post hoc test). The data was then assessed to 
determine whether PLTP activity levels are influenced by gender or APOEε4 
allele status. No significant differences were shown between males and females 
(data not shown), which is in contrast to the gender difference reported in the 
Framingham study [444], where higher plasma PLTP activity was associated 
with an increased risk of cardiovascular disease in men only. The relationship 
between APOEε4 allele carriage and PLTP activity is explored further in the 
following section. 
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5.5.3 Plasma PLTP activity levels and APOEε4 allele status 
Figure 5.7 shows plasma PLTP activity levels APOEε4 allele and non-allele 
carriers. 
 
Figure 5.7: Mean plasma PLTP activity levels in APOEε4 allele carriers compared to 
APOEε4 non-carriers.  
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, APOE E4-: 
Apolipoprotein E ε4 allele non-carriers, APOE E4+: Apolipoprotein E ε4 allele carriers. * p < 
0.05; student’s unpaired t-test. 
 
Figure 5.7 shows that plasma PLTP activity levels are lower in APOEε4 allele 
carriers compared to non-carriers whilst Figure 5.6 demonstrates that plasma 
PLTP activity levels are reduced in MCI and AD groups compared to HC. As 
observed in Table 5.1, more individuals in the MCI and AD groups carry an 
APOEε4 allele, which may account for the observed results in Figure 5.7. 
Consequently, the mean plasma PLTP activity level in APOEε4 allele carriers 
was assessed when the cohort was stratified by clinical classification. 
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Figure 5.8: Mean plasma PLTP activity levels in APOEε4 allele carriers and non-carriers 
in each clinical classification group. 
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, HC: Healthy 
control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease, -: APOEε4 allele non-carriers, 
+: APOEε4 allele carriers, * p < 0.05; One way ANOVA with Bonferroni post hoc test. 
 
Figure 5.8 illustrates that plasma PLTP activity levels are significantly different 
between APOEε4 allele carriers compared to non-carriers within the AD group, 
with levels lowest amongst APOEε4 positive individuals. A trend towards lower 
plasma PLTP activity levels is also seen amongst APOEε4 allele carriers in the 
HC and MCI groups. Having considered the relationship between plasma PLTP 
activity levels and APOEε4 allele status, a known genetic risk factor for AD, the 
relationship between PLTP activity levels and neuroimaging biomarkers of AD, 
such as MRI determined hippocampal volume and PiB-PET determined 
cerebral amyloid burden was explored. 
 
5.5.4  Plasma PLTP activity levels and hippocampal volume 
Hippocampal atrophy is an end stage feature of AD [560]. To investigate any 
association between PLTP activity and hippocampal volume, plasma PLTP 
activity levels were compared to MRI-determined hippocampal volume. The 
results of this analysis are shown in Figure 5.9. 
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Figure 5.9: Correlation of hippocampal volume with plasma PLTP activity levels. 
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour. Pearson’s 
correlation controlled for age, gender, APOEε4 allele status, years of education and intracranial 
volume (factors which significantly influence hippocampal volume).  
 
No significant association was seen between plasma PLTP activity levels and 
hippocampal volume when all clinical classifications were considered together 
(Figure 5.9), or when the PLTP cohort was stratified by APOEε4 allele carriage 
or by amyloid status, i.e. PiB-positive or PiB-negative. In each case the 
following factors known to significantly influence hippocampal volume were 
controlled for; age, gender, APOEε4 allele carriage (except during stratification 
by APOEε4 carriage), years of education and intracranial volume. To ensure 
that the established relationship between decreased hippocampal volume and 
AD was not ‘masking’ any potential relationship between hippocampal volume 
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and PLTP activity amongst the HC group, the analysis was repeated for the HC 
group alone and for the HC group following stratification by APOEε4 allele 
carriage and amyloid status. Once again, no significant association was 
observed between hippocampal volume and PLTP activity (data not shown). 
It is possible that reduced statistical power due to small sample size may 
account for the lack of significance observed (MRI + PLTP cohort; HC n=145, 
MCI n=32, AD n=17). However, it is also important to note that hippocampal 
atrophy is one of the last clinical manifestations of AD and the significant 
reduction in plasma PLTP activity levels observed in the AD and MCI groups 
compared to the healthy controls (see Figure 5.6) may be representative of an 
ongoing pathological process affecting PLTP levels that precedes, or is 
unrelated to end-stage hippocampal atrophy. 
As mentioned previously, structural changes in the AD brain such as loss of 
hippocampal volume are end stages of the disease spectrum. Functional 
changes in the AD brain such as cerebral amyloid deposition predate structural 
changes with amyloid deposition, represented by PiB-PET determined SUVR, 
commencing approximately 20 years before clinical diagnosis is possible. 
Consequently, the relationship between plasma PLTP activity levels and SUVR 
was investigated. 
 
5.5.5  Plasma PLTP activity levels and cerebral amyloid burden 
The relationship between plasma PLTP activity levels and SUVR, a measure of 
PiB-PET determined cerebral amyloid burden was assessed. Figure 5.10 shows 
the correlation between plasma PLTP activity levels and SUVR amongst the 
PiB-negative (SUVR < 1.5) and PiB-positive (SUVR ≥ 1.5) groups when 
controlling for age, gender and APOEε4 allele status. 
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Figure 5.10: Correlation of plasma PLTP activity levels with brain amyloid burden 
represented by SUVR.  
SUVR: Standardised Uptake Value Ratio, PiB: Pittsburgh Compound B, PiB –ve: Individuals 
with a SUVR value of < 1.5, PiB +ve: Individuals with a SUVR value of ≥ 1.5, PLTP: 
Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour. Pearson’s 
correlations adjusted for age, gender and APOEε4 allele status. 
 
No statistical significance was observed when PiB-PET determined SUVR was 
plotted as a continuous variable against PLTP activity with the PLTP cohort 
stratified by PiB-PET status (independent of clinical classification). Previously 
published AIBL data indicate that 98% of the AD group are PiB-positive (mean 
SUVR amongst PLTP sub-cohort is 2.28) whilst approximately 30% of healthy 
controls have a significant cerebral Aβ burden with an SUVR of > 1.5 [477]. 
Therefore to investigate the potential of PLTP to distinguish PiB-negative from 
PiB-positive ‘cognitively normal’ individuals (i.e. individuals at increased risk of 
developing AD) we considered the HC group separately. First, the mean plasma 
PLTP activity levels were plotted against SUVR as a categorical variable where 
individuals are classified as either PiB-positive or PiB-negative. Figure 5.11 
shows the mean difference in plasma PLTP activity levels between the PiB-
negative and PiB-positive HCs. 
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Figure 5.11: Mean difference in plasma PLTP activity between healthy controls classified 
as either PiB-negative or PiB-positive. 
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, PiB: 
Pittsburgh Compound B, SUVR: Standardised Uptake Value Ratio, PiB –ve: Individuals with a 
SUVR value of < 1.5, PiB +ve: Individuals with a SUVR value of ≥ 1.5. p > 0.05; student’s 
unpaired t-test.  
 
Figure 5.11 shows no significant difference in PLTP activity levels between the 
PiB-positive and PiB-negative healthy controls. However, there is a trend 
towards lower plasma PLTP activity levels amongst PiB-positive individuals 
which may become statistically significant with a larger sample size. To 
increase statistical power, we assessed the relationship between PLTP activity 
levels and SUVR plotted as a continuous variable among the healthy controls: 
The relationship was not significant (data not shown). However, it can be 
argued that the PiB-positive individuals within the healthy control group 
represent a biologically distinct sub-group within whom the processes 
associated with AD pathogenesis are more advanced, and these individuals are 
at increased risk of transitioning to AD. Consequently, we further investigated 
the association between PLTP activity and SUVR following stratification of the 
healthy control cohort by amyloid status i.e. PiB-positive or PiB-negative. 
Figure 5.12 shows the correlation of plasma PLTP activity against SUVR plotted 
as a continuous variable, following stratification of the HC group into PiB-
positive and PiB-negative status. 
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Figure 5.12: Correlation of plasma PLTP activity levels with SUVR in the healthy control 
group following stratification into (A) PiB-negative individuals or (B) PiB-positive 
individuals. PiB: Pittsburgh Compound B, SUVR: Standardised Uptake Value Ratio, PiB-
negative: Individuals with a SUVR value of < 1.5, PiB-positive: Individuals with a SUVR value of 
≥ 1.5. PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour. 
Pearson’s correlations adjusted for age, gender and APOEε4 allele status. 
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Figure 5.12A shows a significant negative correlation between plasma PLTP 
activity and SUVR amongst PiB-negative HC individuals (p<0.01), where higher 
SUVR is associated with lower plasma PLTP activity, whilst figure 5.12B shows 
no significant correlation in the PiB-positive HC group (p=0.748).  
As SUVR is indicative of cerebral Aβ burden and PLTP is suggested to have a 
role in peripheral Aβ metabolism the relationship between plasma PLTP activity 
levels and plasma Aβ was also investigated. 
 
5.5.6 Plasma PLTP activity levels and potential blood biomarkers of AD 
A recent publication from the AIBL study showed a decrease in the plasma ratio 
of Aβ1-42:Aβ1-40 and an inverse correlation with SUVR in AD patients compared 
to healthy controls. Additionally a reduction in plasma Aβ1-42 was reported in 
MCI and those participants who transitioned from the healthy control to MCI 
group [561]. Lower plasma Aβ1-42 levels and plasma ratios of Aβ1-42:Aβ1-40 in AD 
compared to healthy controls have also been reported in other studies [562]. A 
relationship between lipoprotein metabolism, Aβ and PLTP was described at 
the beginning of this chapter and therefore the association between plasma 
PLTP activity levels and plasma Aβ1-42 as well as the ratio of Aβ1-42:Aβ1-40 in 
plasma was investigated. The results are shown in Figure 5.13. 
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Figure 5.13: Correlation of (A) plasma Aβ1-42 and (B) plasma ratio of Aβ1-42:Aβ1-40 with 
plasma PLTP activity levels. 
Aβ: Amyloid beta, PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per 
hour. Pearson’s correlations adjusted for age, gender and APOEε4 allele status; p < 0.05. 
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Figures 5.13A and 5.13B show significant positive correlations between plasma 
Aβ1-42 and the ratio of Aβ1-42:Aβ1-40 with plasma PLTP activity levels 
respectively, i.e. lower plasma PLTP activity levels are associated with lower 
plasma Aβ1-42 and a lower Aβ1-42:Aβ1-40 ratio. This is consistent with Figure 5.6 
where plasma PLTP activity levels were shown to be significantly lower in AD 
patients compared to healthy controls. 
A weakly statistically significant (p=0.049) positive correlation was also 
observed between Aβn-42 and plasma PLTP activity levels (data not 
presented). 
Additionally, plasma PLTP activity levels were also compared to plasma apoE, 
clusterin (apoJ) and apoAI levels, with no significant correlation observed for 
any of these blood biomarkers (data not shown). Plasma HDL-cholesterol 
subfraction levels were also compared to plasma PLTP activity levels, yet no 
significant relationship observed (data not shown). In the case of plasma HDL-
cholesterol subfractions, the results are likely to be influenced by medication 
use (e.g. statins); a factor that was not controlled for during this analysis. 
 
5.6  Discussion 
Differences in plasma lipid species between clinical classifications were 
investigated in Chapters 3 and 4 for their potential use as blood biomarkers to 
reliably differentiate those with AD and MCI from healthy controls. By measuring 
the plasma levels of many different lipid species, some insight into AD-
associated aberrant biochemical pathways can also be obtained. However, 
when using blood to investigate processes that are brain-related, a major 
assumption is that processes in the brain correlate with those in the periphery, 
and while this has been shown for some markers, it has also been shown not to 
apply to others. AD is a chronic age related progressive disease in which co-
existence of other age related factors, impacting lipid metabolism, is inevitable: 
These factors include dietary intakes, digestive capacity, nutrient status, 
hormone balance, the existence of co-morbidities and medication use. These 
factors present a major challenge when studying blood lipid biomarkers as 
considerable interference from systemic metabolic dysfunction may be present. 
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The purpose of the study presented in this chapter was to measure the activity 
levels of a protein (PLTP) that potentially connects plasma lipids to some 
features of AD pathology, to determine if there is any correlation between PLTP 
and established blood and neuroimaging markers of AD. Research investigating 
the relationship between AD and PLTP activity is relatively new and so a pilot 
study was undertaken on a subset of the baseline AIBL cohort to determine 
whether the results justified analysis in a larger sample size. According to a 
recent report, the sensitivity and specificity of clinically diagnosing AD is 80%, 
with neuroimaging biomarkers not improving this accuracy [563]. The lipid 
panels identified in Chapters 3 and 4 were also able to distinguish AD from 
healthy controls with a sensitivity and specificity of 80%. Plasma PLTP activity 
was investigated to determine whether there was any merit in its measurement 
in the AIBL cohort and whether it may show potential in terms of improving the 
sensitivity and specificity of a diagnostic biomarker panel. The major findings 
from the study presented in this chapter were: 
 A significant positive correlation was seen between plasma PLTP activity 
levels and the plasma mean total LysoPE, total SM and total PG species. 
 A significant positive correlation was seen between plasma PLTP activity 
levels and the lipid SM18.20.1, the levels of which were shown in 
Chapter 3 to differ significantly between clinical classifications; this lipid 
was also later chosen in the variable selection pathway for predicting 
clinical classification (Figure 3.15 and Section 3.4.3.1). 
 Plasma PLTP activity levels were significantly lower in the MCI and AD 
groups compared to healthy controls. 
 When comparing the cohort as a whole, APOEε4 allele carriers had 
significantly lower mean plasma PLTP activity levels than non-carriers. 
 When stratified by clinical classification, only in the AD group did the 
APOEε4 allele carriers have significantly lower plasma PLTP activity 
levels than non-carriers. 
 No significant correlation was seen between plasma PLTP activity levels 
and hippocampal volume. 
 When investigating the cohort as a whole, no significant correlation was 
seen between plasma PLTP activity levels and cerebral amyloid burden 
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amongst PiB-positive or PiB-negative individuals. However, when the 
healthy control group was stratified into PiB-positive and PiB-negative, a 
significant negative correlation was observed between SUVR and PLTP 
activity levels amongst the PiB-negative group. 
 Significant positive correlations were observed between PLTP activity 
levels and Aβ1-42 levels in plasma, as well as between PLTP activity 
levels and Aβ1-42:Aβ1-40 ratios in plasma.  
Statistically significant positive correlations were seen between plasma PLTP 
activity levels and the mean total levels of LysoPE, SM and PG. The total levels 
of LysoPE did not significantly differ between clinical classifications when 
assessed in Chapter 3. However, the mean plasma level of LysoPE16.0, the 
most abundant LysoPE species (see Chapter 3), was higher in AD compared to 
healthy controls. On the other hand, no correlation was observed between 
LysoPE16.0 and plasma PLTP activity levels in this chapter. 
A statistically significant association was seen between plasma PLTP activity 
levels and plasma mean total SM as well as levels of the SM species 
SM18.20.1. Figures 5.2B and 5.5 show that lower plasma PLTP activity levels 
are associated with lower total SM, and lower SM18.20.1 respectively. When 
mean plasma SM species levels were assessed in Chapter 3 all sub-species 
measured were significantly different between clinical classifications with mean 
plasma levels lower in the AD and MCI groups compared to the HC group. 
Studies into cellular ceramide homeostasis have shown that PLTP can transfer 
sphingomyelin (SM) from vesicles to HDL [164]. There is also evidence to 
suggest that newly synthesised hepatic ceramides are secreted via VLDL, and 
PLTP is believed to be one of the proteins that facilitates the transfer of 
sphingolipids onto nascent lipoproteins [164, 526, 527]. A reduction in this 
PLTP mediated secretion may adversely affect SM levels as SM are 
synthesised from newly synthesised ceramides. Other evidence that PLTP 
influences ceramide/VLDL production comes from studies of PLTP-deficient 
mice, which show an impairment in hepatic secretion of VLDL, whereas an 
overproduction of PLTP in mice has been shown to lead to excessive hepatic 
VLDL production [564, 565]. All these studies indicate that changes in PLTP 
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levels may influence several aspects of sphingolipid metabolism, and thus lower 
PLTP activity may be reducing the transfer of sphingomyelin (SM) from vesicles 
to lipoproteins such as HDL, leading to reduced plasma SM levels seen in this 
study. Conversely, the ceramide pool can be elevated by the breakdown of 
other sphingolipids and therefore ceramide levels may be unaffected by a 
reduction in PLTP activity (see Chapter 4, Section 4.5). Further analysis of 
plasma PLTP activity levels and plasma sphingolipid levels in a larger sample 
number is required to investigate the potential of PLTP and sphingolipids as a 
combined blood biomarker panel, for the purpose of distinguishing between 
clinical classifications. 
Plasma PLTP activity levels were significantly lower in the MCI and AD groups 
compared to the healthy control group. In other studies, AD patients have been 
shown to have lower CSF PLTP activity [535, 536]; showing a level of 
agreement between studies, if one assumes plasma PLTP activity levels 
parallel CSF levels. Due to the role of PLTP in lipoprotein metabolism and 
reverse cholesterol transport, PLTP has been extensively studied for its role in 
cardiovascular disease (CVD) and other metabolic diseases, such as diabetes 
[444, 445, 520, 566], where plasma PLTP activity levels have been reported to 
be elevated. The AIBL recruitment process excludes potential participants with 
a history of insulin dependent or uncontrolled diabetes, or a history of CVD or 
recent cardiovascular event and therefore the potential influence of these co-
morbidities on PLTP activity levels in our study should have been minimised. 
The link between atherosclerosis and PLTP levels was suggested by studies of 
various mouse models which reported a marked reduction in HDL as a result of 
increased PLTP expression [567]. On the other hand, PLTP expression in 
macrophages has been shown in animal studies to reduce atherosclerosis 
[568], suggesting that protective or disease-promoting effects may be tissue 
specific. Nevertheless, most but not all studies suggest elevated plasma PLTP 
activity levels are associated with an increased risk of CVD. The results 
presented in this chapter show reduced plasma PLTP activity levels in AD 
compared to healthy controls which may appear counter-intuitive given that 
CVD is proposed to contribute to the development of AD. There are, however, 
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several potential explanations for our findings: Firstly, the cohorts are 
significantly different in terms of age (cohorts investigating CVD are usually 
comprised of younger participants compared to studies of AD), although PLTP 
activity is also suggested to increase with age [518]. Secondly, there is a 
suggested correlation between plasma PLTP activity levels and the acute 
phase response protein, C-reactive protein (CRP) [539], which is reportedly 
elevated in CVD. CVD may involve a more acute type of inflammatory 
response, reflected in an elevated CRP and PLTP, whereas in AD more chronic 
inflammatory processes are present which are not reflected by a peripheral 
increase in acute inflammatory markers. Therefore, it may be that different 
factors in AD and CVD are influencing plasma PLTP activity levels. It would be 
interesting to investigate plasma PLTP activity in the context of other forms of 
dementia, specifically vascular dementia, to determine whether the differences 
shown in this study between clinical classifications are driven by specific 
features of AD pathology. As mentioned previously, the relationship between 
PLTP activity and vascular disease is neither predictable nor straightforward: 
Some studies have shown an association between elevated PLTP activity and 
coronary artery disease as well and left ventricular dysfunction [445, 569], while 
others have shown reduced PLTP activity is associated with peripheral vascular 
disease [447]. 
Significantly lower plasma PLTP activity levels were found in APOEε4 allele 
carriers compared to non-carriers, in the cohort as a whole. When the cohort 
was stratified according to clinical classification, the significance between 
carriers and non-carriers remained in the AD group (see Figure 5.8). A study of 
PLTP activity, serum apoE concentration and APOEε4 in a Finnish population 
showed serum apoE levels to be highest in those carrying an APOEε2 allele 
and lowest in those carrying an APOEε4 allele but failed to show a difference in 
PLTP activity [534], however this study utilised a ‘cognitively healthy’ population 
with an age range of 30-94. Our study reports lower PLTP activity levels in 
APOEε4 allele carriers, and a published study from the AIBL cohort has 
described significantly lower plasma total apoE levels in patients with AD and 
specifically those carrying the APOEε4 allele. This study also demonstrated an 
APOEε4 gene dose effect in further reducing plasma apoE levels [84]. ApoE 
Chapter 5 – Plasma PLTP Activity Levels 
258 
 
complexes with, and stabilises its activity, and therefore a role for the regulation 
of plasma PLTP activity by apoE is suggested [570]; the results presented in 
this chapter are consistent with this suggestion. 
As mentioned previously, pathological changes in the AD brain such as cerebral 
amyloid deposition (which can be quantitated by SUVR) predate the onset of 
clinical symptoms. Brain atrophy in selected regions such as the hippocampus 
has also been shown, mostly by structural magnetic resonance (MRI), to 
predate symptom onset [560]. The entorhinal cortex is the first region to display 
atrophy in AD, this is followed by atrophy in the hippocampus, amygdala and 
parahippocampal gyrus [571]. The next region to display atrophy includes the 
posterior cingulate cortex; eventually the atrophy becomes generalised to the 
temporal neocortex and neocortical association areas [572]. Thus, the 
neuroimaging findings on MRI closely mirror the progression of 
neurodegenerative pathology, suggesting that regional brain volume 
assessment using MRI could be used for early diagnosis and disease 
monitoring. However, the MRI technique is time-consuming and requires 
expensive technology, and a blood biomarker test would clearly be preferable. 
In our study, no significant correlation was found between hippocampal volume 
and plasma PLTP activity levels. Unfortunately, hippocampal volume data was 
only available for 17 out of 63 AD participants in whom PLTP activity levels 
were measured; an increased sample size is required to confirm any lack of 
correlation.  
When the whole cohort was divided into two groups - the PiB-negative and PiB-
positive groups - no relationship could be observed between plasma PLTP 
activity levels and cerebral amyloid burden as measured by SUVR. However 
when the HC group was stratified into PiB-positive or PiB-negative, a significant 
negative correlation was observed between SUVR and PLTP activity levels 
amongst the PiB-negative group. This correlation was ‘masked’ when the PiB-
negative and PiB-positive groups were considered collectively, and as referred 
to in earlier text, may be due to different biochemical processes occurring in the 
pathologically distinct groups. This result could reflect the suggested roles of 
PLTP in Aβ metabolism, as lower plasma PLTP activity may reduce Aβ removal 
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from the brain to the periphery for degradation. A significant positive correlation 
was observed between plasma PLTP activity levels and plasma Aβ1-42, as well 
as the ratio of plasma Aβ1-42:Aβ1-40, which is consistent with a role for PLTP in 
the transfer and metabolism of Aβ. Plasma levels of Aβ1-42 and the plasma ratio 
of Aβ1-42:Aβ1-40 were recently shown in the AIBL study to be lower in AD; these 
Aβ measures also showed a negative correlation with SUVR. The correlation 
reported in this chapter between plasma PLTP activity levels and both plasma 
(positive correlation) and cerebral Aβ (negative correlation) strengthens the 
hypothesis that PLTP may be involved in Aβ transport from the brain. The 
“peripheral sink” hypothesis assumes that a balance exists between peripheral 
and brain levels of soluble Aβ, and posits that efficient removal of Aβ from the 
periphery (by enzymatic breakdown or tissue uptake followed by breakdown) 
should help decrease brain levels of Aβ. According to the hypothesis, a 
disruption or decrease in clearance from the brain contributes to cerebral 
retention of Aβ, Aβ aggregation and amyloid formation [573, 574]. This 
hypothesis remains controversial, as pharmacological intervention efforts to 
reduce peripheral and cerebral Aβ have sometimes reduced Aβ in one or both 
compartments. However, the animal models or people in most of these 
pharmacological trials have not shown significant cognitive improvement [16, 
575, 576]. A recent animal study using the Aβ degrading enzyme neprilysin, 
showed an effective degradation of Aβ in the periphery but no alteration in brain 
or CSF Aβ levels [577]. Some studies have shown promise however, for 
example intravenous application of a form of low-density lipoprotein receptor-
related protein-1 (LRP) in an AD mouse model was found to reduce Aβ 
accumulation and aggregation in the brains of the mice, and also was shown to 
improve their learning and memory [578]. The concept of improving clearance 
of brain Aβ via increasing Aβ removal from the periphery is a relatively new 
idea, and although many trials have not yet shown symptom improvement, as 
one review has suggested - it may take longer than expected in ongoing trials 
for such neurobiological effects to translate into measurable clinical 
improvements [579].  However, whilst such studies are still debating whether 
the “peripheral sink” hypothesis offers an effective therapy for AD, the results do 
not dispute suggested roles of PLTP in Aβ metabolism, transport and removal 
from the brain, or its potential use as a biomarker of AD. A very recent study of 
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PLTP-deficient mice has found that a lack of PLTP causes an increase in 
cerebral and hippocampal Aβ1-42 levels and a decrease in cerebral Aβ1-40 levels. 
The PLTP deficiency also increased brain expression of γ-secretase catalytic 
units and decreased the content of apo E, and was found to impair learning and 
memory in the mice [580]. Collectively, studies such as these together with the 
findings reported in this chapter suggest that the relationship between PLTP, 
peripheral and cerebral Aβ warrants further investigation. 
No significant correlations were seen when plasma PLTP activity levels were 
compared with plasma apoE, clusterin (apoJ) or apoAI levels. The plasma HDL-
cholesterol subfractions also failed to show significance when compared with 
PLTP activity levels. It should be noted however, that the use of medications 
such as statins and fibrates which would have been likely to impact on such an 
association was not included as a covariate during analysis, and thereby 
represents a limitation and significant caveat when interpreting the results of 
this aspect of the study. Indeed, a recent investigation, as part of the Diabetes 
Atorvastatin Lipid Intervention study (DALI), showed that PLTP activity and 
plasma apoE were both lowered by treatment with Atorvastatin over a 30 week 
period [581]. Furthermore, fibrates (PPARα activators) also lower plasma 
triglyceride and can increase HDL-cholesterol levels. In PLTP studies utilising 
‘healthy’ cohorts, the level of triglycerides has been the parameter that has 
consistently contributed to variations in plasma PLTP activity levels, which is 
likely due to its role in transferring lipids from apoB containing lipoproteins [518, 
534]. Thus, a logical recommendation for future investigation is controlling for 
medications that can potentially affect biomarker levels.  
A genetic polymorphism has been identified in the PLTP gene (rs7679) and 
interestingly this has been shown to predict both serum triglyceride levels as 
well as mRNA PLTP expression in the liver [582]. The rs7679 T allele was 
shown to be associated with increased PLTP expression, increased plasma 
HDL and lower plasma triglycerides. Another study showed higher PLTP 
activity, higher plasma HDL and lower plasma triglycerides were associated 
with the T allele, suggesting a cardioprotective effect of increased PLTP activity 
[583]; adding to the confusion surrounding the influence of PLTP on 
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cardiovascular disease. The association of AD with this rs7679 polymorphism 
and other variants of the PLTP gene should be investigated in future studies; if 
any of these genetic variants can predict PLTP activity, this may circumvent 
methodological disparities associated with measurement of PLTP and thereby 
enhance comparability of results between cohorts. 
The results presented in this chapter strongly suggest a relationship between 
PLTP activity levels, certain plasma lipid species levels, cerebral and plasma 
Aβ levels. In the quest to identify a sensitive and specific blood biomarker for 
AD, plasma PLTP activity levels may prove to be an important additional 
measurement, and PLTP warrants further assessment both cross-sectionally 
and longitudinally. 
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Chapter 6 – General Discussion and Future Directions 
6.1  Introduction 
Over the past few decades the role of lipids in brain biochemistry and the 
involvement of particular lipid species in the pathological processes associated 
with AD have been more clearly defined. A key protein central to AD pathology 
is the transmembrane protein APP. Processing of this protein, which appears to 
be highly regulated by the membrane lipid environment, leads to the production 
of the Aβ peptide which is neurotoxic when its levels are elevated. Undoubtedly, 
progress in lipid research and our understanding of AD pathology has been 
driven by advances in technologies enabling the more precise investigation of 
the lipidome; the repertoire of lipid species present in cells and tissues. The 
specific type, concentration and flux of these lipid species present at a given 
time or associated with a pathological state are the net result of gene and 
protein expression, which are influenced by the cellular environment. Abnormal 
lipid metabolism, involving cholesterol, phospholipids and sphingolipids has 
emerged as a key component of the pathological processes leading to the 
development of AD. While selected factors, including abnormal lipid metabolism 
have been identified as key features of AD pathology, it is unlikely that any of 
these factors is the sole disease causing culprit. It is more reasonable to 
assume, due to the highly integrated nature of metabolic pathways, that these 
multiple factors work together in response to perhaps a series of insults that 
eventually lead to AD. Lipidomic studies, therefore, are vital for gaining a 
greater understanding of disease mechanisms, aberrant biochemical pathways, 
and importantly for biomarker discovery. The identification of sensitive and 
specific biomarkers is a priority not only in terms of early AD diagnosis, but to 
assist in the validation and monitoring of clinical interventions that target these 
aberrant pathways and their associated lipids and proteins. The results 
presented in this thesis add to the existing body of knowledge and open new 
avenues of exploration in the pursuit of diagnostic tests and therapeutic 
strategies for AD.  
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The challenge for future research is to answer the following questions with more 
certainty:  
 What factors control lipid metabolism, how are they integrated, and which 
signals go wrong in AD?  
 How does this lead to amyloid deposition, tau pathology and 
neurodegeneration; the hallmarks of AD?  
 Is abnormal lipid metabolism a driver or is it influenced by aberrant 
upstream signals that effect cell metabolism, cell survival and DNA 
repair?  
 How can this information be used to diagnose, prevent and treat AD? 
 
When considering the measurement of blood lipids, the influence of dietary and 
lifestyle factors cannot be ignored. Diet and lifestyle factors have an effect on 
the complex network of hormones and transcription factors that orchestrate 
metabolism and influence anti-ageing and pro-survival proteins. Such proteins 
include the sirtuins and other metabolic sensors such as PPAR-gamma 
coactivator 1 α (PGC1) and adenosine monophosphate kinase (AMPK), which 
allow proper adaptation to energy requirements and environmental challenges. 
The existence of these factors may be a major reason why the identification of 
highly specific and sensitive blood lipid biomarkers has been difficult in AD due 
to the interference of plasma abnormal lipid profiles associated with metabolic 
dysfunction and other co-morbidities.  
A highly complex relationship between AD pathology and lipid metabolism 
exists and this association was investigated by measuring plasma lipid species 
to identify which lipids groups were significantly different between clinical 
classifications and if these lipids correlated with other AD biomarkers. The 
ability of certain plasma lipids species to predict clinical classification and 
disease progression was also assessed. Additionally, the activity of the lipid 
transfer protein PLTP was measured in plasma and assessed for its association 
with plasma lipid profiles, clinical classification and other AD biomarkers. 
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6.2 Plasma lipid profiles and their association with clinical 
 classification 
In Chapters 3 and 4, 189 plasma lipid species were investigated to determine 
their feasibility as blood biomarkers for AD. Following complex statistical 
modelling, several lipids were identified as differing significantly in levels 
between clinical classifications, after adjustment for age, gender, APOEε4 allele 
status and collection site in samples collected at both baseline and the 18 
month follow up. Further, lipid panels were determined at baseline and the 18-
month follow up which could distinguish between healthy control and AD 
participants with a sensitivity and specificity of 80%, which compares to the 
current sensitivity and specificity of both clinical diagnosis and neuroimaging 
biomarkers for diagnosing AD [563]. Lipid panels identified at both time points 
for their ability to distinguish MCI from healthy controls, and AD patients from 
MCI, demonstrated reduced sensitivity (69% and 71% respectively), possibly 
due to the heterogeneity of the MCI group. The lipids selected at baseline and 
18 months for inclusion in the HC vs. AD panel were not the same (excepting 2 
lipids), and although the change in characteristics of the cohort between 
baseline and 18 months may explain the differences, further work is 
recommended to improve the diagnostic utility of the blood lipid biomarker 
panels presented in this thesis. The analytical platform chosen for this study 
simultaneously identified a broad range of lipids (189 species) in a large cohort 
(n=1112) at two time points. While this has been extremely useful in identifying 
lipids that differ with clinical classification, and providing information that can 
contribute to an understanding of altered lipid metabolism in AD, the lipid panels 
as they stand cannot be used in a routine setting for the diagnosis of AD. 
However these results have generated many future research avenues to 
pursue, for example they have provided a selection of lipid groups which should 
be investigated for biomarker discovery by a more targeted analytical approach. 
A recent study by Mapstone et al. [493] has just reported the identification of a 
panel of ten lipid biomarkers that predicted conversion to either amnestic mild 
cognitive impairment or AD within a 2-3 year timeframe, with greater than 90% 
accuracy. Using a combination of untargeted and targeted lipidomic 
methodologies, eight PC species and two acyl carnitine species were identified 
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for inclusion in the panel. As part of our study acyl carnitines were not 
measured, and only four of the PC species identified by Mapstone et al. were 
measured. Additionally, analysis of the transition group data reported in this 
thesis was undertaken at 18 months, whilst according to the report by Mapstone 
et al, phenoconversion occurred on average at 2.1 years. The results presented 
in this thesis agree with the report by Mapstone et al. showing lower mean 
plasma levels of the four PC species measured (PC38.6, PC40.6, PC40.6p and 
LysoPC18.2) between the HC and AD groups and analysis of  AIBL samples at 
additional time points may identify important lipids able to predict transition 
groups. 
The lipid differences that were noted between clinical classifications were not 
identical at the two time points; however similarities exist in terms of sub-class, 
acyl chain length and number of unsaturated bonds. In addition, the relative 
levels of some species compared to others enabled plausible explanations of 
the biological relationships and allowed speculation of possible interference in 
the lipid pathways by dietary and metabolic factors. 
In general agreement with other studies, the major lipids that were shown to 
differ between clinical classifications at either or both time points were several 
PE, PC, plasmalogen, sphingomyelin  and ceramide species. Of note was the 
directional change (increased or decreased) with clinical classifications of the 
various species differing in acyl chain length and degree of saturation in the PE 
and PC species. The majority of species levels that were increased in AD and 
MCI compared to healthy controls in the PE and PC groups had shorter chain 
lengths and less saturated bonds: this may suggest abnormalities with the 
desaturase and elongation enzymes required to produce long chain 
unsaturated fatty acids from shorter omega-3 or omega-6 precursors, including 
the essential fatty acids, linoleic and α-linolenic acids. It may also suggest 
essential fatty acid deficiency (and therefore reduced production of AA (20.4n-
6) and DHA (22.6n-3)) or a combination of fatty acid deficiency and reduced 
enzyme activity. If abnormal desaturase or elongase activity exists, shorter 
chain fatty acids with few saturated bonds would accumulate. However, if the 
desaturase and elongation activities were normal yet there was a deficiency of 
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essential fatty acids, the unsaturated mead acid (22.3n-9) would accumulate in 
plasma. The preferred substrates of the delta 6 and delta 5 desaturase 
enzymes are omega-3 and omega-6 fatty acids which produce the long chain 
polyunsaturated fatty acids. If there is a deficiency in the essential fatty acids 
(18.2n-6 and 18.3n-3), the desaturase and elongase enzymes are then free to 
act on their less preferred fatty acid substrates, omega-9 series (18.1n-9). 
Consequently, mead acid accumulates which acts as a marker for essential 
fatty acid deficiency.  
While inferences can be made from the lipid species identified in Chapters 3 
and 4, the analytical platform used does not allow precise determination of the 
fatty acid composition of all species when two fatty acids are present in a 
particular phospholipid species. For example, PE38.4 indicates two fatty acids 
with a combined total of 38 carbon chains and 4 unsaturated bonds, which is 
likely but not certain to be 18.0 at sn-1 and 20.4 at sn-2. Further studies are 
needed to identify the individual acyl groups in the lipid species, which will also 
determine whether abnormal desaturase and elongase activities or essential 
fatty acid deficiencies are the cause of reduced acyl chain length and 
desaturation in the PE and PC species. A more targeted analysis coupling 
chromatography to mass spectrometry and the measurement of plasma fatty 
acids will meet this need. Such information would possibly lead to increased 
sensitivity and specificity of a plasma lipid biomarker panel when added to those 
lipid subspecies identified in Chapters 3 and 4. 
Interestingly a recent study has shown an upregulation of stearoyl-CoA 
desaturase (SCD) in the AD brain, and increased nervonic (24.1n-9) acid; 
resulting in an increased ratio of monounsaturated fatty acid to saturated fatty 
acid [584]. This is interesting for several reasons. The first step in the synthesis 
of nervonic acid (22.1n-9), a crucial component of myelin sphingolipids including 
sulphatide, is the desaturation of stearic (18.0) to produce oleic acid (18.1n-9). 
Oleic acid is then elongated to form nervonic acid. The authors found no 
increase in nervonic acid containing sphingolipids, and subsequently concluded 
that the reported increase in nervonic acid was unlikely to result from 
sphingolipid breakdown and was more likely due to upregulation of SCD, 
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although they were unable to exclude sampling effects. Chapter 4 of this thesis 
showed plasma ceramide containing nervonic acid (C.d18.1.24.1) to be one of 
the lipids with the greatest difference in levels between the healthy control and 
AD groups and was later selected in the statistical model for predicting AD. It is 
certainly feasible that the increase in C.d18.1.24.1 seen in our AD patients 
results from both breakdown of sulphatide and increased de novo synthesis of 
nervonic acid containing ceramide. Sulphatide is a crucial component of myelin 
and its degradation appears to be accelerated in AD, thus it is also possible that 
there is a compensatory increase in nervonic acid production to supply 
precursors for synthesis. The authors reporting upregulation of SCD in the AD 
brain also reported elevated mead acid (22.3n-9). Mead acid is the only 
polyunsaturated fatty acid that can be synthesised de novo, with SCD being the 
rate limiting enzyme. When DHA deficiency is present in the brain, mead acid 
production may be increased as a compensatory mechanism to maintain a 
minimum unsaturation level of fatty acids in the membrane to preserve function. 
Assuming that these changes are related to plasma lipid species, their 
measurement may contribute to a biomarker panel that reflects an aberrant 
brain pathway. As previously mentioned, a future addition to the lipid 
biomarkers measured in Chapters 3 and 4 will be the measurement of both 
mead and nervonic acids as components of plasma fatty acid profiling.  
The results of Chapters 3 and 4 also provide several indicators of peroxisomal 
dysfunction, a reported feature of AD [498]. These indicators include the 
decrease in plasma ether lipid species containing greater than six unsaturated 
bonds (DHA, 22.6n-3) in the AD group compared to healthy controls; the supply 
of both the plasmalogen precursors (1-alkyl-glyceryl ether lipids) and the final 
desaturation step in DHA production which is carried out in peroxisomes. Again, 
plasma fatty acid profiling, including measurement of the peroxisomal DHA 
precursor tetracosahexaenoic acid (24.6n-3) and targeted lipidomics for 
plasmalogen species, will assist in determining the utility of peroxisomal 
dysfunction and specific plasmalogen species as sensitive and specific AD 
biomarkers. 
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In agreement with other studies, the plasma lipid profiles reported in Chapters 3 
and 4 showed significant changes in sphingolipids between clinical 
classifications [163, 422, 423, 474]. Generally, the sphingomyelin species levels 
were decreased and the ceramide species were elevated in AD. Ceramide is 
the central sphingolipid from which other complex sphingolipids (including 
sphingomyelin (SM), cerebrosides and gangliosides) are derived. The reduced 
sphingomyelin species seen in AD may result from decreased synthesis via SM 
synthase or increased catabolism via SMases or a combination of both. As 
described in detail in Chapter 1 (Section 1.5.4), a tight connection exists 
between cholesterol and sphingomyelin, and a reduction in sphingomyelin has 
consequences for membrane biology and APP processing. Furthermore, 
reduced sulphatides have been reported at an early stage of disease in the AD 
brain [413]. The increase in ceramide species in AD may be a net result of 
increased de novo synthesis from serine and palmitoyl CoA and increased 
catabolism of sphingomyelin and sulphatide. In agreement with previous reports 
[163, 502], this study reports a reduction in plasma sphingomyelin levels in AD 
patients. As previously mentioned, the ceramide containing nervonic acid 
C.d18.1.24.1 was one of the lipids with the greatest difference in levels between 
clinical classifications and was also selected as part of the predictive panel in 
Chapter 4: this data may represent an intriguing link to brain sulphatide 
degradation.  
When the ceramide containing nervonic acid C.d18.1.24.1 and three other 
ceramides chosen in the HC vs. AD predictive panel were compared with SUVR 
categories, used as a measure of cerebral amyloid burden (see Chapter 4, 
Figure 4.21), mean plasma levels of all four lipid species rose with the SUVR up 
to a value of 2, this was followed by a marked decline in levels when the SUVR 
levels were greater than 2. This striking relationship may suggest that plasma 
ceramides increase as the rate of Aβ accumulation increases in the brain and 
then decline as the Aβ accumulation rate plateaus: This warrants further 
investigation both through validation in other cohorts and through studying the 
correlation between intra-individual rates of Aβ accumulation and ceramide 
species in this cohort. 
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The results presented in this thesis show that markers of sphingolipid 
metabolism have the potential to be sensitive and specific biomarkers for AD. 
Studies have shown that there are several enzymes involved in sphingolipid 
metabolism which have altered activities in AD resulting in accumulation of 
ceramides and alterations in other specific sphingolipids [471, 511, 514]. 
Potential therapeutic targets for AD are emerging from these studies and 
measurement of plasma sphingolipids will provide a valuable tool to assess 
efficacy and monitor progress of therapeutic interventions. A more targeted 
approach coupling chromatography with mass spectrometry for 
sphingolipidomic studies would enable identification of specific species and 
their ratios which may facilitate discovery of more sensitive and specific 
biomarkers. For example the measurement of sphinganine and 
dihydroceramide may provide information on the de novo ceramide synthesis 
pathway and the relative activity of the enzymes serine-palmitoyl transferase 
(SPT) and dihydroceramide desaturase (DES); the activities of which are 
reportedly altered in AD, thereby identifying them as potential therapeutic 
targets for reducing ceramides. 
 
6.3  Plasma PLTP activity levels and their association with plasma 
  lipid species and clinical classification 
Phospholipid Transfer Protein (PLTP) in involved in lipoprotein metabolism and 
lipid transfer and has suggested roles in processes involved with AD pathology, 
including Aβ metabolism. Therefore, any association of PLTP with the lipid 
species measured in Chapters 3 and 4, clinical classification and other AD 
biomarkers was investigated, to determine whether PLTP shows promise as a 
potential biomarker of AD. Plasma PLTP activity, measured in a subset of the 
AIBL baseline samples, correlated with several of the lipid species measured in 
Chapters 3 and 4 as well as with other AD biomarkers. Plasma PLTP activity 
levels showed the strongest correlation with mean plasma levels of SM18.20.1; 
this lipid species was also shown in Chapter 3 to be lower in the AD group 
compared to healthy controls. The relationship of PLTP with individual lipid 
species should be reassessed when PLTP activity measurement is undertaken 
in the entire baseline cohort and when the 18 month samples are assessed. 
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Plasma PLTP activity levels were measured and found to be lower in the MCI 
and AD groups compared to the healthy controls. Additionally, PLTP activity 
levels were lower in APOEε4 allele carriers compared to non-carriers. However, 
no correlation was observed between plasma apoE levels and PLTP activity. 
When comparing PLTP activity levels with neuroimaging results, no significant 
correlation was observed with hippocampal volume or PiB-PET determined 
SUVR as a marker of cerebral amyloid burden, when assessing all clinical 
classifications together. To investigate the potential of PLTP to distinguish PiB-
negative from PiB-positive ‘cognitively normal’ individuals (i.e. individuals at 
increased risk of developing AD, or in the early pre-symptomatic stages of AD) 
the HC group was investigated further. Following stratification into PiB-positive 
and PiB-negative groups, a significant negative correlation was observed 
between PLTP activity and SUVR in the PiB-negative HC group, suggesting 
that PLTP activity may be indicative of cerebral amyloid load in the early stages 
of Aβ deposition; an effect which diminishes as SUVR increases beyond a 
certain point. 
Interestingly, of all the blood biomarkers assessed for their relationship with 
plasma PLTP activity levels (Aβ, apoE, clusterin and HDL subfractions) only 
plasma Aβ showed a significant positive correlation, with lower plasma PLTP 
levels associated with lower plasma Aβ1-42 and the plasma ratio of Aβ1-42:Aβ1-40. 
Lower levels of both these Aβ measurements have been reported in AD in the 
AIBL study [561], which is in agreement with a suggested role for PLTP in Aβ 
metabolism. 
Collectively, the results of PLTP activity measurement in the healthy control 
group of the baseline AIBL samples clearly suggest further investigation of this 
protein is warranted. Assessing a larger sample number longitudinally will assist 
with determining PLTP’s potential as a biomarker of AD. How plasma PLTP 
activity levels and SUVR vary for a particular individual over time should also be 
investigated.  
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6.4  Future directions 
Plasma lipid profiles show great potential as blood biomarkers of AD, with the 
lipid panels identified in Chapters 3 and 4 distinguishing AD patients from 
healthy controls with a sensitivity and specificity of 80%. The analytical platform 
used in this study enabled the simultaneous measurement of 189 plasma lipid 
species in each sample. The method confers the advantages of facilitating the 
identification of both differences in individual lipid species between clinical 
classifications, and also patterns within related groups, such as the 
sphingolipids; therefore directing future investigations to specific lipid targets. 
The shotgun lipidomics method allows high sample throughput but suffers from 
a compromise in the resolution, which may be addressed by a more targeted 
approach utilising chromatographic separation prior to MS analysis. However, 
before any further analyses are undertaken, the AIBL study has a wealth of 
existing biomarker and lifestyle data that will continue to accumulate and 
assessment of this data in the context of the plasma lipid profiles measured in 
this study is required.  
The results presented in this thesis have also opened up many areas of 
potential future investigation, which may contribute towards the identification of 
a sensitive and specific plasma AD biomarker panel that can be used in a 
routine diagnostic laboratory setting; a necessity given the predicted marked 
increase in the number of AD cases. Such lipidomic studies will likely lead to a 
greater understanding of the pathological processes involved in AD and may 
identify novel targets for which therapeutic interventions are directed. The 
following summarises suggested areas for further investigation: 
 To improve the diagnostic sensitivity and specificity of the existing lipid 
profiles, assessing ratios of lipid species may provide additional 
information. The ratio of ceramides to sphingomyelin with same acyl 
chain and the ratio of dihydroceramides to ceramides, may provide 
information regarding SMases and dihydroceramide desaturase (DES) 
respectively. The ratio of LysoPLs with their corresponding PL may be 
altered by abnormal phospholipase activity, which is also reported in AD. 
Additionally, the saturated to unsaturated ratio of the acyl species of the 
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phospholipids may indicate problems with fatty acid metabolism. The 
ratio of PE to PC species may indicate abnormal methylation patterns 
and reduced choline availability, which is required for the synthesis of 
both SM and acetylcholine.  
 
 Plasma fatty acid analysis will enable identification of important 
polyunsaturated fatty acids such as DHA and also reveal whether there 
is an essential fatty acid deficiency or abnormal metabolism involving 
desaturase and elongase enzymes. Additionally measurement of 
nervonic (24.1n-9), mead (22.3n-9) and tetracosahexaenoic (24.6n-3) 
acids, which have been shown to be altered in AD, may be useful 
additions to existing lipid profiles.  
 
 LC-MS/MS analysis of sphingolipids is justified as many ceramide and 
sphingomyelin species were significantly different between clinical 
classifications and changes in sphingolipids have been reported to 
predict memory impairment [163]. Additionally in light of the recent report 
by Mapstone et al, more targeted analysis of PC species with the 
addition of acyl carnitines may identify an accurate panel for predicting 
phenoconversion. 
 
 Chapter 1 described the interconnection of cholesterol, sphingolipid and 
phospholipid metabolism, which suggest that the measurement of 
cholesterol metabolites such as oxysterols may improve the sensitivity 
and specificity of a lipid biomarker panel.  
 
 Determining PLTP activity levels within the entire baseline cohort is 
recommended, as the pilot study reported in Chapter 5 showed 
promising results. PLTP activity should also be assessed longitudinally 
and compared to intra-individual SUVR. Additionally, the potential of 
PLTP as an AD biomarker should be explored, both in combination with 
plasma Aβ, and also as a component of a potential biomarker panel 
including inflammatory markers. Ceramides are connected to 
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inflammatory cytokines and insulin resistance [207, 265] and as a role for 
PLTP in inflammatory signalling is suggested; an intriguing relationship 
may be uncovered. The combined measurement of specific ceramide 
species, inflammatory markers and PLTP could form an additional 
biomarker panel. 
 
6.4  Limitations 
This thesis had the aim of identifying a sensitive and specific blood biomarker 
panel for AD and reports the association of plasma lipid profiles and a lipid 
transfer protein with clinical classification and various other AD biomarkers. 
However, several limitations should be considered when interpreting the 
findings.  
Although samples were analysed at two time points in the AIBL cohort, further 
longitudinal analysis is required. Whilst the baseline and 18 month lipid species 
results were compared, the characteristics of the cohort changed over the 18 
month period in terms of age, disease progression and non-returning 
participants: Factors which must be considered when comparing the cross 
sectional results at both baseline and 18 months. When analysing the data 
longitudinally over 18 months, statistical power was limited in the context of 
clinical classification transition, as only 54 of the participants who returned at 18 
months transitioned to MCI or AD. It is likely that analysis of samples collected 
at additional time points (i.e. 36 and 54 months) will reveal greater diversity in 
the lipid profiles of individuals transitioning between clinical classifications, 
compared to those who remain within their original classification group, thereby 
facilitating the identification of a more sensitive and specific biomarker panel for 
predicting clinical classification transition. 
‘True comparison’ of the data collected at each of the two time points may also 
have been affected by sample handling, as storage of the two sample sets 
differed. The 18 month samples were stored in liquid nitrogen until the lipids 
were extracted whereas the baseline samples, while initially stored in liquid 
nitrogen, were stored for several years at -80°C prior to lipid extraction. The 
effect of -80°C versus liquid nitrogen storage on lipid profiles was not tested. 
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A “shotgun” lipidomics method was used for this study which simultaneously 
measured a large number of lipid species with high throughput. This method 
may have had lower resolution compared to a more targeted approach, and 
therefore the measurement of some less abundant lipid species may have been 
compromised. However, this analytical platform forms a solid foundation to 
indicate which lipid species may need further investigation for their association 
with AD. 
When investigating plasma PLTP activity, only a sub-set of the cohort was 
assessed. This analysis should be extended to include the whole cohort to 
improve the power of the study.  
 
6.5  Conclusion 
The results presented in this thesis indicate that levels of several plasma lipids 
significantly differ between healthy control, MCI and AD individuals and that 
further investigation using complimentary lipidomic analytical approaches may 
reveal highly sensitive and specific blood biomarkers for predicting AD. The 
analytical platform chosen for this study was based on simultaneously 
identifying a broad range of lipids (189 species) in a large cohort (n >1000). 
Several lipid species were identified in both the baseline and 18 month samples 
as being different between clinical classifications and a panel of lipids was 
identified at each time point that was able to distinguish participants with AD 
from healthy controls with a sensitivity and specificity of 80%. While this is 
extremely useful in identifying lipids that differ with clinical classification and 
providing information that can contribute to an understanding of altered lipid 
metabolism in AD, the lipid panels as they stand cannot be used in a routine 
setting for the diagnosis of AD. However several specific lipid species, in 
particular ceramides and sphingomyelins showed great potential as blood AD 
biomarkers; therefore further, more targeted lipidomic studies are 
recommended. In addition the results from the measurement of plasma PLTP 
activity revealed some important associations with other AD biomarkers which 
warrant further investigation. 
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